category,datetime,headline,id,image,related,source,summary,url
company,2022-09-24 09:29:00,Biotech Valuations Remain In a Slump,116233215,,BIIB,Yahoo,"Biotech stocks continue to slump and have taken a beating for over 12 months, but some promising data could lead to a rebound.  The cheap valuations of the sector right now could be good entry points for investors, experts said.  One catalyst coming up in the fall is the pending decision from the FDA for the clinical trial of an Alzheimer drug, Eisai's  lecanemab that is being jointly developed with Biogen .",https://finnhub.io/api/news?id=85edd3906f12782025d0435b7cf53b60ab79d3bc70fea9662e80df88214878d2
company,2022-09-23 16:41:53,IBD Stock Of The Day: Could 'The Biggest Drug Ever' Drive Eli Lilly Stock Even Higher?,116222877,https://s.yimg.com/uu/api/res/1.2/24s6Kd.Y6aRuhzGjmvKs7g--~B/aD00MzA7dz04MTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/46cf1b249c8e0e05c03323b0349611ee,BIIB,Yahoo,"Eli Lilly is the IBD Stock Of The Day as investors watch the company's obesity and Alzheimer's drugs, which could help shares skyrocket.",https://finnhub.io/api/news?id=11c085151ad3417b193b57c362293f5b856cf6b0575d21d19c966d90299bd27f
company,2022-09-23 12:40:00,"Biogen Inc. stock falls Friday, still outperforms market",116223227,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.42% to $197.78 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=15cf594343b8c47aa1575c72c36ad1b6b11723b21e673baeb7fc578565872900
company,2022-09-23 00:00:16,Alzheimer’s drug trial brings pivotal test of maligned brain plaque theory,116206199,,BIIB,Yahoo,"A late-stage trial of an Alzheimer’s drug set to generate results within weeks is shaping up as a pivotal moment in a three-decade quest to prove that removing sticky amyloid plaques from the brain can slow down the disease.  The phase 3 trial is being led by Eisai, a Tokyo-based pharmaceutical company that has partnered US biotech Biogen to develop lecanemab.  Earlier studies suggested the monoclonal antibody treatment can clear plaques known as beta amyloid that are at the centre of an increasingly acrimonious scientific debate over what causes Alzheimer’s.",https://finnhub.io/api/news?id=3fc5a4b3d5517d008acf1b4d877b8151936bcaf53b474c586db57e63a33b0aba
company,2022-09-22 23:30:00,Mizuho Securities Reaffirms Their Hold Rating on Biogen (BIIB),116219386,,BIIB,TipRanks,"In a report released today, Salim Syed from Mizuho Securities maintained a Hold rating on Biogen (BIIB &#8211; Research Report), with a price target of $207.00. The...",https://finnhub.io/api/news?id=c23678ce3a69b131467a311e0f12c789f7b62f8dfd9e19c97b85b07f2a2a1040
company,2022-09-22 21:22:00,Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick,116235002,,BIIB,The Online Investor,"the online investor,BIIB,",https://finnhub.io/api/news?id=caf0e355c531af6581cd20a3b23c3bbd81b2eceacb784b7e288b6c069c13f896
company,2022-09-28 17:28:24,"Dow Jones Jumps 549 Points As Treasury Yields Tumble, But Now What? Eli Lilly Leads 7 Bullish Stocks",116312650,https://s.yimg.com/uu/api/res/1.2/PpHQWLIKatr9D7NT7X6nnw--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/89039c0e4d3b6c6a5f27c761dcb0809f,BIIB,Yahoo,The major indexes rebounded as Treasury yields tumbled from 4% as the Bank of England resumed bond buying. Eli Lilly led stocks showing bullish action. Here's what to do now.,https://finnhub.io/api/news?id=dd7b5102c636ca527fdd64221477eb93a54efae85b46cff250765ae2843d0404
company,2022-09-28 16:31:02,Biogen Alzheimer's drug may be 'first effort of a clear win': Analyst,116313069,https://s.yimg.com/ny/api/res/1.2/1k_dxdr9fwELzNDNq9f7bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2022-09/4cc01cf0-3f6c-11ed-bfed-2b0b4b04beed,BIIB,Yahoo,"Baird Senior Research Analyst Brian Skorney joins Yahoo Finance Live to discuss the breakthrough of Biogen's Alzheimer's drug, which is pushing the stock higher.",https://finnhub.io/api/news?id=1e87a97ed1728d73c0dac41bd12eafcd1317a8c625f2c5e19e4f829a7c72455b
company,2022-09-28 16:23:27,Biogen Rally Adds $11 Billion in Value on Alzheimer’s Win,116313070,https://s.yimg.com/ny/api/res/1.2/YtYHRhZByIANXWAIwghgEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/66c61daa3e85c954c7c92930b366228f,BIIB,Yahoo,(Bloomberg) -- Biogen Inc. rose the most since November 2020 after a key clinical trial with its partner Eisai Co. showed the therapy lecanemab slowed the progression of Alzheimer’s disease.Most Read from BloombergApple Ditches iPhone Production Increase After Demand FaltersGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesS&P 500 Roars Back From Six-Day Slide; Bonds Surge: Markets WrapPutin’s Mobilization Hits Russia’s Economy in Its Weak SpotsRussia Declares Victory in Sham Ukraine ‘,https://finnhub.io/api/news?id=96729285471e428bd9bb045c4def9b933d2efdbf6b51d8d7b88ad33887658b58
company,2022-09-28 16:12:02,Biogen Explodes Higher After Potential Mega Blockbuster Alzheimer's Drug Succeeds,116310721,https://s.yimg.com/uu/api/res/1.2/gGtWauwwpKBZXOY5aJgvTw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/62ea04b193c69f632062452b474d8cea,BIIB,Yahoo,Biogen stock catapulted Wednesday — bringing shares of other Alzheimer's plays with it — after its experimental treatment succeeded in a test.,https://finnhub.io/api/news?id=f9801885bd0fd6c874763e8c82af7b41ad2f7325bb5990deae35b66d1c971e1f
company,2022-09-28 14:47:00,Biogen Stock Clings to Key Level After Explosive Rally,116313072,https://s.yimg.com/ny/api/res/1.2/W8rCoXA_5zauGmAuhmjNbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/665f08b97dbb8f6a2a9566ebe2fcb176,BIIB,Yahoo,Biogen stock is up almost 40% on Wednesday but is barely holding above a key level. Let's look at the chart.,https://finnhub.io/api/news?id=7f5744688728e9b7b10524e5dcbd20eb4ab843be63735808ba283b9dea5f8d31
company,2022-09-28 14:13:14,Alzheimer's patient advocates hopeful — but cautious— on Biogen news,116313073,https://s.yimg.com/ny/api/res/1.2/T2zcvuIfKZuWMxpvJ0aMpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/a145bac4656f48a6bf2a6c8424389b65,BIIB,Yahoo,Positive data on the Cambridge company's Alzheimer's drug released late Tuesday restored some investor and analyst confidence. But patient advocates are holding out for full study results.,https://finnhub.io/api/news?id=b4054b4f478c5436dc909ef959181d0e0be523c2923e76d6e0d6399fe8727c1d
company,2022-09-28 14:06:35,Call of the Day: Netflix jumps on Atlantic Equities upgrade,116316647,https://image.cnbcfm.com/api/v1/image/107126146-4ED3-FM-E-BLOCK-092822.jpg?v=1664402795&w=1920&h=1080,BIIB,CNBC,"Atlantic Equities upgrades Netflix and the traders respond. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Karen Finerman and Courtney Garcia.",https://finnhub.io/api/news?id=d72b339cad34eea935a2f0c1822c78956a64fa6bc0ea4dc66d67d3f55bad347e
company,2022-09-28 13:59:54,Big win for Biogen: Alzheimer's drug results spark huge gains,116316648,https://image.cnbcfm.com/api/v1/image/107126144-16644023794ED3-FM-C-BLOCK--092822.jpg?v=1664402394&w=1920&h=1080,BIIB,CNBC,"Oppenheimer's Jared Holz on Biogen after the company's stock soared on positive Alzheimer trials. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Dan Nathan, Karen Finerman and Courtney Garcia.",https://finnhub.io/api/news?id=5371c8ce2c9feac2d0ee1dfd39cffc04ac8b8e0fab355b2b7eef4a4fe52c30b6
company,2022-09-28 13:22:00,Health Care Up as Biogen Surges -- Health Care Roundup,116720803,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"Health-care companies rose after a jump in the price of one bellwether. Shares of biotech giant Biogen surged by roughly 40% after lecanemab, an Alzheimer's...",https://finnhub.io/api/news?id=528d2813632aab82936b2f1709b962a62b06fbbe80aaf4c30f4a29799757713b
company,2022-09-28 13:07:32,"DaVita: Solid Valuation And Cash Flow, Price Recovering After SCOTUS Ruling",116312268,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1339090478/image_1339090478.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Marietta vs. DaVita ruling by the SCOTUS in June sided with the health plan, which allowed self-insured plans to exclude certain dialysis providers. Read more here.",https://finnhub.io/api/news?id=398e31bddec8e868108d433ab9cd3e56b4eef4e99eb6c1691bae065c4e6c2450
company,2022-09-28 12:35:00,NEW YORK MARKET CLOSE: Wall Street moves green as BoE offers support,116311229,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=75a2572043b9ceee43a0f322d36ce0e6c79cfef63537ac748d417eac99a6b145
company,2022-09-28 12:14:00,"Biogen, Thor rise; Apple, Equitrans Midstream fall",116310785,,BIIB,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=48acb8ad0edce1bff6a83f425bec5b0bf57ffe6a6de5b153b099e5cdfac2de9e
company,2022-09-28 12:11:00,"A Positive Amyloid Trial, Finally?",116310673,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/648706624/image_648706624.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"The big news last night was the announcement of a positive readout in Eisai and Biogen's trial of lecanemab, another attempt at an anti-amyloid antibody for Alzheimer's therapy.",https://finnhub.io/api/news?id=5d40395d14e672a15a23633223afff35180e1d08df2d787dfacc5a2c2224649b
company,2022-09-28 12:08:22,Biogen's Lecanemab Data Blows Alzheimer's Race Open Again,116310674,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220785248/image_1220785248.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Data from Biogen's Lecanemab is strong enough to suggest the drug could be approved. Read why this could deliver a mutli-billion revenue opportunity for BIIB.,https://finnhub.io/api/news?id=83bd798407ff29c92823d256500e7b729a2fd37b033b4744c5e479adb7cad6c4
company,2022-09-28 12:01:00,"Why Biogen, Lilly, and Prothena Stocks Are Skyrocketing Today",116310722,https://s.yimg.com/ny/api/res/1.2/azG4nfjCwRLBw.L3_yVdZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0094381fb77eb674d3e4f91b41eef843,BIIB,Yahoo,Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday.  The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease.  The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.,https://finnhub.io/api/news?id=b173c4fc6ee7d433c4c017b9e15baddb015431396da641e67578f6f6f105ae94
company,2022-09-28 11:46:03,Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study,116308772,https://s.yimg.com/uu/api/res/1.2/HtLR.3pPwvCu5d5IUSCWtQ--~B/aD00OTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.,https://finnhub.io/api/news?id=df332b551fde69f7ed554d34a2783f5c67700973253d4e800cb2dd31933e3a7c
company,2022-09-28 11:42:00,Cyclo Therapeutics Up 21%; Company 'Pleased' With Progress on Drug Programs,116717564,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Josh Beckerman Cyclo Therapeutics Inc. shares rose 21% to $2.09 as it provided a business update and several companies working on treatments for...,https://finnhub.io/api/news?id=926e3384ef252c7aba2b703921e62691001ba1d60ad6da78f95c110c696ba7bc
company,2022-09-28 11:17:00,New Alzheimer’s Drug Success Was a Shock. Now There Are 5 Big Questions.,116305363,https://s.yimg.com/ny/api/res/1.2/ADvyL.6iIHvAtL8HSl1mew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/463a18c9d651b0854bce640957f8a136,BIIB,Yahoo,"Data from Eisai and its partner Biogen are startling because their drug lecanemab slowed cognitive decline, and suggest that a theory that seemed all but disproved still has legs.",https://finnhub.io/api/news?id=7e110bde2bbaa5ce4b6cd32cd2ec1fabce1e5fd2450e8b1cbce947bdbde8f974
company,2022-09-28 11:11:42,"ANALYSIS-Alzheimer's drug trial breakthrough boost for Roche, Eli Lilly",116308177,,BIIB,Reuters,"Drugs from Roche and Eli Lilly target the same protein as Biogen, Eisai compound",https://finnhub.io/api/news?id=ba273b0c6d6090eba55bcdecaa2d84a9ef5cafeae954e6985a4219991ed68496
company,2022-09-28 10:56:01,4 Alzheimer’s Penny Stocks To Watch After Biogen Stock Explodes,116304691,https://pennystocks.com/wp-content/uploads/2021/02/best-penny-stocks-to-watch-biotechnology.jpg,BIIB,PennyStocks,Penny stocks to buy [or avoid] after Biogen Alzheimer's news.,https://finnhub.io/api/news?id=bba95be04af36e18072806e81d73b963f8107c0adc9ec8e39504bf1842739d51
company,2022-09-28 10:29:18,Wall Street bounces back as Treasury yields dip,116308408,,BIIB,Finnhub,"Wall Street rebounded strongly onWednesday following its recent sell-off, helped by easingTreasury yields, while Apple dropped on concerns about demandfor iPhones. The gains came... | September 28, 2022",https://finnhub.io/api/news?id=2f1e4fefb8649c3f3eb22d11d3b5ac07481f78617c674e24ff98744eb83ff377
company,2022-09-28 10:24:51,"Analysis-Alzheimer's drug breakthrough big boost for Roche, Eli Lilly",116308178,https://static.reuters.com/resources/r/?m=02&d=20220928&t=2&i=1610033943&r=LYNXMPEI8R0P0,BIIB,Reuters,"The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.",https://finnhub.io/api/news?id=09259056e3ad666600f26e76700680c39bac9737ec83df4d659a2632541ab9da
company,2022-09-28 10:17:00,Biogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks Game,116303942,https://s.yimg.com/uu/api/res/1.2/xe_N13d5.Se4qxIVNEKfVQ--~B/aD03Njg7dz0xMTUyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet.com/3417e7a4102cb2b7b6708430e33c2910,BIIB,Yahoo,"Cambridge, Massachusetts-based biotech Biogen  and Japanese drug maker Eisai  reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial.  The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo.  This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic.",https://finnhub.io/api/news?id=b9b355db0f1654fa88b5e9dab6f8e99639444da14877b4e1993c82cc09d26b1e
company,2022-09-28 10:12:42,"Biogen shares soar on landmark Alzheimer's data, lift rivals",116308173,https://static.reuters.com/resources/r/?m=02&d=20220928&t=2&i=1610012960&r=LYNXMPEI8R0DU,BIIB,Reuters,"Biogen Inc was set to add more than $10 billion to its market capitalization on Wednesday, as a surprise trial success of the experimental Alzheimer's drug it developed with Eisai was hailed as an unequivocal win by analysts.",https://finnhub.io/api/news?id=26ae888ac71972a02bcd18f57d02013f85921245e328fb311e4e421d45404d09
company,2022-09-28 10:00:32,Drug Slows Progression of Alzheimer’s in Big Trial,116303943,https://s.yimg.com/uu/api/res/1.2/OUhwBxHYB4WXw7YNq.RNjA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/5da9c97ed9a9548ca63b6f7a3e9e2775,BIIB,Yahoo,(Bloomberg) -- Biogen Inc. and partner Eisai Co. surged and led other drugmakers’ shares higher amid optimism about their breakthrough trial results on Alzheimer’s disease. Most Read from BloombergApple Ditches iPhone Production Increase After Demand FaltersGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesAlzheimer’s Progression Slowed by Drug in Major TrialPutin’s Mobilization Hits Russia’s Economy in Its Weak SpotsRussia Declares Victory in Sham Ukraine ‘Referendums’The two partners,https://finnhub.io/api/news?id=3e778b0d75e2ba547aabc23859577d76962a20415b4f523767c77d18ad585fd5
company,2022-09-28 10:00:00,Is This the First Alzheimer's Drug to Actually Work?,116303944,https://s.yimg.com/ny/api/res/1.2/SN1qKm6pLX3a2Q_qO93XnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/thestreet.com/ad53552aad8d511f530d3fdbacdde7b4,BIIB,Yahoo,Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study.,https://finnhub.io/api/news?id=257e33594a03df8e7dcbd5b4d1b11a2220d6d44391287dd59a92564cb444db46
company,2022-09-28 09:59:00,Biogen Soars 40% on Alzheimer’s Drug Trial. Mizuho Raises the Stock to Buy.,116313083,https://s.yimg.com/ny/api/res/1.2/e6UIij2V6wwvjpnjaaSpkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/37613bca82ae067ac5d9c74aaf0084e5,BIIB,Yahoo,"Mizuho analyst Salim Syed says there are enough data on the drug ""that likely allows for regulatory approval.",https://finnhub.io/api/news?id=ff42bdd9627b5ab889987921e3f545897b7dab560d04ef0456a9be375603d80b
company,2022-09-28 09:49:36,"Midday Movers: Biogen, Apple, DocuSign and More",116313084,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Liz Moyer,https://finnhub.io/api/news?id=3dd2c0823f68a35fdc07daaa60c59c9902b84c14d685d328c76cb8324d684498
company,2022-09-28 09:39:33,Biogen stock soars on promising data from Alzheimer’s drug trial,116313086,https://s.yimg.com/ny/api/res/1.2/QGtO5Y9w4JFkDy8uZMxW8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2022-09/7216b980-3f32-11ed-b7f5-174eaec9cfc2,BIIB,Yahoo,Yahoo Finance Live anchors discuss Biogen stock performance on promising Alzheimer’s drug trial data.,https://finnhub.io/api/news?id=ddbc70c9c08900204fdade4b08911eca22881c93a4c02c745b2158cd511ea112
company,2022-09-28 09:20:00,"As Biogen Surges on Alzheimer Trial Results, Here's How to Play It",116313088,https://s.yimg.com/uu/api/res/1.2/e21l4QVuygnv2Rh1Lz_g8w--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet.com/e4298c0cb41665bbd0a85456b0e8a2f0,BIIB,Yahoo,Biotechnology firm Biogen and their Japan-based partner Eisai Co. Ltd reported better-than-expected results from a late-stage study of their developing Alzheimer's treatment. A successful treatment for Alzheimer's could be worth tens of billions in sales for Biogen.,https://finnhub.io/api/news?id=38011787c501adfd4672819edd226da21c6eaca0bb8e4d284d8dd5dc4452ea92
company,2022-09-28 09:16:44,A Biotech Breakthrough Means Big Gains for These 2 Stocks,116310729,https://s.yimg.com/ny/api/res/1.2/DZ9c38I1Mp1FG_LUlh1Dqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NjU-/https://media.zenfs.com/en/motleyfool.com/c12420e3c62611b416f92fa7b07cbdb3,BIIB,Yahoo,"Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge.  Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease.  Biogen's favorable outcome also gave industry peer Eli Lilly (NYSE: LLY) a boost, on optimism that a new way of coming up with important treatments could spur further successes.",https://finnhub.io/api/news?id=e96ea6752f1fc9b13ec2d263e694b3b53d5cbfa22482d0788960e8040fd8d72d
company,2022-09-28 08:59:40,"Stocks making the biggest moves midday: Apple, Netflix, Biogen, Canopy Growth and more",116311288,https://image.cnbcfm.com/api/v1/image/106936821-1630602069094-biogen.jpg?v=1664384505&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=05070d4fb51a1abc163fce92233425b3c89ec50ff4bc90bf198065b35cf8f742
company,2022-09-28 08:57:00,"Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations",116310136,https://image.thefly.com/catalog/201811/img_112.jpg,BIIB,Thefly.com,"Netflix upgrade, Lockheed Martin downgrade and Sunrun initiation among today's top calls on Wall Street NFLX, BIIB, ILMN, SHOO, SSB, TFC, LMT, LHX, CSX, ETRN, AVNT, RUN, IE, GNRC, SABR, ENVX",https://finnhub.io/api/news?id=fc2c17c28dd66e868fbe48237d918d9debbc9dd12d75cc254bc7c6b64eb8c2b2
company,2022-09-28 08:56:00,Which Alzheimer's stock may be next to jump after Biogen's 'clean’ win?,116310423,https://image.thefly.com/catalog/202209/img_1421.jpg,BIIB,Thefly.com,Mizuho views the data as a ,https://finnhub.io/api/news?id=5a3fc9b82f59509edc41f298bb3ad2bb9196aa6c6da5a34398043e83b54300f3
company,2022-09-28 08:43:00,"Biotech Stocks LLY, ESALY Gain on Biogen's Positive Trial Results",116310424,https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063.png,BIIB,InvestorPlace,"Biogen produced an outstanding Phase 3 result for its Alzheimer’s treatment, sending associated biotech stocks soaring.",https://finnhub.io/api/news?id=98301fa1fd2805da2827a9f0a27dacdfbe4f3284369e12c4b526e071b66e3a44
company,2022-09-28 07:12:50,"Dow Jones Futures Volatile On Bank Of England Reversal; Apple Falls On iPhone Report, Biogen Soars On Alzheimer's Drug",116297640,https://s.yimg.com/uu/api/res/1.2/kyVa4iQub4Y21M4Uz6qBsA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/680604af00f1693843ede6253e55ddae,BIIB,Yahoo,"Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.",https://finnhub.io/api/news?id=c88f85fd64f5872397743c6b223f3c5f6c6e9f0793243c37fe74128dbb9cb663
company,2022-09-28 08:14:10,Stock market today: 4 tickers trending on Yahoo Finance,116304025,https://s.yimg.com/ny/api/res/1.2/qEa5By.3rfGdz8J3syqapA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2022-09/e7820b40-3f26-11ed-adfc-04a8e80f7d7e,BIIB,Yahoo,Here are 4 tickers trending on Yahoo Finance in premarket trading.,https://finnhub.io/api/news?id=b014ebd263d81718e5764c5a4d79bcbfd7fe4bc68ddf0b365dc6deb82d33be07
company,2022-09-28 07:53:00,Why Is Prothena (PRTA) Stock Up 75% Today?,116310789,https://investorplace.com/wp-content/uploads/2021/06/alzheimers.jpg,BIIB,InvestorPlace,Prothena (PRTA) stock is seeing massive gains on Wednesday despite a lack of recent news from the late-stage clinical company.,https://finnhub.io/api/news?id=67a2dac7ef3bd4b58dea11ba8f3aa765fe43298d622df9a5d5ca32b1c082b3e4
company,2022-09-28 07:37:00,Why Is Acumen (ABOS) Stock Up 95% Today?,116308649,https://investorplace.com/wp-content/uploads/2020/07/alzheimers-memory-loss.jpg,BIIB,InvestorPlace,Acumen Pharmaceuticals (ABOS) stock is rocketing higher on Wednesday but it's not due to any recent news from the company.,https://finnhub.io/api/news?id=804c865308a8589582de3e9eee5b11b1be485d058a848caf417be6f42dc153ba
company,2022-09-28 07:23:00,What You Missed On Wall Street This Morning,116308347,https://image.thefly.com/catalog/201904/img_457.jpg,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. AAPL, BIIB, ESALY, BTRS, PATH, MSFT, MAN, NFLX, LMT, ILMN, ETRN, LYFT, TGI, BR, M, GM, FYBR, DOCU, ASTL, SAND, CTAS, BB, THO, VFC, PAYX, BCS, BAC, C, CS, DB, MS, UBS, JEF, NMR, CSX, NSC",https://finnhub.io/api/news?id=8f8468f75c3ce167fb239bbd85f1f6ade9416a611ac1ad6f5a02f2fc11c33a92
company,2022-09-28 07:18:27,"Alzheimer's drug study yields positive results, say makers Eisai and Biogen",116308180,https://static.reuters.com/resources/r/?m=02&d=20220927&t=2&i=1609969875&r=LYNXMPEI8Q132,BIIB,Reuters,"An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.",https://finnhub.io/api/news?id=211996a1f2ccbf44c2797071372ec44f225e61eeee36f6eb186e3d69d28a155a
company,2022-09-28 07:15:11,Biogen stock explodes higher after potential 'mega blockbuster' Alzheimer's drug study,116299791,https://s.yimg.com/os/creatr-uploaded-images/2022-09/251a1af0-3f1e-11ed-afff-a79f86e83581,BIIB,Yahoo,Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.,https://finnhub.io/api/news?id=e68fd3e65c45e0b7b97964cf773b81fe534bcd0d267cebf0a35e61c5710a4dac
company,2022-09-28 06:53:00,Synaptogenix 'welcomes' Lecanemab Phase 3 trial results,116308652,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com,"Synaptogenix (SNPX) comme... SNPX, BIIB, ESALY",https://finnhub.io/api/news?id=fc23003e06d92085481a1ace927ca1e39e92e46ef6f65e35b675670667c244ee
company,2022-09-28 06:41:00,Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?,116593706,https://images.mktw.net/im-256570/social,BIIB,MarketWatch,Some analysts are tempering their expectations of lecanemab until they get a better idea if Medicare will pay for the drug.,https://finnhub.io/api/news?id=0068b594e8f5333f52c4727d06312d890c2835b41663901df4459ccb4a55f234
company,2022-09-28 06:28:00,Biogen (NASDAQ:BIIB) Surges on Positive Phase 3 Trial Results,116310793,https://blog.tipranks.com/wp-content/uploads/2022/07/shutterstock_1329494753-750x406.jpg,BIIB,TipRanks,"Shares of Biogen (NASDAQ:BIIB) are trending about 50% higher in the pre-market trading session today. Last night, the biopharmaceutical company announced that its A...",https://finnhub.io/api/news?id=6760b2faacab942d30b467eda5c1593e25c1cd1819319884bf4f452ae7773af7
company,2022-09-28 06:04:00,"Stocks Resume Slump, Apple, Biogen, Elon Musk And Hurricane Ian - Five Things To Know",116295935,,BIIB,Yahoo,"Stock futures resume slump on rate hike, recession concerns; Apple shares slide on report of waning iPhone demand; Biogen shares soar after positive results from Alzheimer's trial; Elon musk seeks to overturn sec rule on Twitter vetting and Hurricane Ian to slam Florida coast as category 4 storm.",https://finnhub.io/api/news?id=72da595b882ee731d6a86da14861fae5d481028b97333285b34865ef4f324a84
company,2022-09-28 06:02:00,Why Is Cassava Sciences (SAVA) Stock Heating Up Today?,116308653,https://investorplace.com/wp-content/uploads/2022/01/shutterstock_1938998998.png,BIIB,InvestorPlace,"SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target.",https://finnhub.io/api/news?id=62b8e7f77a1f6ca63992949b51fac206b7e962a1400ed9cf5ef25460c5eed0eb
company,2022-09-28 05:45:00,Why Is Biogen (BIIB) Stock Up 40% Today?,116308655,https://investorplace.com/wp-content/uploads/2019/07/biib1600.jpg,BIIB,InvestorPlace,"Positive results from a clinical trial offer encouragement for the medical community, as well as for downtrodden BIIB stock investors.",https://finnhub.io/api/news?id=f2846a88d156d6554b490395f102ecd4de6e2af7a6ab2aab24f474825eeb8655
company,2022-09-28 05:43:00,Alzheimerâs Stock Prothena (NASDAQ:PRTA) Takes Wings,116310797,https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_104922437-1-750x406.jpg,BIIB,TipRanks,Shares of clinical-stage company Prothena (NASDAQ:PRTA) are soaring today as Biogenâs (NASDAQ:BIIB) promising results for lecanemab put the spotlight on Alzheimerâs...,https://finnhub.io/api/news?id=71a7c06860fc019e218eb59385a4e7afd38eaa3c489736e9ea1ba370833b1dbb
company,2022-09-28 05:27:35,"EISAI - LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE",116301669,,BIIB,Finnhub,"TOKYO - Eisai Co., Ltd. and Biogen Inc. announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid... | September 28, 2022",https://finnhub.io/api/news?id=f8ac012e99a7e4f5682c0fc31969211c77c3961700b77099140d2ed4164b8722
company,2022-09-28 05:13:54,"Biogen, Eisai stocks soar on Alzheimer's success, lifting rival shares",116295918,https://static.reuters.com/resources/r/?m=02&d=20220928&t=2&i=1610005674&r=LYNXMPEI8R0DU,BIIB,Reuters,"Shares in Biogen and Eisai soared on Wednesday reflecting the surprise trial success of their experimental Alzheimer's drug, which also lifted the stocks of rival drugmakers Roche and Eli Lilly.",https://finnhub.io/api/news?id=1a5a563a4d8bafffe32f8acf21af60061653e0894ec3edd4d8657bed5656315b
company,2022-09-28 05:16:00,Eisai upgraded to Equal Weight at Morgan Stanley after lecanemab success,116308656,https://thefly.com/images/meta/streetresearch_upgrade.jpg,BIIB,Thefly.com,"Morgan Stanley analyst Sh... ESALY, BIIB",https://finnhub.io/api/news?id=fbaf4874354d947dff9b878b0f6cb1ed5aaaa1258e96b6fce9034c680f6d518e
company,2022-09-28 05:06:00,Alzheimer's drug shows promise in early results of study,116308658,,BIIB,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=766def384647bd55b7431781a554df76f750f89be8951362e96875c4d12b21ad
company,2022-09-28 05:00:12,"Alzheimer's drug succeeds in slowing cognitive decline, makers Eisai and Biogen say",116295922,https://static.reuters.com/resources/r/?m=02&d=20220927&t=2&i=1609969875&r=LYNXMPEI8Q132,BIIB,Reuters,"Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs.",https://finnhub.io/api/news?id=086c1cf29a87c86f6359d1bfd39d3eb0b14fea31ac17693b739b0937cf352089
company,2022-09-28 04:55:00,Early notable gainers among liquid option names on September 28th,116310428,https://thefly.com/images/meta/options.jpg,BIIB,Thefly.com,"Notable gainers among liq... BIIB, LLY, ILMN, NEM, EXPE",https://finnhub.io/api/news?id=8ed23c19c146054a56c2e2c1861ddf51f9ce6d464ee7edc08476b10b9d6639bc
company,2022-09-28 04:46:00,Prothena upgraded at BofA as Biogen data seen strengthening amyloid thesis,116308659,https://thefly.com/images/meta/streetresearch_upgrade.jpg,BIIB,Thefly.com,"BofA analyst Tazeen Ahmad... PRTA, BIIB, ESALY",https://finnhub.io/api/news?id=bb57db59694a18fb240cdf2ca741b7f084dc128d44517c00dcdb9c5144defa10
company,2022-09-28 04:40:00,Unusually active option classes on open September 28th,116305886,https://thefly.com/images/meta/options.jpg,BIIB,Thefly.com,"Unusual total active opti... NNOX, BIIB, OCGN, SHY, SH, LLY, SAVA, LI, AAPL",https://finnhub.io/api/news?id=cdd11fa95b35ba43c19dd324ad0c8a2e3f7761da3b8c66c3dcd1aca080f51f9a
company,2022-09-28 04:17:00,"Path for Biogen's lecanemab to be 'multi-step' process, says Needham",116310804,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Needham analyst Ami Fadia... BIIB,https://finnhub.io/api/news?id=c0e4614d2e11b54dccf0684dfcfb5f93cfc158c7b387d8c1fd27f9e444eeeaf7
company,2022-09-28 04:14:00,Biogen price target raised to $321 from $251 at RBC Capital,116310805,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,RBC Capital analyst Brian... BIIB,https://finnhub.io/api/news?id=9b6362e1e40bcd32689b97c67a902198518f0b18ccbd6fbc80aae886109b4a26
company,2022-09-28 04:02:00,Fly Intel: Pre-market Movers,116310433,https://image.thefly.com/catalog/202004/img_793.jpg,BIIB,Thefly.com,"Biogen skyrockets following positive Alzheimer's study results, Eli Lilly and MorphoSys jump in concert BIIB, LLY, MOR, OCGN, THO, CGNT, BB, AAPL, MNMD, LYFT, LMT",https://finnhub.io/api/news?id=3bcf04133da227901c06186459163fc2e367f041e55eacd803a412ba16164cff
company,2022-09-28 03:53:00,"Analystsâ Top Healthcare Picks: Biogen (BIIB), HCA Healthcare (HCA)",116308545,,BIIB,TipRanks,There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w...,https://finnhub.io/api/news?id=3aa76f94b8d95c9eb622eb561ebcea551e83d547fa4c7c28e8cdc9f137639b49
company,2022-09-28 03:48:00,Prothena up 60% in premarket at $49.59 following Biogen/Eisai data on lecanemab,116310812,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com," PRTA, BIIB",https://finnhub.io/api/news?id=ff4c0d7704364a2df6966dc040cdbb5dad38397b2270d86c75300698b700da90
company,2022-09-28 03:46:00,Prothena price target raised to $81 from $50 at JMP Securities,116308660,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"JMP Securities analyst Ja... PRTA, BIIB, ESALY",https://finnhub.io/api/news?id=fc2a7bd249bd54819fb02b6dbf4dfa0cca1da8c4e7db697a20e252d5ff7b0ba6
company,2022-09-28 03:45:00,7 Growth Stocks to Buy to Tap Into a Hidden Bull Market,116317336,https://investorplace.com/wp-content/uploads/2019/07/stock-market-bull-bear-money.jpg,BIIB,InvestorPlace,It's become a bit easier for investors to find growth stocks to buy hidden amid the bear market.,https://finnhub.io/api/news?id=ed1ba7e2141736d0e796e086b83a42b27cdf57298d14704f50f02a4e20ae8641
company,2022-09-28 03:35:00,"Lecanemab success has 'bullish readthrough' for Acumen, says Stifel",116308661,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Stifel analyst Paul Matte... ABOS, BIIB, ESALY",https://finnhub.io/api/news?id=56babb412adf31dedeac880691327b6c014beb6ee00b60e1d5a4e9236e9dd1be
company,2022-09-28 03:16:00,GLOBAL BROKER RATINGS: Berenberg likes Renault; Biogen raised,116306176,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fc81229d06d9fbd33e79bef82fcede41846318ded5bf20282786d5e8a2b27842
company,2022-09-28 03:16:00,"Biogen's 'near best case' data should lead to lecanemab approval, says Jefferies",116308662,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"After Biogen (BIIB) and E... BIIB, ESALY",https://finnhub.io/api/news?id=ed0edb587fa27c85e474caef330f20feaf97b8300e092e973a0c07fb64396c5e
company,2022-09-28 03:06:00,TOP NEWS: Biogen shares rocket on Alzheimer's study success,116308663,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8ab81d83cdf1188e722e82cab4226b7fd4e84c3b01c01a8a68fa1406b8855bf0
company,2022-09-28 03:00:00,"Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley",116308664,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"After Biogen (BIIB) and E... LLY, BIIB, ESALY",https://finnhub.io/api/news?id=44eff15fbcf8e30fcb85b3aff2039965ddd0bde49577a1ed69865d2fe9e1d8a1
company,2022-09-28 02:59:00,"Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald",116308665,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Cantor Fitzgerald analyst... LLY, BIIB, ESALY",https://finnhub.io/api/news?id=87545d0928b197c6cd45d8eb5d23446e2dd9d160790a5f894ad3f1fe2eb5e7d1
company,2022-09-28 02:48:00,Biogen price target raised to $350 from $265 at Wells Fargo,116310822,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Wells Fargo analyst Mohit... BIIB,https://finnhub.io/api/news?id=7111722aa866f999df9a26dc108e368fb14ed93e654d24f818929eaa0ed976c6
company,2022-09-28 02:47:00,"Biogen's CLARITY AD trial data best case scenario, says Cowen",116310823,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Cowen analyst Phil Nadeau... BIIB,https://finnhub.io/api/news?id=b6151a9003d4a3e531e019698c9a808f63244f05dd4d96fe5a47370db6b1011d
company,2022-09-28 02:43:00,Biogen price target raised to $217 from $183 at Wedbush,116310824,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Wedbush analyst Laura Chi... BIIB,https://finnhub.io/api/news?id=02b8210d80275059cc6dc0f113dbc7a39fa2524ea2f6e3a97a9cb2c4e4048c76
company,2022-09-28 02:40:00,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday,116308688,https://investorplace.com/wp-content/uploads/2021/04/wall-street-federal-hall.jpg,BIIB,InvestorPlace,It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.,https://finnhub.io/api/news?id=3d96c7a9b5240a4675df09c8558509ba50bee6f35903d19236ecd59d384f65b8
company,2022-09-28 02:12:00,Mizuho says Biogen data will serve as catalyst for these stocks,116310826,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Mizuho analyst Graig Suva... ALEC, BIIB, ATHA, AXSM, BTAI, CERE",https://finnhub.io/api/news?id=044c5c81a136ce388c676fba0602b7a39d3cf4176d43f6b03e6d4e1d4b53ba56
company,2022-09-28 02:00:00,"Alzheimer's trial success 'a major positive' for Biogen, says Morgan Stanley",116310827,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,After Biogen (BIIB) and E... BIIB,https://finnhub.io/api/news?id=ba695ae55b4050041e60bbf658b9bff5e0ce75f6637bc458e9eb13acc95c7c6e
company,2022-09-28 01:51:00,"Biogen lecanemab data is 'major development' in Alzheimer's disease, says UBS",116308666,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"UBS analyst Colin Bristow... BIIB, ESALY",https://finnhub.io/api/news?id=9d4a846b9b14dfd552ef5a0fce4bc17f71042dc76a4c4b9a8631340065260256
company,2022-09-28 01:40:00,"MorphoSys up 20%, Eli Lilly up 7% after Biogen data for lecanemab in Alzheimer's",116309547,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com,"Shares of MorphoSys (MOR)... LLY, MOR, RPRX, BIIB",https://finnhub.io/api/news?id=11be8d22c2c2850ca9316273648bfbf1580cb156f9a04d0b95bb722c5ad1d4ed
company,2022-09-28 01:25:00,Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression,116295043,https://s.yimg.com/ny/api/res/1.2/IL1aB25iKsZQDfUNtd5uwg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/marketwatch.com/072dfbeef92f0c0fb132076f37e02454,BIIB,Yahoo,"Eisai and Biogen BIIB said Wednesday that their drug, lecanemab, reduced cognitive and functional decline by 27%, compared with a placebo, over 18 months in a Phase 3 study of 1,800 patients with early-stage Alzheimer's.",https://finnhub.io/api/news?id=c9d37c2033ae6d195694f2ea11cfc24123b2c0c82461418765411cf8f8d6790e
company,2022-09-28 00:59:00,Biogen (BIIB) Gets a Buy from Needham,116310830,,BIIB,TipRanks,Needham analyst Ami Fadia maintained a Buy rating on Biogen (BIIB &#8211; Research Report) today and set a price target of $250.00. The company&#8217;s shares close...,https://finnhub.io/api/news?id=ce082ee950dbda6a8066f018cf66543fe4b19ba3b565a5526dd91138019acb34
company,2022-09-28 00:18:50,"Dow Jones Futures Fall On Apple iPhone Report, Rising Treasury Yields; Biogen Alzheimer's Drug Slows Decline",116289672,https://s.yimg.com/uu/api/res/1.2/kyVa4iQub4Y21M4Uz6qBsA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/680604af00f1693843ede6253e55ddae,BIIB,Yahoo,Futures fell as Apple reportedly curbs iPhone production plans while the 10-year yield is just below 4%. A Biogen Alzheimer's drug shows promise.,https://finnhub.io/api/news?id=bbcef72550987e2201ffc94972a83a5729c88c4558b03a1e14931a210a99c437
company,2022-09-28 00:41:00,Biogen shares jump 40% to $276.02 following positive Alzheimer's study,116310831,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com, BIIB,https://finnhub.io/api/news?id=249edaeec7587b1e22b7dc3fa6699645fc5915185df74519d86460edc9aa31c7
company,2022-09-28 00:40:00,Biogen upgraded to Buy from Neutral at Mizuho,116310832,https://thefly.com/images/meta/streetresearch_upgrade.jpg,BIIB,Thefly.com,Mizuho analyst Salim Syed... BIIB,https://finnhub.io/api/news?id=2c6234597b68ca8aa2864de0acfce45801441ac92608d0811cd752c058d94c0f
company,2022-09-27 21:20:39,"Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline",116288095,https://static.reuters.com/resources/r/?m=02&d=20220927&t=2&i=1609969875&r=LYNXMPEI8Q132,BIIB,Reuters,"Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs.",https://finnhub.io/api/news?id=fadce94c8b39279bb830af18f9a654148cf4dbacb6af6ce553362981c5112c6c
company,2022-09-27 20:17:18,"UPDATE 3-Eisai, Biogen say Alzheimer's drug succeeds in slowing cognitive decline",116291229,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Eisai Co Ltd and Biogen Inc on Tuesday said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs.  ""It's not a huge effect, but it's a positive effect,"" said Ronald Petersen, director of the Mayo Clinic Alzheimer’s Disease Research Center in Rochester, Minnesota.  Eisai, leader of the 50-50 partnership's lecanemab program, is seeking FDA approval under an accelerated pathway, with a decision expected in early January.",https://finnhub.io/api/news?id=a88fa2c219f34a4065964c078dd6dd4dbba6c1c176b38ce05c7dee9b7bda86b7
company,2022-09-27 19:45:21,Factbox-Eisai-Biogen Alzheimer's drug success follows many failures,116288096,,BIIB,Reuters,"Eisai Co Ltd and Biogen Inc reported late-stage data from their Alzheimer's disease drug lecanemab that showed it significantly slowed cognitive decline, a big win for patients after a long string of failures to find an effective treatment for the memory-robbing disease.",https://finnhub.io/api/news?id=cb24f967399d59faf31a53177cf5b0b145b280f754364d9ea364812c764c73ef
company,2022-09-27 19:31:43,Drugmakers Eisai and Biogen claim success in Alzheimer’s drug study,116291230,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Eisai and Biogen said they would apply for regulatory approval for a new Alzheimer’s drug following the results of a late-stage clinical trial that showed it slowed the rate at which the disease progresses.  The companies said on Tuesday that the phase-three trial had demonstrated that giving lecanemab, a monoclonal antibody treatment, to patients in the early stages of the disease reduced the rate of cognitive decline by 27 per cent compared with participants who received a placebo.  The results from the clinical trial will provide hope to the roughly 50mn Alzheimer’s suffers worldwide that progress is being made in the search for treatments to slow the disease.",https://finnhub.io/api/news?id=0a973f9c79fefeee943563d658735560ab7361023276c13040675875e6cad0ca
company,2022-09-27 19:30:05,Eisai says Alzheimer's drug succeeds in slowing cognitive decline,116291231,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"An experimental Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday.  Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.  Lecanemab, like the companies' previous drug Aduhelm, is an antibody designed to remove those amyloid deposits.",https://finnhub.io/api/news?id=81141d0a3a1069c747ac3a8dd3c56c00c1544010c8b8b608550470aad306d4aa
company,2022-09-27 19:30:00,"LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET PRIMARY ENDPOINT, SHOWING HIGHLY STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN LARGE GLOBAL CLINICAL STUDY OF 1,795 PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE",116291232,https://s.yimg.com/uu/api/res/1.2/Qx2K2BT.dXBNjzpJ40qIkg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c1c91d42516ec408a4f8d027fc2e0aae,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, ""Biogen"") announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collective",https://finnhub.io/api/news?id=db2f017c66a6b127f7e40da8d3547bb0fc17cd394cdd59ab4c8dfef85b3c8eec
company,2022-09-27 18:29:00,Biogen Makes Big Payout to Settle DOJ Whistleblower Case,116291233,https://s.yimg.com/ny/api/res/1.2/BrzJcU1.8sEvMp7Ne2e.3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/1250326855deb08fba4b12911a3bc9e6,BIIB,Yahoo,"Qui Tam is perhaps better known as ""whistleblower litigation"" and it is included in the False Claims Act, which President Abraham Lincoln signed into law in 1863.  The False Claims Reform Act of 1985 changed the so-called ""Lincoln Law"", making it easier for the government to investigate False Claims Act cases and lowering the required burden of proof, as well as increasing the potential whistleblower's share to 15-30%, among other items.  Today, Qui Tam can translate into an awful lot of money changing hands .",https://finnhub.io/api/news?id=deffb2b80433e60975af0ba34febc44fb3f0fc2a275a4bdfa1472b3bd846c5a6
company,2022-09-27 15:44:05,UPDATE 1-Biden Medicare costs victory due mostly to Alzheimer's drug change,116291234,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"U.S. President Joe Biden claimed victory on Tuesday for a drop in costs for tens of millions of Americans covered by the Medicare health program, though it is primarily due to a decision to severely limit coverage of an expensive, new Alzheimer's drug.  Biden highlighted a drop in premiums next year for the first time in over a decade for Medicare Part B, which among other things covers doctor and hospital visits as well as drugs they administer.  ""It's going to be a godsend for many families,"" Biden told healthcare advocates in a White House Rose Garden event.",https://finnhub.io/api/news?id=547364bd481e7e170debd6ccae871d1a48299acb46f937593ab42990b97fad16
company,2022-09-27 13:07:05,Biden Medicare costs victory due mostly to Alzheimer's drug change,116291235,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"U.S. President Joe Biden will claim victory on Tuesday for a drop in costs for tens of millions of Americans covered by the Medicare health program, though it is primarily due to a decision to severely limit coverage of an expensive, new Alzheimer's drug.  The White House said Biden would highlight a drop in premiums next year for the first time in over a decade for Medicare Part B, which among other things covers doctor and hospital visits as well as drugs they administer.  The government Medicare plan covers some 35 million Americans aged 65 and older or who are disabled.",https://finnhub.io/api/news?id=4888aa6af719375bac35d152b675c975c6b57673719fff5da85e98bef427d8b8
company,2022-09-27 10:41:05,"Hurricane Ian to intensify, Biogen settles lawsuit, Ford asks for new trial after $1.7 billion loss",116290345,https://s.yimg.com/ny/api/res/1.2/_S51Sh0rQuAvSbGcc54yEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/hd/cp-video-transcode/production/4abd06c4-f531-30b9-baf6-51e489fce326/2022-09-27/14-41-05/488dd49f-65c2-551a-a0b7-f4269b88da7d/stream_1280x720x0_v2_3_0.jpg,BIIB,Yahoo,"Notable business headlines include Hurricane Ian becoming a Category 4 hurricane before hitting Florida, Biogen settling a lawsuit that alleged the company paid doctors to prescribe drugs, and Ford asking for a new trial after rollover accident suit.",https://finnhub.io/api/news?id=55d1438a92d4c6226cb8c71b05427a8011a26ba5c82c1fe0a64a704ffa909dc2
company,2022-09-27 06:25:51,Biogen Settles For $900M In Bribe Case For Prescribing Multiple Sclerosis Drugs,116291238,https://s.yimg.com/uu/api/res/1.2/tvPgCgysCBwfCkU.c8joRg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a164519615f943601b1752fa77a24fc4,BIIB,Yahoo,"Biogen Inc (NASDAQ: BIIB) has reached a $900 million settlement with a whistleblower who accused the firm of paying doctors bribes to encourage them to prescribe its multiple sclerosis drugs. The whistleblower behind the report, Michael Bawduniak, will receive about $250 million directly, according to a statement released Monday by the U.S. Justice Department. About $843 million will essentially go to the federal government and a smaller part-$56 million to 15 American states that had joined the",https://finnhub.io/api/news?id=6ccd1b400640baad4c06a0aba7d2864e7f358a4f4c3a5f9d231518c4fd721c5a
company,2022-09-27 03:01:49,Wall Street Breakfast: Dollar Vs. Stocks,116275581,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Dollar vs. Stocks The U.S.",https://finnhub.io/api/news?id=c2cf63d6bc9cc770fa012680b40c2ff1c3d166e22bf0ca6cbb9e032deccc9ff3
company,2022-09-27 00:51:36,PRESS DIGEST- Wall Street Journal - Sept 27,116271415,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The following are the top stories in the Wall Street Journal.  - Pfizer Inc and BioNTech SE asked U.S. health regulators to clear use of their updated Covid-19 booster in children 5 years to 11 years.  - Ford Motor Co is asking a Georgia court for a new trial, after a jury reached a $1.7 billion verdict against the auto maker last month involving a truck rollover accident that left two people dead.",https://finnhub.io/api/news?id=3bcb136aa3ac70b6d194bed6c0154cc8db4b5736f8f37812676fcc10e0c36818
company,2022-09-26 19:25:22,"Biogen finalizes $900 million drug kickback settlement, U.S. says",116268801,https://static.reuters.com/resources/r/?m=02&d=20220926&t=2&i=1609860582&r=LYNXMPEI8P11V,BIIB,Reuters,"Biogen Inc has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs, the U.S. Department of Justice said on Monday.",https://finnhub.io/api/news?id=7cca9c79c6e697dc7af3008601e8660d9ceb4a41c66196e07345bd6dfe735f0c
company,2022-09-26 19:19:00,Biogen Agrees to Pay $900 Million Over Alleged Improper Physician Payments,116271416,,BIIB,Yahoo,The pharmaceutical company allegedly used speaking and consulting fees to persuade doctors to prescribe its multiple sclerosis drugs.,https://finnhub.io/api/news?id=596996976ee3668cfa456f2485e01310ff26af3b83b9d7f292623ca50d880cd7
company,2022-09-26 18:07:28,"UPDATE 2-Biogen finalizes $900 mln drug kickback settlement, U.S. says",116271417,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen Inc has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs, the U.S. Department of Justice said on Monday.  The settlement resolves a long-running whistleblower lawsuit in Boston federal court that a former employee pursued on the government's behalf.",https://finnhub.io/api/news?id=0f20fcdb9779d9733be2668a62bf934efe53aeaa1ae5e319197743dc50bc75ac
company,2022-09-26 17:59:00,DOJ says Biogen agrees to $900 million settlement over allegations of false Medicare claims,116271418,,BIIB,Yahoo,The Justice Department said Biogen Inc. agreed to pay $900 million to resolve allegations that it caused the submission of false claims to Medicare and Medicaid by allegedly paying kickbacks to doctors.,https://finnhub.io/api/news?id=070ddad56efe2f25c1261ada7f95d5be7ca5b3b116a0c7c3affa2bb39760672a
company,2022-09-26 17:25:54,"Biogen agrees to $900 mln drug kickback settlement, U.S. Justice Dept says",116268802,,BIIB,Reuters,"The U.S. Justice Department said on Monday that Biogen Inc had agreed to pay $900 million to resolve allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs, leading to the submission of false Medicare and Medicaid claims. (Reporting by Eric Beech and...",https://finnhub.io/api/news?id=c8150be3dcbd872153657ea19cd5cac172e8ca9e2da68086c3127bcede128124
company,2022-09-26 15:08:08,Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs,116269134,https://image.cnbcfm.com/api/v1/image/106936821-1630602069094-biogen.jpg?v=1664233688&w=1920&h=1080,BIIB,CNBC,"A former Biogen employee, Michael Bawduniak, alleged Biogen paid kickbacks to doctors to encourage them to prescribe its multiple sclerosis drugs. ",https://finnhub.io/api/news?id=e7a90aefa7c8f596a31fc15f07f54e9de69272e51a0ec8291b887bd7598ab918
company,2022-09-26 13:26:50,"Biogen agrees to $900 million drug kickback settlement, U.S. Justice Dept says",116265568,,BIIB,Finnhub,"The U.S. Justice Department said on Monday that Biogen Inc had agreed to pay $900 million to resolve allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs, leading to the... | September 26, 2022",https://finnhub.io/api/news?id=475d702067d453842900b33f7afc2749241b30b6395bb8039ad36b6d1b220fed
company,2022-09-26 11:02:21,Alkermes: Nothing Stands Out As Interesting,116261243,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305501354/image_1305501354.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Alkermes is producing losses despite being in business this long, and thereâs very little coverage of the company. Read more here.",https://finnhub.io/api/news?id=935993c2e92325dd5857bb3d65f8b1b403d74a42775e43245e76b6895594e2b4
company,2022-10-02 05:05:00,Social Security Recipients Might Actually Get to Keep Their 2023 Raise,116390880,,BIIB,Yahoo,"One of the biggest advantages of Social Security is that its payments get annual cost-of-living adjustments (COLAs).  2022's COLA boosted benefits by 5.9% this year, and early estimates make it likely that the COLA that will take effect in early 2023 will be between 8% and 9%.  What's even better news is that, unlike in 2022, many Social Security recipients are more likely to see the full amount of their cost-of-living adjustment actually hit their bank accounts.",https://finnhub.io/api/news?id=462ac241ccbeb8b859cb1c6982d6b2773678b7159c26597d3e96e6bfb9bd6699
company,2022-10-01 09:47:00,Why the Porsche IPO Generated So Much Excitement,116372831,https://s.yimg.com/ny/api/res/1.2/2501sk8dXfvUjwnsG6q1nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/fb29d3144a49c76e9aa721cffa482e8f,BIIB,Yahoo,"In this podcast, Motley Fool analyst Dylan Lewis and Motley Fool senior analyst Tim Beyers discuss:  Why Porsche is going public while other companies are holding off. Down rounds in the private markets.",https://finnhub.io/api/news?id=2399d7c6e8e373fc61ab8df1c2af6d191a0518ccd32899fe596139ffbf8ad9e7
company,2022-10-01 04:45:15,When Should You Sell A Stock?,116370829,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/104271845/image_104271845.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"The broader market fell ~3% over the past week, but price action remained volatile. Check out our thoughts on when should you sell a stock.",https://finnhub.io/api/news?id=8725edadd1ea8049a4b2ca48d09ba7251a9d1c1d6f868f078f9e7b8e79017131
company,2022-10-01 03:33:26,Wall Street Breakfast: What Moved Markets,116370579,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The major U.S.",https://finnhub.io/api/news?id=e64ae37e7207fb5f8bdf584fc3919d683870b0122ba535b1993eb71cac9ce2c7
company,2022-09-30 18:28:00,"Nike, Biogen, CarMax: Stocks That Defined the Week",116366019,https://s.yimg.com/ny/api/res/1.2/_60HOXE_2l7EwjBHZa_X.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/418cbc20d0fb1bba02585facdc3b7939,BIIB,Yahoo,"Nike is stepping up its discounts.  Nike’s results are the latest sign of how rapidly retailers and manufacturers found themselves with a surplus of goods, after two years of scrambling to have enough to sell during the pandemic.  Nike shares tumbled 13% Friday.",https://finnhub.io/api/news?id=9b21d9fb27b9d3f454886344aa29b820bb619444382db4ed35980066deff18f5
company,2022-09-30 17:23:00,An Alzheimer’s Drug’s Big Surprise: What It Means,116720798,https://images.barrons.com/im-634123/social,BIIB,MarketWatch,Biogen and Eisau reported positive results in a trial for their latest attempt to develop a drug that can combat Alzheimer’s. The good news buttressed the...,https://finnhub.io/api/news?id=0a49830392f6015738495d8f5dfe7b2b19539def56b0817bba1bbe9af0539ce7
company,2022-09-30 16:59:26,"Stocks moving in after hours: FedEx, Nvidia, Intel, AMD, Biogen",116366999,https://s.yimg.com/ny/api/res/1.2/TyHTVLKXUBqb2vPaGUJSEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2022-09/c2313c20-4102-11ed-acef-f784014eaef1,BIIB,Yahoo,Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session.,https://finnhub.io/api/news?id=e82f6a1cac01bfc3714c4234378de6919fe98f63c530b8e112e132086e1805ec
company,2022-09-30 16:42:00,The 5 Best—and 5 Worst—Stocks in the Nasdaq This Quarter,116365184,https://s.yimg.com/ny/api/res/1.2/xBIvl7hydBqFwLZz6xAA7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/e89c586f85ef64e4101c63f927ac810c,BIIB,Yahoo,Constellation Energy was the best performer in the Nasdaq 100 for the third quarter. Okta was the worst.,https://finnhub.io/api/news?id=d85127eb101434ac5b0d2fba0959bcf4e0c1f1fb330635947459555f7820650c
company,2022-09-30 16:34:00,The 5 Best—and 5 Worst—Stocks in the S&P 500 This Quarter,116368239,https://s.yimg.com/ny/api/res/1.2/EgOdeTyclf51ajLmBcEtpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/3a0454cb630057d1f48fe096d952b776,BIIB,Yahoo,The market has had a terrible run. Barron's takes a look at the winners and losers this quarter.,https://finnhub.io/api/news?id=c18c3d331297244dce2c28b320621dd234f170923f11bc2e198f1ad83f2ca02f
company,2022-09-30 16:26:24,"9 Stocks Turned $10,000 Into $130,465 In 9 Months",116373360,https://s.yimg.com/uu/api/res/1.2/RH5pfiAY1a6CsRYutw2ISA--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/77ba43811544c14b01391ff80e411bf5,BIIB,Yahoo,It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.,https://finnhub.io/api/news?id=f8b3a62a284be2e63098c78e3d5aed6b2de7bcfa7014e7c387bd16421840f9d5
company,2022-09-30 13:23:40,Why Biogen Stock Popped as Much as 37.1% This Week,116373361,https://s.yimg.com/ny/api/res/1.2/l7uzgmJg7_qqzfh3eaP1dA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/b51a66f527f185016701320377fbf0c4,BIIB,Yahoo,"Shares of Biogen (NASDAQ: BIIB) shot up as much as 37.1% this week, according to data from S&P Global Market Intelligence.  The large-cap drugmaker with a market cap of $39 billion announced that its new Alzheimer's drug it developed in a partnership with Eisai showed tremendous promise in a clinical trial.  As of 12:42 p.m. ET on Friday, shares of Biogen were up 35.5% this week.",https://finnhub.io/api/news?id=7e94de746385a88a047369456a6667e5cf18738ab7162957639de57c5f871cca
company,2022-09-30 12:28:00,Amylyx Shows FDA Can Be Flexible on Drugs for Diseases With Few Treatments,116373362,https://s.yimg.com/ny/api/res/1.2/_HJjiEEcccF5JxHJUG81kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/628d01c7e6ba27c5150c9c5f67c92f63,BIIB,Yahoo,"Relvyrio, Amylyx's drug to treat ALS, a neurological disorder without a cure, was approved even though the treatment is very expensive.",https://finnhub.io/api/news?id=e8efaf33173377e69175f6e710ef28360f6d7cd2ef8eaed46bc17bd8dddf94d5
company,2022-09-30 10:48:51,"Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review",116368069,https://s.yimg.com/uu/api/res/1.2/IDw45NrGZ_.swugxAahJGQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/565866f3c4ddb1ee1c428951724d63d0,BIIB,Yahoo,"The major indexes fell, with the S&P 500 breaking below bear market lows. Biogen soared on an Alzheimer's drug while Nike dived.",https://finnhub.io/api/news?id=19c136e48b71f69119b6711ef8316ae33e91b6011c1b0972455196a1338b88f6
company,2022-09-30 07:56:03,"Eisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The Rescue",116359976,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1218507501/image_1218507501.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Eisai and Biogen get another chance. Read why the latest from the two companies is a big step forward even though it's still just a glimmer of hope for Alzheimerâs sufferers.,https://finnhub.io/api/news?id=af40d6dc71dff198f63eb6a5bb6bea9b3370884d5a878ecce2726434ebc7ad2b
company,2022-09-30 07:00:00,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)",116373364,https://s.yimg.com/uu/api/res/1.2/Usad_0vByWWo5BOAvLTZHg--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. RoACTEMRA® is indicated in Europe as an intravenous formulation for severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate, moderate to",https://finnhub.io/api/news?id=bf58c0b8ab44903e1ac7f5659ea5f54d7ecbf05ac532c1fb60b21bf6385a5990
company,2022-09-30 06:10:13,Analysis-Eisai's trial success raises hope for Alzheimer's prevention,116361129,https://static.reuters.com/resources/r/?m=02&d=20220930&t=2&i=1610241209&r=LYNXMPEI8T0GC,BIIB,Reuters,Clear evidence this week that Eisai and Biogen's drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer's researchers toward a tantalizing goal - preventing dementia even before symptoms start.,https://finnhub.io/api/news?id=77c8eb8b377a1a8cab4c2f40a8de21ce94c27115c6ec46b7ab5ed426bec2588e
company,2022-09-30 03:38:00,GLOBAL BROKER RATINGS: Deutsche Post raised to 'outperform',116360020,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=03e75102701b6b6d1760770f91aaf24948e9de161a2f82182380b7bb38d7e978
company,2022-09-30 03:26:00,Biogen: EMA Accepts Application for RoActemra Biosimilar >BIIB,116720801,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"By Colin Kellaher Biogen Inc. on Friday said the European Medicines Agency has accepted its application seeking approval of BIIB800, a proposed biosimilar to...",https://finnhub.io/api/news?id=69914bb7802b6152cab3ab918a10d35c941b029a2b087e5c2cf605df537f8d8c
company,2022-09-30 02:11:00,Biogen price target raised to $275 from $221 at JPMorgan,116360715,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"JPMorgan analyst Chris Sc... BIIB, RHHBY",https://finnhub.io/api/news?id=8ca2327f988cc1e4277013bb9f0292de62d03948f700a3de89c6940845301ee2
company,2022-09-30 02:05:00,Biogen announces EMA filing acceptance of BIIB800,116361358,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com,Biogen announced that the... BIIB,https://finnhub.io/api/news?id=0eb7b29bc2fcb2acbab45d3b9021e43b65abfd5ee26a80b4317525f80f77a1e1
company,2022-09-29 12:30:00,NEW YORK MARKET CLOSE: Stocks shelled as recession fears confirmed,116339146,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b70cf63dd8e1cb3bc306f8ca4e94618aa3bb1c42f57e97b9367bc7e363a0bff8
company,2022-09-29 12:12:04,"Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates",116334709,https://s.yimg.com/uu/api/res/1.2/gw9hjYsV9oVXUgeEGEfgLQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3,BIIB,Yahoo,Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=95114d70e3e00726c744376c0cadc782e56463127381bed1c0acf8c162c9be25
company,2022-09-29 10:15:27,Biogen's Alzheimer’s drug could generate ‘$8 billion in peak sales’: Analyst,116334710,https://s.yimg.com/ny/api/res/1.2/51DCo4cG3Rsgf.xGWg1CHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2022-09/29353050-4001-11ed-9cab-83206e2972d3,BIIB,Yahoo,"Mizuho Americas Senior Biotech Analyst Salim Syed joins Yahoo Finance Live to discuss encouraging Phase 3 data from Biogen’s Alzheimer’s treatment lecanemab, how many sales the drug could generate, and what this means for the pharmaceutical industry.",https://finnhub.io/api/news?id=3047531b8f085c367957ef5a99acd9e2b3a784af8eb8b52f903c8a077fb1f89c
company,2022-09-29 09:39:01,LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data,116333262,https://s.yimg.com/uu/api/res/1.2/tsWYAfY6SuBuC3962BZpAA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7d0a870e8718511cdf6e5d72d84220a5,BIIB,Yahoo,The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.,https://finnhub.io/api/news?id=0dfe53bdb7e7f7df4049ea57775e0969bdcd340a4e223885bc8f27aad5358c27
company,2022-09-29 06:20:24,Dow Jones Futures Fall As Treasury Yields Rebound; Eli Lilly Leads 7 Bullish Stocks,116324656,https://s.yimg.com/uu/api/res/1.2/PpHQWLIKatr9D7NT7X6nnw--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/89039c0e4d3b6c6a5f27c761dcb0809f,BIIB,Yahoo,"Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.",https://finnhub.io/api/news?id=5596d102dae6d549536ed411eb8b5d7e71235e1e8ae25344a07eb7046363fb72
company,2022-09-29 08:09:53,"Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug",116333288,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320308217/image_1320308217.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Positive clinical results announced for lecanemab, a novel treatment for Alzheimerâs disease. BIIB and ESALY are up over 35% on the news, although final decision is not until next year.",https://finnhub.io/api/news?id=6a0e223e4e7ecb7a14584e739c3f6727cdb5ac2a54bbf54e9d72ae2d15fc106f
company,2022-09-29 06:36:46,Are Investors Undervaluing Biogen Inc. (NASDAQ:BIIB) By 40%?,116334713,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,In this article we are going to estimate the intrinsic value of Biogen Inc. ( NASDAQ:BIIB ) by taking the forecast...,https://finnhub.io/api/news?id=ea4e15ed656f97a572090c2912c9d1de64dbc98e8c959461166d957447a9d949
company,2022-09-29 06:36:00,November 11th Options Now Available For Biogen (BIIB),116339356,,BIIB,Stock Options Channel,"Staff article entitled November 11th Options Now Available For Biogen (BIIB), about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=0611161aa040a52b89d9d33317c414f31bd7e1ddad2cce640b66fd4027684177
company,2022-09-29 06:12:32,Five questions around Biogen in wake of the new Alzheimer's drug data,116334714,https://s.yimg.com/ny/api/res/1.2/3P0f89UtzxkdZ7ULV_7w5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/bizjournals.com/05eb0e16459d375c63114baf8a831ad1,BIIB,Yahoo,Biogen has spent much of the year shedding assets following the disastrous rollout of its first Alzheimer's disease drug. Will its new Alzheimer's drug stop that decline?,https://finnhub.io/api/news?id=1cdf5685c45cb563f5d80c857cd808634d0c1a25fe26c6e157379cecb5d2e47a
company,2022-09-29 05:13:00,Is Biogen a Smart Biotech Stock to Buy Right Now?,116334715,https://s.yimg.com/ny/api/res/1.2/57R2NXDQv1P6H3tS2EzYbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/db0b765cbd6733cf7aa85f4f726d1861,BIIB,Yahoo,"New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.",https://finnhub.io/api/news?id=b723f39a791e7b388755abed42c01e8e9ad857dab2b2f84b204908070ea81e09
company,2022-09-29 04:40:00,Unusually active option classes on open September 29th,116333605,https://thefly.com/images/meta/options.jpg,BIIB,Thefly.com,"Unusual total active opti... HOG, CS, CLNN, BIIB, GM, HD, RIVN, LVS, EWG",https://finnhub.io/api/news?id=8886af70104345495cbae83a67fab251595fcfea3c3ed39caf3003785fdc980e
company,2022-09-29 03:39:00,"Biogen's lecanemab could be positive revenue driver for Akumin, says Clarus",116339358,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"After Biogen (BIIB) and p... AKU, BIIB, RDNT",https://finnhub.io/api/news?id=93150628ef9f7a151fc166926ea6d201b0e94f2d6325bfb411d62831177b74c9
company,2022-09-29 02:42:00,Biogen price target raised to $300 from $230 at Oppenheimer,116339359,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Oppenheimer analyst Jay O... BIIB, ESALY",https://finnhub.io/api/news?id=039d9ea16cb2b05d440badd9d0a5a9b39cab324a92aeaa1ee1d09eb5bc03987c
company,2022-09-29 02:39:00,Prothena price target raised to $110 from $100 at Oppenheimer,116339360,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Oppenheimer analyst Jay O... PRTA, BIIB, ESALY",https://finnhub.io/api/news?id=31b1474932430c8569af1afe501cb9c971904573d9f40af86805759a94777622
company,2022-09-29 02:08:00,BIIB Crosses Above Average Analyst Target,116339361,,BIIB,ETF Channel,"Staff article entitled BIIB Crosses Above Average Analyst Target, about ETFs, from ETF Channel.",https://finnhub.io/api/news?id=54724d9ed9750fdd3f4876cdc61072244b664dfc0be6a7a3fe6d317a35f45330
company,2022-09-28 22:20:00,"Noteworthy Thursday Option Activity: BIIB, TREE, RAD",116339363,,BIIB,Stock Options Channel,"Staff article entitled Noteworthy Thursday Option Activity: BIIB, TREE, RAD, about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=1e08f41b316e46e74f6b063f9be18f9c91dde43fa6fc14d7436edf340c73eb5c
company,2022-09-28 21:00:35,Biogen's Alzheimer's Drug Success Pops Stocks Across the Industry,116320587,,BIIB,Yahoo,For the 55 million people around the world who suffer from Alzheimer's and related dementias -- not to mention their loved ones -- Biogen's...,https://finnhub.io/api/news?id=2d52d411667fb740d116403699d04f7eee399c6a0d70814e56fc160d13fb1c96
company,2022-10-06 09:30:00,Is This Stock a Buy After Soaring by 37%?,116519302,,BIIB,Yahoo,"Biotech giant Biogen (NASDAQ: BIIB) was underperforming the market this year -- that is, until the company's shares soared by as much as 37% last week.  The drugmaker's major win in the stock market came after it reported positive top-line results from a phase 3 clinical trial for lecanemab, a potential therapy for Alzheimer's disease (AD).  Biogen is developing lecanemab in collaboration with Japan-based Esai.",https://finnhub.io/api/news?id=1f2d2cc8455014ba491f6fbe99dbc1f348a4669ecf4a538836aa9ab9863b9d6a
company,2022-10-06 07:30:11,"Zacks Market Edge Highlights: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA",116509793,https://s.yimg.com/uu/api/res/1.2/0XJsmCRQIKxNY9TtQ.k50A--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ead80764882dffe3925053b7b28f3ed,BIIB,Yahoo,"ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA are part of the Zacks Market Edge article.",https://finnhub.io/api/news?id=9117b3c15a952a45b77a6f095174170e3749b4e1768c295c61347cb377d1916a
company,2022-10-06 07:12:00,Interesting BIIB Put And Call Options For November 25th,116504952,,BIIB,Stock Options Channel,"Staff article entitled Interesting BIIB Put And Call Options For November 25th, about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=037948698c140ab7447c97f30ce289026f1e7c2750eadc3b6d7394b57756fdc2
company,2022-10-06 05:51:40,"The Petri Dish: Moderna nabs Novartis exec as new CTO, Ginkgo acquires two companies",116499575,,BIIB,Yahoo,"Biogen's patent battles over Tecfidera are over after SCOTUS decision; Ginkgo Bioworks delves into the RNA therapeutics; and Peter Thiel invests in Waltham startup creating ""humanized"" mice.",https://finnhub.io/api/news?id=50cf871e8b34386e8138f0a763f69049f3922d902e1abb2d06a0eb7d542a745a
company,2022-10-06 02:48:00,Biogen price target raised to $309 from $238 at UBS,116504953,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,UBS analyst Colin Bristow... BIIB,https://finnhub.io/api/news?id=8ac59063c8e1328601a867552de32d3cac3e031081eba6d4090c6a4a8a475c4c
company,2022-10-05 23:24:00,Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB),116504954,,BIIB,TipRanks,Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB &#8211; Research Report) today and set a price target of $270.00. The company&#8217;s s...,https://finnhub.io/api/news?id=094b8517404ff134ef06391b25ac0ad1529676cc118bd69fe09d9f6ef8cd0604
company,2022-10-05 15:25:07,Should You Sell Your FANGMAN Stocks?,116477570,https://s.yimg.com/uu/api/res/1.2/iA0pEpik6fVUsCBAoxgiUg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8a61c7cb9a22ca41cfb9605a78d42897,BIIB,Yahoo,Tracey and Kevin discuss the rocky 2022 stock market and the future of growth stocks.,https://finnhub.io/api/news?id=0b3569729834f1d236f72c1d0cd7bb776846995ff9309e5b2350c2164e6f999d
company,2022-10-05 12:04:05,"Hey Biogen Investors, Don’t Chase BIIB Stock!",116553270,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Reportedly, Biogen (NASDAQ:BIIB) and Japanese pharmaceutical company Eisai (OTCMKTS:ESALY) achieved positive test results for their Alzheimer’s disease treatment. As you might expect, BIIB stock exploded higher on this news. However, these are early-stage results and prospective investors should read the fine print. Besides, if the good news has already been priced in, then buying now is tantamount to chasing, which generally isn’t a recommended strategy. Just to provide the backstory, Biogen an",https://finnhub.io/api/news?id=f189f81830e3c78a3f6dc61ba6a30d5cedae971761caefe5fbaa4daffd762181
company,2022-10-05 10:00:00,Better Alzheimer's Disease Stock: Eli Lilly or Biogen?,116466863,https://s.yimg.com/ny/api/res/1.2/Rr8XfkNffUgcpiFLUAMdgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/7d294f4ea2e9dc34a34d09f7bfb59566,BIIB,Yahoo,One of these stocks has significantly outperformed the other over the past year. Will that continue?,https://finnhub.io/api/news?id=5c4914d1c0851a9b95c9b7cf301b1bd742b0defe6c6316519dbb2c3cd6c30c06
company,2022-10-05 07:08:00,"Hey Biogen Investors, Don't Chase BIIB Stock!",116471211,https://investorplace.com/wp-content/uploads/2021/06/biogen-biib.jpg,BIIB,InvestorPlace,"If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.",https://finnhub.io/api/news?id=0ac1e23bbcdadd5675d2fb1bbe895849ccf827f6e38c1a78556c8d01892c9c53
company,2022-10-05 03:14:00,Should You Sell Your FANGMAN Stocks? ,116483606,https://cdn.pixabay.com/photo/2016/12/13/22/15/chart-1905225__340.jpg,BIIB,TalkMarkets,"In addition to energy, investors have been fleeing to healthcare stocks for safety. And they have been selling the big tech names, especially the semiconductors.",https://finnhub.io/api/news?id=97c93b12e16735e963c710733dbcfeea9fef915536e9b90317660f0da5a8b407
company,2022-10-05 01:22:00,Acumen price target raised to $22 from $15 at BTIG,116470260,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"BTIG analyst Thomas Shrad... ABOS, BIIB",https://finnhub.io/api/news?id=c737017f73cd189ced215b2b063de9bb55475811f231aab8950a2923ab6b4747
company,2022-10-05 01:21:00,"Keep an Eye on SAVA Stock, as Last Month's Frenzy Fades",116471214,https://investorplace.com/wp-content/uploads/2021/09/sava-stock-1600.jpg,BIIB,InvestorPlace,"SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play.",https://finnhub.io/api/news?id=b85e4c43a60ed4cb2931ab980b216faa57d950d67ad66e83abcf935f059d20af
company,2022-10-04 10:23:00,3 Revolutionary Stocks I'd Buy Right Now Without Hesitation,116436642,https://s.yimg.com/ny/api/res/1.2/hnZFB7fl9o8lqdw2dmj0Eg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/50dc77772b8361f2764b3b6e9b2d5476,BIIB,Yahoo,"Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date.  The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue.  The company's sales of the treatment ended late last year when government contracts for the therapy ended.",https://finnhub.io/api/news?id=0da62927d857d82005a1a42b9d3cccac3a20b124d22d516c5b00bbbb66f8f59a
company,2022-10-04 08:43:26,Eisai And Biogen: Only APOE4 Carriers Benefit From Lecanemab For Alzheimer's Disease,116429360,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/476020106/image_476020106.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Non-APOE4 carriers do not benefit from treatment with lecanemab, which reduces the rate of progression of APOE4 carriers. Read more here.",https://finnhub.io/api/news?id=2f50bff295face8e22c615789fd670f1d1a525ed884f262d718f1889ccfe1b9a
company,2022-10-04 07:34:00,Biogen Shares Climb Again on Results From Alzheimer`s Study,116430761,,BIIB,GuruFocus,,https://finnhub.io/api/news?id=33505e4745b735db4e4e07d56d50929db062de05817a2e50e0e0d93a1bb551a7
company,2022-10-04 03:37:22,Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson's disease Associated with LRRK2 Pathogenic Mutations,116421281,,BIIB,Finnhub,"Cambridge - Biogen Inc. and Denali Therapeutics Inc. today announced that dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate the efficacy and safety profile of BIIB122 , as... | October 4, 2022",https://finnhub.io/api/news?id=69892db11d8b8473194c01150492e9ac3b674f420a220f29d1fa1392416a8da5
company,2022-10-03 14:14:58,US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent,116413984,https://s.yimg.com/uu/api/res/1.2/sLYbc2PQWnr98sTYxusKhQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/f0055c4438b19d95a5e192f58f200e9d,BIIB,Yahoo,"The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. The ruling clears the way for Viatris Inc (NASDAQ: VTRS) to continue marketing its generic version of the drug, launched more than two years ago. The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent. Related: These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win. Biogen sued Mylan, n",https://finnhub.io/api/news?id=859726b79501546272f01a6980c43110365882f1f789986e8b99c2d70f7a28c5
company,2022-10-03 14:02:38,U.S. Supreme Court turns away Biogen bid to reinstate MS drug patent,116407544,https://static.reuters.com/resources/r/?m=02&d=20221003&t=2&i=1610492331&r=LYNXMPEI920N9,BIIB,Reuters,The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc.,https://finnhub.io/api/news?id=3dc51872859104fd0993d1870e5c35c1d2dc41ea01bd018421fa85a612328f81
company,2022-10-03 11:40:00,"The 1-Minute Market Report October 2, 2022",116401656,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1334907481/image_1334907481.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Asian markets continue to struggle this year, thanks in large part to the weak China market. The only asset class showing positive performance is volatility.",https://finnhub.io/api/news?id=8085a2416292eaabac197502eca434cfbd0652d9a3354d4bfe35f22f49be8612
company,2022-10-03 10:37:00,Is Eli Lilly Stock a Buy Following This Competitor's Major Win?,116413986,https://s.yimg.com/ny/api/res/1.2/GYKLivljrmWq37RAXs0bHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0329e0c4330771bd84ee4869e53213d7,BIIB,Yahoo,"Eli Lilly (NYSE: LLY) was already having a great year in the stock market, but on Sept. 28, the company's shares jumped by about 7%.  The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab.  Eli Lilly is working on its own AD treatment, donanemab, and the market counted Biogen's win as Eli Lilly's too.",https://finnhub.io/api/news?id=54c0e13698bfe89aa9ca18629c46fad87929f2ca65345ee5f8909465edec310f
company,2022-10-03 10:08:55,UPDATE 1-U.S. Supreme Court turns away Biogen bid to reinstate MS drug patent,116413988,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary Mylan Pharmaceuticals Inc.  The justices turned away Biogen's appeal of a lower court's decision to invalidate the patent in a ruling that helped clear the way for Mylan's generic version of Tecfidera.  Biogen sued Mylan, now part of Canonsburg, Pennsylvania-based Viatris, in West Virginia in 2017, saying Mylan's proposed generic version of Tecfidera would infringe Biogen patents.",https://finnhub.io/api/news?id=7a6457d4d8f16b23d12e3e11f4c2e427c860867783aabc20e4aaccc6c0915833
company,2022-10-03 09:35:01,Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?,116408437,https://s.yimg.com/uu/api/res/1.2/J5PJq8rtkuiBcDVdnbD5LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227,BIIB,Yahoo,"AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.",https://finnhub.io/api/news?id=8b4fbc1afed6106b659d1a2cde4ae32b590439bb3bd9d4ef06a2a68817dbe59e
company,2022-10-03 09:15:01,Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?,116406968,https://s.yimg.com/uu/api/res/1.2/c23rHSrGLTeyi6ecjtGakg--~B/aD0zNDY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b,BIIB,Yahoo,"Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.",https://finnhub.io/api/news?id=ea02120b068e54f8d1fe7e8a5b4c55d856e357077006392f4b46ca43f9fdc751
company,2022-10-03 08:00:00,Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations,116413992,https://s.yimg.com/ny/api/res/1.2/l7uLiMxvb9OqaSx5ShRNWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zMDg-/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b,BIIB,Yahoo,"Global Phase 3 study to evaluate efficacy and safety of BIIB122, a small molecule inhibitor of LRRK2LRRK2 mutations are one of the most common genetic drivers of Parkinson’s diseaseTargeting LRRK2 has the potential to impact the underlying biology and slow the progression of Parkinson’s disease CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that dosing has commenced in the",https://finnhub.io/api/news?id=d231fc532480dd3a63032261cfc267914df443cd0c375c486d2ddda4d6739006
company,2022-10-03 07:59:00,Biotech Alert: Searches spiking for these stocks today,116428902,https://image.thefly.com/catalog/201812/img_174.jpg,BIIB,Thefly.com,"Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly DNLI, TCRR, PRTA, MOR, QTRX, BMY, BIIB, NVO",https://finnhub.io/api/news?id=c03247d069ae0b3be2a2334c8e50e7bf5a2e47a8a9d440275eeee4415a2ceda0
company,2022-10-03 05:32:50,U.S. SUPREME COURT REJECTS BIOGEN BID TO REVIVE PATENT FOR MULTI…,116397997,,BIIB,Finnhub,"U.S. SUPREME COURT REJECTS BIOGEN BID TO REVIVE PATENT FOR MULTIPLE SCLEROSIS DRUG IN DISPUTE WITH MYLAN PHARMACEUTICALS ... | October 3, 2022",https://finnhub.io/api/news?id=5e49f1ff3d87d362ad32149c4df62a3751123a43d6bd2a1adfbb98d171a63265
company,2022-10-03 05:18:18,"Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA",116397454,,BIIB,Finnhub,"CAMBRIDGE - Biogen Inc. announced that the European Medicines Agency has accepted the Marketing Authorization Application for BIIB800, a biosimilar candidate referencing RoACTEMRA1, an... | October 3, 2022",https://finnhub.io/api/news?id=36096946462f2b84655b7005a6a3fa9c78d8544ee848735d2597257250723661
company,2022-10-03 03:14:00,"Biogen, Denali announce initiation of Phase 3 LIGHTHOUSE study",116400627,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com,"Biogen (BIIB) and Denali ... BIIB, DNLI",https://finnhub.io/api/news?id=15ec9f22a630a4d987618c68357e3fc68da5306f1c22ea1b95e5a746e4c6e101
company,2022-10-03 01:43:00,Doctor Mizuho spoke to 'very enthusiastic' about Biogen Alzheimer drug,116471221,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Mizuho analyst Salim Syed... BIIB,https://finnhub.io/api/news?id=59b9d7550bb18800cb5a2a326796672cdda51f40d263d5dcbf16e3052579b3a7
company,2022-10-03 00:36:00,Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio ,116429088,https://cdn.pixabay.com/photo/2018/07/15/10/44/dna-3539309_960_720.jpg,BIIB,TalkMarkets,Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.,https://finnhub.io/api/news?id=e586d7b067baa4caedf4f0bf0873b3145abd9657570bee9335d39e0401f9311e
company,2022-10-02 23:40:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,116431253,,BIIB,TipRanks,There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w...,https://finnhub.io/api/news?id=c84c4e3d30cc3811d3d30bf70f9f84b6e8f876472f2a37c21f3c267bf7e92403
company,2022-10-10 15:14:05,"Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers",116580567,https://s.yimg.com/uu/api/res/1.2/Tf4SIUcx_m9eaz5v44CsnA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/6d253ad9e6c7a64f8070c19e0838286f,BIIB,Yahoo,"Recently, Biogen Inc (NASDAQ: BIIB) and Eisai Co (OTC: ESALY) announced encouraging data from the most-watched Alzheimer's therapies in the clinic. Lecanemab cleared accumulations in the brain of beta-amyloid, sticky protein fragments that researchers have long suspected contribute to Alzheimer's. Citing physicians and neurology researchers, Wall Street Journal reported that the drug's benefit to patients might be limited. They said the reduction of cognitive decline that patients experienced wa",https://finnhub.io/api/news?id=9c9e4c25367a5e8661edbd6c352a06d6567cf39c5d3f53c4668d1643187ad7cb
company,2022-10-10 07:00:00,Alzheimer’s Drugs Advance but Slowing Disease Remains a Challenge,116576118,https://s.yimg.com/ny/api/res/1.2/6fEh.Ya_RiMSAxqAIYC.OQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/c0e0a28fc4dd8b482c858525c82f593e,BIIB,Yahoo,"Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited",https://finnhub.io/api/news?id=b7733d845d27a2ac313a033d61e7520ee856238f0e0495a0da816c74c760d06a
company,2022-10-10 06:15:48,These 7 Biotech Stocks Are Set to Boom in 2023,116622884,https://s.yimg.com/uu/api/res/1.2/pW9aO0H8tivOegZ.fyiNIg--~B/aD00MDA7dz03Mjg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investorplace_417/9bb111fcd366518d135337b181372598,BIIB,Yahoo,"Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good measure. This combination makes these companies attractive to value investors. In general, however, investing in biotech stocks is not for risk-averse investors. Many of these companies are smaller players. They may or may not be generating revenue, much less profit. But it’s usually at these compa",https://finnhub.io/api/news?id=6c165fc065cc7261bb4f333620af57d49ee8ab21a6ac8ae8cdd4b5e2a28c4fa7
company,2022-10-10 04:30:00,Biogen announces first patient dosed in Phase 2/3 AMETHYST study,116590303,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com,Biogen announced that the... BIIB,https://finnhub.io/api/news?id=fa9d019c20236f01f3f7d3114a24c1e3cf122a4f28d4fa408e8b38ff62cfcba9
company,2022-10-10 01:20:00,7 Biotech Stocks Set to Boom in 2023,116574701,https://investorplace.com/wp-content/uploads/2021/11/shutterstock_1667119063.png,BIIB,InvestorPlace,This article looks at seven biotech stocks that look like good options to move significantly higher in 2023,https://finnhub.io/api/news?id=4058fe2d03c000dcbefa38211357ac3e738f205fae0e796f38aaf2d8855c3126
company,2022-10-07 12:44:00,Former J&J executive emerges as front-runner for Biogen top job - STAT News,116526396,https://static.reuters.com/resources/r/?m=02&d=20221007&t=2&i=1610891744&r=LYNXMPEI960VK,BIIB,Reuters,"Mathai Mammen, a former executive at drugmaker Johnson & Johnson, has emerged as a top candidate to head Biogen as chief executive officer, news website STAT reported on Friday, citing people familiar with the discussions.",https://finnhub.io/api/news?id=75c92d1006713bede8d3a11015f07ff989c6967566463f56c8fcf9a2c3513a8a
company,2022-10-07 07:03:00,What You Missed On Wall Street This Morning,116527275,https://image.thefly.com/catalog/201904/img_457.jpg,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. DKNG, DIS, JNJ, BIIB, AMD, CVS, CANO, BAC, AMBC, LEVI, LYFT, UBER, ZM, GS, NSC, U, META, AAPL, GOOG, GOOGL, PAYO, DXCM, CS, LAC, ALLO, ACCD, AEHR, TLRY, LPRO, NRIX",https://finnhub.io/api/news?id=69ad311d3a6594dbb78c363196580400dfd838711ad6afad44e6a977014bb4fc
company,2022-10-07 05:06:00,"Former J&J exec emerges as top candidate to become Biogen CEO, Statnews reports",116536620,https://thefly.com/images/meta/periodicals.jpg,BIIB,Thefly.com,"Mathai Mammen, a senior r... BIIB, JNJ",https://finnhub.io/api/news?id=fbcc83ae63a15a493ca96e3c58fc81a68b8a8c8f0ef4ee73cadf7fac081048bb
company,2022-10-07 04:35:00,"Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations",116523412,https://image.thefly.com/catalog/201811/img_112.jpg,BIIB,Thefly.com,"Federal Signal upgrade, Lyft downgrade, and Chewy initiation among today's top calls on Wall Street LYFT, UBER, SFT, FSS, GS, NSC, ZM, CHWY, LEVI, HP, U, PSTV, PGR, BIIB, CLB, ZION",https://finnhub.io/api/news?id=16021aadbc6a17ef1eff339cfc24513b67f1a357c5b1929b93ce5890c2812a8f
company,2022-10-07 04:23:00,Unum Group price target raised to $48 from $44 at Truist,116530825,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Truist analyst Mark Hughe... UNM, BIIB",https://finnhub.io/api/news?id=8b1095889267c13d1fad1c669be5b0453c79486614564fe515e4b31ce2575b81
company,2022-10-07 03:37:00,Biogen upgraded to Buy at Argus on positive lecanemab data,116537848,https://thefly.com/images/meta/streetresearch_upgrade.jpg,BIIB,Thefly.com,Argus analyst Jasper Hell... BIIB,https://finnhub.io/api/news?id=465e25873058dcc6fb6e810311385a71d418f8c15e2d94a7bac8129ad600426b
company,2022-10-07 02:28:00,Biogen upgraded to Buy from Hold at Argus,116537849,https://thefly.com/images/meta/streetresearch_upgrade.jpg,BIIB,Thefly.com,Argus upgraded Biogen to ... BIIB,https://finnhub.io/api/news?id=b5b9624bcf6309a8e623fe4a9798ae98a4387249d4819196b98cc5856302c7bf
company,2022-10-07 00:42:00,Biogen price target raised to $275 from $200 at Barclays,116537850,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Barclays analyst Carter G... BIIB,https://finnhub.io/api/news?id=15251303dc95616b6d067d87d1114c95aae65c5049708a7ffcb54f5ac0472b5b
company,2022-10-14 12:40:00,"Biogen Inc. stock falls Friday, still outperforms market",116720795,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.97% to $264.63 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=4b807c88be752919eced442b1aa611df4a1ebf9344d48255f1ff074dc369c5b3
company,2022-10-14 05:31:00,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Brookdale Senior Living (BKD),116666387,,BIIB,TipRanks,Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (<a href...,https://finnhub.io/api/news?id=624c1643e5590305c531be8bd436e2b67ba8b7a8c75bbb2622c4b5209cb7a87d
company,2022-10-13 16:05:13,"Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity",116626903,https://s.yimg.com/uu/api/res/1.2/v0L.vSpXNHZMNBvSu3fuVg--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c1625f1f8b75121675b6ada9243ba22d,BIIB,Yahoo,"Biogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday as he upgraded Biogen stock.",https://finnhub.io/api/news?id=405233652c82c5ff1bf9fe07244023961783066220440e0c033502e1fe57e669
company,2022-10-13 13:45:04,"Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts",116633142,https://s.yimg.com/uu/api/res/1.2/g2IJ1dUpYNU56BZ0mP77Ig--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/bcb574a92ceda9a1102b80d5796a3ae7,BIIB,Yahoo,"Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's. It raised the price target from $223 to $299. The analyst worries about residual competitive/commercial risks, notwithstanding the uncertainty around Biogen's future CEO. Stifel views upcoming Roche Holding AG's (OTC: RHHBY) gantenerumab data are unlikely to live up to the high bar lecanemab recently set and thinks there's a meaningful commercial role for lecane",https://finnhub.io/api/news?id=7aa8602bfa82310077637df5b3a319764d663666b3df8292b704017ae897aa6c
company,2022-10-13 12:40:00,"Biogen Inc. stock rises Thursday, outperforms market",116720796,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 6.41% to $269.94 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=0fa32fae3629f6dbe991990a8650ea73c8998dd6dfc3141ea15516c2cff7b63c
company,2022-10-13 09:10:00,Biogen Community Lab: 20 Years of Inspiring Future Scientists,116633143,,BIIB,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / October 13, 2022 / Biogen ""I remember this one girl from Cambridge: she was filling out the survey we give to students on their last day,"" says Tracy Callahan, Biogen's first Community Lab teacher. ""She said to ...",https://finnhub.io/api/news?id=94fe071ceb65b422531ebf1cb43f20be084719544a164e22476e379b765f7ae3
company,2022-10-13 09:00:00,GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®,116623596,https://s.yimg.com/uu/api/res/1.2/MwJEkGEqF_HOgAhlsgNFMA--~B/aD0yNTM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c3f08b7ff08c566575f2a38d35b1cbc3,BIIB,Yahoo,"SANTA MONICA, Calif., October 13, 2022--GoodRx (NASDAQ: GDRX), a leading consumer-focused digital healthcare platform, today announced a collaboration with Biogen (NASDAQ: BIIB) that aims to improve the patient and healthcare provider (HCP) experience when initiating a new specialty therapy. HCPs who have decided to start patients with relapsing forms of multiple sclerosis (MS) on VUMERITY® (diroximel fumarate) may now find the enrollment form and submit to the specialty hub through Provider Mod",https://finnhub.io/api/news?id=b4758639fb50a673823b2c386f19996b74bda1ac5943a0448558d066e03fb2c7
company,2022-10-13 08:37:58,"Stocks making the biggest moves midday: Digital World, Domino's, Revlon, Albertsons and more",116627492,https://image.cnbcfm.com/api/v1/image/107077754-16554938222022-06-17t184516z_1433191743_rc2zsu965qg3_rtrmadp_0_revlon-bankruptcy.jpeg?v=1665679078&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=57d4ac97e8e681f6b63e8505db0fac66ead89a7e5db9360ffb230f93c992b524
company,2022-10-13 07:13:00,What You Missed On Wall Street This Morning,116625176,https://image.thefly.com/catalog/201904/img_457.jpg,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. DPZ, QDEL, ACCO, ACMR, WBA, DAL, KR, ACI, CMCSA, AMAT, PDCO, ATUS, BIIB, AXP, LVS, NKE, LULU, GOOG, GOOGL, AMZN, TTE, AAPL, SONY, HMC, DWAC, INMD, TSM, CNHI, RLMD, PGR, FAST",https://finnhub.io/api/news?id=f4f94faef31bf8d78dc585c55cc6ecd84ef883c0bc7e8d65453c445788291055
company,2022-10-13 05:10:00,"Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations",116622457,https://image.thefly.com/catalog/201811/img_112.jpg,BIIB,Thefly.com,"Comcast upgrade, American Express downgrade and Nike initiation among today's top calls on Wall Street CMCSA, CMCSK, LVS, ATUS, SHW, BIIB, RHHBY, AXP, GEF, ALB, BP, AVY, NKE, LULU, SKX, UAA, SMAR, ASAN, DOCS, MNDY",https://finnhub.io/api/news?id=66ea4a5091128000f4ce7b73775a6a4406cd021fcc5d1a35a57296e5d2c2d56e
company,2022-10-13 04:55:00,Early notable gainers among liquid option names on October 13th,116640885,https://thefly.com/images/meta/options.jpg,BIIB,Thefly.com,"Notable gainers among liq... DPZ, DAL, WBA, BIIB, JPM",https://finnhub.io/api/news?id=a68340468c197f7c8db910ade2796c5beaae157e73da5b612e3b195a19527f85
company,2022-10-13 03:51:58,"Delta, Walgreens, BlackRock, Domino's Rise Premarket; Applied Materials Drops",116624602,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Peter Nurse,https://finnhub.io/api/news?id=a22e4c8da377b08856f9d44ef15eae8123438b9f485c1100d247a8c9c9cc5f20
company,2022-10-12 23:55:00,"Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13",116641776,https://www.biogen.com/content/dam/corporate/en_us/images/biogenrefresh/News/Sangamo-dna-1838x1024.jpg,BIIB,TalkMarkets,"Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside.  ",https://finnhub.io/api/news?id=29fc809e2c98f8a97ab73e890924c91c632367e4f53554e0284ca5baafc19661
company,2022-10-12 23:28:00,What You Missed On Wall Street On Thursday,116639632,https://image.thefly.com/catalog/201810/img_66.png,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. WBA, DAL, AMAT, PDCO, NFLX, CMCSA, CMCSK, ATUS, BIIB, AXP, LVS, NKE, LULU, KR, ACI, GOOG, GOOGL, AMZN, AAPL, SLB, DWAC, INMD, TSM, CNHI, RLMD, PGR, FAST, DPZ, QDEL, ACCO, ACMR",https://finnhub.io/api/news?id=c32b895e7777f54f266922fe8c655c4bdc7fdb606e15a0e4e6b185c8e98e8373
company,2022-10-12 12:40:00,"Biogen Inc. stock falls Wednesday, still outperforms market",116720797,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 0.16% to $253.67 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=21ce8ec63a64f98d07591a8c1ac58ce550341688ae89bf0624c1e82679cf4380
company,2022-10-12 12:34:04,"Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More",116623437,https://s.yimg.com/uu/api/res/1.2/obPyvmV.XkzkKLrDxW_bcA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5bd570f285e4b6d4e9b1a8c6dc8600e6,BIIB,Yahoo,Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=73bab1444254d34cffd971bf20536fb92f76b93cd54830b806235adbc1cef66c
company,2022-10-12 10:00:02,Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?,116633147,https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9,BIIB,Yahoo,Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=cff4a2158b0755c0641485ab21c2a3c3f43381c36e180780363f31bd61b9562b
company,2022-10-12 08:13:00,Biotech Stocks Well-Positioned For The Fourth Quarter,116608405,https://prudentbiotech.com/wp-content/uploads/2022/10/Yield-and-XBI.jpg,BIIB,TalkMarkets,"The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
",https://finnhub.io/api/news?id=0ad3a9e9b6729c15f64581c61f91c3dec7d060353ccceeada4fb3b51cdb32ab7
company,2022-10-12 05:56:00,Does Biogen's Recent Win Make It a Must-Buy Stock?,116603289,https://s.yimg.com/ny/api/res/1.2/tyRQr3Hkr0.0q7lqstgDBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/9ca11b3fa243107f2eb146e09cf3064f,BIIB,Yahoo,"Shares of Biogen (NASDAQ: BIIB) soared late last month after the company again received positive results around one of its Alzheimer's treatments.  It wasn't Aduhelm this time, but a new promising treatment called lecanemab, which the company is hoping can slow down the disease.  Does the price jump signal a turnaround for Biogen, and is now the time to buy shares of the healthcare company before its value rises even further?",https://finnhub.io/api/news?id=728019ded93859e682e603b801c326735b95c04c92d1497f97f0a7af9d8a79b5
company,2022-10-12 05:29:00,4 Biotech Stocks With Huge Incoming Catalysts,116603290,https://s.yimg.com/ny/api/res/1.2/rjDJOTgYlzJo2PN_Ho0Kdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/640849c7b0ed3c19e85370846f2e6dd8,BIIB,Yahoo,All four of these drugmakers are expecting important FDA approval decisions over the next few months.,https://finnhub.io/api/news?id=9ab433458952f1b87ff198115f881b1211858704683817bc92a1e8962f59e1a4
company,2022-10-12 02:01:00,Fly Intel: After-Hours Movers,116623545,https://image.thefly.com/catalog/202004/img_793.jpg,BIIB,Thefly.com,"QuidelOrtho jumps over 7% after positive Q3 revenue pre-announcement; Applied Materials slips 1% on Q4 guidance cut DCT, GOL, VSCO, QDEL, DWAC, NVRO, AVEO, BMRN, BIIB, AMAT",https://finnhub.io/api/news?id=2ac6ece08bdf587abd546fddea73c76e318e1aa5993f88e776de0192ed3c55a6
company,2022-10-12 00:13:00,Biogen upgraded to Buy from Hold at Stifel,116641780,https://thefly.com/images/meta/streetresearch_upgrade.jpg,BIIB,Thefly.com,"Stifel analyst Paul Matte... BIIB, RHHBY",https://finnhub.io/api/news?id=0f3c5922ffe8216b16fb8a7e6447d18a255fa4fd2237e05aff303ac4c336c59a
company,2022-10-11 17:50:09,Biogen Inc. (BIIB) Stock Moves -0.28%: What You Should Know,116603291,https://s.yimg.com/ny/api/res/1.2/gZA5XMnsr1RRZw6lGNAcdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD05NDA-/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $254.07 in the latest trading session, marking a -0.28% move from the prior day.",https://finnhub.io/api/news?id=e2990f6ad85a3480990b429280b2d84564dfe15aebfea32c9e13679b9a05b621
company,2022-10-11 14:37:58,Jim Cramer goes over the best and worst Q3 performers in the S&P 500,116597911,https://image.cnbcfm.com/api/v1/image/105841883-1554839951795img_1153r.jpg?v=1665527878&w=1920&h=1080,BIIB,CNBC,Cramer said he wouldn't touch this stock with a 10-foot pole.,https://finnhub.io/api/news?id=d7ad0edc9ad43d1af11161a707c96f80f1b62afc2a62a72c1d6989a9c4b9edfd
company,2022-10-11 09:00:21,12 Best Ethical Stocks To Buy Now,116584092,https://s.yimg.com/uu/api/res/1.2/xlrbY_hL8gKYJR0hBfnZzA--~B/aD0yNjc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/76cab0686691ff14bc2c440f0df574d7,BIIB,Yahoo,"In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […]",https://finnhub.io/api/news?id=365d42203164526b78739dcf9e4634aee00a178a8c4bd2f0e452bdba4fd49531
company,2022-10-11 04:30:00,Biotech Stocks Well-Positioned For Fourth Quarter,116583186,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442152/image_1284442152.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Biotechs benefit if a slowdown pushes the longer-term yields lower. Check out why are biotechs relatively well-positioned now.,https://finnhub.io/api/news?id=255eb6cf5283a97253688ac6beb242e0edf169dd589c7c6e2e2a0b083c9b4b0e
company,2022-10-18 13:29:32,An Overview Of Today's Alzheimer's Disease Development Field,116705677,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397344064/image_1397344064.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Alzheimer's is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. Click here to read more.",https://finnhub.io/api/news?id=2ea13da4d842b2fa6cf28fba2db5e8ad12f0493c3b8b6ac2ab991d26ae567ce5
company,2022-10-18 12:40:00,"Biogen Inc. stock rises Tuesday, still underperforms market",116720791,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.27% higher to $270.28 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=caa1101f2ecaa5c29ce39287bef544d8ccb9745db33ca59fa11f6dcf749db6d1
company,2022-10-18 11:50:03,Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension,116709668,https://s.yimg.com/uu/api/res/1.2/HtLR.3pPwvCu5d5IUSCWtQ--~B/aD00OTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,"The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.",https://finnhub.io/api/news?id=38a60d9e82602a893c3d9e5cb8ea5145c9189c56b2b599c6117b16c73aec0845
company,2022-10-18 09:01:55,Roche exec says Biogen Alzheimer's data was reassuring,116697259,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"A Roche executive said on Tuesday that positive trial data on an Alzheimer's disease drug candidate by rival Biogen was encouraging for companies such as Roche also pursing amyloid beta proteins as a drug target.  ""Before that readout there was quite a raging debate, as to whether targeting a amyloid beta does anything whatsoever to clinical signs and symptoms of Alzheimer's. After that data that debate has to take on a different character and it reassures us in the validity of the pathway,"" the head of Roche's pharma unit Bill Anderson said in an analyst call.",https://finnhub.io/api/news?id=227cd8e04d9aa2d36ddac3bc41b124232433192a873e24399849d3215eeefa41
company,2022-10-17 17:50:09,Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know,116688484,https://s.yimg.com/uu/api/res/1.2/I67vygGrP1BjgOjVx.apeA--~B/aD03Mjg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $269.55 in the latest trading session, marking a +1.86% move from the prior day.",https://finnhub.io/api/news?id=632ab606d307db826ed212d26510500f601fbdb27cc010a52fb274f47ef216d3
company,2022-10-17 12:56:15,Biogen: How To Assess Lecanemab's Potential? Invert The Market's Reaction,116687471,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157564919/image_157564919.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Lecanemab's successful Phase 3 clinical trial led to Biogen's stock price jumping by 33% in one day. Read why some option strategies might be worth considering.,https://finnhub.io/api/news?id=058b12656f70e1af96cefe89f61d7c60e4c6c9674015ee33ab6d5cb7bd91c45d
company,2022-10-17 12:40:00,"Biogen Inc. stock rises Monday, still underperforms market",116720792,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.86% to $269.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=8e2e707bbc0ba7bb36fbee2ba9c4f531f14257df42cac652b87e8c895139e327
company,2022-10-17 11:28:34,FDA Pushes Extends Review For Biogen's Amyotrophic Lateral Sclerosis Drug,116690933,https://s.yimg.com/uu/api/res/1.2/2bRKsEtsZ8xsl79NJckE1Q--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/aa6774c950e797ceb5c4bc540a798e24,BIIB,Yahoo,"The FDA extended the review period for Biogen Inc's (NASDAQ: BIIB) experimental Tofersen treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months. Biogen had submitted responses to the FDA's information requests, which the agency said would require additional time for review, and set a new target action date of April 25, 2023. The agency had accepted Biogen's application for the drug, tofersen, under its accelerated approval pathway in July, with an approval decisio",https://finnhub.io/api/news?id=4622fd2864abacc4d8bf194aa225474912ca1530d0df65882fbd220dc966f378
company,2022-10-17 10:49:44,Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate,116690934,https://s.yimg.com/uu/api/res/1.2/mTGWxvbBMAH1Jun8eiCe3w--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/adff88d72d5bba13d1233eb8e1e54514,BIIB,Yahoo,"Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD). The SKYLARK Study, as previously reported, achieved the primary and all key secondary endpoints. Zuranolone 50 mg showed a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to the placebo. In the presentation at the European College o",https://finnhub.io/api/news?id=52f84312e8e24e0f641945e084b18525e318849e31a3d0a724b271918909cf4e
company,2022-10-17 09:04:00,IN BRIEF: Biogen application review period in US extended for tofersen,116729906,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1aa76a4a1873ddb4e3adc45837630a95eab20acf70fecbf476aa0cc659873588
company,2022-10-17 08:14:02,FDA extends review time for Biogen's ALS treatment candidate,116680491,https://s.yimg.com/uu/api/res/1.2/S8SCotpO9m2XQyQUIGU5dw--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BIIB,Yahoo,"Shares of Biogen Inc. gained 1.4% in premarket trading on Monday after telling investors that the Food and Drug Administration extended the review period for its experimental treatment for amyotrophic lateral sclerosis (ALS) by three months. The new decision date is April 25. Biogen's stock is up 10.3% this year, while the S&P 500 is down 24.8%.",https://finnhub.io/api/news?id=b127bace4f30f4d623ce9b0ceb1404ebe0a634730508d23f0f31e4ede3261ffa
company,2022-10-17 07:57:58,U.S. health regulator extends review of Biogen's ALS drug,116688292,https://static.reuters.com/resources/r/?m=02&d=20221017&t=2&i=1611702000&r=LYNXMPEI9G0GM,BIIB,Reuters,"The U.S. Food and Drug Administration has extended the review of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months, the company said on Monday.",https://finnhub.io/api/news?id=ce0627211b5c88b12938e520dbb91fd846e9af06741e66dbe01567c811642946
company,2022-10-17 07:57:56,UPDATE 1-U.S. health regulator extends review of Biogen's ALS drug,116690936,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The U.S. Food and Drug Administration has extended the review of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months, the company said on Monday.  Biogen said it had submitted responses to the FDA's information requests, which the agency said would require additional time for review and set a new target action date of April 25, 2023.  The agency had accepted Biogen's application for the drug, tofersen, under its accelerated approval pathway in July this year, with an approval decision expected by Jan. 25.",https://finnhub.io/api/news?id=6aace81cc606fb8e66973c2b19b9b2b163e876eb7d67705ac03db6f432c06297
company,2022-10-17 07:38:41,U.S. health regulator extends review of Biogen's ALS drug ,116688293,,BIIB,Reuters,Biogen Inc said on Monday the U.S. Food and Drug Administration had extended the review of its experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months.,https://finnhub.io/api/news?id=bf63961d897bbec930e510f921a1fafcbfc07fe85858de3867ecfcd155fb8d9d
company,2022-10-17 07:30:00,Biogen Announces FDA’s 3-Month Extension of Review Period for the New Drug Application for Tofersen,116690937,https://s.yimg.com/uu/api/res/1.2/Usad_0vByWWo5BOAvLTZHg--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for tofersen by three months. Tofersen is an investigational treatment for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The updated Prescription Drug User Fee Act (PDUFA) goal d",https://finnhub.io/api/news?id=bec8b44c09679ddb22aebdeeab4183445607b6fb8acf0f9b00d807122108a8c2
company,2022-10-17 03:49:00,Biogen: FDA Extends Review of Tofersen in Rare Form of ALS >BIIB,116720794,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Colin Kellaher Biogen Inc. on Monday said the U.S. Food and Drug Administration extended its review of its proposed drug for a rare genetic form of...,https://finnhub.io/api/news?id=c37fc555d4af54e52cacb17cf02e97a873560ebe43b7f679bd5211aa63298f52
company,2022-10-16 23:36:00,"Roche's AD drug expected to fall short in trial, says Morgan Stanley",116729488,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Morgan Stanley analyst Ja... MOR, RHHBY, BIIB",https://finnhub.io/api/news?id=151c1152892f78430ad4b62e7eea14fb0b7960cf102a2ff24d44f1e96b0139c0
company,2022-10-21 12:40:00,"Biogen Inc. stock rises Friday, still underperforms market",116791256,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.89% to $267.62 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=49763615f7adbb123517e0aa23570e54e741c19b2087943e5373763a07e9458e
company,2022-10-21 10:35:02,Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect,116776098,https://s.yimg.com/uu/api/res/1.2/m4HB314mWNtMsu4YAqAJlw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d,BIIB,Yahoo,Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.,https://finnhub.io/api/news?id=c9631371c9cb0f87527cfafeeaf80bbfb706d2b857f344f1a9c794b0db9cfe63
company,2022-10-21 09:37:00,3 Alzheimer's Therapy Stocks to Invest in,116773580,,BIIB,Yahoo,"Alzheimer's therapies are big news lately.  The disease is the leading cause of dementia and memory loss.  The Alzheimer's Association estimates that 6.5 million Americans 65 and older are living with Alzheimer's dementia (AD) and by 2050, the number of people 65 and older with AD is projected to reach 12.7 million.",https://finnhub.io/api/news?id=22e17af989872971d569e7167cf96af0e37ba214117901c59ae8be40241b0c7e
company,2022-10-20 12:40:00,Biogen Inc. stock underperforms Thursday when compared to competitors,116780006,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 0.68% to $262.65 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=098fa83c4bcdd4f5f73a9dc230fceefc95c13afe9c74d783b8cb57d4f46eed93
company,2022-10-20 11:28:03,"Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More",116746227,https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96,BIIB,Yahoo,Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=1600d9cefa361e8fe8099322e3d8a7bb0f61b4cf35fcc04aa0965445294d7089
company,2022-10-20 10:07:00,Where Will Biogen Be in 5 Years?,116743179,,BIIB,Yahoo,"Shares of Biogen (NASDAQ: BIIB) have been volatile in the past few years, largely hinging on success of the company's Alzheimer's treatments.  Sales in recent years have been declining, and the loss of patent protection for top-selling multiple sclerosis treatment Tecfidera is only exacerbating those concerns.  What will the company's business look like over the next five years, and is it promising enough for investors to buy shares of Biogen today?",https://finnhub.io/api/news?id=61105b7302972f1bbb45b3924cf4b1b341cadc8eec8d71b1f1c80ab7a2ab665f
company,2022-10-20 07:13:00,Top 5 3rd Quarter Trades of Ri - GuruFocus.com,116747366,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=a31de5239270ed9bad269aa139a30ff0024a24c594927586c87d1a6f3db23f67
company,2022-10-20 07:13:00,"Empirical Asset Management, LL - GuruFocus.com",116747986,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=b81e3ac67cad3214d8a269129f7a50f28ca4e68728735f904f050d384b5f7689
company,2022-10-20 00:31:33,HQH: A Dividend Paymaster That Fails To Register Price Growth,116736568,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363842522/image_1363842522.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy.,https://finnhub.io/api/news?id=44e3ceaa6735a44d2ae48e01c7a49530361cf5019b93c83838fca7214c20dbc4
company,2022-10-19 12:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",116780007,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 2.16% to $264.45 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=2f089fa60ac2c84d9df749edd4c90a9d26c57a854e27353f1d5c6e52d47b8654
company,2022-10-19 09:11:14,15 Best Drug Stocks to Buy Now,116714405,https://s.yimg.com/uu/api/res/1.2/5pauLosoN1w4T3nTn6aJWQ--~B/aD01MTI7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d7b54ab6c172424f8eb29273c1277201,BIIB,Yahoo,"In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […]",https://finnhub.io/api/news?id=535617df1d1e377855a29827c2ac087d4bc17c9f9d9e2e59c0e0268518a28be2
company,2022-10-18 21:30:00,Biogen and 10 Other Healthcare Stocks Thriving in This Bear Market,116717576,https://images.barrons.com/im-646794/social,BIIB,MarketWatch,"Of the 56 stocks in the S&P 500 that have seen their share prices climb at least 10% since Jan. 3, 11 are healthcare stocks, a Barron's screen found.",https://finnhub.io/api/news?id=50a85e508a1c05cbd2584647931cefb92229bfec998f0bfed400dbfe0ea76bdf
company,2022-10-26 12:40:00,"Biogen Inc. stock rises Wednesday, outperforms market",116888627,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 2.51% to $280.43 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=43445f260d13fa3d614fea29fd432db074148aef9d440300e6ef6b28b1534777
company,2022-10-26 12:07:04,"Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study Update",116840345,https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093,BIIB,Yahoo,Earnings updates from BIIB and BMY are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=4e2c9104ba5364a8ef1835059972a1826c07e302b46a9a889992b716afb073ad
company,2022-10-26 09:00:49,"Stocks making the biggest moves midday: Harley-Davidson, Visa, Microsoft, Biogen and more ",116840361,https://image.cnbcfm.com/api/v1/image/106870580-1618870020225-har.jpg?v=1666803649&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=15ad1e5be5a9a6c5f5b7ff7d40e7011b0c8c014f70a5098eef491ae4e4019a0e
company,2022-10-25 14:26:00,Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA,116822699,https://s.yimg.com/ny/api/res/1.2/ma9E4NUiIjeuC8dI0049ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/marketwatch.com/62366a6f9856d91d4ed66e15a3ab0259,BIIB,Yahoo,"The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial.",https://finnhub.io/api/news?id=911cc6d7b0f5ab620efafe70d44968aeedc265ad3219555a33d3d6b6f01bbffb
company,2022-10-26 06:05:00,Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS,116947204,https://s.yimg.com/uu/api/res/1.2/Usad_0vByWWo5BOAvLTZHg--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Data demonstrate potential of Manual Dexterity Test and Konectom™ smartphone-based technology in measuring MS disease progressionRetrospective analysis applying machine learning, artificial intelligence and radiomics identifies brain imaging patterns that may further the understanding of MS disease and lesion heterogeneityTwo-stage precision medicine models leveraging real-world data from MS PATHS network provide new insights on enabling more individualized predictions of treatment effect CAMBRI",https://finnhub.io/api/news?id=08660656b511e59b7e3a0c88644e89b01cb70258f93c33f52bb3aa7084dd1d2f
company,2022-10-26 06:02:00,New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS,116947205,https://s.yimg.com/uu/api/res/1.2/Usad_0vByWWo5BOAvLTZHg--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY® (diroximel fumarate) consistent with previous assessmentsPatient-reported outcomes favored TYSABRI® (natalizumab) compared to Ocrevus® (ocrelizumab); new insights on subcutaneous administration one year after approval in GermanyData on interferon exposure during pregnancy showed that treatment with PLEGRIDY® (peginterferon beta-1a) or AVONEX® (in,https://finnhub.io/api/news?id=005cdff21e05f11a1d8cdeb3713071309fa036887bf543e77fb620cc761248e2
company,2022-10-26 05:52:00,Is Biogen a Buy After It Boosted Guidance?,116839900,https://s.yimg.com/ny/api/res/1.2/6GIXjXx59ogpU5mum4cAYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/d7d271f0802405e993d2cbd6c0a3b374,BIIB,Yahoo,"The good news keeps coming in for Biogen (NASDAQ: BIIB). On Tuesday, the drugmaker reported its third-quarter results, and for the first time in a while, investors found something in one of its earnings updates to cheer about.",https://finnhub.io/api/news?id=266813cb17eac34695db52fdb8adef17f10e6ece6d8d0c064ffc41a54289a8bd
company,2022-10-26 03:45:00,Atlantic Equities Sticks to Its Hold Rating for Biogen (BIIB),116849929,,BIIB,TipRanks,"In a report released today, Steve Chesney from Atlantic Equities maintained a Hold rating on Biogen (BIIB &#8211; Research Report), with a price target of $220.00. ...",https://finnhub.io/api/news?id=081eae1f0d15d15c6082fcfc4accc315cc9fd10492855230886f87790b590540
company,2022-10-26 03:45:00,"Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Timber Pharmaceuticals (TMBR)",116849927,,BIIB,TipRanks,There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w...,https://finnhub.io/api/news?id=9246c462011034205d06f85a1cf54d4272c16e2111025d465f8726b9b6a7e8d9
company,2022-10-26 03:24:00,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Taysha Gene Therapies (TSHA),116849930,,BIIB,TipRanks,There&#8217;s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (<span class='tr-stock-ticker' style='color:blue; font-w...,https://finnhub.io/api/news?id=be4dc9eec1e49d7673b73a575fb30e7942d8b242a12ae2ce4fe4cdfa87fe0ce0
company,2022-10-26 03:19:00,Biogen price target raised to $325 from $321 at Morgan Stanley,116849932,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Morgan Stanley analyst Ma... BIIB,https://finnhub.io/api/news?id=6d97017ba07b90bf573f595017a560fc4297b3266dcc2dd99964cb5b3e42001c
company,2022-10-26 02:38:00,Biogen price target raised to $300 from $270 at Cowen,116849934,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Cowen analyst Phil Nadeau... BIIB,https://finnhub.io/api/news?id=8facc8a7fdf77f1a99ca35b8fa1ef7a3217c5bb29a5182ad3f6ed3759736adf3
company,2022-10-26 02:22:00,Biogen price target raised to $325 from $285 at Canaccord,116849936,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Canaccord analyst Sumant ... BIIB,https://finnhub.io/api/news?id=96d638670ac00202a7bc9d5d4f7ac05444d4f64e6775751399cebcfa59f77701
company,2022-10-26 01:39:00,Biogen price target raised to $331 from $310 at RBC Capital,116849940,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,RBC Capital analyst Brian... BIIB,https://finnhub.io/api/news?id=7743bed1738140f4754c63a336ead32b490e824dcf2a9a287853e203585295fb
company,2022-10-26 01:09:00,Biogen price target raised to $325 from $240 at H.C. Wainwright,116849942,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,H.C. Wainwright analyst A... BIIB,https://finnhub.io/api/news?id=7e802ef4579e543f5762585e34f0a72d269ebfb2e7c66c841e2db0373c4895b3
company,2022-10-26 01:06:00,Needham Releases a Buy Rating on Biogen (BIIB),116849943,,BIIB,TipRanks,"In a report released yesterday, Ami Fadia from Needham assigned a Buy rating to Biogen (BIIB &#8211; Research Report), with a price target of $300.00. The company&#...",https://finnhub.io/api/news?id=13830dd9d6bda30caf20f36ec72760a84abb3be9e1c560bade73bbe81a5aa635
company,2022-10-25 16:28:25,"Nasdaq And Small Caps Power Stock Market Gains; Medpace, GM And Coke Earnings Pace Stocks",116825392,https://s.yimg.com/uu/api/res/1.2/lWvzFl3ESOZ2f8ElL44fDw--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6968e5629802ea340f49654a6a333a2e,BIIB,Yahoo,"Stock market gains despite slide in consumer confidence General Motors, Coca-Cola, Medpace and others posted earnings bumps.",https://finnhub.io/api/news?id=b8de10e9cb822f85624d49644c092f6c477c3855d73cbcd905814c5933c98299
company,2022-10-25 09:00:40,Biogen Skids Despite Beat-And-Raise Quarter As Pressure Builds In Alzheimer's Market,116819493,https://s.yimg.com/uu/api/res/1.2/v0L.vSpXNHZMNBvSu3fuVg--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c1625f1f8b75121675b6ada9243ba22d,BIIB,Yahoo,Biogen stock fell Tuesday despite a beat-and-raise quarter and continued enthusiasm for its experimental Alzheimer's treatment.,https://finnhub.io/api/news?id=7ae644ba9dc623e5fe04f14719eb678b3745e230f3f848704a39fd6cab402cb6
company,2022-10-25 15:40:00,Biogen Lifts Profit Estimates as Investors Look to Alzheimer’s Drug,116834222,https://s.yimg.com/ny/api/res/1.2/1J690ZQE87B.uLQHts7JLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/3793624146f3838a8b88645c0d9cc746,BIIB,Yahoo,The biotech raised its earnings per share estimate to $16.50 to $17.15 from the previously estimated $15.25 to $16.75 range.,https://finnhub.io/api/news?id=f10a6a6e1ac7542a1ba1be6d783b7c3371098c2ab2e6c446194c0120cb88d814
company,2022-10-25 13:59:05,"Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook",116833511,https://s.yimg.com/uu/api/res/1.2/HtLR.3pPwvCu5d5IUSCWtQ--~B/aD00OTY7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.,https://finnhub.io/api/news?id=f4548884c2394049269f8b61a26161856df8c04136bd0c93a3934d6167ab068b
company,2022-10-25 12:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,116888629,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.39% to $273.56 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=eb568547825eabe6614c966296035933693795a0d9d644e3dd500965d0d1d1aa
company,2022-10-25 12:23:00,NEW YORK MARKET CLOSE: Well-received earnings paint Wall Street green,116826097,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9f22e56c8d4be397aab05fc25e8246ae1701a8eef333386bede776a949c49f45
company,2022-10-25 12:00:16,Biogen (BIIB) Q3 2022 Earnings Call Transcript,116819490,https://s.yimg.com/uu/api/res/1.2/dJCmfHkRZ5yjepfdwTkzOA--~B/aD00NTA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/9423776c936289a42895d326bcfb918f,BIIB,Yahoo,"At this time, I'd like to welcome everyone to the Biogen third quarter 2022 earnings call and business update.  As a reminder, during the Q&A portion of the call, we kindly ask that you limit yourself to one question.",https://finnhub.io/api/news?id=e9d0161920c80e51557e7f2ac9b94a104e87f001b6e8837cf2a07bef6123bc53
company,2022-10-25 11:44:45,Biogen paints an optimistic picture ahead of critical FDA decision,116819491,https://s.yimg.com/ny/api/res/1.2/3P0f89UtzxkdZ7ULV_7w5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/bizjournals.com/05eb0e16459d375c63114baf8a831ad1,BIIB,Yahoo,"Biogen Inc. on Tuesday laid out an optimistic picture for analysts and investors, even as questions remain around its new Alzheimer's drug and its leadership team.",https://finnhub.io/api/news?id=98427040daf3eb90c78f29e1131b6cf06c5fa02148cc0b27aebb2d095e57cfce
company,2022-10-25 11:08:11,Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition,116834225,https://s.yimg.com/uu/api/res/1.2/Y99xEhMxIVVBIJYm96Tu3A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/b0f4e786940a9e99066f985694422e36,BIIB,Yahoo,"Biogen Inc (NASDAQ: BIIB) posted Q3 sales of $2.51 billion, beating the consensus of $2.47 billion, down 10% Y/Y and 8% at constant currency (CC). Multiple sclerosis revenue, including royalties on sales of Ocrevus, of $1.62 billion decreased by 11% (down 9% CC). Spinraza's revenue of $431 million decreased by 3% at actual currency (increased by 2% at CC). Aduhelm generated sales of $1.6 million in Q3, compared to $0.3 million a year ago. Biosimilars' revenue of $188 million decreased by 7% vers",https://finnhub.io/api/news?id=71d53ac94d115cc3bd25346923d339687f9e8a78d9444af0ffa67d4aa225febd
company,2022-10-25 10:42:42,Biogen confident in Alzheimer's drug ahead of rivals' data,116820621,https://static.reuters.com/resources/r/?m=02&d=20221025&t=2&i=1612409589&r=LYNXMPEI9O0FA,BIIB,Reuters,Biogen Inc on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co and Roche.,https://finnhub.io/api/news?id=2e8559ea54f7fc8e7202406f6c692d1750737d841c4274173ed6cebad7c2cb5c
company,2022-10-25 10:26:00,Biogen and Eisai make plans to take another Alzheimer's drug to the FDA next year,116886129,https://images.mktw.net/im-651471/social,BIIB,MarketWatch,"The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial.",https://finnhub.io/api/news?id=c03808550caf99548a70783888e193b7a9d6a3c934a060a7f508fb46ce5ecf9d
company,2022-10-25 08:25:12,Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates,116819494,https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248,BIIB,Yahoo,"Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=4cda1e3d42e668cb6be24e8a459238e281f66e26d7b59345d5f9b60f153cbbca
company,2022-10-25 07:36:33,Biogen beats revenue expectations in the third quarter,116815243,,BIIB,Yahoo,"Biogen's stock was up 0.7% in premarket trading on Tuesday after it beat expectations for earnings and revenue in the third quarter of the year. The company had earnings of $1.1 billion, or $7.84 per share, in the third quarter of 2022, compared with $2.5 billion, or $2.22 per share, in the same quarter a year ago. Adjusted earnings per share were $4.77, against a FactSet consensus of $4.13. Biogen said revenue was $2.5 billion for the quarter, down from $2.7 billion in the same three months of",https://finnhub.io/api/news?id=e2cf98b73090b95d6d82ca13774d48b315e45d7dd3f9be24338eb4bf45a37bb2
company,2022-10-25 07:17:59,UPDATE 3-Biogen confident in Alzheimer's drug ahead of rivals' data,116819496,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen Inc on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co and Roche.  The drug, lecanemab was shown to slow the progress of the disease by 27% in a trial last month, and additional data is expected next month.  Lecanemab and experimental drugs for the mind-wasting disease from Lilly and Roche belong to a class of treatments that reduces amyloid beta proteins in the brain believed to be an underlying cause of Alzheimer's.",https://finnhub.io/api/news?id=b366e8afe504c1a57e4f6af5ae4d79e1fdcacc08f74277ee7b3e418ddb4711c9
company,2022-10-25 07:09:43,Biogen sales fall 9.7% on Tecifdera competition,116820622,,BIIB,Reuters,"Biogen Inc reported a 9.7% drop in quarterly sales on Tuesday due to rising competition for its blockbuster multiple sclerosis drug Tecfidera, while investors awaited more data on its new Alzheimer's disease drug next month.",https://finnhub.io/api/news?id=98a63a3ceade29b6536080eae76146e394cdd02142a63b9e62abc0078341adca
company,2022-10-25 05:57:03,Biogen Inc. (BIIB) Q3 2022 Earnings Call Transcript,116816520,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q3 2022 Earnings Conference Call October 25, 2022 08:00 AM ET Company Participants Mike Hencke - Head, Investor Relations Michel Vounatsos - Chief Executive...",https://finnhub.io/api/news?id=307a52440c1b814374735005f5d13d64636bab7985a499632c1109202c716d06
company,2022-10-25 05:05:00,Biogen nudges revenue outlook higher despite third-quarter slip,116819623,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=18ef9b89de723af6b7467e47d9621fa0e369b5320d5261d0028401da3f77ae07
company,2022-10-25 04:56:00,Biogen tops 3Q expectations as cost cutting continues,116819625,,BIIB,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=079f7304a96eb0fcb1dd280756df09db47957bfc49c477e278ac895b2b5ad0e8
company,2022-10-25 03:57:00,Fly Intel: Pre-market Movers,116819626,https://image.thefly.com/catalog/202004/img_793.jpg,BIIB,Thefly.com,"General Motors rises, JetBlue falls following quarterly earnings MULN, TSHA, WEBR, KO, UPS, GE, RTX, GM, JBLU, MMM, ITW, CNC, BIIB, ST",https://finnhub.io/api/news?id=c18fd55b6f88c99ac86b95d1044fa8eb8b5159741f60978ca47a3a4bfed0c4e7
company,2022-10-25 03:55:34,Biogen Inc. 2022 Q3 - Results - Earnings Call Presentation,116814529,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,The following slide deck was published by Biogen Inc.,https://finnhub.io/api/news?id=eacd6d9b99a7f6f37294dad7b555e15b4ce5c852c4002c7ad06fca8b5f31d3df
company,2022-10-25 02:16:00,"Biogen raises FY22 EPS view to $16.50-$17.15, consensus $16.49",116819628,https://thefly.com/images/meta/earnings.jpg,BIIB,Thefly.com,Raises FY22 non-GAAP EPS ... BIIB,https://finnhub.io/api/news?id=ec777cf0de2b60c975cf47456645824647e9d761a07ce9f23eed0fdf12bde520
company,2022-10-25 02:14:00,"Biogen reports Q3 adjusted EPS $4.77, consensus $4.15",116819630,https://thefly.com/images/meta/earnings.jpg,BIIB,Thefly.com,"Reports Q revenue $2.51B,... BIIB",https://finnhub.io/api/news?id=356c94e11a16a35f90e735b30c853a62293c591c86bb8fada61269d4975d7971
company,2022-10-24 23:30:00,What You Missed On Wall Street On Tuesday,116825295,https://image.thefly.com/catalog/201810/img_66.png,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. KO, GE, GM, WBD, ADDYY, GPS, ROST, ANET, PLNT, HRT, UPST, TM, DWAC, INTC, TWTR, UL, WEBR, MEDP, CGC, CCK, BRO, PYPL, AMZN, MMM, BIIB, XRX, UPS, AAN",https://finnhub.io/api/news?id=058e32c9fc2a09e225535d8f31da5519d316c3dd71a2790d76479a7c90a0c65f
company,2022-10-21 10:38:16,"US Earnings to Watch This Week: Apple, Microsoft, Boeing, Exxon, Biogen",116802912,https://s.yimg.com/ny/api/res/1.2/CVKdxK0hgZHst1Eiq2gRVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_technology_68/6dda6af519b2ce968d1a6825df04f9aa,BIIB,Yahoo,"(Bloomberg) -- Schlumberger’s rosy report Friday -- including its best profit in seven years and a boost to its full-year guidance -- supports expectations for oil giants Exxon and Chevron to continue their earnings expansion streak when they deliver results at the end of the week. Meanwhile, the technology megacap companies reporting this week will look to shake off souring sentiment on digital advertising rates, after Snap’s slowest quarterly sales growth triggered a sell off that wiped out $3",https://finnhub.io/api/news?id=9332a15e55ba50471ec4838b59aeeb73a73ac5eb13d7b37381dfb6152666dc4c
company,2022-10-24 07:59:41,"With 86% ownership of the shares, Biogen Inc. (NASDAQ:BIIB) is heavily dominated by institutional owners",116802421,https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its...",https://finnhub.io/api/news?id=f3af95d7deb3f00a4b75edbe0a97223f774681699f03777f8177f9450efd8dfa
company,2022-10-24 05:45:00,Three things investors will be looking for in Biogen's Q3 earnings,116802422,https://s.yimg.com/ny/api/res/1.2/T2zcvuIfKZuWMxpvJ0aMpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/a145bac4656f48a6bf2a6c8424389b65,BIIB,Yahoo,The drugmaker will again face analysts on Tuesday amid cautious hope for its neurodegenerative disease drugs and an ongoing CEO search. Here's what to watch for.,https://finnhub.io/api/news?id=a764ab1a380b1f2a60f042f37a9d8ea9c5c1a33326b772b394486d51483a9ac5
company,2022-10-29 15:05:00,Patient Death in Alzheimer's Study May Limit Drug's Reach,116875876,https://s.yimg.com/ny/api/res/1.2/_.0xTM4._CP.we.CzTdqWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/d99b4a0c1b9a12373972785bcb1668ca,BIIB,Yahoo,Brain swelling and inflammation is a common side effect among plaque-clearing drugs. It may make some patients ineligible for treatment.,https://finnhub.io/api/news?id=9f150118584c38c2b748975a3fcc73ed24b17e279f7651ebf4195982abaf9233
company,2022-10-29 05:30:00,Don't Get Used to Lower Medicare Part B Premiums -- Here's Why,116875877,https://s.yimg.com/ny/api/res/1.2/4gAfeYSk8907XKfby23rWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03NDA-/https://media.zenfs.com/en/motleyfool.com/952402b0847fb722be573d09f6faf4d1,BIIB,Yahoo,Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future.,https://finnhub.io/api/news?id=3b3700c9308b2404e17be5a9bab9a9dc32e6121e5b0896affe39569736732458
company,2022-10-28 15:29:00,Volunteer Dies Testing Eisai-Biogen Alzheimer’s Drug During Study,116875878,https://s.yimg.com/ny/api/res/1.2/TrNcQl31SoRaK2wbuMpKFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/ba4624f3950009abc5d5b72be3bf84a1,BIIB,Yahoo,"The subject experienced swelling and bleeding in the brain, an Eisai spokeswoman said. It wasn’t clear if the death was directly caused by the drug lecanemab in a clinical trial.",https://finnhub.io/api/news?id=167c5449af19cb0a5ca6ab2be3c9f3ce20b965fee6b8650c996b173ce789ac9f
company,2022-10-28 12:40:00,"Biogen Inc. stock rises Friday, still underperforms market",116888625,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 2.31% to $284.29 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=933b8d2d439cb4f737a06802752c8fd075e01679ae8e312d00379a4a5e4f16aa
company,2022-10-28 00:17:00,Parnassus Fund Comments on Bio - GuruFocus.com,116902072,https://static.gurufocus.com/logos/0C00000KPI.png,BIIB,GuruFocus,GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Guru stock highlight,https://finnhub.io/api/news?id=0489252a663817bb3bbbb0400f8788c1c7219086a6c11a7e8e139c4867fc2706
company,2022-10-28 00:01:00,Jerome Dodson's Parnassus Ende - GuruFocus.com,116857256,https://static.gurufocus.com/photos/others/shareholder_letter_typing_investor_guru.jpg,BIIB,GuruFocus,GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Discussion of markets and holdings,https://finnhub.io/api/news?id=101a2ee11ba6da2046c23e4aace86f331fe5413f1ccf3ea848bfc8848ba854e3
company,2022-10-27 12:40:00,"Biogen Inc. stock falls Thursday, underperforms market",116888626,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.91% to $277.87 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=0ccb24df67f775e1307ae4151fad307c12933cbf2d29da85e3c2c30bcf2e5141
company,2022-10-27 03:14:00,GLOBAL BROKER RATINGS: Kepler cuts Adidas to 'hold' from 'buy',116846730,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8edeae97e0ac300b70f714a3267d813865b7fcefc8ba5fb188e9ae660f474da4
company,2022-10-26 21:08:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Teladoc (TDOC) and Taysha Gene Therapies (TSHA)",116849242,,BIIB,TipRanks,Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (<a href...,https://finnhub.io/api/news?id=55e8e6add0657e87a09963dd39f0d5798dcc067dfcfb019e1d3b3e3ce08ae9a0
company,2022-11-03 12:40:00,Biogen Inc. stock outperforms competitors on strong trading day,116975673,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.68% higher to $280.25 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=626a4af4d6c21048ecd2fc7a6ac409bd82ad3d3bef85c6ce2c14d07d8643ee4c
company,2022-11-03 09:30:00,Is Biogen Poised for a Bull Run?,116947197,,BIIB,Yahoo,"Biogen (NASDAQ: BIIB) has been a volatile investment in recent years and its outlook still remains cloudy at best.  Meanwhile, its Alzheimer's treatment Aduhelm went from a hero to a zero within a span of just months as questions were raised about its efficacy.  Now, however, there's renewed hope around Biogen.",https://finnhub.io/api/news?id=ee62b3d5d743a7d429f70f19124b7ecfd7ddeed4612009bf8a6d98847469b89a
company,2022-11-02 12:40:00,Biogen Inc. stock outperforms competitors despite losses on the day,116928495,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.60% to $278.37 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=d771c0a584a616bafe90f319f93b89a9462491464e8d30b85ce33b2c1f34379c
company,2022-11-02 11:27:40,Trading Ideas On The Upcoming CTAD 2022 Conference,116917061,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357752804/image_1357752804.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"The Clinical Trials on Alzheimerâs Conference will take place from November 29, 2022 to December 2, 2022. Click to read my analysis ahead of the conference.",https://finnhub.io/api/news?id=dbec267743595c5311fa00198d9256163419a43804fdb8ad7bbfef9e44511ecb
company,2022-11-01 23:01:00,Top 5 3rd Quarter Trades of Jo - GuruFocus.com,116918719,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=425e9911e70ec6c211da507bfa16ca75f848d1a34b7d48c14ea0e708357d3c96
company,2022-11-01 12:40:00,"Biogen Inc. stock falls Tuesday, underperforms market",116888623,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.20% to $280.04 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=f74a3b9aed54e56f9ff929d57f1d0c183478c390af7c3936435afccdf5990ebd
company,2022-11-01 03:10:00,ClearBridge All Cap Growth Strategy Q3 2022 Portfolio Manager Commentary,116879289,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/500619014/image_500619014.jpg?io=getty-c-w750,BIIB,SeekingAlpha,The ClearBridge All Cap Growth Strategy performed in line with its Russell 3000 Growth Index benchmark in the Q3 2022. Click here to read the full fund letter.,https://finnhub.io/api/news?id=496bfc2fd011a06400545cceb35649d2e42823d3810db7af8ad7745aa0aa977f
company,2022-11-01 01:37:00,Biogen price target raised to $325 from $270 at Mizuho,116902070,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,Mizuho analyst Salim Syed... BIIB,https://finnhub.io/api/news?id=d3b4af7cc87e2709f502d646b539c82888eaa732215034d84f9d9b6b7cc3c513
company,2022-10-31 20:37:31,Biogen: Second Time's A Charm,116875473,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367780024/image_1367780024.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Biogen appears set to obtain approval of a second Alzheimer's drug. Read why any failure to obtain drug approval or payment would send BIIB likely to new lows.,https://finnhub.io/api/news?id=f2cf0d823a7700a0af82fefa7e6e091fd4c3883d08c3764edfa5f4c107274804
company,2022-10-31 19:35:56,Deal Activity Could Jumpstart Biotechnology,116874960,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Biotechnology failed to ride the tailwinds of COVID vaccine development. Despite poor sentiment toward biotech, see why we see reasons for optimism.",https://finnhub.io/api/news?id=35c31a1df9e45ee8c796981d6bea436e904ef7d4cd8951122da739d4b55ca020
company,2022-10-31 18:05:00,ClearBridge Value Equity Strategy Q3 2022 Portfolio Manager Commentary,116874175,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277592662/image_1277592662.jpg?io=getty-c-w750,BIIB,SeekingAlpha,The ClearBridge Value Equity Strategy outperformed its Russell 1000 Value Index during the third quarter 2022. Click here to read the full fund letter.,https://finnhub.io/api/news?id=898940cf85fd8010c1b078beddad4858480d06affef381c50180764ff3749e4d
company,2022-10-31 12:40:00,"Biogen Inc. stock falls Monday, still outperforms market",116888624,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.30% to $283.44 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=e4d62f57d598b7edc1e13d6692c7acd0e466664a3eb4b4b7fb737e7af70174cc
company,2022-10-31 10:51:27,Biogen: Super-Strong Momentum In A Defensive Sector,116872770,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/164478117/image_164478117.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock.",https://finnhub.io/api/news?id=02cc49fce4d5cfc67af2c78349a703259b473657c3c0dfc24fa85d4c927866f4
company,2022-11-07 11:40:04,BIIB vs. RGEN: Which Stock Is the Better Value Option?,117002557,https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f,BIIB,Yahoo,BIIB vs. RGEN: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=8951586a096b27c7a0b8926c5bce6749e81a3f6aae07180bbe74897fb9d1a920
company,2022-11-07 11:40:00,"Biogen Inc. stock rises Monday, outperforms market",117038614,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.99% higher to $284.62 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=bae6b4b97d0305bc3543707c1fa9bb5cc38865a7c0481e1b28f249eab51f3b58
company,2022-11-06 21:19:00,"Biogen weighing new CEO options after talks with J&J exec hit impasse, STAT says",116997478,https://thefly.com/images/meta/periodicals.jpg,BIIB,Thefly.com,"Biogen (BIIB) is consider... BIIB, JNJ",https://finnhub.io/api/news?id=026d82cd9f0d1d7c42de96dcdda822e5a9d5ca704f21d84303ebf9f817711994
company,2022-11-05 07:01:00,Top 5 3rd Quarter Trades of Re - GuruFocus.com,116987233,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=cf83168a9a2f1054089cb78e0769a88f66283cb8a395dfed04ba2201ad767af4
company,2022-11-04 12:40:00,"Biogen Inc. stock rises Friday, still underperforms market",116975672,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.56% higher to $281.82 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=ebc23ef8744ac68d0e89ccdf24758a9df4aad38277927a3ed290819ecf9940a7
company,2022-11-11 11:40:00,Biogen Inc. stock outperforms competitors despite losses on the day,117128081,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.43% to $289.45 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=f13a6c9648ede36709327430a0edd1fc1a17e00c6e0f5ea2a232116baa751453
company,2022-11-11 06:21:43,Here are three things to know about Biogen's new CEO,117109463,,BIIB,Yahoo,"Here's a few things to know about Christopher Viehbacher, the former Sanofi CEO who will soon step into the corner office at Biogen.",https://finnhub.io/api/news?id=06de650b12b78905e85a55ff7835b3e70fab26704587eefe96eaa4a676058352
company,2022-11-10 22:33:00,Why Are Healthcare Stocks Down Today?,117118744,https://investorplace.com/wp-content/uploads/2019/08/healthcare1600d.jpg,BIIB,InvestorPlace,Healthcare stocks are falling after a false tweet from a Twitter account impersonating Eli Lilly. Here's what this news means for investors.,https://finnhub.io/api/news?id=4aed3dcc2a5c31916ed718740e9e02357c0df1316bc824acec1d46e904cf5986
company,2022-11-10 12:57:15,"Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles",117076052,https://media.zenfs.com/en/ibd.com/9412ff55f8137e25eeecaa7e447fd2ad,BIIB,Yahoo,Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.,https://finnhub.io/api/news?id=c2cc2a73d532c81b0bbc4f57ced527ca7a75e623b8951e24f77226c37dba9387
company,2022-11-10 11:06:00,Biogen Names Christopher Viehbacher New CEO,117067830,https://media.zenfs.com/en/wsj.com/a8fac1f423522701c257410f13766c47,BIIB,Yahoo,The veteran pharmaceutical executive takes charge after the failed launch of Biogen’s once-promising Alzheimer’s disease drug Aduhelm.,https://finnhub.io/api/news?id=e399211a189fd6d444ae33ae6e3baea62e8c30a554c98dfbc9c4df7640be4f1e
company,2022-11-10 11:48:04,"Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up",117076056,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,BIIB,Yahoo,Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.,https://finnhub.io/api/news?id=4bad832a9737c82a353ab11ee8908807ad968e66781981ad264a64a4d7ec1874
company,2022-11-10 11:40:00,"Biogen Inc. stock rises Thursday, still underperforms market",117128082,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 2.97% to $290.70 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=14b256af9bedf18b12ad5dfcca2367c6ad6484f99a9c9a61986b8b32cf12118d
company,2022-11-10 11:34:00,Biogen Taps a New CEO. He Faces a Tough Road After Alzheimer’s Drug Failure.,117076058,https://s.yimg.com/ny/api/res/1.2/E1dQfvmyrZqIN6H3o25A9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/43fe485de581201aa4cf0849327aac33,BIIB,Yahoo,"Biogen's new CEO is Christopher Viehbacher, former head of French pharma giant Sanofi. Biogen faces challenges after the commercial failure of Alzheimer’s disease therapy Aduhelm.",https://finnhub.io/api/news?id=1daf37d4b0c889eb8d50e10155e30d1f3769fe65117df77a636c47e0d3d50cee
company,2022-11-10 09:36:38,Biogen hires former Sanofi head Viehbacher as CEO,117069987,https://static.reuters.com/resources/r/?m=02&d=20221110&t=2&i=1613934079&r=LYNXMPEIA90JP,BIIB,Reuters,"Biogen Inc on Thursday tapped former Sanofi boss Christopher Viehbacher as its new chief executive, betting on an industry veteran to help the U.S. drugmaker put behind it a series of setbacks for Alzheimer's drug Aduhelm.",https://finnhub.io/api/news?id=7ac74174e04806a1d609d7fa21550b9c3fb23d0fd71aeed7129306c16a765269
company,2022-11-10 09:20:54,Biogen announces new CEO,117076059,https://media.zenfs.com/en/bizjournals.com/a2d6b918a6765481b10ed9f480a23f54,BIIB,Yahoo,"Biogen Inc. has finally announced a new CEO, six months after Michel Vounatsos said he would be stepping down.",https://finnhub.io/api/news?id=70df1a47fb3cd2efc1d39406568cee0858fd738de5b4006fb650a0fe32663ecc
company,2022-11-10 08:08:27,"Biogen names former Sanofi chief as new CEO, shares rise",117067834,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BIIB,Yahoo,"Biogen Inc. stock rose 1% in premarket trades on Thursday after Christopher A. Viehbacher was named president and chief executive officer and a member of the board, effective Nov. 14. Viehbacher succeeds CEO Michel Vounatsos, who has led the company since 2017. Biogen Chairman Stelios Papadopoulos said Viehbacher's innovation and understanding of the complexities of the pharma business enabled him to turn around Sanfoi when he was CEO and leave it a much better company. Vounatsos will be leaving",https://finnhub.io/api/news?id=c8ccaa70191a380ca35cdbd17aa506f369bf94b9a10fe84f572f7281cb7cd6e5
company,2022-11-10 07:38:51,UPDATE 2-Biogen names industry veteran Christopher Viehbacher as CEO,117076064,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen Inc on Thursday tapped pharmaceutical industry veteran Christopher Viehbacher as its new chief executive, after a months-long search for a successor to Michel Vounatsos.  The appointment comes at a crucial time for the U.S. drugmaker as it grapples with intense competition for top-selling drugs and a rocky launch of its highly anticipated Alzheimer's disease drug Aduhelm.  Investors and analysts are now pinning hopes on the second Alzheimer's drug the company is developing with Japan's Eisai Co Ltd after it slowed the progress of the memory-robbing disease by 27% in a trial.",https://finnhub.io/api/news?id=53dbb95007201586661d8992f9edbea4ea84b74c3b3e2a47b34c9a445a23aa44
company,2022-11-10 07:30:00,Biogen Names Christopher Viehbacher President and Chief Executive Officer,117076068,https://s.yimg.com/ny/api/res/1.2/Z6J2nGELg_muIecxxPDwVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xODAw/https://media.zenfs.com/en/globenewswire.com/f075034f616fa045155c348651140acf,BIIB,Yahoo,"Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies Christopher A. Viehbacher Christopher A. Viehbacher CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Viehbacher succeeds Michel Vounatsos, who has l",https://finnhub.io/api/news?id=c0e11bb45ce29b1feab781efe5aac55bdd80a571ae111447529ce73308412c80
company,2022-11-10 06:34:16,Seres Gets Closer To Good Times,117067882,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358641817/image_1358641817.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. Read more here.",https://finnhub.io/api/news?id=1c64a2d6de3411e857747dbe77e3b5f812bc2c923cd54ae27fb39c249da4575f
company,2022-11-10 05:59:00,Biogen tabs veteran pharma leader Viehbacher as next CEO,117075143,,BIIB,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1f32e9cbe75854c4ee03214def37dd467d2a49e44e4d8d4f2fdd92d3221308c7
company,2022-11-10 05:00:00,The Petri Dish: Biogen's CEO search stalls again; A setback for Verve,117059588,https://s.yimg.com/ny/api/res/1.2/o9HN4iBu6Xxshjpwl5TYpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDI-/https://media.zenfs.com/en/bizjournals.com/01e667f4bbc7bbf59f5ba702818b6c69,BIIB,Yahoo,"The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.  Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.  Inhibikase slapped with clinical hold  The U.S. Food and Drug Administration has ordered a stop to a Phase 1 trial of a drug made by Inhibikase Therapeutics Inc. (Nasdaq: IKT), which has offices in Lexington.",https://finnhub.io/api/news?id=f44408b07de0dd8ba908fbb9e60c5249e2f3584a6a4ad841f6969538892de9d7
company,2022-11-10 02:58:00,"Biogen Names Former Sanofi Chief Christopher Viehbacher President, CEO >BIIB",117128085,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"By Colin Kellaher Biogen Inc. on Thursday said it named veteran pharmaceutical executive Christopher Viehbacher president and chief executive, capping a...",https://finnhub.io/api/news?id=57670bb1d8c224047ed9b5750df1d8c640f9a17cb01a2acf71f2fe3b90e2ac21
company,2022-11-10 01:44:00,"Biogen names Viehbacher president, CEO",117084145,https://thefly.com/images/meta/hotstocks.jpg,BIIB,Thefly.com,Biogen announced that its... BIIB,https://finnhub.io/api/news?id=0c1f4a89c39c7678c60b08f2a8c4f3f165e1a26ea10aaeab9c53691cdf36af0d
company,2022-11-09 23:30:00,"Elliott Wave Technical Analysis: Biogen Inc. - Thursday, Nov. 10",117084146,https://cdn.pixabay.com/photo/2020/11/27/16/59/man-5782411_960_720.jpg,BIIB,TalkMarkets,Looking for a clear three-wave move pullback before considering any long-term longs.,https://finnhub.io/api/news?id=d5b4505e79182050dc60f9296c69e3ae5b59c47e1f07c999fcbf679a6b639918
company,2022-11-09 20:31:00,"Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Apyx Medical (APYX) and Phathom Pharmaceuticals (PHAT)",117079192,,BIIB,TipRanks,Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (<a href...,https://finnhub.io/api/news?id=22e658b9942701be71091a394f5e97b1dfc51eb0addfce87cc2807107c3527d6
company,2022-11-09 11:40:00,Biogen Inc. stock outperforms market despite losses on the day,117038612,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.35% to $282.31 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=3ad225d87d7294c8d90661334325e84988d9161c503b7bfda4d30353592507d1
company,2022-11-08 11:40:00,"Biogen Inc. stock rises Tuesday, still underperforms market",117038613,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.54% higher to $286.16 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=e675ee85bc85fa7690e8b0c6a819b375b653257d4ba591df3c0b49f508002e76
company,2022-11-08 10:16:03,Here’s Why Biogen (BIIB) Outperformed in the Quarter,117002555,https://media.zenfs.com/en/insidermonkey.com/efbce124e25466a32befc26ebb32d9da,BIIB,Yahoo,"ClearBridge Investments, an investment management company, released its “ClearBridge Aggressive Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark index, Russell 3000 Growth Index, in the third quarter. The healthcare sector was the primary contributor to the strategy’s performance, while communication services detracted from […]",https://finnhub.io/api/news?id=59d6e7d4bf3ded68ee21de183045f13881f9ebf91189b34a0c87f65b21c2546f
company,2022-11-08 06:06:00,What You Missed On Wall Street This Morning,116996341,https://image.thefly.com/catalog/201904/img_457.jpg,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. TTWO, ATVI, DD, LYFT, KSS, LEVI, HIMS, AMGN, SQ, WSM, NVDA, AAPL, GS, TWTR, BIIB, JNJ, SEDG, CTIC, TASK, RIDE, HNHPF, NSTG, RCM, MAPS, PLNT, TWOU, FIVN, NCLH, TRIP",https://finnhub.io/api/news?id=caf371477b665657046f77c6ebe48622d4206db586d0d0871d3930899b481b52
company,2022-11-08 05:10:07,Biogen Third Quarter 2022 Earnings: Beats Expectations,117002556,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Biogen ( NASDAQ:BIIB ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.51b (down 9.7% from 3Q 2021). Net...,https://finnhub.io/api/news?id=24048b610e66ecf2311833809a2e9d808b9c33b8338775321c601c193d2ee67a
company,2022-11-08 01:01:00,"GREATMARK INVESTMENT PARTNERS, - GuruFocus.com",117004246,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=88feea18168b789e71450d7b9c16e782dffffde0db48f80b98a88c8d723512e2
company,2022-11-15 12:01:00,Second Time Might Be the Charm for Alzheimer’s Blockbuster,117188752,https://s.yimg.com/ny/api/res/1.2/.vtQeldzIHlg4KACXDX7.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/6f7c64b630e80a42c8cf4821079b8001,BIIB,Yahoo,"Biogen had been a sinking ship following its Alzheimer’s flop, but positive results in September have changed the company’s trajectory.",https://finnhub.io/api/news?id=d1f181f508a328b003ec119c3c0660d8befa5c97c9cbc1fd7a1409999f518cb7
company,2022-11-15 11:40:00,"Biogen Inc. stock rises Tuesday, still underperforms market",117204619,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.24% higher to $299.78 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=0756c29a151af7bca647d3203c9af15c92135226ca506eb7a5bb84b9d3961dc9
company,2022-11-15 09:55:02,Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others,117162626,https://media.zenfs.com/en/zacks.com/d12eb3cde35a8fdb0f38466dd3f64a4d,BIIB,Yahoo,"Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.",https://finnhub.io/api/news?id=27fc9ad120d07295933e815953952a975f3f55e683a458212f089870754bdf22
company,2022-11-15 06:57:00,Retailers Prepare for Another Reveal on Inflation. It’s Key Intelligence for the Fed.,117155929,,BIIB,Yahoo,"Amazon.com is reportedly planning to cut about 10,000 workers, Berkshire Hathaway buys shares of Taiwan Semiconductor, Biden-Xi meeting adds to Chinese market optimism, crypto firms rush to calm fears, and other news to start your day.",https://finnhub.io/api/news?id=0609e3fe7ff82de5f3d8332043bd14b44deff1b6f632e42d68c127e9286c83ca
company,2022-11-15 03:03:00,Biogen price target raised to $350 from $265 at Truist,117168825,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Truist analyst Robyn Karn... BIIB, RHHBY",https://finnhub.io/api/news?id=5fa30cdeba736cb6bdefb774297e2fb509bf378eace49af227ba392975085fa9
company,2022-11-15 03:01:00,"HealthCor Management, L.P. Buy - GuruFocus.com",117164842,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=a2ff905a6e733755d257b1d53340062bac28ff684805dc876d9a30fa16d9acd7
company,2022-11-15 00:56:00,Biogen Reaches Analyst Target Price,117168827,,BIIB,ETF Channel,"Staff article entitled Biogen Reaches Analyst Target Price, about ETFs, from ETF Channel.",https://finnhub.io/api/news?id=378392d75c15faa4abc088d342620b8e47bd7550458dc9c06745cd0bb80fc950
company,2022-11-15 00:30:00,Hedge Fund Point 72 Builds Position in These Stocks; Should You?,117159579,https://blog.tipranks.com/wp-content/uploads/2021/11/Steven-Cohen-1124-750x406.jpg,BIIB,TipRanks,Billionaire investor and hedge fund manager Steve Cohen’s Point 72 Asset Management has disclosed some interesting stakes in its September quarter holdings. A Form ...,https://finnhub.io/api/news?id=ee937bac1b8412b3a40cdfeb6ad8f37b594144dfd80636ddff312ac59f5657bc
company,2022-11-14 09:55:46,"Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others",117144685,https://media.zenfs.com/en/ibd.com/085cc3649e38a61d9620a95c3e958aaa,BIIB,Yahoo,"Roche said its experimental Alzheimer's treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.",https://finnhub.io/api/news?id=7c53b9c7bb001b5aab37445140c02e0f6f9249a0e63c011780df7d0cb3094b84
company,2022-11-14 14:34:00,"One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments",117148224,https://s.yimg.com/ny/api/res/1.2/._yTcRfYCaBB0J8xRugJ2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/marketwatch.com/8eb46f609c4f76f7df6c01656878dab3,BIIB,Yahoo,Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.,https://finnhub.io/api/news?id=7428bbdb0a67d64c8c95ddbe6f0b50aabb9568fbf947135ed1334bab86594c84
company,2022-11-14 13:17:39,"Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers",117148225,https://media.zenfs.com/en/Benzinga/6725b9d7ea0e19e3eab5702847e1c15e,BIIB,Yahoo,"Earlier today, MorphoSys AG (NASDAQ: MOR) and its partner Roche Holdings AG (OTC: RHHBY) reported disappointing results from gantenerumab studies in mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. Needham writes that with both GRADUATE studies failing to meet the primary endpoint, it removes a potential competitor for Eisai Ltd (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) lecanemab. Roche's data was much awaited after Biogen and Eisai said the global Phase 3 con",https://finnhub.io/api/news?id=e50cf478890d3334c56e3ff7d0469a7dbb205a759feab400f62e7c66a9286e48
company,2022-11-14 11:40:00,Biogen Inc. stock outperforms market on strong trading day,117204622,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 3.32% to $299.06 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=b5969f8dcc28386d23c736c3b62fc7be6865d51bff85800fd3ccf745999fe09b
company,2022-11-14 11:27:37,Stock market today: Dow lower in choppy trade as Fed officials stress more hikes,117148032,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Yasin Ebrahim,https://finnhub.io/api/news?id=1e448c1362a34ab72f813e2f35eada22bd3df6875c2f351cdced873c7f42acdf
company,2022-11-14 11:16:00,"Moderna, Biogen rise; Oatly, Dentsply fall",117161045,,BIIB,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3ff59f14d2c63ab750e243c7dd56698ca21a753e6d93fa6d1256c131fdccba23
company,2022-11-14 11:00:45,"Roche's Alzheimer drug failing was a tailwind for a Biogen rally, Mizuho's Salim Syed",117150004,https://image.cnbcfm.com/api/v1/image/107151490-16684594091668459406-26584259306-1080pnbcnews.jpg?v=1668459645&w=1920&h=1080,BIIB,CNBC,"Salim Syed, Mizuho senior biotech analyst, joins 'Closing Bell' to discuss Biogen stock ticking up after Roche's new Alzheimer's drug didn't meet its goals.",https://finnhub.io/api/news?id=1b4fa4f10157862d3194a9ca27569175a23fad317ba8db211d1afc8786fca8ea
company,2022-11-14 10:47:00,Biogen in Pole Position After Roche’s Alzheimer’s Drug Disappoints,117144683,https://s.yimg.com/ny/api/res/1.2/odOlEkPifdmvGwojuoxTQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/1d040509b5eaf41c5cb368d02c80bedc,BIIB,Yahoo,"Swiss pharmaceutical company Roche said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen earlier this year.",https://finnhub.io/api/news?id=be51c2926b3da2e56655717405b71fab53b8512e92860e3b13188a71b4a36c5e
company,2022-11-14 10:19:35,S&P 500 struggles for direction as fed officials signal higher for longer rates,117148035,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Yasin Ebrahim,https://finnhub.io/api/news?id=fd7eb54e5d34379ebb8ced9bed4f77d9fd66e08d46d42efea7749fcebbfbdd3f
company,2022-11-14 09:34:00,"One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments",117164679,https://images.mktw.net/im-665833/social,BIIB,MarketWatch,Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.,https://finnhub.io/api/news?id=6f0b32cc4c825b4f0f178275d325dfae394dd65b6a2cff8da9552a10975e5c9e
company,2022-11-14 08:31:00,"Biogen Stock Leaps, Eli Lilly Gains As Roche Alzheimer's Drug Trial Falls Short",117144686,https://media.zenfs.com/en/thestreet.com/e2026491b9020b2a3152d63503fe8cc3,BIIB,Yahoo,"""While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer's dataset to the field,"" Roche said.",https://finnhub.io/api/news?id=1126b4b6fc819c39931a7e999bd50833599560423c6df2bbf516e82ebb26c673
company,2022-11-14 07:53:36,"Stocks making the biggest moves midday: Oatly, Amazon, Hasbro and more",117149999,https://image.cnbcfm.com/api/v1/image/106885903-1621515979105-gettyimages-1228558733-OATLY_IPO.jpeg?v=1668448577&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=63285c11752c8a05501d693df15fd6a40eb2ab803005dc748d15a225dd0c3f90
company,2022-11-14 06:41:51,Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab,117148230,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BIIB,Yahoo,"Biogen Inc. shares rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed shares of MorphoSys fell 30% on the news, while Roche was down 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia did not meet their primary endpoint of slowing clinical decline. Biogen, which las",https://finnhub.io/api/news?id=5685a70f54d198c7a7cc240aba356b2bfbf11e91e34d30f714953a1a1904a00c
company,2022-11-14 06:06:00,What You Missed On Wall Street This Morning,117145275,https://image.thefly.com/catalog/201904/img_457.jpg,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. BIIB, LLY, RHHBY, DIS, AAPL, OPNT, AMZN, TSLA, GOOG, GOOGL, WMT, META, AGEN, FREY, RIDE, GOEV, BBBY, TSN, MNDY, TSEM, OTLY, PIII, CAN, AMC",https://finnhub.io/api/news?id=728471c88617c79e4876525e52740a985a3c408e0c5a153b0c062a3e9361b38b
company,2022-11-14 05:36:40,U.S. stocks waver ahead of retail earnings week,117148231,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Liz Moyer,https://finnhub.io/api/news?id=934df1e041b6689deb809fd9737d4caa051bb6bc74e29331b6976df88c959a75
company,2022-11-14 05:01:00,Top 5 3rd Quarter Trades of Ma - GuruFocus.com,117144383,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=55ee9dba019ed4d36c474fd04dd8c623369fd629f5571eb86b02fda7b323b265
company,2022-11-14 03:16:09,Roche's Alzheimer's drug fails to meet goal in long awaited trial,117141890,https://static.reuters.com/resources/r/?m=02&d=20221114&t=2&i=1614238901&r=LYNXMPEIAD06U,BIIB,Reuters,"Roche's Alzheimer's drug candidate could not be shown to markedly slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as clear leaders in a high-stakes race to launch a treatment for the memory-robbing disease.",https://finnhub.io/api/news?id=6b055182194b9efa170805b0cd7dd1e024e2048f24eaa48a782d79bc5cf2a956
company,2022-11-14 03:01:00,SEEYOND's Top 5 Buys of the 3r - GuruFocus.com,117163378,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=14157c75716bb53d478fb5305a8b45ce687b5d9ba5b4b9b490ea68b49178c603
company,2022-11-14 02:47:00,Needham Remains a Buy on Biogen (BIIB),117146386,,BIIB,TipRanks,"In a report released today, Ami Fadia from Needham maintained a Buy rating on Biogen (BIIB &#8211; Research Report), with a price target of $300.00. The company&#82...",https://finnhub.io/api/news?id=79d9d9ed2dae3ce85d86ec50c6df3050bcadd93d6bc6b1321f0eb9140445f2c9
company,2022-11-14 02:37:11,"Stocks making the biggest moves in the premarket: Hasbro, Oatly, Advanced Micro Devices and more",117150008,https://image.cnbcfm.com/api/v1/image/107104768-gettyimages-1242541458-AFP_32GL9QP.jpeg?v=1668429431&w=1920&h=1080,BIIB,CNBC,"The stocks making the biggest moves in premarket trading include Hasbro, Oatly, Advanced Micro Devices, and more.",https://finnhub.io/api/news?id=17b6b247121214d88f0f6244d141bf78b61240df350fdf69909a862725192889
company,2022-11-14 02:19:00,"Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies",117143983,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"After Roche (RHHBY) repor... BIIB, RHHBY, ESALY",https://finnhub.io/api/news?id=796d2ddc89b097be0cfd99cc5669792cf4624c9ebe03924b991cc973672b2d48
company,2022-11-14 01:01:00,Steven Cohen's Top 5 Buys of t - GuruFocus.com,117163077,https://static.gurufocus.com/images/logo_global.png,BIIB,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=62dd0f52f01cb09aee524aa4af76c9fe08091e797cf1fc10f99139ba6e6cc4bc
company,2022-11-14 00:38:00,Biogen price target raised to $315 from $300 at Oppenheimer,117145027,https://thefly.com/images/meta/streetresearch_recommendations.jpg,BIIB,Thefly.com,"Oppenheimer analyst Jay O... BIIB, SNY, GSK",https://finnhub.io/api/news?id=61a570a4d0562cf361534bbcaf6a01efc0fa2fade809b71daf05b3ce9f095a8d
company,2022-11-14 00:22:15,MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals,117166484,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,German-listed shares of MorphoSys undefinedundefined lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche...,https://finnhub.io/api/news?id=83241e73d356e081c1c7fecea476377bb7749c9613c07bc843c990c81434591f
company,2022-11-13 23:03:00,What You Missed On Wall Street On Monday,117159869,https://image.thefly.com/catalog/201810/img_66.png,BIIB,Thefly.com,"Five top five lists with the news and calls moving stocks, powered by The Fly. RHHBY, BIIB, LLY, DIS, AAPL, MRNA, AMD, HAS, NIO, BAC, GPN, AMZN, TSLA, GOOG, GOOGL, META, DSKE, FREY, CAN, AMC, RIDE, GOEV, BBBY, TSN, MNDY, TSEM, OTLY, PIII",https://finnhub.io/api/news?id=6be8e747148a9499781834d8aee85b7285c44ebe426c661885ed4bdfca92d18a
company,2022-11-13 20:39:00,Why Is Cassava Sciences (SAVA) Stock Up Today?,117159916,https://investorplace.com/wp-content/uploads/2021/09/sava-stock-1600.jpg,BIIB,InvestorPlace,Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.,https://finnhub.io/api/news?id=5947b84bb27fb0879001fb559ade51b8f5d464a8b36bf361d63be726836fd768
company,2022-11-13 13:28:25,Vertex: High Growth For Years Ahead,117138953,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326625612/image_1326625612.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3.,https://finnhub.io/api/news?id=dd7b258b859f483ba7892042f817363216b6d69ae6da141055e9c4c0b7fa6eac
company,2022-11-13 06:16:09,"Last week's biggest management and board changes:  Kohl's, Biogen, adidas",117139144,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Sarina Isaacs and Senad Karaahmetovic,https://finnhub.io/api/news?id=65c5ca9b85beaae2c11e6a99b1f30ef7ea2d9656c617089ebe949b97c32fd2ef
company,2022-11-18 11:39:00,"Biogen Inc. stock rises Friday, still underperforms market",117204615,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.28% higher to $302.89 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=b506a089cde9bf678922ceb5f39a48b884ad48c0a585ac907b4055c21f5604ff
company,2022-11-18 10:55:54,Teva Pharmaceutical: Warren Buffett Likely Made A Mistake Selling Shares,117198688,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346401654/image_1346401654.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Teva Pharmaceutical was able to achieve a nationwide settlement to the opioid crisis, proving the ability of the company's management to overcome difficulties.",https://finnhub.io/api/news?id=71168192678549f6d12f020791cd2f201e73e9366889b05f7edd94f34fe414b1
company,2022-11-17 11:40:00,"Biogen Inc. stock rises Thursday, outperforms market",117204616,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.68% higher to $302.05 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=99b9d582c3e53130bf197bc9d2cf9d911cd4ff92861ffc70c4947ca23a8e7360
company,2022-11-17 10:01:03,Novartis (NVS) Reportedly Looking to Sell Its Business Units,117187636,https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9,BIIB,Yahoo,"Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.",https://finnhub.io/api/news?id=a29d3620dceb2f2cf8f8564a70eb9fe8aa5f1b03c06f0827e061b92f27eeea25
company,2022-11-17 09:40:02,Is Biogen (BIIB) a Great Value Stock Right Now?,117188749,https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85,BIIB,Yahoo,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",https://finnhub.io/api/news?id=996f90163529667dc2750eeb04aa031ad8f7796bb0b078dba06bc7910310bd92
company,2022-11-17 09:23:00,3 Stocks to Avoid Right Now,117188750,https://s.yimg.com/ny/api/res/1.2/g9EmCgvmElT3SeMNFb9ALg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/7da03c54843abbf103a78040299f504c,BIIB,Yahoo,"Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.",https://finnhub.io/api/news?id=ddae9f8f91ca85bf605b1d605cb5fa85921454f6d86e689f67c998ef30ab07b3
company,2022-11-16 11:40:00,Biogen Inc. stock underperforms Wednesday when compared to competitors despite daily gains,117204618,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.08% higher to $300.01 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=63d6f6bd7b13bfb9b98672d735ea1130036cec4e160a99dae8dd4b77b69ff483
company,2022-11-16 11:00:32,"Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm",117179492,https://media.zenfs.com/en/ibd.com/bcaf607294e800729dba020cc045b3df,BIIB,Yahoo,The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.,https://finnhub.io/api/news?id=7bbc74d405cb28e9e06517f007c8026c4a317d8a692379b7d36272ebe4730522
company,2022-11-23 11:40:04,BIIB or RGEN: Which Is the Better Value Stock Right Now?,117270475,https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a,BIIB,Yahoo,BIIB vs. RGEN: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=0e50f03d3bac135e3fb762732f9b790353de66793e1bfe0f44887f10e11a00b6
company,2022-11-23 11:39:00,Biogen Inc. stock underperforms Wednesday when compared to competitors,117336673,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.07% to $303.45 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=501bab20c8a356bcc261c25c45024af74baa92f448efd1163a97c26ccf8a27c4
company,2022-11-23 10:41:03,Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer,117269231,https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,BIIB,Yahoo,Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.,https://finnhub.io/api/news?id=66ee3b792d378ba9356c602dd100181c95784b6f7c318b1b4159380a109a0726
company,2022-11-23 09:40:02,Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?,117271970,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,BIIB,Yahoo,Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.,https://finnhub.io/api/news?id=fea7c8ea09dfc004fb8de104b2eb56aa89fcab68bfe532ff10029f28109feddb
company,2022-11-22 10:00:15,"We still think there's more room for biotech to go higher, says Jefferies' Yee",117256583,https://image.cnbcfm.com/api/v1/image/107155846-16691460531669146051-26734515867-1080pnbcnews.jpg?v=1669147215&w=1920&h=1080,BIIB,CNBC,"Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector.",https://finnhub.io/api/news?id=7e21fa18916b8fe72f13b787205058eb3ead11af4c663d86fb3db5f7728da2f5
company,2022-11-21 11:51:21,Teva hires ex-Novartis executive to succeed CEO Schultz,117241096,https://static.reuters.com/resources/r/?m=02&d=20221121&t=2&i=1614936042&r=LYNXMPEIAK0GV,BIIB,Reuters,Teva Pharmaceutical on Monday appointed former Novartis and Biogen executive Richard Francis to succeed chief executive officer Kare Schultz who is due to retire later this year.,https://finnhub.io/api/news?id=f38d379740e9b944bfbb5f4b2e8f0545c8bdae81d48d2ba571b04f18f20e6b2c
company,2022-11-21 02:16:24,Teva names former Sandoz chief Richard Francis as new CEO,117301209,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,"Teva Pharmaceutical Industries Ltd. undefined on Monday said its current CEO Kåre Schultz will retire on Dec. 31. Robert Francis, former CEO of Sandoz and an...",https://finnhub.io/api/news?id=bf352955ea750c68754c6bdeb312d9195dd696f450a9702c82e37d0c800a7383
company,2022-11-26 07:22:40,Biogen Inc.'s (NASDAQ:BIIB) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?,117295891,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Biogen (NASDAQ:BIIB) has had a great run on the share market with its stock up by a significant 54% over the last three...,https://finnhub.io/api/news?id=ac36ee5c34b8415bcd57a9674c36e0d35c7e729e719fcf72bbc8e73d7a3c5b14
company,2022-11-25 11:31:04,Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?,117288200,,BIIB,Yahoo,BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=304cc62ca5fdfd12be3206cf2cb74ed1915ff6084fc0d4c1bf77a71fca57af54
company,2022-11-24 11:30:04,Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?,117277935,https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4,BIIB,Yahoo,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=af478b8d1b420524553a871aeba8ee78d04ceba1e4e6146da351fc50abab6020
company,2022-12-01 16:28:10,Biogen Inc. (BIIB) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript),117368463,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Biogen Inc. (NASDAQ:NASDAQ:BIIB) 5th Annual Evercore ISI HealthCONx Conference Call December 1, 2022 10:30 A.M.",https://finnhub.io/api/news?id=06fa4d5d1ca45a26bda227ef16c4d3032deccef30ce021b8928b79380c00c340
company,2022-12-01 11:42:00,Biogen Inc. stock underperforms Thursday when compared to competitors,117407868,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.09% to $301.85 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=9cf241ae8b53a25080b20b62969add85ac3c8c0c1939dfb9b53f9f793f8224a0
company,2022-12-01 11:31:04,Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?,117362570,https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4,BIIB,Yahoo,Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=533bde61a5f25ff5c647c5f1906dd5229152ab78244a4780b42352973b0abea4
company,2022-12-01 09:15:00,Protecting Patients from Climate Risks: A Conversation with Frontline Health Clinics on Resources,117360972,https://media.zenfs.com/en/accesswire.ca/025a343f5360ae5219a0a359321a620a,BIIB,Yahoo,"After a year of more frequent climate-induced extreme weather, the Center for Climate, Health, and the Global Environment at Harvard T.H.",https://finnhub.io/api/news?id=e01342bc8d06c66419fc1d2cb9ee501fcc498a0fd01235a4137fc2cf3d2fa12d
company,2022-12-01 08:09:01,Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug,117359899,https://media.zenfs.com/en/zacks.com/f84faa3d65021260b4cd14c75493ef6c,BIIB,Yahoo,Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.,https://finnhub.io/api/news?id=b48b94618316b2c70b6b17b95d93e4b83a4696f1d020147b58e006a27cafcace
company,2022-12-01 03:20:37,Lilly said its Alzheimer's drug clears more amyloid plaque than Aduhelm,117407869,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Eli Lilly & Co. undefined said Wednesday night that its experimental Alzheimer's treatment did a better job at clearing amyloid plaque than Eisai and...,https://finnhub.io/api/news?id=57ed2aedd4022d7394000f26c48c13c5e931fedec438b0288202be975f44432f
company,2022-11-30 23:05:00,Lecanemab And Alzheimer's: More Data,117356733,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367780024/image_1367780024.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Lecanemab, developed by Eisai and Biogen as anti-amyloid antibody therapy for Alzheimerâs, shows strong numbers in its latest trial. But will the drug really make a difference in treatment?",https://finnhub.io/api/news?id=a06588f4920ad9a65f3248fef8b66e9e9404407569cf6d8475c7349fb479b9e6
company,2022-11-30 15:19:49,"Eisai, Biogen Alzheimer's drug could be available to some next year",117352427,https://static.reuters.com/resources/r/?m=02&d=20221130&t=2&i=1615792871&r=LYNXMPEIAT14P,BIIB,Reuters,"Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients...",https://finnhub.io/api/news?id=389879e156e0e96f309030f01212adff2125573d04524ace41432f2f811bd2c8
company,2022-11-30 14:44:00,Newest Alzheimer’s Drugs Take Large but Fraught Step Toward Approval,117350751,https://s.yimg.com/ny/api/res/1.2/wdtVOpEeo6YH_38Lb1SObw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/6a6a4ae769d77a234d7dfe1894440f59,BIIB,Yahoo,Positive study results for Eisai-Biogen lifted the prospects for its medication and one from Eli Lilly—although regulators will have to weigh risks.,https://finnhub.io/api/news?id=f6ad33715f28ed0f9aa1f049c89de4d4e26aa07ae721a4b2aa2d2716ca72e5ab
company,2022-11-30 13:03:22,"Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate",117352468,https://media.zenfs.com/en/Benzinga/6960f0d72c35cfb4a0699d0174030a1e,BIIB,Yahoo,Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). William Blair analyst says that overall the data is robust and of high impact to both the AD clinician community and regulators and CMS as the next three to nine months carry critical regulatory and reimbursement milestones for the anti-amyloid therapy drug class. Related: Open Questions On Safety Lingers After Eisai-B,https://finnhub.io/api/news?id=d37707a5c93f3e91e2e5c55e46cbd6d19457feefa8c008156c2c8845aebe7e44
company,2022-11-30 11:44:00,"Health Care Up as Biogen, Horizon Surge -- Health Care Roundup",117407872,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,Health-care companies rose as traders rotated into sectors less sensitive to the vagaries of economic growth. Biogen shares surged after the biotech giant's...,https://finnhub.io/api/news?id=b3b174022d5c98f471624d00e1c05585064d6eb9a6a2fe4379a2c987c044a7a3
company,2022-11-30 11:38:00,5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners,117346309,,BIIB,Yahoo,Results of clinical trial point to a stable future for Eisai and Biogen's lecanemab once the therapy is approved by the Food and Drug Administration.,https://finnhub.io/api/news?id=f301a44f1ab3c0d701bb0f87ffe402c0c1d388e9142c44645fde401026d5338d
company,2022-11-30 10:45:00,Biogen Stock Surges As New Drug Offers 'Meaningful Change' For Alzheimer's Patients,117346310,,BIIB,Yahoo,"""These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently,"" the Alzheimer's Association said.",https://finnhub.io/api/news?id=f6d169c704e40c8d2436ae61086e359b9d885e48fad756029249857d2d8af409
company,2022-11-30 10:32:00,Big Alzheimer’s News for Biogen Just Landed. The Company Didn’t Get a Mention.,117346311,,BIIB,Yahoo,"Japan's Eisai presented full data on a new Alzheimer's drug, but without mentioning the U.S. pharmaceutical company, its partner on the treatment.",https://finnhub.io/api/news?id=22bbdb3decedbb44d7d1653f39ec3ae93674733088904651195bf521f9fc40a9
company,2022-11-30 09:50:47,Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's,117346312,https://media.zenfs.com/en/Benzinga/be5d78bf86c044f6c7b5efe64c8ec192,BIIB,Yahoo,"According to detailed data, Eisai Limited (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) closely watched trial of an experimental Alzheimer's drug slowed cognitive decline but may carry a risk of side effects for certain patients. Lecanemab was associated with a type of brain swelling in 12.6% of trial patients, a side effect previously seen with similar drugs. 17.3% of patients had microhemorrhages in the brain— a symptom linked to two recent deaths of people receiving lecanemab in a follow-on st",https://finnhub.io/api/news?id=1c9737c21e80561b513ffc3c619b9d1628ba0032e7e8432783d3fb1ed50c41e2
company,2022-11-30 08:53:01,Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects,117346313,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.,https://finnhub.io/api/news?id=71804be07b812414bf1d8967c280f2c663a0b38118cfcfa7fa29e844cd8b12c7
company,2022-11-30 08:46:00,Biogen Surges on Alzheimer's Drug News: How to Play the Stock,117346959,,BIIB,Yahoo,"Trading volume has picked up in the past three months to help confirm the price gains.  The math-driven On-Balance-Volume (OBV) line shows a rising pattern from June telling us that buyers of the stock have been more aggressive than sellers.  Yes, the OBV line can lead prices!",https://finnhub.io/api/news?id=f9c94aefa2fa7bed489604aae2edb64f8e1ac54dad3571c1df2f0f0a28a55171
company,2022-11-30 08:10:57,"Stocks making the biggest moves midday: CrowdStrike, Horizon Therapeutics, Petco and more",117348493,https://image.cnbcfm.com/api/v1/image/106824475-1610633003847-gettyimages-1228437200-PETCO-IPO.jpg?v=1669831857&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=6a71570b75009e6cf5b30012f6ed852649748199d5b9b52681995e7b6338d7b7
company,2022-11-30 08:01:00,"Alzheimer’s Breakthrough Is Boost for Biogen, Eli Lilly Despite Side-Effect Concerns",117344176,https://s.yimg.com/ny/api/res/1.2/nR.Jay9EfIwSvdPhMhoaOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/b161a7284e4148d79cb5c4b0c4153dbd,BIIB,Yahoo,Shares in pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of the lecanemab drug.,https://finnhub.io/api/news?id=ec735230edc4f478286c27e66ceaf9439d3102cd52684e05fa346ca9c7bd0761
company,2022-11-30 07:40:16,US STOCKS-Futures rise as focus turns to Powell speech,117345786,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"U.S. stock index futures edged higher on Wednesday, with those of the Nasdaq rising the most on gains in Tesla shares, while investors treaded cautiously ahead of comments from Federal Reserve Chair Jerome Powell later in day.  Powell's speech will be closely watched for signs of a slowdown in the pace of interest rate hikes by the central bank as well as to assess the general health of the U.S. economy.  ""Fed Chair Powell is speaking, but past comments have done little other than chant 'hike, hike, hike',"" said Paul Donovan, chief economist, UBS Global Wealth Management.",https://finnhub.io/api/news?id=6b5c8c2a66ad5d6456a21615add780b06b80cac47a106d174624cca1cbaac81d
company,2022-11-30 07:01:00,Pharma Stocks Rise on Alzheimer’s Breakthrough  Despite Side-Effect Concerns,117342101,,BIIB,Yahoo,Shares in pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of lecanemab.,https://finnhub.io/api/news?id=f1de94944313dd1fb3bdab6052bae5b1e6eb816dca7422d463d8eb358a173c24
company,2022-11-30 06:48:10,Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy rating,117342102,,BIIB,Yahoo,"Biogen Inc. stock rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimental Alzheimer's drug being developed with Japan's Eisai moderately reduced cognitive decline after a year and a half. The study assessing lecanemab as a treatment for people with early forms of Alzheimer's disease was published Tuesday night by the New England Journal of Medicine. Eisai also presented the full findings from the trial on Tuesday night at the Clini",https://finnhub.io/api/news?id=45f8ddb0b23fb4dcf085666f1d9b08899ad4cde56630a4a18642b15dec64b460
company,2022-11-30 06:02:00,Biogen Stock Gains On Promising Final Data From Alzheimer's Drug Trial,117341760,https://s.yimg.com/ny/api/res/1.2/BrzJcU1.8sEvMp7Ne2e.3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/1250326855deb08fba4b12911a3bc9e6,BIIB,Yahoo,"""These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently,"" the Alzheimer's Association said.",https://finnhub.io/api/news?id=c1d8b38f96d355cedde2c9604c073b5c5b4f92dd7021df93155e68b543af0ddd
company,2022-11-30 05:39:00,"Stocks Nudge Higher, Powell, Bankman-Fried, Biogen, HPE in Focus -Five Things To Know",117341750,https://s.yimg.com/ny/api/res/1.2/F3N2U7AnQMPzjbco7N0MEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/6c57fef498f7a090af3244d0780e4194,BIIB,Yahoo,"Stock futures nudge higher will Powell, jobs data in focus; Powell speech may challenge Fed's new rate hike outlook; Sam Bankman-Fried set for DealBook summit appearance after FTC collapse; Biogen shares jump after promising Alzheimer's treatment data and HPE shares surge after Q4 earnings beat, solid near-term outlook.",https://finnhub.io/api/news?id=cc81c6d2ccdb7723dbfa4e50d2bf2b4d251d1ae59ef97bbad13ab6d63441bdbe
company,2022-11-29 22:02:00,Biogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.,117337285,,BIIB,Yahoo,"Japan's Eisai, which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the therapy worked surprisingly well.",https://finnhub.io/api/news?id=737a992ee5f97d67c775007c4e8269c97336773b5d13e9189785b06818f8704c
company,2022-11-30 03:00:03,"Workday, Boeing, Tesla and Airbnb rise premarket; Crowdstrike falls",117345787,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Peter Nurse,https://finnhub.io/api/news?id=7420578b8040dcb1ec57764494cd97cde50f638a45ee309f82b26df72e928187
company,2022-11-30 02:54:06,"Stocks making the biggest moves premarket: Hormel, Petco, CrowdStrike and more",117346458,https://image.cnbcfm.com/api/v1/image/107108159-1661280895813-gettyimages-1242669885-PETCO_EARNS.jpeg?v=1669812846&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves before the bell.,https://finnhub.io/api/news?id=57283b8c1c338ea3159f252838fddcc3049f9bf11bdf948f69be881c72524103
company,2022-11-30 02:52:08,"Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus",117341239,https://static.reuters.com/resources/r/?m=02&d=20221130&t=2&i=1615726655&r=LYNXMPEIAT0BD,BIIB,Reuters,"An experimental Alzheimer's drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of serious side effects for certain patients, according to detailed data presented on Tuesday.",https://finnhub.io/api/news?id=476e3a063f49ab33f332dcb4126b4eec65771a51020cef13f30d980ca5b5be4f
company,2022-11-29 23:55:00,Dow ends over 700 points higher to exit bear market after Powell signals smaller interest-rate hikes ahead,117407871,https://images.mktw.net/im-676472/social,BIIB,MarketWatch,U.S. stocks finished sharply higher Wednesday after Fed Chair Powell said the central bank's pace of interest-rate increases can slow as soon as its December...,https://finnhub.io/api/news?id=cb92ab810fd3083d08393b5c091168bdcf3f7494a81c927b53c2ddfdde1df88c
company,2022-11-29 21:31:33,"UPDATE 1-Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus",117337286,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.  The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer's, found that treatment with lecanemab reduced the rate of decline on a clinical dementia scale (CDR-SB) by 27% compared to a placebo.  ""All of these amyloid-lowering drugs carry a risk for increased brain hemorrhage,"" said Dr. Ronald Petersen of the Mayo Clinic in Rochester, Minnesota.",https://finnhub.io/api/news?id=3f45294e0c898049e1c4467d032f75c36cbbe33e5fc317d248f15a856e37d498
company,2022-11-29 21:31:09,Biogen shares hit one-year high on new Alzheimer's drug data,117346317,,BIIB,Yahoo,"The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study.",https://finnhub.io/api/news?id=767d5b5ff2b190f5cee375d64c2cad23100f4268e20519d3181ba78eb9e58c56
company,2022-11-29 21:31:09,Biogen's new Alzheimer's drug slows cognitive decline: study,117337287,,BIIB,Yahoo,"The new Alzheimer's disease drug made by Eisai Inc. and Biogen Inc. is capable of slowing cognitive decline by 27%, as confirmed by a peer-reviewed study.",https://finnhub.io/api/news?id=18f1641edc903f442f57e7a943ff113edad24112890b464488cc8c3e085b28fa
company,2022-11-29 20:44:07,Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors,117336060,,BIIB,Yahoo,Biogen stock was muted late Tuesday after Eisai unveiled Alzheimer's treatment results likely to spark a debate over the drug's benefits.,https://finnhub.io/api/news?id=2fad8ab67cdd8633589ea7b4d5dcd3f512bc873125955760c3c183614a3360bf
company,2022-11-29 20:23:00,"A new Alzheimer’s treatment may help some patients, though researchers say more safety data is needed",117336061,,BIIB,Yahoo,A new study found that Eisai and Biogen's experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half.,https://finnhub.io/api/news?id=422d9b3787dd2a6116f0b28232703d5034edd146a83a6e5b37c56732e127f3f1
company,2022-11-29 19:54:49,"Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus",117335467,https://static.reuters.com/resources/r/?m=02&d=20221130&t=2&i=1615702220&r=LYNXMPEIAT00X,BIIB,Reuters,"An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely-watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.",https://finnhub.io/api/news?id=b4d038de3277c047df050e9aca46dd704d2168f40d7d17c5c596b70ff74d0122
company,2022-11-29 19:50:00,New Alzheimer’s Drug Shows Positive Results but Side Effects,117335180,,BIIB,Yahoo,"The drug from Eisai and Biogen slowed cognitive decline in study volunteers, but many had brain bleeds, swelling or other side effects.",https://finnhub.io/api/news?id=5b68ee91c517703984aefa8d652e1da7835ab4ad802f6e7623c875c7c29c136b
company,2022-11-29 19:50:00,EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE,117335179,https://media.zenfs.com/en/prnewswire.com/bc7f829160e529c760202dda02b0d1b1,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (col",https://finnhub.io/api/news?id=ae8bef36110d529b379470a0c48372b014049bc1c3df7b789b4a462cadef7a8e
company,2022-11-29 19:50:00,ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE,117335178,https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (col",https://finnhub.io/api/news?id=85f9ce314571edd48013663d8fb5bc02a133735dc5be27de25f6e6fcb8770f53
company,2022-11-29 15:23:00,"A new Alzheimer's treatment may help some patients, though researchers say more safety data is needed",117336664,https://images.mktw.net/im-675846/social,BIIB,MarketWatch,A new study found that Eisai and Biogen's experimental Alzheimer’s drug moderately reduced cognitive decline after a year and a half.,https://finnhub.io/api/news?id=8bbb6d64d896fc0cbf5bfc2aadfc88d61faf3845263c51c294f26a123aa6d82a
company,2022-11-29 12:59:00,It’s Crunch Time for Biogen Stock. Data on Alzheimer’s Trial Are Due Tonight.,117335171,,BIIB,Yahoo,"Japan's Eisai , which is developing the treatment with the U.S. pharmaceutical company, said in a September press release that the therapy worked surprisingly well.",https://finnhub.io/api/news?id=f24b70eec2e8c7985f1454bf3e6320a60b3f5f92969ea05c516eca7cbd49b7f8
company,2022-11-29 12:42:05,Biogen (BIIB) Down on Report of Death in Alzheimer's Study,117329679,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.,https://finnhub.io/api/news?id=3fe56b4fa40a1de4de111140415acb0abec16b45e5e6dff17c0355cd6c893c70
company,2022-11-29 11:42:00,"Biogen Inc. stock falls Tuesday, underperforms market",117336667,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.17% to $291.41 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=c609995cd595babca2adf6c6286e71761b7869a5c3de3824f51b6c0a15c9e31b
company,2022-11-29 10:38:50,FOCUS-Rare success for Alzheimer's research unlocks hope for future therapies,117325696,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives.  The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer’s patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau.  Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco.",https://finnhub.io/api/news?id=9ccc0edac20acaed7919ee904b1f2b25b5abfab881ffd2c1e520d9e168b02664
company,2022-11-29 09:35:37,Japanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial,117327841,https://static.reuters.com/resources/r/?m=02&d=20221129&t=2&i=1615601560&r=LYNXMPEIAS027,BIIB,Reuters,Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman who was enrolled in a trial of the company's Alzheimer's disease treatment had died from brain haemorrhage.,https://finnhub.io/api/news?id=fc04cfdd25fd4b163351349fa104203a7dbfb53ebd234e7f2eb987512343fe9e
company,2022-11-29 02:06:46,Eisai shares plunge in Tokyo after report of death in Alzheimer's trial,117321727,https://static.reuters.com/resources/r/?m=02&d=20221129&t=2&i=1615601560&r=LYNXMPEIAS027,BIIB,Reuters,Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died.,https://finnhub.io/api/news?id=1fc32069fe79373e5aad27ea517d9fb7f062faa9911707e89c4b8e87ca30298f
company,2022-11-29 02:06:44,UPDATE 1-Eisai shares plunge in Tokyo after report of death in Alzheimer's trial,117320906,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died.  A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday.  Eisai's shares sank 6.2% to 8,988 yen, leading decliners on the benchmark Nikkei index, which closed 0.5% lower.",https://finnhub.io/api/news?id=f5e4e62f7516e04c9f00070994d83076748fca96604080f7ff38c93543b854df
company,2022-11-28 23:00:47,Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug,117320907,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Just weeks ago at the company’s headquarters, Haruo Naito, the 74-year-old chief executive of Japan’s Eisai, was feeling vindicated after almost four decades of trying to develop an Alzheimer’s drug.  Ahead of the release of detailed information on Eisai’s new drug lecanemab, developed with Biogen, the company’s share price surged 60 per cent after results of a late-stage clinical trial showed that it slowed the progression rate of the memory-degenerating disease.  Initial results published by Eisai in September raised hopes of a new treatment for a disease that pharmaceutical companies have spent billions of dollars over several decades researching, only to be disappointed by repeated failures.",https://finnhub.io/api/news?id=ebc5056de1b4c4f406a0526a3011fccafefff7fba7224ba086c0a7cc6431f494
company,2022-11-28 21:36:39,"Eisai, Biogen Plunge After Report of Second Death in Groundbreaking Alzheimer’s Drug Trial",117320908,https://s.yimg.com/ny/api/res/1.2/GfnAuK.pmgeS7t44vuuu8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/37e4eef2b9a7d57a7c9720d52d8db8b0,BIIB,Yahoo,"(Bloomberg) -- Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsThere’s a Job-Market Riddle at the Heart of the Next RecessionStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThe case invol",https://finnhub.io/api/news?id=e0d80795e1b266b822ee1c48b9f9ae18f7140fca169f8584f6cbc7387d32fcd1
company,2022-11-28 19:57:22,Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trial,117320909,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Shares in Japanese drugmaker Eisai Co headed for their biggest plunge in more than a year on Tuesday after a report that a woman  in a trial of the company's Alzheimer's disease treatment died.  A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday.  Eisai's shares sank 10% to 8,595 yen, leading decliners on the benchmark Nikkei index, which slid 0.5% in the morning session.",https://finnhub.io/api/news?id=23855c4aaf0f7107215b38bb8caa3c13d7ae0789aeeb3232da5583acbbb31746
company,2022-11-28 16:49:00,Eisai shares fall following report of patient death in Alzheimer’s trial,117331082,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,Eisai Co.'s shares fell Tuesday following a report that a woman died after receiving the company's experimental Alzheimer's drug.,https://finnhub.io/api/news?id=8ec12b0df130c541e2a25806d8096b01149adb37eb8118f3c735e695d83250b3
company,2022-11-28 14:46:52,"US STOCKS-Wall Street drops, weighed down by Apple and China worries",117316044,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"US STOCKS-Wall Street drops, weighed down by Apple and China worries",https://finnhub.io/api/news?id=e520e9dc575f50665fac7c042b44b1cb104edb5e0d3f87d352e0a4d2ac090181
company,2022-11-28 13:23:32,Dementia/Biogen: causal controversy means investors must take a stance,117315753,,BIIB,Yahoo,Dementia drug candidates still have one of the highest failure rates in clinical development — 97 per cent according to one study.  Shares in Biogen fell 4.5 per cent on Monday after the website Science reported the early death of an Alzheimer’s disease patient participating in trials of lecanemab.  The US biotech has been developing the treatment with Eisai of Japan.,https://finnhub.io/api/news?id=06cc5ca6e15793db05cb0941cfd5bf5c3cca868b8515788ee54d9ca52c682e05
company,2022-11-28 10:23:32,Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A Setback,117310351,,BIIB,Yahoo,"Axsome Therapeutics said its Alzheimer's treatment met the goals of a Phase 3 study, sending AXSM stock into the stratosphere.",https://finnhub.io/api/news?id=272da7cc1e09557bf9d7248b19b444dfc9ba65e1c5b65c831d11b537b1d4a5b5
company,2022-11-28 11:42:00,"Biogen Inc. stock falls Monday, underperforms market",117336670,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 4.34% to $291.90 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=963fb99be46e9498ccebfb8e401a0249058fcd10cdbc3506d3865d8f669a7eab
company,2022-11-28 09:20:00,Biogen Is Set to Release Data on Its New Alzheimer’s Drug. Here Are 4 Things to Watch.,117310352,,BIIB,Yahoo,"Until September, there was little reason to expect that the new treatment, called lecanemab, would work.",https://finnhub.io/api/news?id=ea24e7a5be79263233134391fe727019553d67aa5cb980c8f969000e8a568979
company,2022-11-28 11:15:01,Biogen Stock Drops After Report of Patient Death,117313207,,BIIB,Yahoo,"Biogen shares are down 3.7% on Monday morning, making the stock the second-worst performer in the S 500. [Science](https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease) on Sunday [reported](https://www.wsj.com/livecoverage/stock-market-news-today-11-28-2022/card/stocks-to-watch-apple-wynn-resorts-disney-CwtsIjxRS3HMm4KtVe8C?page=1) that a woman receiving Biogen’s experimental Alzheimer's drug lecanemab had died from a brain hemorrhage. It i",https://finnhub.io/api/news?id=1a28f6e4b53cf92ddcb79c153021b48e96d2ad6a31c55e407a67f42c248dc003
company,2022-11-28 11:04:00,What to know about the Alzheimer’s drug data coming out this week,117318264,https://images.mktw.net/im-674893/social,BIIB,MarketWatch,Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.,https://finnhub.io/api/news?id=441a19e03cf757ec6814a66e83bae924ed655f80188a776d3ac3efbf25fd6fbd
company,2022-11-28 10:40:53,US STOCKS-Wall St losses limited as Amazon gains on upbeat Cyber Monday,117311214,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Wall Street's main indexes fell on Monday amid worries about protests in major Chinese cities against strict COVID-19 policies, although gains in Amazon helped limit losses as Cyber Monday sales were set for a record.  Shares of the e-commerce giant rose 2% following an industry report that spending on Cyber Monday, the biggest U.S. online shopping day, might go as high as $11.6 billion, encouraged by some of the biggest discounts and deals to attract inflation-wary consumers.",https://finnhub.io/api/news?id=c4bebd4a0664c80c55375feda90617b5e58820e0663a6cdead69fc2c056a82e1
company,2022-11-28 08:54:56,"Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall",117313209,https://media.zenfs.com/en/Benzinga/cccab3f5556a51b7fb97f47a416310a0,BIIB,Yahoo,A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that some researchers link to the drug. Clinical trial death is the second thought associated with the lecanemab. STAT recently reported that an 80-year-old man in lecanemab's phase 3 trial died of a brain hemorrhage linked to the possible interaction between the experimental antibody and the blood thinne,https://finnhub.io/api/news?id=a597a2831d429df1e4ddb18825698b3214c513ff7bee4440f933132eca7d8a66
company,2022-11-28 08:02:52,"Stocks making the biggest moves midday: Apple, DraftKings, Biogen, Williams-Sonoma and more",117315710,https://image.cnbcfm.com/api/v1/image/106936821-1630602069094-biogen.jpg?v=1669658572&w=1920&h=1080,BIIB,CNBC,"These are the stocks posting the largest moves midday Monday, Nov. 28.",https://finnhub.io/api/news?id=c6e7cd485cebdf7e26996afedcaea5fa8d66941a7422d4e661dcd1f0e9ddf100
company,2022-11-28 07:50:00,Biogen Stock Slumps On Report of Death in Alzheimer's Drug Trial,117310353,,BIIB,Yahoo,Science.org reported Sunday that a woman participating in the joint Bigoen-Eisai Clarity AD trial of an experimental Alzheimer's treatment has died of a brain hemorrhage.,https://finnhub.io/api/news?id=ee92b904f40b572b121ecfd4108974ae8d2b1fa999017f30f75b94ae0424091e
company,2022-11-28 07:33:07,"Midday movers: Wynn Resorts, Biogen, Apple and more",117316831,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Liz Moyer,https://finnhub.io/api/news?id=e3e004c5f2e15cd55f2084e00f53eaf268073c5f7161f6335ca084f08e21cc69
company,2022-11-28 05:33:00,2 Stocks Near 52-Week Highs That Could Climb Higher,117308464,https://s.yimg.com/ny/api/res/1.2/Q6NZU4lt1Y3RKHavB6WL3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/d6272472236be1e037147b7993e1bd60,BIIB,Yahoo,"Rising interest rates and a looming recession that those higher rates could cause are weighing heavily on stock prices across the board.  Shares of Biogen (NASDAQ: BIIB) have been on a roller coaster over the past couple of years.  The stock rocketed higher in 2021 after the FDA granted a highly controversial approval to the company's Alzheimer's disease drug, Aduhelm.",https://finnhub.io/api/news?id=18305e0e5fef076411e9ae8da2f8070f123e956fc0562767727ff03ccf380f5e
company,2022-11-28 02:59:34,"Apple, Chevron, Biogen fall premarket; Univar, Pinduoduo rise",117313213,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Peter Nurse,https://finnhub.io/api/news?id=149a3d6554f15d60a5db50f621433c493c050cf8d8b0e8d4a13bb31969de7513
company,2022-11-28 02:41:23,"Stocks making the biggest moves in the premarket: Apple, Taboola, Biogen and more",117315686,https://image.cnbcfm.com/api/v1/image/107007639-16433161212022-01-27t203447z_1583787139_rc2t7s9ztkym_rtrmadp_0_apple-results.jpeg?v=1669639283&w=1920&h=1080,BIIB,CNBC,"The stocks making the biggest moves in premarket trading include Apple, Taboola, Biogen, and more.",https://finnhub.io/api/news?id=f7984af3a480bbeec6de6def71c99347f94da3d5384a971552b7527b915c9e36
company,2022-11-28 02:30:00,"Premarket Movers: Univar Solutions, Ansys, Wynn Resorts",117317118,https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png,BIIB,MarketWatch,"With U.S. stock markets set to open in two hours, (UNVR) was up 10.6% in pre-market trading, and (WYNN) was up 5.9%. (SHOP), (SRPT), and (LVS) were all...",https://finnhub.io/api/news?id=a5df7c463cfea6763ca397c7e3bafed2362588d7e51889a2324c26c9d12e6920
company,2022-11-27 22:30:00,Biogen Is Set to Release Data on Its New Alzheimer’s Drug. Here Are 5 Things to Watch.,117318266,https://images.barrons.com/im-520992/social,BIIB,MarketWatch,"Until September, there was little reason to expect that the new treatment, called lecanemab, would work.",https://finnhub.io/api/news?id=c6a4557f4c45bc0ca052d9aad3fd60e5d00ef4ddc6552800eef54273c492445b
company,2022-12-05 11:56:29,Johnson & Johnson: Alzheimer's Disease Pipeline Could Dominate,117406079,https://media.gettyimages.com/id/1325253083/photo/world-alzheimers-day-paper-silhouette-of-human-head-with-red-tangled-threads-on-blue.jpg?b=1&s=170667a&w=0&k=20&c=5ftgPL7CtkfIUy2Cq1DEeGjK21lJFuYCjuOz0qhUb3I=,BIIB,SeekingAlpha,JNJ selected a vaccine to take to Phase 3. Another rival amyloid beta antibody could appear on the market next year. Click here to read more.,https://finnhub.io/api/news?id=404c6eda127713faf5c08c3eea0e9a84e218f9b85186c22a2541dc157c620909
company,2022-12-05 11:42:00,Biogen Inc. stock underperforms Monday when compared to competitors,117407864,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 2.06% to $292.75 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=93d36d10397956da9c204b8a9230aba46f9d89e08e5ad19c8c84383820d1c3b0
company,2022-12-05 07:30:00,"European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS",117401474,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"SOD1-ALS is a rare, genetic form of ALS,1 comprising approximately 2% of people with ALS2If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-AL",https://finnhub.io/api/news?id=4960d9630d37da5ec13cddec7c8a6872516b9eb2231db68cf5875e48c84d4c6b
company,2022-12-05 02:55:00,Biogen: EMA to Review Tofersen in Rare Form of ALS >BIIB,117407865,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"By Colin Kellaher Biogen Inc. on Monday said the European Medicines Agency has accepted its application seeking approval of tofersen for a rare, genetic form...",https://finnhub.io/api/news?id=5361e179127010c09c942e5d916e4cdd1aa732ab49606ce0a6694d2b9011f4f7
company,2022-12-04 09:37:00,Can These 2 Stocks Crush the Market Again in 2023?,117396298,,BIIB,Yahoo,"The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and Biogen (NASDAQ: BIIB).  Regeneron was having an unimpressive year on the stock market until its shares soared by double-digit percentages in one day in September.  As is often the case with biotechs, Regeneron owes this move to positive clinical developments.",https://finnhub.io/api/news?id=be1e0f1972d63b9b747ce485bd241e107eb608e7b5cf7e722db08c88e4456954
company,2022-12-04 08:30:00,Is Biogen Stock a Buy Now?,117396299,,BIIB,Yahoo,"Thanks to well-received clinical trial data for its investigational Alzheimer's therapy, lecanemab, shares of Biogen (NASDAQ: BIIB) are up by more than 51% in the past three months -- and the company hasn't even made a single dollar from the positive findings yet.  Including lecanemab, Biogen has a dozen programs in late-stage clinical trials, all but four of which are being developed for indications in neurology.  Its areas of focus within neurology are Alzheimer's disease and Parkinson's disease, though it also has a trio of programs for multiple sclerosis (MS) in development.",https://finnhub.io/api/news?id=9fbbe79229eb163f78672f10c1e7a6318350bc711030972a122a39af48186658
company,2022-12-03 05:23:00,Is Anavex Life Sciences a Smart Stock to Buy Now?,117388928,,BIIB,Yahoo,"Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher.  Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2.  Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes?",https://finnhub.io/api/news?id=05cc8ff0ebf3a2b15873a454575148bffc227869a0ec89348b586824b33f8796
company,2022-12-02 11:42:00,Biogen Inc. stock underperforms Friday when compared to competitors,117407867,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. sank 0.98% to $298.90 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=1b5f2b402c28fac169659a7bc647b28ca52e27c27a9cbd24266ca1c54278f1c0
company,2022-12-02 11:31:04,Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?,117378897,https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94,BIIB,Yahoo,Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=3c1c0b609f8bd710817565268466910890b911da6c695a853fd694e53c3e2024
company,2022-12-02 09:45:08,BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns,117378542,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358625679/image_1358625679.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more.",https://finnhub.io/api/news?id=5e5f3f8e58df8e06fb2eb5be86c731e7de3eec7229b466a5c6ffc5c13a637f5a
company,2022-12-02 07:55:12,"Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal",117375117,https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307,BIIB,Yahoo,Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.,https://finnhub.io/api/news?id=d597afcef4f40a17a6f045ba59ce9ad1b5b7176f1470ea67368c97fe4470e752
company,2022-12-02 05:30:00,Why Shares of Vaxxinity Soared This Week,117373661,https://s.yimg.com/ny/api/res/1.2/mMca5M046yjQBQeznZecuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/333bef775d1d9c5655e3be513e02be6c,BIIB,Yahoo,Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.,https://finnhub.io/api/news?id=3021790df56451e6e02dd358e1048c0212ad3e26ffe8fb41cd5535f3f0f693c8
company,2022-12-02 02:32:00,Here's how one hedge fund is going aginst the grain and beating the markets,117407866,https://images.mktw.net/im-677726/social,BIIB,MarketWatch,This fund is crushing it. Here are its top 5 stock picks,https://finnhub.io/api/news?id=57d3daa6f54c6f2bdfc3ed1259a35987bb8e50f349e71d2063136d28c51c79ae
company,2022-12-09 17:50:10,Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know,117464669,https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session.",https://finnhub.io/api/news?id=5c824ea372d5c73ae74f91038c899d3e7aa0b5a3fff10af7bad8ba8037d82cc7
company,2022-12-09 12:01:04,Medicare Part B Premiums Could Be Lower in 2023 – Here’s Why,117457021,https://s.yimg.com/ny/api/res/1.2/nqPWFs2Q4ZOFKzZ0o3rffA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/gobankingrates_644/b35b18ff15af591a0305724f77ef97c6,BIIB,Yahoo,"Seniors in the United States haven't had much to cheer about this year, with inflation running well ahead of the 2022 Social Security cost-of-living adjustment and spiraling healthcare costs cutting...",https://finnhub.io/api/news?id=0119c0415faeabb5f4e17d8a3eff4e1b07cbfe034779f37a3142dc1dd0f992f1
company,2022-12-09 11:40:04,BIIB vs. TECH: Which Stock Is the Better Value Option?,117457022,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,BIIB,Yahoo,BIIB vs. TECH: Which Stock Is the Better Value Option?,https://finnhub.io/api/news?id=c0ea80b06af29612cb1c8d8fff0648fad7ed5b88be674a03a2bb00d024177f6f
company,2022-12-09 11:40:00,Biogen Inc. stock underperforms Friday when compared to competitors,117477246,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.29% to $285.37 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=2f38dad09dae97449e7956dfae124e94a34c186c61ccf04e031db4ee96ddb1fe
company,2022-12-09 07:30:00,"FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)",117457023,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"CAMBRIDGE, Mass., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA®1 (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. ACTEMRA® is indicated for several indications, including moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis and sy",https://finnhub.io/api/news?id=a5525011be74237a13c2e79f6317b6b64db7142561fcdfc41e31fa939f57bd9f
company,2022-12-09 05:54:00,IN BRIEF: Biogen gets FDA review of biosimilar to Actemra,117754388,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a1a28b175e555003988a2d9615e3713aa93f760455212ac0b7c4f5735868fb39
company,2022-12-09 05:50:00,New Alzheimer’s drug appears to slow cognitive decline but is ‘not a breakthrough’,117477247,https://images.mktw.net/im-682178/social,BIIB,MarketWatch,"Lecanemab, the drug being tested by Biogen and Eisai, was found to have a modest benefit to patients in a Phase 3 study.",https://finnhub.io/api/news?id=0930a27dbc4fd51c125afbd4db2431c2d2d6490f1629e0eaa4b01a7678ad2d1a
company,2022-12-09 04:51:00,New Alzheimer`s drug appears to slow cognitive decline but is ���not a breakthrough`,117754391,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=60485c0defec825a4a82cee0050d01c58c3d17de55f34801e954a1777f6fc48a
company,2022-12-09 04:42:43,Biogen (BIIB) Investor Presentation - Slideshow,117453226,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,The following slide deck was published by Biogen Inc.,https://finnhub.io/api/news?id=15bdbffeffc915b91e10fc27b0485229b61dbedc312332411d44c3aafe8547ed
company,2022-12-09 02:50:00,Biogen: FDA Accepts Application for Actemra Biosimilar >BIIB,117477248,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"By Colin Kellaher Biogen Inc. on Friday said the U.S. Food and Drug Administration has accepted its application seeking approval of BIIB800, a proposed...",https://finnhub.io/api/news?id=d8bd546eabff3a669edb86d9f42dac549ec60d218c64f387a47be0bd7dc1351a
company,2022-12-09 02:07:00,Biogen granted FDA review for Actemra biosimilar,117734725,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=66671130274618dba77da7b6eceabde9520f77ff2088e20a68f20e2f2c478e00
company,2022-12-09 01:32:00,Biogen announces FDA accepted for review the aBLA for BIIB800,117754403,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d3e02e2fa1cd41803c2107aaf35a75297c9ab3e22611fe104ede95051276381b
company,2022-12-08 11:42:00,"Biogen Inc. stock falls Thursday, underperforms market",117477249,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 1.04% to $289.10 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=23991e4cec445a9f8f0f1f7571a7e615258147f65562324bd6ff4f52dad4df2d
company,2022-12-08 11:30:04,Why Is Mirati (MRTX) Down 19.9% Since Last Earnings Report?,117443768,https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9,BIIB,Yahoo,Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=87f86828492e4ce28dbb56dc6efbf6c20b6b3f272524f3dbf12394326c1cfb6f
company,2022-12-08 09:40:02,Is Biogen (BIIB) Stock Undervalued Right Now?,117443769,https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94,BIIB,Yahoo,"Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",https://finnhub.io/api/news?id=c8a09896bdcef4da97ec279f162335a9770771df79c022b1d31f053c33be9df9
company,2022-12-08 07:21:00,See How Biogen Ranks Among Analysts` Top Picks With Strong Buyback Activity,117754407,,BIIB,The Online Investor,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=71d27f273e1e169946945f409e6d9f3bc954fa354705139a8822ad27fb9d75c6
company,2022-12-08 04:48:09,"Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage",117443770,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,"ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.",https://finnhub.io/api/news?id=29b39c4d64edfd003fa05f34c85a216e51fb92035cc51040c036180126969962
company,2022-12-07 20:42:00,"Biogen, Eisai prompt Medicare to reevaluate Alzheimer`s coverage after new data",117754413,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=85da3d8afd8af90bdb32c9910e21db35d6a00f864a740a1f7e112175dff8cf9d
company,2022-12-07 11:42:00,Biogen Inc. stock outperforms market on strong trading day,117477250,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.23% higher to $292.15 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=d93304b052c260349eb5d5a4a18ead0fc2f9996f46350ffb9fc267e8ef4443fb
company,2022-12-07 10:38:00,Why 2023 Could Be a Big Year for Biogen,117431448,,BIIB,Yahoo,"Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales.  With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective.  Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business.",https://finnhub.io/api/news?id=fcf9c0d042f50b1f54d3fa296c7b403567c156ef7804e4d5a9562f3aecdabe9b
company,2022-12-07 10:27:03,"Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression",117431449,https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b,BIIB,Yahoo,"Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.",https://finnhub.io/api/news?id=e1ea0123c36666d7a2810c6bf6cfa02f27d40f1ef639a6211a14aaac8364a84e
company,2022-12-07 08:15:00,Biogen-funded Climate Toolkit for Health Clinics Formally Launched,117429847,https://media.zenfs.com/en/accesswire.ca/025a343f5360ae5219a0a359321a620a,BIIB,Yahoo,"NORTHAMPTON, MA / ACCESSWIRE / December 7, 2022 / Biogen: Thousands of U.S. community health centers that care for uninsured or underinsured patients around the U.S. face an increasing number of systemic challenges due to extreme weather as a result ...",https://finnhub.io/api/news?id=97baeee37e2feeff1e8284c53e291bfac925565ba67ea7c781eaf76de9536c70
company,2022-12-06 20:16:01,3 Biotech Stocks Aiming to Reinvent Mental Health Treatment,117429443,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,"Atai, Biogen, and Sage are working to develop new treatments for mental illness.",https://finnhub.io/api/news?id=64ba86b3f10e2fd4dfe35382f4c39a5dd73cdb8f2a913ca46d656cd0e3b730bc
company,2022-12-06 11:43:00,Biogen Inc. stock outperforms competitors despite losses on the day,117477251,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.44% to $291.47 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=18e751724d62af62078cf4d97fa4406511f750bee55491c9d978f468f1a187a0
company,2022-12-06 09:44:02,Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe,117418473,https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b,BIIB,Yahoo,"Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.",https://finnhub.io/api/news?id=e7de82b6d5070453034ddfc3e9fbcf234e59f8b57d067f6df3ccc315a9f574a8
company,2022-12-06 07:51:31,Anavex Life Sciences: The Little Company That Did,117418187,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341839326/image_1341839326.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Anavex likely has an effective treatment for early Alzheimer's disease. Click here to read our analysis of AVXL stock.,https://finnhub.io/api/news?id=2c9d792fb7ee309e2ae206a3c5b9f683b02c79082251bd231a92d112a626d379
company,2022-12-06 07:00:00,Alzheimer’s Treatment Thrills Investors as Doctors Debate Effect,117415567,,BIIB,Yahoo,"The data presented for Eisai and Biogen’s drug wasn’t convincing enough to settle a debate among experts, but investors are betting on commercial success anyway.",https://finnhub.io/api/news?id=84b5e4d79013eb54257978694148eaca2b821208d2756c73cc88fa0a8e1ac6e6
company,2022-12-06 06:40:22,Biogen Inc. (BIIB) Biogen and Sage Zuranolone Webcast Transcript,117417278,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Biogen Inc. (NASDAQ:NASDAQ:BIIB) Biogen and Sage Zuranolone Webcast December 6, 2022 8:00 AM ET Company Participants Helen Rubinstein â Director-Investor Relations-Sage Therapeutics Chris...",https://finnhub.io/api/news?id=4047d38382c7daa54568edb656f9c7c04f6a65868291bdf48c7946cd0b7112bd
company,2022-12-06 06:30:00,Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression,117415568,https://media.zenfs.com/en/business-wire.com/a1e4c541f60b820856565db7cf1bcde9,BIIB,Yahoo,"CAMBRIDGE, Mass., December 06, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission",https://finnhub.io/api/news?id=029ce0bbe9b406983bd2cc5405d23364d73d0830ba9b8d59a8fdbba8afe997a2
company,2022-12-06 04:31:09,Biogen and Sage Zuranolone Webcast Presentation,117415750,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,The following slide deck was published by Biogen Inc.,https://finnhub.io/api/news?id=35afbd5fc39d346295c96c86c60e2139afd54d23927625315ec8f47f5f9bdf1e
company,2022-12-13 13:34:12,Biogen: A Comprehensive Look At The Clarity AD Study Results,117502658,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367780024/image_1367780024.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Pivotal trial data suggest that lecanemab offers similar modest clinical benefits and safety risks as Aduhelm. Results may have been affected by bias. Click here to read more.,https://finnhub.io/api/news?id=918cc37f3029860e3ee81daff6a13202e489e186b1f3b66b292ccf3cd92c03f1
company,2022-12-13 11:40:00,"Biogen Inc. stock rises Tuesday, still underperforms market",117559812,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.22% higher to $291.24 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=9da420248a6373e37a834f5e3946f73cf3a73e53515ee7c0e67370ad4631eb7f
company,2022-12-13 10:39:27,15 Best S&P 500 Stocks That Don’t Pay Dividends,117498373,https://s.yimg.com/ny/api/res/1.2/ewJkRdFaq.2XGQWUyjLf7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xODAw/https://media.zenfs.com/en/insidermonkey.com/d56904bb36b5a45d4abc684b7368cf3c,BIIB,Yahoo,"In this article, we will be taking a look at the 15 best S&P 500 stocks that don’t pay dividends. To skip our detailed analysis of these stocks and the performance of the S&P 500 so far this year, you can go directly to see the 5 Best S&P 500 Stocks That Don’t Pay Dividends. […]",https://finnhub.io/api/news?id=90ff9030b8df1b846d707851e0980e6e723719f807660c1e281da202ffc7b6bb
company,2022-12-13 05:16:36,AbbVie: Clouds Keep Thickening Due To Lack Of Revolutionary Drugs,117497535,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1400621080/image_1400621080.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Humira's international sales were $603 million in Q3 2022, down 25.7% year-over-year. Read more on how AbbVie is facing a lack of revolutionary drugs.",https://finnhub.io/api/news?id=7014562d34e684b361b365f203d19709a641560108d2eb2e1e77a785ba57eefc
company,2022-12-13 02:00:46,Sage Therapeutics Could Be In For A Depressing FDA Review,117494957,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181076506/image_1181076506.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"Sage Therapeutics completed its rolling submission to the FDA for zuranolone, a better formulation of its marketed postpartum drug. See why SAGE stock is a Hold.",https://finnhub.io/api/news?id=a667322e0a5441ba272569ab6f4f73f7f3a711b459c1d7d1f6dab1737e3026a8
company,2022-12-12 11:56:00,"CSL appoints current COO Paul McKenzie CEO, replacing Paul Perreault",117630075,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dc3bdb4610ee433120657c7910146a8ba72ee031241835787249b7ef95e9774a
company,2022-12-12 11:40:00,"Biogen Inc. stock rises Monday, outperforms market",117559813,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 1.83% to $290.59 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=5f197308985fe28e0b9f5c8aaee27beeb7ee768463919b8dbf1e63e9bde274d9
company,2022-12-12 06:22:35,Pfizer: The Best Long-Term Investment Setup Since 2009,117483239,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344323367/image_1344323367.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here.,https://finnhub.io/api/news?id=0e74d2cf86a7d6ee6bf5b3f5638c57c73af098e1f08b0737c71762970272a841
company,2022-12-12 03:10:00,"Frontage partners with Eisai, Biogen to complete the Clarity AD study",117680370,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f1bf517d8a92da19aefd6e7c0bafdc114881ea1a111bf1c52990daa7ada18a13
company,2022-12-11 09:08:00,"Among the Best-Managed Companies of 2022, Some Warning Signs",117474658,,BIIB,Yahoo,These companies score well overall in the WSJ Management Top 250. But there are red flags in at least one area.,https://finnhub.io/api/news?id=853507e6c02690e73138166e6b8e95f0876d74a7515b204df1ed46006bb47460
company,2022-12-09 23:15:05,Sage Therapeutics: Zuranolone NDA Near-Term Tailwind,117466140,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1405956991/image_1405956991.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Sage's collaboration with Biogen looks to be building momentum around zuranolone. Read more to see why we think there is market potential in SAGE stock.,https://finnhub.io/api/news?id=cdb18c53de8e616bcb675385a4fba95baeaa0cb88cf204a5e9d86d98e3214a7e
company,2022-12-16 11:40:00,Biogen Inc. stock outperforms competitors on strong trading day,117559809,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.54% higher to $284.98 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=baa9614017da9612a421fc6c47a5c7e5b4883459f27d3531f6c20ce81eab3de5
company,2022-12-16 00:11:00,Eating these simple foods may slow Alzheimer`s by a third,117680364,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=77c8047a5e607f76619193022194652fbc0fb3d045429ea4d4b5f08dd95db733
company,2022-12-15 22:06:00,Primecap Odyssey Funds` 2022 Annual Shareholder Letter,117650830,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=577f1fe945f914f28916dddc99b1b1d27e7a30ea5dabaedbf280c877e6355de2
company,2022-12-15 17:50:10,Biogen Inc. (BIIB) Stock Moves -1.94%: What You Should Know,117534681,https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $283.44 in the latest trading session, marking a -1.94% move from the prior day.",https://finnhub.io/api/news?id=ffecbca02d542bacfc693db65d736b3805045210135f32bb14f58bce48bc1d87
company,2022-12-15 11:40:00,"Biogen Inc. stock falls Thursday, still outperforms market",117559810,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.94% to $283.44 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=b9e5fe82910c7414e85cb6e14841a7a09f1466ec0d17bb1503031f8d068d7513
company,2022-12-15 11:25:52,Cassava Sciences: Not Betting On This Moon Shot,117526914,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359176290/image_1359176290.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Cassava Sciences' stated mission is to detect and treat Alzheimer's disease. See why I am passing on any investment recommendation around SAVA stock.,https://finnhub.io/api/news?id=de07008a58636af5e44abe1ee67bdd795fba07e6954db42a4b065304f755510b
company,2022-12-14 11:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",117559811,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. sank 0.75% to $289.05 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=9b74eb568c13fadbfc611699c363d17a9e9bd9b388554879ab858c27357f1c8d
company,2022-12-14 11:39:04,"Eli Lilly (LLY) 2023 Guidance Falls Short, Stock Declines",117519297,https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707,BIIB,Yahoo,Eli Lilly's (LLY) 2023 EPS guidance falls short of the Zacks Consensus Estimates and our model estimates. The company plans to launch four new drugs next year.,https://finnhub.io/api/news?id=0e0cf5295092b334d7e2032219a2924c1485b295bbf1f06dad0d7d66f7f10144
company,2022-12-21 17:50:10,Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know,117610913,https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $286.86 in the latest trading session, marking a -0.23% move from the prior day.",https://finnhub.io/api/news?id=543b1b651a7913f505bdb91aa8a4f04548222cf37557511f8042a657d33cc886
company,2022-12-21 11:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",117607336,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.23% to $286.86 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=d7fbb85aedb10b8f1e4cf52ec43871e1f2eaf36b96cd086408b9e0726e6ef48d
company,2022-12-21 08:08:55,How Well Does Anavex's New Alzheimer's Drug Compare Against Biogen's New Drug?,117603630,https://media.gettyimages.com/id/820952986/photo/dementia-and-occupational-therapy-home-caregiver-and-senior-adult-woman.jpg?b=1&s=170667a&w=0&k=20&c=-4urgPTbX4ua8f805cc80_XYcjaFt3SIAi2fQBxv23Y=,BIIB,SeekingAlpha,"The Phase 2b/3 trial of Anavex's Blarcamesine demonstrates major, statistically significant effects in slowing Alzheimer's Disease. Read more here.",https://finnhub.io/api/news?id=29d6e6d17b66d27d182e6b4d8f5795133512fdc4cd95d803d6f3c3e8e3888d7a
company,2022-12-21 07:13:00,How Well Does Anavex`s New Alzheimer`s Drug Compare Against Biogen`s New Drug?,117682313,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=04564adebe9e8acf986dad3e66466ca27b3c91940ba4beb0dfaa7a6a449b350a
company,2022-12-21 03:47:00,Top Biotech Companies Are Making Progress In The Fight Against Alzheimer`s Disease,117734690,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=54c34fcbfe5c6aaed55e697abc19c42fd66d0101d931d6a3ab1ea019002c70be
company,2022-12-21 03:46:00,Top Biotech Companies Are Making Steady Progress In The Fight Against Alzheimer`s Disease,117734691,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5a18af918bab70ef8f2e087b1266f942386210b3a4918fa17f3c5a2779888b44
company,2022-12-21 02:41:00,Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer`s Disease,117734692,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4caaf4f37b7433b884332de15f9037095b91c46c69909ff4263f20d5ee1a37d0
company,2022-12-20 11:40:00,"Biogen Inc. stock rises Tuesday, outperforms market",117607337,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 1.10% to $287.51 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=7f5b61ff421973ba2d4f7bd6d3d3ee878554ce922e31b90029b9b96f6df0bb2f
company,2022-12-20 05:30:14,Top Net Payout Yields - December 2022,117585695,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1285391934/image_1285391934.jpg?io=getty-c-w750,BIIB,SeekingAlpha,The top net payout yield stock failed to match the total return of the S&P 500 during 2H' 22 as tech stocks soared. Check out our list of stocks.,https://finnhub.io/api/news?id=a6b724624bc5857c4b0adcfacc6d91445b0254feda670e02a10f760a59fde47a
company,2022-12-19 20:55:00,Mizuho Securities Remains a Buy on Biogen (BIIB),117754336,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2e9998edf168dae5fbd63535f885fb5900d0d1779fddb9b3a177dc521ea7cf06
company,2022-12-19 11:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,117607338,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.21% to $284.38 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=a0048c5b8a21c46c872a8a91d96dd1290db89f265363eb010ee5e0c5ae32bdd7
company,2022-12-19 07:30:00,Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration,117578314,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Glofitamab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other blood cancers CAMBRIDGE, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen will have no payment obligations and will receive tie",https://finnhub.io/api/news?id=d800b7e537b6d1c5bb14b8453d29d4206fd6e76c544a9de1eacc6f45099ac4e7
company,2022-12-19 01:33:00,Biogen reaches agreement with Genentech related to glofitamab commercialization,117734697,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b65c36df0b31e16d36ee322c07a42a8876490052580619c26760fb012baeb63
company,2022-12-18 23:51:00,Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Biogen (BIIB),117754341,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e93559fa576a98201d3548b7b202d6de50a1e87f0b0a6a5c7a4e684e353d4417
company,2022-12-18 09:04:41,The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond,117598951,https://media.zenfs.com/en/investorplace_417/7a6d7cf8fd09137bc1a8f5746ab0adba,BIIB,Yahoo,"Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks. With company-specific catalysts outweighing negative macro factors such as high inflation, rising interest rates, and slowing economic growth, scores of healthcare stocks have delivered strong returns in 2022. However, far from a “one and done” phenomenon,",https://finnhub.io/api/news?id=c691af512babc214352acbf5f7084b9050d1043561cd10f6a83e3b6107918a00
company,2022-12-18 06:45:00,Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move,117566087,,BIIB,Yahoo,"Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatments.  Vertex's latest CF drug, Trikafta, still has plenty of revenue growth ahead.  Instead, it has to do with Vertex's candidate for blood disorders, exa-cel -- a one-time curative treatment for two blood disorders with limited treatment options today.",https://finnhub.io/api/news?id=9895ab05bea087165fbf18dfaa4fa7379b9f1a89cbe660a36d62116bb8c0019c
company,2022-12-18 06:00:00,Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock,117566088,,BIIB,Yahoo,The bear market has weighed on stocks across industries this year.  Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX) have both climbed in the double digits -- and for good reason.  Which one of these top stocks represents the better bear market buy right now?,https://finnhub.io/api/news?id=cf2f92fa5f20d2d4c83c580b629a5c7d054e2984d3db8852b4fe611833490a69
company,2022-12-18 00:00:17,IBBQ: Healthcare Dashboard For December,117565452,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310024666/image_1310024666.jpg?io=getty-c-w750,BIIB,SeekingAlpha,The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF.,https://finnhub.io/api/news?id=e5bf97def27912b4a2d83c6964251e037ef37a2457f0e776d37832fcc5e3cfcb
company,2022-12-25 06:03:00,Goldman Sachs highlights key healthcare themes for 2023,117754301,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4f08a25860152070e92858132f57cacd10bc563993a7ac5e587f6b9a4f8168b0
company,2022-12-23 12:53:38,Roche's Follicular Lymphoma Therapy Scores FDA Approval,117635648,https://media.zenfs.com/en/Benzinga/9620e200f69b7f9c49ab4532f0566e4d,BIIB,Yahoo,"The FDA approved Roche Holding AG (OTC: RHHBY) unit Genentech's Lunsumio (mosunetuzumab-axgb) for relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate, making Lunsumio the first CD20xCD3 bispecific to be authorized for this form of non-Hodgkin lymphoma (NHL). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a",https://finnhub.io/api/news?id=a3a18734e5bc26a2a53cdc8c4c07cc68df60a5b94140836f7c75562023ce0693
company,2022-12-23 11:40:00,"Biogen Inc. stock falls Friday, underperforms market",117743291,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.52% to $279.16 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=567a391c19ee8fb223ea5a3589cccb45c949e9aa765b11f114d14f9983180476
company,2022-12-23 11:00:32,"Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report",117629803,https://static.reuters.com/resources/r/?m=02&d=20221223&t=2&i=1618036096&r=LYNXMPEIBM0C3,BIIB,Reuters,An influential drug pricing research group said Eisai Co Ltd and Biogen Inc's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.,https://finnhub.io/api/news?id=f1908b2325544d8d3c0168cda239eb279f24ea61e9705060f48268adb4201894
company,2022-12-23 11:00:30,"UPDATE 1-Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report",117627759,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"An influential drug pricing research group said Eisai Co Ltd and Biogen Inc's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.  In a draft report released on Thursday, the Institute for Clinical and Economic Review (ICER) said a price range of between $8,500 and $20,600 annually for lecanemab would meet some commonly used thresholds for cost effectiveness.  Biogen halved the price of its first Alzheimer's drug Aduhelm last year to $28,200 for a person with average weight, amid tepid sales and reimbursement hurdles.",https://finnhub.io/api/news?id=01846fd11c446c70e81eb9a65c5b3ecf5a82896516191cf0742090777e137677
company,2022-12-23 10:05:03,Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma,117631289,https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0,BIIB,Yahoo,"Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.",https://finnhub.io/api/news?id=b66a09959d2cb8d1acc81d0bdbbceeb2bb95c9bb6823864038f7f6f1882dae7d
company,2022-12-23 09:53:00,3 Nasdaq Stocks That Are Up 25% in 3 Months,117627760,,BIIB,Yahoo,"The Nasdaq Composite has plummeted 33% this year, but there are signs that for at least some stocks, brighter days could be on the horizon.  Entering this week, three Nasdaq stocks were up 25% in just the past three months.  Among the hottest buys of late are chipmaker Nvidia (NASDAQ: NVDA), and healthcare companies Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD).",https://finnhub.io/api/news?id=ddb1abccb6b1a5a82ba7ccf653217376494e1974573f024c0ddd6c3b1c892373
company,2022-12-23 06:58:50,"Stocks making the biggest moves midday: Mission Produce, Nutanix, Alphabet, Tesla and more",117630625,https://image.cnbcfm.com/api/v1/image/107071087-16542873122022-06-03t194242z_962376127_rc2jku994ea0_rtrmadp_0_tesla-jobs-musk.jpeg?v=1671814730&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=a54c25472a48228583de38aac481787c3b3c830ea8c497cd17066d82bae29f11
company,2022-12-23 06:33:45,"Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report ",117629805,,BIIB,Reuters,An influential drug pricing research group said Eisai Co Ltd and Biogen Inc's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.,https://finnhub.io/api/news?id=a9b25dec39eb374986d0ab6361e0f6a33d7c7ca58bf5ba0f57e4201c579c5230
company,2022-12-23 06:30:00,1 Green Flag and 1 Red Flag for Biogen,117624506,https://s.yimg.com/ny/api/res/1.2/mksmpvc4Avyl8OnQX1QmmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/340a68e35dbd7b225734953ff37e9ac1,BIIB,Yahoo,"Biogen (NASDAQ: BIIB) is one of the biotech-industry's giants and success stories. At its peak in 2015, the company's market value topped $100 billion. And its annual revenue reached more than $14 billion at its highest, thanks to its blockbuster multiple sclerosis drugs.",https://finnhub.io/api/news?id=26cb61ba41c7ab33e494b9ec5dce95b1dfd34966194addb3f7025316c0af6b9f
company,2022-12-23 04:59:00,"New Alzheimer’s Drug Could Be Priced Up to $20,000 a Year: Group",117624507,https://s.yimg.com/ny/api/res/1.2/9kpJtpA4YmjcdRKBnBqjCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/2cf85bccaf37e97b900eab93a21449d5,BIIB,Yahoo,"Essai and  Biogen  could price their new Alzheimer’s drug as high as $20,000 a year.  The Institute for Clinical and Economic Review, which issues recommendations on drug pricing, said that the drug Lecanemab would need to be priced between $8,500 and $20,600 per year to meet “traditional cost-effectiveness thresholds.”  The institute’s conclusions are preliminary.",https://finnhub.io/api/news?id=2b1001d96b5400d216c28ed6dc0a549470b1111400ed8c52121cb9a52d559b80
company,2022-12-23 04:15:00,Biogen`s Alzheimer`s Drug Could be Expensive,117680346,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7e5ba944cd350a3b5ecec5247f07f8fbe5b5e52237a423f2c415cabec96abe4b
company,2022-12-23 03:43:00,Biogen/ Eisai deserve $30K price tag for new Alzheimer`s drug ��� Wells Fargo,117754305,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d6faf80b3290b8587409eb2a19a71a58755334ca00d4d3b076992632fec3f9e8
company,2022-12-23 02:53:28,"Stocks making the biggest moves premarket: Tesla, Nutanix, Meta and more",117630615,https://image.cnbcfm.com/api/v1/image/103447821-GettyImages-144059167.jpg?v=1671800008&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves before the bell.,https://finnhub.io/api/news?id=ef4016c64e457dbc8132cf0082e5fd69a3d53d48e5d490e5e6851b7fe75065dd
company,2022-12-22 23:15:00,"Third trial death tied to Biogen and Eisai Alzheimer`s drug, Science reports",117680348,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=66e51410cebf3b7cffa6ae8f58fb9db4f232dc4fd8383b4c7c589034b18e7a72
company,2022-12-22 20:42:00,Biogen and Eisai submit BLA data for lecanemab in China,117680350,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9383c80326f4af173fca1c9d8622444a8be9213ff15df34d737983eaede3e8f5
company,2022-12-22 19:00:14,A Deadly Legacy Raises the Stakes in the War Over Fast Drug Approvals,117621915,https://s.yimg.com/ny/api/res/1.2/pwyFYTGzXvBMp10tkbPXhw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/c23042eac2593e76b6a8f485a41cf46d,BIIB,Yahoo,"(Bloomberg) -- For years, a family tree spanning two pages of blueprint paper gathered dust at the back of Cynthia Weber’s closet. Going back to a family matriarch born in 1812, it detailed the relationships and causes of death of more than 350 ancestors. It wasn’t packed away because the family had forgotten about it. Nobody wanted to look at it. Two of Weber’s great grandfather’s cousins died in their 20s, her uncle died at 30, her fourth cousin succumbed at just 25. Three capital letters are",https://finnhub.io/api/news?id=249c1c8f29ad5783a28ade75c0b0c116c16d967b72f0014dc7d5b2e5e7730282
company,2022-12-22 18:30:00,EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA,117621034,https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai has initiated submission of data for Biologics License Application (BLA) to the National Medical Products Administration (NMPA) of China for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody.",https://finnhub.io/api/news?id=ac83d701badb53f1a1a098ac71536f4c5d9a0096c6aa9659e5b03f6063719fb0
company,2022-12-22 13:59:34,Biogen's Alzheimer's Antibody Might Have A Third Death Associated With,117621917,https://media.zenfs.com/en/Benzinga/b30290c94e877ca19fc7e1a1b36c1ab9,BIIB,Yahoo,"A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab. Science has obtained medical records showing that a 79-year-old Florida woman participating in an ongoing antibody trial died in mid-September after experiencing extensive brain swelling, bleeding, and seizures. Treatment with lecanemab reduced clinical decline on the global cognitive and functional scale by 27% at 18 months, relative to the placebo, which was the primary endpoint",https://finnhub.io/api/news?id=55541ae9219a99071b50fb70cca0bbe10d20cc564008c08ba139d190155a517d
company,2022-12-22 11:40:00,"Biogen Inc. stock falls Thursday, underperforms market",117743295,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 2.18% to $280.61 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=7c6154a6f95c7ac26012b8bd1195ef52d8afc2dcbfcf2cab6577e9d515f18cd3
company,2022-12-21 21:00:00,PureTech Provides End of Year Report on Key Progress,117651820,,BIIB,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a90ff488c1b1e938de8afbfe6cf285c1d5b2cc8c43555cc4bf05dd5f38755b0
company,2022-12-29 18:20:28,"Congressional investigation reveals 'atypical,' 'inappropriate' collaboration between FDA, Biogen",117891809,,BIIB,Yahoo,"A report released by the House Energy and Commerce Committee paints a damning picture of the approval process for aducanumab, generically known as Aduhelm, the first Alzheimer's drug made by Biogen Inc. and Eisai Inc.",https://finnhub.io/api/news?id=b3af045909cb8eeecc66232842ade24d0a8fcb71048ef7d3effa028a6371acf2
company,2022-12-29 15:33:15,Congress faults US regulator’s approval of Biogen Alzheimer’s drug,117874341,,BIIB,Yahoo,"Two US congressional committees have accused the Food and Drug Administration of inappropriately collaborating with Biogen before approving the company’s Alzheimer’s drug.  A joint report by the House committees on Oversight and Reform, and Energy and Commerce accused the FDA of granting Aduhelm, Biogen’s Alzheimer’s drug, accelerated approval in 2021 despite an internal advisory committee’s refusal to issue a favourable recommendation, and concerns about the drug’s inconsistent clinical data.",https://finnhub.io/api/news?id=5ec8082be28b90e8aede884a861618fc97de6d3d6fe40bdb3972aef17ef9f26f
company,2022-12-29 13:12:53,Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drug,117888774,https://static.reuters.com/resources/r/?m=02&d=20221229&t=2&i=1618520083&r=LYNXMPEIBS0G0,BIIB,Reuters,"The U.S. Food and Drug Administration failed to adhere to its own guidance and internal practices during the approval process for Biogen's Alzheimer's drug Aduhelm, which was ""rife with irregularities,"" a congressional report showed on Thursday.",https://finnhub.io/api/news?id=fdf7af5680ba3a21906dcc1e1f114d10700e577c43f5c9bebadfaa17b66db76b
company,2022-12-29 13:04:00,FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s Drug,117860363,,BIIB,Yahoo,"Aduhelm’s approval followed an ‘atypical’ number of contacts between the agency and the company, a congressional report says.",https://finnhub.io/api/news?id=f9bb3798bb0be14a8fc1c5f82227237ff2cf089784257a39567e5b25d0b79764
company,2022-12-29 11:57:00,US congressional report slams FDA approval of Biogen Alzheimer's drug,117881191,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a215b9cf5d9656af190e3a6f66eb75c1d1a9c8515334aeb8454ef627f74854cf
company,2022-12-29 08:41:37,Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels,117862712,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157399901/image_157399901.jpg?io=getty-c-w750,BIIB,SeekingAlpha,A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged. Click to read my analysis of BIIB stock.,https://finnhub.io/api/news?id=b7ca787bf154cfc81176a971e3613e1a70fed95286ac7abf576cdd1a597160db
company,2022-12-29 07:44:00,Biogen`s Alzheimer`s Drug Likely To Be Approved With Warning Labels,117881194,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=765ba976135086f847066a5d88374d975c6ba6d1e2ba26ffb29e7c5dd7c5cd9c
company,2022-12-29 07:39:00,"Biogen, FDA faulted in congressional inquiry into Alzheimer`s drug approval",117881196,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e94266fbd2060dd9cb2fb871ca0dfeb7828e3d4d57bb97c0db60f672249438a7
company,2022-12-29 07:12:00,House Committee says FDA interactions with Biogen` failed to follow` protocol,117881199,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1d0563da9677ce8f2676e23e56d85221dd9cc752f7ac2d4f72cf6dab436211a0
company,2022-12-29 07:12:00,"Biogen responds to Committee on Oversight, stands by `integrity` of actions",117881197,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fb11672697643e9074e39ff47f1b22cf14160e2f25ed4e7cea7610a9b0e5003d
company,2022-12-29 05:30:00,"The Petri Dish: Group eyes Biogen Alzheimer's drug price, FDA rejects psych drug application",117855633,,BIIB,Yahoo,"The FDA has elected not to accept a new drug application from Minerva Neurosciences Inc., sending shares plummeting. Read this, and more, in the latest biotech news roundup, The Petri Dish.",https://finnhub.io/api/news?id=43b000117acf0ac188a99b53980950c6c539aa8d6406bca34acf77d40ccfd35c
company,2022-12-29 05:29:00,BIIB February 2023 Options Begin Trading,117881200,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=86df10a5233f7ffd042d22a20c85f2fb1f7ee96f2cb33893ae844f95c9c4453a
company,2022-12-28 22:41:00,"Biogen Inc. stock rises Thursday, still underperforms market",117881201,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=676413060c96b14cd2adde23a0d028285c14f48e1522bd2d9501e3aa5720a7ae
company,2022-12-28 22:35:00,What You Missed On Wall Street On Thursday,117877877,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a6c2e2828ecba85272f4e7144f6427114aa1b0acc9ef6fc4dd079b216cc9d0eb
company,2022-12-28 18:00:11,Biogen Inc. (BIIB) Stock Moves -0.27%: What You Should Know,117845083,https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $274.04 in the latest trading session, marking a -0.27% move from the prior day.",https://finnhub.io/api/news?id=c39597d6666c65f5880839459a8e1be20724ff8599135bf235d4a71d45483280
company,2022-12-28 17:56:40,Genentech wins approval of 1st 'chemo-light' bispecific blood cancer drug,117845084,https://s.yimg.com/ny/api/res/1.2/zldQ1ELv7G4wb1ZL.3h0Tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTg-/https://media.zenfs.com/en/bizjournals.com/15427b577c8476c387c25be292b04b42,BIIB,Yahoo,Another bispecific antibody — linking to two key players in the fight against cancer — could be approved by regulators as soon as this spring.,https://finnhub.io/api/news?id=276d9bb5a7d32f9a1186af68814341057b8e43a72ac6d08185fb32e0157b1afd
company,2022-12-28 12:05:32,The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock,117819425,,BIIB,Yahoo,"Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.",https://finnhub.io/api/news?id=1d9ba372e2ce15a449813d2e2a9b45d6194d25626e4d65e3eb76676cae4e2803
company,2022-12-28 07:45:00,Is Biogen's Stock Too Risky to Invest in?,117821579,,BIIB,Yahoo,"Healthcare company Biogen (NASDAQ: BIIB) has been a volatile one to invest in over the years, to put it mildly.  Sharp movements in the share price have been par for the course for Biogen because news about its Alzheimer's treatments has at different times created bullishness and bearishness.  Have things stabilized for Biogen, and is it a good buy right now, or is there still too much risk involved with the company?",https://finnhub.io/api/news?id=8c7210652441dfca90f14b80e0a965705e13680afc77d85d9f31ec03805cc6f8
company,2022-12-28 06:26:00,Needham health/pharmaceuticals analysts hold analyst/industry conference call,117842513,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8a9d031f10da2858bc61de6344ac44b2ccc5b88afe256a3bae1f686c02e10371
company,2022-12-27 22:41:00,Biogen Inc. stock outperforms competitors despite losses on the day,117881204,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=090fa3f7542b4571057d1e19b25646e3ee777716402b975ec7336bb54655bcf4
company,2022-12-26 22:41:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,117881205,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=38595a87805d1a64a68c1e250b35158be8686ed7445463819babfa096270b3a5
company,2022-12-25 23:19:29,Acumen Pharmaceuticals: An Alzheimer's 'Lottery Ticket',117797131,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1343098807/image_1343098807.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Acumen Pharmaceuticals is an early-stage developmental concern focusing on development treatments for Alzheimer's. Click here to read ABOS' investment analysis.,https://finnhub.io/api/news?id=5397344987fe1209e07bc5b414ef9e8abf8ff39694a7ebdac3e17f21ab3031f7
company,2022-12-25 22:25:00,Acumen Pharmaceuticals: An Alzheimer`s `Lottery Ticket`,117797422,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7ae7fdf47d7a720693739f3c9c76915265cda9e281c4eab5adccdf0fb1242513
company,2022-12-31 17:52:13,Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks,118034914,https://media.zenfs.com/en/insidermonkey.com/00d514a054884081553dae19073f6d33,BIIB,Yahoo,"In this article we take a look at Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks. Click to skip ahead and see Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks. Gilead Sciences, Inc. (NASDAQ:GILD), Novo Nordisk A/S (NYSE:NVO), and Molina Healthcare, Inc. (NYSE:MOH) are three of the healthcare companies that Jim Simons’ quant fund has identified as […]",https://finnhub.io/api/news?id=f9b4731747f162f815cfd5f58bfa8b1a1e52c06f56cf786ae4c10e0f771715ca
company,2022-12-30 12:22:04,Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease,117947133,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389406635/image_1389406635.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Biogen's Lecanemab only slows down the progression of Alzheimer's disease in APOE4 carriers and is suspected of causing deaths. Click for more on BIIB.,https://finnhub.io/api/news?id=c44d761456730068067afed84064999dfd2b074b071f67cd4f086b34cf007532
company,2022-12-30 11:21:00,NEW YORK MARKET CLOSE: Stocks fall at end of brutal year for equities,117959441,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1b00ef92bb276707a6602f20f14d776902e0fc92ce549a0c427ba559018f473
company,2022-12-30 04:04:13,House Democrats fault FDA for collaborating improperly with Biogen,117940550,https://image.cnbcfm.com/api/v1/image/107172578-16724082631672408260-27446739305-1080pnbcnews.jpg?v=1672409053&w=1920&h=1080,BIIB,CNBC,A new report from House Democrats found that the U.S. Food and Drug Administration inappropriately collaborated with Biogen before approving its Alzheimer's treatment Aduhelm. CNBC's 'Squawk Box' team reports.,https://finnhub.io/api/news?id=2492311769c7df6cd2d2cd8efe74bb023856cde81681094f9a5d24d066a4cc68
company,2022-12-29 23:26:00,Eisai And Biogen`s Lecanemab: A Flawed Treatment For Alzheimer`s Disease,117978278,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=eaf9c26bcda35132201ec44dc86ad3efd38fc1d19c3eb0b9b37b3562577fb6b2
company,2022-12-29 22:55:00,Biogen (NASDAQ:BIIB) in Trouble Over Aduhelm Drug,117933077,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07e9a60b5020103966d16cdd12395b88db4d7c35ed6a3a90dbc59e145b7a7070
company,2022-12-29 22:41:00,Biogen Inc. stock outperforms competitors on strong trading day,118023403,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c951ff683f18b0efe0a868109b7696df3c7c249633e688c277448da3a6dd7575
company,2022-12-29 20:02:00,"Catalyst watch: Tesla deliveries, CES reveals and healthcare updates lead off 2023",117933037,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=96b6a06007f841752ad53373e3b0f9236112c5b516916551efe4d6da4f57617f
company,2022-12-29 19:18:00,"Congress Targets FDA, Biogen on Alzheimer's Drug Approval",117894976,,BIIB,Yahoo,A congressional report finds the FDA's approval process for Biogen's Alzheimer's treatment was 'rife with irregularities' that included 'atypical collaboration.',https://finnhub.io/api/news?id=3a5b3e80e6a475a8cc996ea38eb2ca9ba722214fdf438f7cc091a233b7845c5f
company,2023-01-06 18:56:13,"FDA approves Biogen, Eisai Alzheimer’s drug",118184605,https://s.yimg.com/ny/api/res/1.2/bQKrDCyAx6xv6efoQbt2EQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/fox_business_text_367/ae2dcb1bc420c436e7dde0b355311d77,BIIB,Yahoo,"An Alzheimer’s drug from Biogen and Eisai has received accelerated approval from the Food and Drug Administration, the companies and agency announced Friday.",https://finnhub.io/api/news?id=00a1cc8d82626f0bf7b4d866d2e145b5145ca6f9acb70e6599a516e400230462
company,2023-01-06 18:10:41,"U.S. FDA approves Eisai, Biogen Alzheimer's drug",118181153,https://static.reuters.com/resources/r/?m=02&d=20230106&t=2&i=1619276252&r=LYNXMPEJ050LL,BIIB,Reuters,The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of the mind-wasting disease.,https://finnhub.io/api/news?id=8ef08901bb3e24b354101e70b9f7f7835d6eaef360dcc5228037a007eb19d158
company,2023-01-06 16:43:56,"US STOCKS-Wall St rallies as jobs, services data calm rate hike worries",118173889,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Wall Street's main indexes all gained more than 2% on Friday after December payrolls expanded more than expected even as wage increases slowed and services activity contracted, easing worries about the Federal Reserve's interest rate hiking path.  U.S. nonfarm payrolls rose by 223,000 jobs in December, Labor Department data showed, while a 0.3% rise in average earnings was smaller than expected and less than the previous month's 0.4%.",https://finnhub.io/api/news?id=a1b29a381ee371d553619fe87dc75f1784ce7efaa8573a3297b923a65d390c89
company,2023-01-06 16:07:33,"Biogen Gains FDA Approval For New Alzheimer's Drug, But Medicare Remains A Wild Card",118187589,https://media.zenfs.com/en/ibd.com/9412ff55f8137e25eeecaa7e447fd2ad,BIIB,Yahoo,"Biogen stock jumped late Friday after the Food and Drug Administration approved its second Alzheimer's treatment, now called Leqembi.",https://finnhub.io/api/news?id=30869e834f1c54a92944ee4ea2ead4bd68410a6fa08183b52f95c452055e7253
company,2023-01-06 16:04:26,"FDA approves Biogen-Eisai Alzheimer’s drug, China in talks to make Pfizer Paxlovid generic",118174458,https://s.yimg.com/ny/api/res/1.2/dfvUf93nJoXzEF6Raw26Kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2022-12/a75c2d10-8e05-11ed-a7fe-65aa5227d516,BIIB,Yahoo,Yahoo Finance health care reporter Anjalee Khemlani highlights the progress on Biogen-Eisai's collaborative Alzheimer's treatment drug and China's plans to distribute Pfizer's Paxlovid pill.,https://finnhub.io/api/news?id=abe53bee31ed7073c5258e46bfa4ef05464e1204fb1039d380bfb16fdfae294a
company,2023-01-06 14:19:00,Alzheimer’s Disease Treatments: What to Know About New and Future Drugs,118169128,,BIIB,Yahoo,"The new drug Leqembi promises to slow the disease in patients, but they will have to balance safety risks and reimbursement issues.",https://finnhub.io/api/news?id=081b2f643e5d4a9f65e1d8278c1bd7e1ee177b41b2116f5bf2fa5767766174b7
company,2023-01-06 15:30:01,Biogen Stock Surges After Alzheimer's Approval,118173135,,BIIB,Yahoo,"U.S. health regulators [have approved](https://www.wsj.com/articles/new-alzheimers-drug-approved-by-fda-promises-to-slow-disease-11673032312?mod=hp_lead_pos4) Biogen's new Alzheimer's disease drug, and stockholders are reaping the rewards. Biogen shares were recently up 6% shortly after trading resumed on Friday; the stock had been halted shortly before word of the approval became public. Shares of Eli Lilly, which has similar drugs under development, were up 1.5% on Friday.",https://finnhub.io/api/news?id=11e37fccc7206b690576502b557e438468030a14321dfc48d2ae68eba609bf51
company,2023-01-06 14:15:28,"Alzheimer’s Drug From Eisai, Biogen Gets FDA Accelerated Approval",118169130,,BIIB,Yahoo,"(Bloomberg) -- Eisai Co. and its partner Biogen Inc. gained initial US regulatory clearance for lecanemab, the first treatment clearly shown to slow the advance of brain-wasting Alzheimer’s disease. Most Read from BloombergWhat We Know About the ‘Kraken’ Covid Variant XBB.1.5 and Why It’s Causing ConcernIf You Have Student Loans, Mark These Dates on Your CalendarTrump’s Troubles Mount as Special Counsel Gets New 2020 EvidenceSalesforce Guts Tableau After Spending $15.7 Billion in 2019 DealUS and",https://finnhub.io/api/news?id=1a1c1191a34e2f849a364e0948b5c7e68bc85931ca0e6cb9aff1a0f28b7615fb
company,2023-01-06 14:41:00,FDA approves treatment for people with mild forms of Alzheimer’s,118173929,,BIIB,Yahoo,"The Food and Drug Administration on Friday granted an accelerated approval to Eisai and Biogen’s Alzheimer’s disease treatment, which showed in clinical trials that it can slow the progression of the disease.  U.S.-listed shares of Eisai  (ESALY)  rallied 9.4% after the news was announced on Friday afternoon.  Biogen’s  (BIIB)  stock was halted at the time of publication.",https://finnhub.io/api/news?id=e9a7232fdf7c2bcc67141b315f783f6ddffd7d389b98e1d75bf761c86cd1f997
company,2023-01-06 14:23:00,FDA Approves Eisai and Biogen’s New Alzheimer’s Therapy,118169127,,BIIB,Yahoo,FEATURE  The Food and Drug Administration approved Biogen and Eisai’s Alzheimer’s disease therapy lecanemab on Friday under its accelerated approval pathway.  The approval includes a warning about a side effect known as amyloid-related imaging abnormalities.,https://finnhub.io/api/news?id=f818cad9fc2208dc680b5e4faeba0a4a026993b7b95c9900ea0a40893f758698
company,2023-01-06 14:35:27,FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway,118187596,https://media.zenfs.com/en/Benzinga/39777ed4b65c78f35a9e6f694a8442c5,BIIB,Yahoo,"The FDA has approved Biogen Inc's (NASDAQ: BIIB) second Alzheimer's disease treatment, Leqembi (lecanemab-irmb) via the Accelerated Approval pathway. Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease. Eisai Co Limited (OTC: ESALY)-partnered lecanemab reduced clinical decline on the global cognitive and functional scale by 27% at 18 months, relative to the placebo, the trial's primary endpoint. In Jun",https://finnhub.io/api/news?id=03d66ebba56d918675bc8befbe37d54f608fc8ff9cdb00d5479706e0a364e2b8
company,2023-01-06 14:30:00,FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease,118187597,https://media.zenfs.com/en/prnewswire.com/ece9cbfc4b1b07ae5075e2c44bc00b8e,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.: LEQEMBI™) 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (""prot",https://finnhub.io/api/news?id=4a2e5eb71223c4a7a8eefaa663ad2654865a825d388123843d2fa75fd52adbba
company,2023-01-06 14:27:38,FDA approves second Biogen Alzheimer's drug,118174467,,BIIB,Yahoo,"The U.S. Food and Drug Administration has approved a second Alzheimer's disease drug made by Biogen Inc. with its Japanese partner, Eisai Inc.",https://finnhub.io/api/news?id=c4880199f04a4c0e07f1980913eb8fe9489d806dbfab821c75557d5886b01d15
company,2023-01-06 14:13:26,"UPDATE 1-U.S. FDA approves Eisai, Biogen's Alzheimer's drug",118168702,,BIIB,Yahoo,"The U.S. Food and Drug Administration approved Eisai Co Ltd's and Biogen Inc's Alzheimer's drug lecanemab for patients in the earliest stages of the mind-wasting disease, the agency said on Friday.  The drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic brain protein known as beta amyloid.",https://finnhub.io/api/news?id=eee75f9680aace82962a9ae8d1a16f90d02b4d318891a450137a0d75381278d8
company,2023-01-06 14:11:00,"New Alzheimer’s Drug Approved by FDA, Promises to Slow Disease",118168703,,BIIB,Yahoo,Eisai and Biogen’s Leqembi is the first drug to show that reducing a protein linked to Alzheimer’s helped patients.,https://finnhub.io/api/news?id=96f7749ac928aa047672ea159dd5c9ec2c70150f419cecbfcacb50e0a17c56f3
company,2023-01-06 12:38:40,CNBC Exclusive: Eisai U.S. CEO on Alzheimer's drug approval,118176569,https://image.cnbcfm.com/api/v1/image/107175480-6ED3-FM-B-BLOCK-010623.jpg?v=1673044720&w=1920&h=1080,BIIB,CNBC,"CNBC's Meg Tirrell talks to Ivan Cheung, Eisai U.S. CEO on the company's Alzheimer's drug receiving approval from the FDA today. With CNBC's Tyler Mathisen and the Fast Money traders, Tim Seymour, Bonawyn Eison, Steve Grasso and Jeff Mills.",https://finnhub.io/api/news?id=3e722a754b6e3b9dbeae13a41767d892cc6ee367ef3ecda6c8f91c8c8affdf08
company,2023-01-06 12:14:00,Health Care Up as Biogen Rises on Alzheimer's Drug Progress -- Health Care Roundup,118235273,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,Health-care companies rose after another breakthrough in Alzheimer's drug treatments. Shares of Biogen and Japanese partner Eisai rose after the Food and...,https://finnhub.io/api/news?id=718dcd2e47e3e861ae0faaf2a0c25c1955e8b8cae19a91e86db83fa3cdc3e194
company,2023-01-06 11:50:00,"ADRs End Higher, Shell and Eisai Trade Actively",118227838,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Kathryn Hardison International stocks trading in New York closed higher on Friday. The S&P/BNY Mellon index of American depositary receipts increased 2.2%...,https://finnhub.io/api/news?id=4257369c2f1afec4defa26d7e92e0ef87403038806f6d269ca68da9122e49590
company,2023-01-06 11:40:00,Biogen Inc. stock outperforms market on strong trading day,118235277,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 2.82% to $279.25 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=52541f6bb70bb3876cd54efec3a1c60aee869cc82bd86ed5cf1b53671cdb79f0
company,2023-01-06 11:34:14,"Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks",118168704,,BIIB,Yahoo,"If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also point to a big year for biotech stocks.",https://finnhub.io/api/news?id=deac5e082211c3e39c948643b39ae921683f22a871f09b9e84a736e572f01dff
company,2023-01-06 11:24:00,NEW YORK MARKET CLOSE: Stocks post bumper gains after mixed US data,118172936,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a8a7f08a5f47035776a6245834612f40a2b5d1b16665638ca0c2eb55eb688b43
company,2023-01-06 10:41:33,Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?,118168705,,BIIB,Yahoo,"Biogen stock jumped Friday ahead of an FDA decision on the accelerated approval of its experimental Alzheimer's treatment, lecanemab.",https://finnhub.io/api/news?id=575390d96a4b2b5e33a05ee3be4127e24dc1c0a6bdaef3b0a0c5f72240418a14
company,2023-01-06 09:54:00,"TOP NEWS: US approves new Eisai, Biogen drug to treat Alzheimer's",118172938,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8332c49a31ccf04e912ff3045a54fbcdef5295941b411c66b4ff62d57ab4098c
company,2023-01-06 09:53:00,"1 Stock Defying the Downturn to Buy, and 1 to Avoid",118165994,https://s.yimg.com/ny/api/res/1.2/X8.fBderj2qvmDLE9Ve2Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/eb8841f777d44669863c8c7517e8f5d2,BIIB,Yahoo,"AstraZeneca is a U.K.-based pharmaceutical company with a long list of products, many of which are hugely successful and generate well over $1 billion in annual sales.  The company's oncology lineup is particularly impressive, with products such as Tagrisso, Imfinzi, Lynparza, and Calquence, all of which are blockbusters.  AstraZeneca's oncology drugs made up about 35% of the company's revenue in the third quarter.",https://finnhub.io/api/news?id=88c4e5267a6cbe9bb6b6cfc947d21cf5a0f69e179d7a3a51c3794a589c081304
company,2023-01-06 09:41:01,FDA approves Biogen's Alzheimer's drug,118200775,https://image.cnbcfm.com/api/v1/image/107175339-16730325651673032563-27578514921-1080pnbcnews.jpg?v=1673034061&w=1920&h=1080,BIIB,CNBC,CNBC's Meg Tirrell reports on Biogen and the company receiving FDA approval for an Alzheimer's treatment.,https://finnhub.io/api/news?id=3efbad08a92a5f4d3c9af36d61f8bc816eb722210bf83e611392b62b19e7e1d0
company,2023-01-06 09:41:00,FDA approves treatment for people with mild forms of Alzheimer's,118227836,https://images.mktw.net/im-651471/social,BIIB,MarketWatch,"Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year",https://finnhub.io/api/news?id=c35ab779a36b1b284051e550c70e9c4a75f9cc4dc0e97f037df35f916a17c47f
company,2023-01-06 09:10:09,FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial,118169572,https://image.cnbcfm.com/api/v1/image/103821955-GettyImages-512298231.jpg?v=1673032209&w=1920&h=1080,BIIB,CNBC,The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer's.,https://finnhub.io/api/news?id=8ce3f75e565cb94746c4721b4689fea13246a5bbd2d54605c9e288a018c9382d
company,2023-01-06 07:41:00,Top Picks For 2023: Anavex Life Sciences,118176659,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1d120c236007f43f53394e4a2826f13b8fa93f34579ee7986ea1db27d20d2ed
company,2023-01-06 03:34:38,"Biogen Alzheimer's drug could get Medicare coverage in 2025 if approved, says Dr. Scott Gottlieb",118166843,https://image.cnbcfm.com/api/v1/image/107175048-16730101051673010102-27573926214-1080pnbcnews.jpg?v=1673012078&w=1920&h=1080,BIIB,CNBC,"Dr. Scott Gottlieb, former FDA commissioner and CNBC contributor, joins 'Squawk Box' to discuss if Biogen's drug is tackling the root cause of Alzheimer's, what scientists are learning from Biogen's Alzheimer's treatment and more.",https://finnhub.io/api/news?id=014ec33c7e87d3f4aca5a8985822a7306eb623ed1c2b4248b08d8319f48b57cd
company,2023-01-06 03:22:44,Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments,118166844,https://image.cnbcfm.com/api/v1/image/107175037-16730095491673009547-27573816038-1080pnbcnews.jpg?v=1673011364&w=1920&h=1080,BIIB,CNBC,CNBC's Meg Tirrell joins 'Squawk Box' to discuss the big day ahead for Alzheimer's medicine.,https://finnhub.io/api/news?id=b2fb21e856a3a0806d3ceb48a8c2617f43ecec38a4aa07a7564be8d2d64368f4
company,2023-01-05 23:55:00,Biogen (BIIB) Gets a Buy from Needham,118178156,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c33a3e54896fd8999d2a5e12ae22b90a1ef11fa5a8057333d954646d240fc962
company,2023-01-05 23:04:00,Piper stays on sidelines as commercial success of Biogen`s Leqembi unsure,118178157,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f89ea85ea0c1225d9efed1f5205e24f569e3327f8dbde6bdbc1ffb56eff816f6
company,2023-01-05 22:34:00,What You Missed On Wall Street On Friday,118172945,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=baa4002824f679ebd8a20a39cd043434c1ab37287f311927ca94c3b184e9fa2c
company,2023-01-05 22:16:00,Mizuho Securities Remains a Buy on Biogen (BIIB),118178160,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8900157d89f210a527452b0411d1fdb2e1fd3069468f2754c65842887f319b52
company,2023-01-05 21:21:00,"Lilly, Anavex, other Alzheimer`s drug developers rise modestly on Biogen lecanemab approval",118172458,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b32d552e04acd3685f6b90a3984fe03e3a29b0833335625892a580e07e27b52a
company,2023-01-05 21:19:00,"Biogen, Eisai May Have an Alzheimer`s Beater on Their Hands",118178176,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=89e0054bcd0e478424e84afbd8ef46bf8cc3ad4e40cd0b56aed09def44e5127d
company,2023-01-05 21:10:00,CMS says Biogen approval falls under existing national coverage determination,118172948,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9a22df3a70930c80d8949b9f7666471b451963c557a647d8e39273c8ea8d02e8
company,2023-01-05 21:07:00,Biogen up 7% to $290.76 after FDA approves Leqembi,118178179,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0ad4329e13c870e786c6757b67267eb3acea74cc9cc0a671b42c22cbf5d57ba8
company,2023-01-05 21:05:00,Biogen trading resumes,118178180,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5cceacc905de872b2bd2509c6304a8d223571635d68ea4b33148b2401f203b34
company,2023-01-05 21:00:00,Biogen to resume trading at 3:05 p.m. ET,118178181,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9d79ce6267bd40d5ede8e9bfca97df8f79c0d420cb9f40fb12453075d7e47aa8
company,2023-01-05 20:42:00,FDA approves treatment for people with mild forms of Alzheimer`s,118172949,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1ec2a1bfe2b924fcec696b5f0e275a7a31c009645ed0e6de613986b3f486786e
company,2023-01-05 20:40:00,"Eisai announces Leqembi U.S. launch pricing at $26,500 per year",118172952,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3462f2e3b5a9b891ceaee7bb63029299ff68012ad6a80a9fbcebf379f11a29d9
company,2023-01-05 20:34:00,"Biogen, Eisai announce FDA approves Leqembi to treat Alzheimer`s disease",118172955,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1bc4c4e74430893c9f3eb57683a967261dd44c982dc4322854e51b5312cfbfa9
company,2023-01-05 20:11:00,FDA grants accelerated approval for Biogen and Eisai Alzheimer`s drug,118172958,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=271103caab5836151068febf36da44882ce249a25b00fe672b3566f33e9a36e4
company,2023-01-05 20:10:00,FDA approves Biogen Alzheimer`s disease treatment Leqembi,118178195,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3124b13cf79f7433de1076dc6ea992d5b4c08fb83ce3cdd3cd9201bf502ee834
company,2023-01-05 20:09:00,Lecanemab Alert: What Would Alzheimer`s Drug Approval Mean for Biogen (BIIB) Stock?,118178197,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a26dcc4953f5d568f8ec85e6b35d78e89a3c7b8f302cf8af995654fce5159cd0
company,2023-01-05 20:00:00,"Biogen trading halted, news pending",118178199,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9c32d2793ce736b507c7ec811cf707a1449f93ff5f58b71972e4dff8f6e31df6
company,2023-01-05 16:15:20,Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision,118148450,https://s.yimg.com/ny/api/res/1.2/KNGwKkTCw9LXNGGdFz8CxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTg-/https://media.zenfs.com/en/ipo_edge_com_346/c83bf57e4577e79cf6903384c4f7b86a,BIIB,Yahoo,"Plus Therapeutics, Inc. (Nasdaq: PSTV) specializes in targeted radiation treatments Rather than traditional radiation beams, Plus uses needle-sized applicators into brain fluid Focused on brain cancer which is difficult to […]",https://finnhub.io/api/news?id=89b48e23d783f31faf60ecf25470ac65e2888699f0bbabccf023ed4b89a21b2b
company,2023-01-05 14:14:07,Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device,118148451,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.,https://finnhub.io/api/news?id=4c4c9d63990e9ae08b198f7fe12e63055ca6cfa78c74310da48ef7d39de13a6e
company,2023-01-05 08:18:34,Biogen splits R&D division ahead of key decision on Alzheimer's drug,118142113,https://static.reuters.com/resources/r/?m=02&d=20230105&t=2&i=1619112770&r=LYNXMPEJ040F5,BIIB,Reuters,Biogen Inc said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.,https://finnhub.io/api/news?id=6db7e47287be3d843d862d663335356f8066bf89300085ab862fbd8d91700baf
company,2023-01-05 08:03:00,Biogen separates research and development into two functions,118144847,,BIIB,Yahoo,"MARKET PULSE Biogen Inc. (BIIB) said Thursday that it separated research and development into two functions that report directly to new CEO Christopher Viehbacher. Priya Singhal, currently the head of global safety and regulatory sciences, was promoted to EVP and head of development.",https://finnhub.io/api/news?id=e4d3a52ffea66b53dc004817c04ce2afc8ec04d5f42f8724de25d533e1de59d0
company,2023-01-05 08:02:39,UPDATE 1-Biogen splits R&D division ahead of key decision on Alzheimer's drug,118144850,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen Inc said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug.  The company named interim R&D chief Priya Singhal as executive vice president, head of development following the separation.  Singhal will also serve as the interim head of research till the company completes its search for a new chief for that division.",https://finnhub.io/api/news?id=5551c050a0d12312a74617e33d634d62cb5ff89c7107545bc251ade010bdad40
company,2023-01-05 07:43:49,Biogen names Priya Singhal as head of development after splitting R&D division,118142115,,BIIB,Reuters,"Biogen Inc on Thursday named Interim Research and Development Chief Priya Singhal as executive vice president, head of development following the separation of the drugmaker's R&D division into two units. (Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)",https://finnhub.io/api/news?id=fd72daa55516e613d4abd6d726f445c982bbab0d1a969e40924fbb5a99863b02
company,2023-01-05 07:30:00,"Biogen Names Priya Singhal as Executive Vice President, Head of Development",118144852,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that Priya Singhal, M.D., M.P.H., currently Head of Global Safety and Regulatory Sciences and Interim Head of Research & Development (R&D), has been promoted to Executive Vice President, Head of Development, following a decision to separate Research and Development into two distinct functions that will both report directly to the CEO. In addition, Biogen has initiated a search for a new Executive Vice Presid",https://finnhub.io/api/news?id=c771a7007261d2bf8679a1a98e09e60da040e228dae23c7f1a6ea72ef70f5de5
company,2023-01-05 07:29:40,"Aurinia's Patent Dispute Is Over, But Without A Buyout, There's No Upside",118143031,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Aurinia Pharmaceuticals recently settled a patent dispute with Sun Pharma. That seems to have rekindled buyout chatter. Read more on AUPH stock here.,https://finnhub.io/api/news?id=81dfb5b5ec302131944238739a4452badf32c0cd51406c8fbe99cbcecafd35b1
company,2023-01-05 06:35:00,"Aurinia`s Patent Dispute Is Over, But Without A Buyout, There`s No Upside",118178201,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9e2d4a57c78a06a4512688231d0bd6ecac227c7976fd19089ccab2f5c84a7c62
company,2023-01-05 05:31:00,Interesting BIIB Put And Call Options For February 24th,118178202,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8e95eb7dec60cc61efcff3a7044879cd5e181e2e3aa5c7952be3d5d925a7e3ff
company,2023-01-05 04:25:00,Needham health/pharmaceuticals analysts hold analyst/industry conference call,118178204,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6dfdb01d62d7aa9a297af3bd6448584bf02e4b4f28e816539e47208561c12cca
company,2023-01-05 03:03:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,118175881,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f7638057312db689f325efc5a91284d6026cc2829b3c83c6d63f9e5b941978ec
company,2023-01-05 01:39:00,"Biogen promotes Singhal to EVP, Head of Development",118178209,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cffa14c29b71878ffe4cc4e76175af381fec32dc8bb80a2f5ea2b9d94e18cd4b
company,2023-01-04 22:41:00,"Biogen Inc. stock rises Thursday, outperforms market",118178211,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e0c3da978772eb4d00448fd931ef7fbf013aff1e79da3fa541e7ca363622c11f
company,2023-01-04 22:25:00,RBC says hotline sign of possible imminent approval for Biogen,118178212,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1608e1750b1c451c041056275afa3a6e72374ade3342e22fa5a59ae6265be0aa
company,2023-01-04 11:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",118128469,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.67% to $270.81 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=9a6f4e626aeec510236b2362be571a99a5372341537f7478ff35916485ef9b5e
company,2023-01-04 08:00:48,Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 26% Undervaluation?,118115193,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,In this article we are going to estimate the intrinsic value of Biogen Inc. ( NASDAQ:BIIB ) by taking the forecast...,https://finnhub.io/api/news?id=7867c948028e21578ca57b896e1237176d5e1c51d4165e08dd11b1f0e3f83c44
company,2023-01-04 07:30:00,Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies,118112042,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development for intrathecal drug delivery CAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space. Through this agreeme",https://finnhub.io/api/news?id=d4c2fee64773a1d4ec1b6c515a9d5009e245e0b438b6fe0eca7229f9a1e6c63c
company,2023-01-04 06:41:00,"Biogen, Alcyone in agreement for medical device for antisense oligonucleotide therapies",118122451,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5aca8fa2c4abe2310e619ae2f6e4f00e2ad48d9dee7d409adc44581176873264
company,2023-01-04 04:26:00,Biogen and Alcyone enter licensing agreement to develop ThecaFlex DRx,118122453,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ed7ead31a921183918f9ad2a93d1c62ba7d4c8506b1a51e423e7d5210127cd1c
company,2023-01-04 01:34:00,"Biogen, Alcoyne announce license, collaboration agreement",118122456,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8cf91215ba65e3c086ea991353e2b8d352d4ece8e8dcd872c0a493171dbb3416
company,2023-01-03 18:00:11,Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know,118106658,https://media.zenfs.com/en/zacks.com/1154d43aaeb65735a640003549116295,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $272.63 in the latest trading session, marking a -1.55% move from the prior day.",https://finnhub.io/api/news?id=47a8b124546d294a95df2aae8167065b394e125d245e4c4b1d60992ca52adabb
company,2023-01-03 17:02:21,"IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock",118102181,https://media.zenfs.com/en/ibd.com/89ba06de855e8e934d24ad5d00e2b706,BIIB,Yahoo,"Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.",https://finnhub.io/api/news?id=b0b9137b083e6e8f9212da751c414efaa9c4f0858530bf66f97dfaac41f1a628
company,2023-01-03 14:47:00,"Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab",118102183,https://s.yimg.com/ny/api/res/1.2/iHFckEmLfZYfLs_rZ2kbWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/marketwatch.com/f4853c1b58fdcae4244f5a99f702ed5e,BIIB,Yahoo,A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021,https://finnhub.io/api/news?id=28db35c8aeb7a8cbedfb8e33c5f435aa978446349250980fee96aac07faf41cd
company,2023-01-03 12:37:00,The FDA’s Next Call on an Alzheimer’s Drug Is Due This Week,118099211,https://s.yimg.com/ny/api/res/1.2/6BFcp5mg4AdBCEw.TlDqQg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/eac454f1b13b8e0a5161931b5f2a59c9,BIIB,Yahoo,Biogen and Eisai are jointly developing lecanemab. A decision on accelerated approval is expected by Friday.,https://finnhub.io/api/news?id=042d9d0431f0398b01652ed5cd04e4494047fea0743962ae156025e8e29df3bf
company,2023-01-03 11:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,118107524,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.55% to $272.63 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=46e64b7b7a4544cf00522ea4983a07d467d0eb0c452614ca89125251236f7946
company,2023-01-03 09:47:00,"Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemab",118107525,https://images.mktw.net/im-696087/social,BIIB,MarketWatch,A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021,https://finnhub.io/api/news?id=a018f978992739b331a3ebe1e6f1bb45254d5c0785643a5c39b22b3011650367
company,2023-01-02 20:48:00,"Amid criticism for its handling of another Alzheimer`s drug, FDA will decide this week whether to approve lecanemab",118122461,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2590ed2eab2c3b51f5ee7c7203189c4a1b58d44f20ae631bf6dc99d39695b912
company,2023-01-10 18:30:00,EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE,118210687,https://media.zenfs.com/en/prnewswire.com/ece9cbfc4b1b07ae5075e2c44bc00b8e,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mil",https://finnhub.io/api/news?id=3d839d219889ee9fa5d2fb4f0d1258ce0944e28e0e83d8b1352b2b067c771b5d
company,2023-01-10 16:48:00,FDA Commissioner Denies Wrongdoing in Approval Process for Biogen Alzheimer’s Drug Aduhelm,118210688,https://s.yimg.com/ny/api/res/1.2/39AZ3r5oSw7bM2UOVHNACA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/d9ae0b4465270723b5e1ad5e5a5a1261,BIIB,Yahoo,Robert Califf acknowledged the agency made mistakes when it failed to properly document interactions with the company.,https://finnhub.io/api/news?id=e4ce6901edb966cb3c2b80cba34c4b8bb789a8a54cd0dd862cc6ded6aaea1756
company,2023-01-10 11:40:00,Biogen Inc. stock outperforms market on strong trading day,118235255,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 2.45% to $281.46 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=f304f7a5b3bf182deff8f8f3371a1e96de38488862c30c950f68fbd882816756
company,2023-01-10 09:41:41,"CMS limiting coverage of Alzheimer's drug not a 'fixed' policy, says FDA's Robert Califf",118200773,https://image.cnbcfm.com/api/v1/image/107176758-16733786651673378662-27646038691-1080pnbcnews.jpg?v=1673379701&w=1920&h=1080,BIIB,CNBC,"CNBC's Meg Tirrell and Dr. Robert Califf, FDA commissioner, joins 'Power Lunch' to discuss Biogen's Alzheimer's drug and the health care sector.",https://finnhub.io/api/news?id=7d7a75f1d71be5dd50a3c13f6b5170caa1104cd0b70632af46c25bad96102ed0
company,2023-01-10 05:55:00,Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?,118199929,https://s.yimg.com/ny/api/res/1.2/kIKD7_XJbdJYkM.AHmacyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/c152b4954d51ee5df0a7f32e8afe7568,BIIB,Yahoo,"You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of déjà vu.  The company, along with its partner, Japanese drugmaker Eisai (OTC: ESALY), received U.S. Food and Drug Administration (FDA) approval for Alzheimer's disease drug Leqembi (lecanemab-irmb) last week.  Biogen has been in this position before.",https://finnhub.io/api/news?id=1aed8f5804a052916e560d42bc1a99b822ce0b1a737b7ad93a05ee1a5b81b877
company,2023-01-10 05:36:00,"Biogen CEO Viehbacher outlines a path, including immunology, rare diseases",118210690,https://media.zenfs.com/en/bizjournals.com/a2d6b918a6765481b10ed9f480a23f54,BIIB,Yahoo,"While Biogen's new CEO says he isn't planning any ""radical left turns,"" he does see some ways the company could tap into new markets, including immunology and rare diseases.",https://finnhub.io/api/news?id=b02823f7b2dd12d5000b4b64c58738624b9cd25633e2d93adca732a39ae5cce7
company,2023-01-10 05:15:00,"What's next for Leqembi, the new Biogen-Eisai Alzheimer's drug?",118199930,https://s.yimg.com/ny/api/res/1.2/c8nJGztU0m_C6zPFwDrYdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTk-/https://media.zenfs.com/en/bizjournals.com/ed58885b6fec0cebb70287b4e8a529c0,BIIB,Yahoo,"There are several things that need to happen before the new Alzheimer's drug from Biogen and Eisai gets into the hands of patients. And, unlike with their first Alzheimer's drug, Aduhelm, Eisai is taking the charge on this one — leaving Biogen in a bit of a wait-and-see position.",https://finnhub.io/api/news?id=ba5186294353bffd54b2db53d459dbacafa8052974bca1eb2d4cd01c01b9f48a
company,2023-01-09 19:20:18,Shares of Japan's Eisai surge after FDA approves Alzheimer's drug,118199931,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Shares of Eisai Co Ltd surged in early trade in Tokyo on Tuesday after the U.S. Food and Drug Administration approved the Alzheimer's drug lecanemab developed by it and Biogen Inc for patients in the earliest stages of the disease.  Shares of Eisai were up nearly 8% at 0015 GMT.  The drug, to be sold under the brand Leqembi, belongs to a class of treatments that aim to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.",https://finnhub.io/api/news?id=9b884a635ee90e88a08150da55c72749f54ff7ad26b9b2fb736811e6d68408c3
company,2023-01-09 18:15:11,Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know,118210693,https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $274.72 in the latest trading session, marking a -1.62% move from the prior day.",https://finnhub.io/api/news?id=a7fcedc049bb36299c6ab65a2e9126ba83eee705188abf76e2e21178d9b7aeed
company,2023-01-09 16:27:00,"These Stocks Are Moving the Most Monday: Tesla, Zillow, Regeneron, Macy’s, and More",118201588,https://s.yimg.com/ny/api/res/1.2/E9inKTn80xPYyMJ9aMBeuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a4c802a649bd2804a8dfecbc620c838a,BIIB,Yahoo,"FEATURE  Stocks were mixed Monday at market close, losing some of the momentum from a rally last Friday to start a new week of trading.  These stocks made moves Monday:  CinCor Pharma (ticker: CINC) surged 144% to $28.",https://finnhub.io/api/news?id=3107dd1472e7611047fead084ee1071ad8fc49917c441837bd4b5cc89a94d9e0
company,2023-01-09 11:40:00,"Biogen Inc. stock falls Monday, underperforms market",118235256,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.62% to $274.72 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=43f88762544dd50a4ae831573952b5a765589a56fcbffe890eb2c9a431026957
company,2023-01-09 10:04:03,"Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's",118199933,https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b,BIIB,Yahoo,FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.,https://finnhub.io/api/news?id=94cc6be04c0cc99919a74fb52c2a34acac57e6d9da0cb7ff63b20d482c08b9ed
company,2023-01-09 08:28:45,"Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts",118194712,https://static.reuters.com/resources/r/?m=02&d=20230109&t=2&i=1619488033&r=LYNXMPEJ080F1,BIIB,Reuters,"The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc's newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall Street analysts said.",https://finnhub.io/api/news?id=5ca41ce63869cbc3f96fea40fb2745b72ae17b7651127e58913249aaa6a3ff06
company,2023-01-09 05:00:00,'The threshold of a new age': CEO of local Alzheimer's group on Biogen's new drug,118199935,https://s.yimg.com/ny/api/res/1.2/9Kmx8M15FtpiTsRFobEGDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTk-/https://media.zenfs.com/en/bizjournals.com/d31e6ca2eb8473128921a6192e54df42,BIIB,Yahoo,"The CEO of the Mass. chapter of the Alzheimer's Association calls the FDA's approval of Leqembi last week ""a disease paradigm change.""",https://finnhub.io/api/news?id=489082f54fe81b252e506f8e116914fe8320f650f1ad4326ef9d30cc9152efcc
company,2023-01-09 04:44:00,"Ionis, Royalty Pharma Enter Into $1.1 Billion Royalty Agreement for Spinraza, Pelacarsen",118218547,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Chris Wack Ionis Pharmaceuticals Inc. and Royalty Pharma PLC said Monday that Royalty Pharma has acquired an interest in Ionis's royalty in Biogen Inc.'s...,https://finnhub.io/api/news?id=5a2a8b2e9c9dc3d2f163d9e3fa60398940494c1a6c96195c048afca4128ce4c9
company,2023-01-09 04:24:56,Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln,118218548,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Royalty Pharma Plc undefined said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. undefined. The...,https://finnhub.io/api/news?id=bf6895139c0d3a5f59e97729b074c6631e88e8a8a15f1b3f794b13cce434cc87
company,2023-01-08 22:23:00,The Year’s Biggest Healthcare Conference Starts Monday. What to Expect.,118220857,https://images.barrons.com/im-698642/social,BIIB,MarketWatch,"The J.P. Morgan Healthcare Conference kicks off on Jan. 9 in San Francisco. On the agenda: M&A news, drug pricing, IPOs, and more.",https://finnhub.io/api/news?id=895e675affb8251399a41456618607e78e39b112d3e42f2879044d909783ddfa
company,2023-01-08 09:00:41,"With 88% ownership, Biogen Inc. (NASDAQ:BIIB) boasts of strong institutional backing",118210699,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,A look at the shareholders of Biogen Inc. ( NASDAQ:BIIB ) can tell us which group is most powerful. And the group that...,https://finnhub.io/api/news?id=5377c7516dc9f2b6c3d8db7e809f3e3f13245eab3350c0e44c668133ae3c534e
company,2023-01-07 09:00:00,New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients,118199936,https://s.yimg.com/ny/api/res/1.2/ln2hHuvRNcPdQdGBQjXh8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/887a8ceb40f43536d62d6b5a1dbab42c,BIIB,Yahoo,Medicare won’t pay for the drug unless patients are enrolled in government-sanctioned trials—and no such studies are under way or planned.,https://finnhub.io/api/news?id=45a23e576267fb8c2ad2251e9fbfde844062fbd79a9ddf6eb10012b88e53ae10
company,2023-01-07 07:16:37,"Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval",118193632,https://static.reuters.com/resources/r/?m=02&d=20230107&t=2&i=1619325231&r=LYNXMPEJ050LL,BIIB,Reuters,The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of the mind-wasting disease.,https://finnhub.io/api/news?id=56ee6839b2b7e36fe8b764ca115727a785a191f0d6c0dca07320d25fb6e8eff7
company,2023-01-06 23:30:00,Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease,118187586,https://media.zenfs.com/en/prnewswire.com/ece9cbfc4b1b07ae5075e2c44bc00b8e,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher ""Biogen"") announced Eisai has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the conversion of the Accelerated Approval of LEQEMBI™ (lecanemab-irmb) 100 mg/mL injection for intravenous use to a traditional approval. This sBLA is subject to validation",https://finnhub.io/api/news?id=bf176cc135ee391dc5319a15c6c21a805127622601eae21a535109ad4e489eb2
company,2023-01-14 10:03:00,"A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.",118271040,https://s.yimg.com/ny/api/res/1.2/VNH.OIncyyvK_uUS.MzzHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/090892b17a3560b81d54877a8bd96aae,BIIB,Yahoo,"Pharmaceutical companies are grappling with the arrival in the U.S. of sweeping new legislation meant to blunt drug prices.  The impact in 2023 may actually be higher drug prices.  President Biden last year signed into law the bill dubbed the Inflation Reduction Act, empowering Medicare, the country’s biggest buyer of prescription drugs, to negotiate how much it pays for certain high-price therapies.",https://finnhub.io/api/news?id=d3fc261dfc2ebdb89bf75cc62c21c804fd409a9570ecde20a3e4dea7d6b94028
company,2023-01-12 11:40:00,Biogen Inc. stock outperforms competitors on strong trading day,118235253,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 1.07% to $288.08 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=a2ec5d4f0a7fd04a9949b3f467624af161e312ed64dd61fb37dc614c221902d9
company,2023-01-12 04:39:56,IBB: A History Of Outperformance During Recessions,118202247,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1354171890/image_1354171890.jpg?io=getty-c-w750,BIIB,SeekingAlpha,iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now.,https://finnhub.io/api/news?id=51425a6aa3e767d662d77e31f174f1780fac56c748fa207e446de56f107023b7
company,2023-01-11 11:40:00,"Biogen Inc. stock rises Wednesday, still underperforms market",118235254,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 1.27% to $285.03 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=87e6b1bacdd8eccd3a29e36e19df880b80a4c6c3188199ac015ae44bb67db718
company,2023-01-11 09:38:02,Biogen's (BIIB) Partner Eisai Files MAA for Lecanemab in Europe,118195790,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,Biogen's (BIIB) partner Eisai files a marketing authorization application to the European Medicines Agency for lecanemab for treating early Alzheimer's disease in Europe.,https://finnhub.io/api/news?id=935376ab0952805645d5ed3fe5ea072a4ba717511f73e7922cd5957ba38e31a6
company,2023-01-11 07:34:48,Ranking The 10 Largest Biotechs By Pipeline,118194522,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153436387/image_1153436387.jpg?io=getty-c-w750,BIIB,SeekingAlpha,"The pipeline is the heart of all drug discovery companies, leading to all growth in the future. Here we rank biotechs by pipeline, click to see the list.",https://finnhub.io/api/news?id=32dc11f2a46a529f7c54d43a690b9fed88795676b63d86e10b9ff57ba95fd9bd
company,2023-01-11 05:30:00,"1 Hot Growth Stock to Buy Now, and 1 to Avoid",118210686,https://s.yimg.com/ny/api/res/1.2/pnqqLao_QdOfI1NUMY6Qyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/f665ba97d7f491be99eb6f7261b3f832,BIIB,Yahoo,"Discerning between popular growth stocks that have room to run and those that will leave your portfolio in the red isn't an easy task, especially for companies in the biopharma sector.  AbbVie (NYSE: ABBV) is a pharmaceutical growth stock par excellence because it will be commercializing new medicines and expanding the prescribable indications of its existing set of medicines at a quick clip throughout the rest of the decade.  In 2023, it aims to submit nine approval packages to regulators and potentially get the final stamp of approval for eight other programs for which it already submitted the paperwork.",https://finnhub.io/api/news?id=968c3f09577a05acff35851daeb1777d95016b1710d2faea381a7c3d613eedea
company,2023-01-10 21:12:27,Eisai files for approval of Alzheimer's drug in Europe,118194711,https://static.reuters.com/resources/r/?m=02&d=20230111&t=2&i=1619668737&r=LYNXMPEJ090U2,BIIB,Reuters,"Japanese drugmaker Eisai Co Ltd said on Tuesday it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States.",https://finnhub.io/api/news?id=847e5d62acdfb2ae1359bf9c32ee468b9afbe7aefc417058d48866d3c7dab626
company,2023-01-18 11:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",118323789,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 2.11% to $283.47 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=0dd6a45a474d3cde326ab04c1461b9fe9ac1f5978d4ea7dd9d6022351b879b03
company,2023-01-18 10:10:09,"Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen",118305707,,BIIB,Yahoo,"Neurodegenerative diseases-focused Aprinoia Therapeutics has announced a business combination with Ross Acquisition Corp II (NYSE: ROSS), a special-purpose acquisition company founded by former Commerce Secretary Wilbur Ross, at an equity value of $280 million. Wilbur Ross has personally invested $7.5 million through convertible notes and committed up to $12.5 million of capital infusion at the closing. Aprinoia, founded in 2015, is a clinical-stage biotech company developing novel therapeutics",https://finnhub.io/api/news?id=2aba85c7c14aa395a5582d9afd2883bc5b5022016413b43d8f5ac7f01b3f24ae
company,2023-01-17 12:10:52,Anavex: Drug Treatments For Early Alzheimer's Disease,118295261,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1381637603/image_1381637603.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Anavex 2-73/blarcamesine at high concentrations in early Alzheimer's disease leads to improvements in cognition. Click here to see our take on AVXL stock.,https://finnhub.io/api/news?id=cbfda429c7e977e89a05c4e00ca73757e4d45cf4f32cf55c7177268eca562c17
company,2023-01-17 11:40:00,Biogen Inc. stock outperforms competitors on strong trading day,118323790,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.54% higher to $289.59 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=9845240ca52ab4fb2a8a6e4a4c193f7eda6f9616ac4e7c0b00ec240054497ddf
company,2023-01-16 12:33:05,Biogen (BIIB) Partner Eisai Seeks Nod for Lecanemab in Japan,118281758,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,Biogen's (BIIB) partner Eisai files a marketing authorization application for lecanemab for treating early Alzheimer's disease in Japan.,https://finnhub.io/api/news?id=4576464be9a56957c3d19ef824c6289514ea6f2203a9a67a52bedc449c29332b
company,2023-01-16 07:15:56,Denali: Need Patient Data To Justify That High Valuation,118281032,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363045045/image_1363045045.jpg?io=getty-c-w750,BIIB,SeekingAlpha,Denali Therapeutics Inc. has major partnerships and an active set of programs. They are flush with cash. Click for more on DNLI.,https://finnhub.io/api/news?id=bf9f95da9766671566049fbcf09f72d9b5491007edeaa5489f74d382b2943552
company,2023-01-15 20:19:54,Eisai files for approval of Alzheimer's drug in Japan,118277166,https://static.reuters.com/resources/r/?m=02&d=20230116&t=2&i=1620212258&r=LYNXMPEJ0F011,BIIB,Reuters,"Japanese drugmaker Eisai Co Ltd said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States.",https://finnhub.io/api/news?id=06fb1e4a9e9b2b5ceee47e5a5f7060769401f47d886e181e1a93c465946edddb
company,2023-01-15 19:30:00,EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN,118277017,https://media.zenfs.com/en/prnewswire.com/ece9cbfc4b1b07ae5075e2c44bc00b8e,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai has submitted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril1 antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively",https://finnhub.io/api/news?id=fb30da5de06cae57e92074c35d46ed9cf8da390134106b2de4902052aff1a013
company,2023-01-15 19:04:18,BioVie Inc: A Catalyst-Rich Year Ahead,118277911,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/648706624/image_648706624.jpg?io=getty-c-w750,BIIB,SeekingAlpha,BioVie's strong scientific profile and large market opportunity have made it a high-risk/high-reward bet with considerable upside potential. Find out why BIVI is a Buy.,https://finnhub.io/api/news?id=84e4b3634bc3263c038f8cf044c3c06925789f7a506909d1cfb44c4f86192222
company,2023-01-20 11:51:27,"In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug",118332761,,BIIB,Yahoo,Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.,https://finnhub.io/api/news?id=fa5002cc07e8cddb78cf7bbd7c8b59fc6113e4f63d1afff08ef6763a1a756864
company,2023-01-20 11:21:00,The FDA Rejected Lilly’s Alzheimer’s Drug. Why It’s Only a Setback.,118332762,,BIIB,Yahoo,"The company had sought accelerated approval, but the agency said its trial data didn't include enough people who had been on the drug for at least a year.",https://finnhub.io/api/news?id=e441ffe3599335d7e793205dbccb76bd8e7b2cb2616f8c70b7343b5797077629
company,2023-01-20 11:10:04,Eli Lilly Alzheimer's drug setback extends rival Biogen's lead,118331959,https://static.reuters.com/resources/r/?m=02&d=20230120&t=2&i=1620761880&r=LYNXMPEJ0J0FP,BIIB,Reuters,"The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.",https://finnhub.io/api/news?id=0da418c737117bf1c846812bad6f7390d80034aada3f58c703b14c8f41812455
company,2023-01-20 09:23:00,Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug,118331509,https://s.yimg.com/ny/api/res/1.2/OmjI5Ix.FHz98thpm7WH3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/marketwatch.com/d17c70feebc9bebb65dbdb7e9a89a6d6,BIIB,Yahoo,The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year,https://finnhub.io/api/news?id=5a02736a460237add7849a3b9b39ed769768676b4b62bb7fcdd845f7f5b65323
company,2023-01-20 07:24:37,Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts,118331960,,BIIB,Reuters,"The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.",https://finnhub.io/api/news?id=cd9d479d8929bd1308b7802f55faca14a2758219ec78dbaa820bcb9d1b3ce3ef
company,2023-01-20 05:34:00,Eli Lilly Stock Slips Lower As FDA Rejects Fast Track Approval For Alzheimer's Drug,118330714,https://s.yimg.com/ny/api/res/1.2/V7sppuadjnf_wiVy__zRiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/a7812097bf610bc1acbb4d2703ab9899,BIIB,Yahoo,"""We are committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need,"" Eli Lilly said.",https://finnhub.io/api/news?id=582183761ad759949c9b37cd6465c9f7aa14bc968c2695bd0aa8cbea1566c8a8
company,2023-01-20 04:23:00,Why the FDA didn't grant an approval to Lilly's Alzheimer's drug,118376580,https://images.mktw.net/im-707210/social,BIIB,MarketWatch,The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year,https://finnhub.io/api/news?id=2fde8c99713fa5fa16460ab18ea05b0e11bb3ec10e65f45613669057eaf1f2f2
company,2023-01-19 18:18:17,Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug,118325288,https://media.zenfs.com/en/reuters.com/e495dc70f54ec7a00598a90027374265,BIIB,Yahoo,"(Reuters) -Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration has rejected accelerated approval of its experimental Alzheimer's drug because it did not submit enough trial data from patients who were treated for at least 12 months.  Lilly said the FDA sent it a complete response letter for donanemab, an antibody designed to remove amyloid protein plaques from the brains of people with early Alzheimer's. Such letters typically outline concerns and conditions that must be addressed to gain U.S. approval.  Lilly said the FDA issued the letter ""due to the limited number of patients with at least 12 months of drug exposure data provided in the submission.""",https://finnhub.io/api/news?id=e8fb66ede63401c0339a559bcad6aaab87e6996d153672ab31ffcda062f6ce73
company,2023-01-19 18:15:11,Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know,118329037,https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session.",https://finnhub.io/api/news?id=2d700c668a2caab244d43a6d25657aa9abaa6df18c4a1e68278422f33b71b02f
company,2023-01-19 11:40:00,"Biogen Inc. stock falls Thursday, underperforms market",118323788,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.18% to $280.13 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=9b0b0ca8c5a0c2db773d3c9bc5c2916a847664651745cf74af343f79fac980c9
company,2023-01-19 09:20:00,Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval,118318924,https://s.yimg.com/ny/api/res/1.2/qIMYU0IPaqwSm5NRQW4Grw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/c33696d5207e2078d506bf6c6c356908,BIIB,Yahoo,The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.,https://finnhub.io/api/news?id=87b9590d5324edeace9545945ea25b90ca02e05b38d35e33206b871464172874
company,2023-01-19 05:25:00,"If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today",118317040,,BIIB,Yahoo,"The stock hasn't been a great investment in recent years, but there's hope for a brighter future.",https://finnhub.io/api/news?id=bb3ce0b3f55d7c0f97c3b104d4583773190d4ab8b85ba06efa3b0825a258a760
company,2023-01-26 18:30:00,Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency,118379809,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of",https://finnhub.io/api/news?id=3c97ec11b90acef51014852d7fe6f54e3465706de421c7a5457049158242cac3
company,2023-01-26 13:56:00,Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization,118503248,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Sabela Ojea Biogen Inc. said Thursday that the European Medicines Agency committee has accepted a marketing authorization application for its Alzheimer's...,https://finnhub.io/api/news?id=2b86f3c055d2ccf219000f50af4ba9131f883b61fdedc102d11cb228074469cb
company,2023-01-26 07:30:00,Is Biogen Stock a Buy Now?,118379810,https://s.yimg.com/ny/api/res/1.2/8d8xFYy9P7ICNnhQxpEzug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MTM-/https://media.zenfs.com/en/motleyfool.com/2c6cee619ceff2e43b6d3ca6d363cbf5,BIIB,Yahoo,"Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns.  Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock.  One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.",https://finnhub.io/api/news?id=8d5261ebabd9570f8e30f7b555651b5cb0769186a6c1b3bf6ca7ff78724169d2
company,2023-01-26 05:54:25,"The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug",118379811,https://s.yimg.com/ny/api/res/1.2/o9HN4iBu6Xxshjpwl5TYpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDI-/https://media.zenfs.com/en/bizjournals.com/01e667f4bbc7bbf59f5ba702818b6c69,BIIB,Yahoo,Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement.,https://finnhub.io/api/news?id=a270436407c76ee86dbd42a4a8f5b9448b6cde5bc864e0e116a85205dfb56893
company,2023-01-25 10:37:27,12 Cheap Biotech Stocks To Buy,118361756,https://s.yimg.com/ny/api/res/1.2/7b0r1_vGfNZHKiXf31EiMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/784ede8f3979aaba79334aeecd7f7d27,BIIB,Yahoo,"In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy. The biotechnology sector has been on the rise over the past three decades. Several forecasts expect the sector […]",https://finnhub.io/api/news?id=6b7c0c22b775d7d66f08c9206eba774a660986fd967c344694c8ce743f4dd147
company,2023-01-25 05:57:00,Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?,118363855,https://s.yimg.com/ny/api/res/1.2/9Kzr9jq4cEBKT34koBw8PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/9da8ca39ffdb72a64a6973c8d4d588f6,BIIB,Yahoo,Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.,https://finnhub.io/api/news?id=956f8f3d6561259809ffd54857651b3894214c97f530caeb78b5937026d4b19b
company,2023-01-25 01:01:24,Eagle Pharmaceuticals: Upside Could Be Lying Ahead Very Nicely,118360279,https://media.gettyimages.com/id/884671156/photo/factory-for-the-production-of-medicines.jpg?b=1&s=170667a&w=0&k=20&c=PgcOIrcdm6mhBMsdhtmdgA4njIsnw-Gsl_1aJ19lgTs=,BIIB,SeekingAlpha,Eagle Pharmaceuticals is an interesting opportunity to benefit from volatility in stock markets. Click here to find out why EGRX stock is a Hold.,https://finnhub.io/api/news?id=a280c2200fe173f94ee96fd92c6eb9263aa221898e985427e222a571f7cb16d9
company,2023-01-24 18:00:11,Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know,118364245,https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,BIIB,Yahoo,"In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.",https://finnhub.io/api/news?id=c72014e57e6d002a581cfce9b6f85f7cc2258b3f60e2701fe2b57b4957c96040
company,2023-01-24 12:10:05,Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again,118364246,https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177,BIIB,Yahoo,Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=a8c8afc6b65d120bfd7b4b945fb8783fd310514e36daa03f729b3a59c91f63f8
company,2023-01-24 06:00:00,ClearBridge Value Equity Strategy Q4 2022 Portfolio Manager Commentary,118355045,https://media.gettyimages.com/id/1313528106/photo/word-value-on-wooden-blocks-on-top-of-ascending-stacks-of-coins-against-gray-background.jpg?b=1&s=170667a&w=0&k=20&c=hz_xtScZOWxAME_PCxxqoS91WktdqPBIfvIbNo0IV7Y=,BIIB,SeekingAlpha,ClearBridge is a leading global asset manager committed to active management. Find out more here.,https://finnhub.io/api/news?id=4dd1122c636effa17c9019b26bdcb14c66dc103702374f9b61872183f1b5677c
company,2023-01-23 05:02:02,Healthcare Outlook 2023,118347941,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345347757/image_1345347757.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. Read more here.",https://finnhub.io/api/news?id=901fdf5f20709c0abeea555b7f59a1eaa98eed8a4b5ad266ce3d68b4334a0ed4
company,2023-01-23 02:30:00,Novartis: Chasing Revenue Might Lose Sight Of Medicine,118347597,https://media.gettyimages.com/id/1437364273/photo/he-gehry-building-of-novartis-pharma-ag.jpg?b=1&s=170667a&w=0&k=20&c=VYi-ms6kfcyODLKeeIluFEaDlyDbSaVicZkgev37mws=,BIIB,SeekingAlpha,Novartis is undergoing major change to become a pure-play innovative medicines company. Read more to see why Iâm on the sidelines on this one.,https://finnhub.io/api/news?id=a1fbbb9f8414520e832577a1d039a5edf41ac094924b0d36a740f25be7607713
company,2023-01-30 18:00:11,Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know,118404555,https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.",https://finnhub.io/api/news?id=e2ec1605617052245f8ba721fdca53645cb3c7d0772e4af7155be6a58f189edc
company,2023-01-30 09:38:03,15 Biggest Neuroscience Companies in the World,118399592,https://media.zenfs.com/en/insidermonkey.com/444b6b806e1bc31c1b67c152dca6ac61,BIIB,Yahoo,"In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip our industry overview and go directly to the 5 Biggest Neuroscience Companies in the World. As the name suggests, neuroscience concerns itself with the development, structure, and functions of the nervous system, intending to enhance neurological health. According […]",https://finnhub.io/api/news?id=c4e557a4fc2ab5ec6a921375dc886707e76ebd2626058625acfb60147ab6dc29
company,2023-01-30 07:13:54,Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved,118399661,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/802921026/image_802921026.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,FDA grants emergency approval of Biogen/Eisai's Leqembi based solely on Phase 2 trial results. Read why approval For Anavex's Blarcamesine looks inevitable.,https://finnhub.io/api/news?id=97f7931e9d6ebbff698fe11229eb5a8a3706920aed13dcb6909ad9af54a771f2
company,2023-01-29 19:44:20,"Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen",118396351,https://static.reuters.com/resources/r/?m=02&d=20230129&t=2&i=1621752054&r=LYNXMPEJ0S0B5,BIIB,Reuters,"Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.",https://finnhub.io/api/news?id=13dad7f90a94f4fe4731a89ea4a9837f28cb8a14b142fc5f790ec9a145a85068
company,2023-01-29 19:44:17,"UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen",118397058,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.  In their Jan. 29 statement, the companies said priority review in Japan is granted to new medicines recognised as having high medical utility for serious diseases.  Once the priority status has been granted, the target total review period is shortened, they said.",https://finnhub.io/api/news?id=3a5e84a06edcad9c16abbbfda0947177a65e7f04381a5e92bc6e27b33ca65f53
company,2023-01-29 18:48:24,Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen,118396352,,BIIB,Reuters,"Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Sunday the Japanese Ministry of Health, Labour and Welfare has given priority review for their Alzheimer's disease drug.",https://finnhub.io/api/news?id=4768a205fe64a2b120f243075c979ab187f39b952d964329ea715d6699975a20
company,2023-01-29 18:30:00,LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN,118404558,https://media.zenfs.com/en/prnewswire.com/ece9cbfc4b1b07ae5075e2c44bc00b8e,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™), an anti-amyloid-β (Aβ) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). Priority Review in J",https://finnhub.io/api/news?id=67a4bf581c80ae554461728c078bd7c249cc38ae0b352e6092505301bd1d73d1
company,2023-01-29 14:35:38,15 Most Famous Hedge Fund Managers and Their Top Stock Picks,118393426,https://media.zenfs.com/en/insidermonkey.com/5e10b7d436d0889c610b18e545065be2,BIIB,Yahoo,"In this article, we discuss 15 most famous hedge fund managers and their top stock picks. If you want to see more hedge fund managers, check out 5 Most Famous Hedge Fund Managers and Their Top Stock Picks. According to data provider Hedge Fund Research (HFR), hedge funds in 2022 reported their worst performance since […]",https://finnhub.io/api/news?id=90c7bffcd86a40a5a345edd53c70817b9a58cc41a8bc82db313c94753d3c7103
company,2023-01-27 09:57:02,Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance,118388791,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,"Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.",https://finnhub.io/api/news?id=1f7c4a3a5752591967505642ec0762247acefdb2bf538296d2da5526881d605a
company,2023-01-26 19:23:00,EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen,118380100,https://static.reuters.com/resources/r/?m=02&d=20230126&t=2&i=1621484475&r=LYNXMPEJ0P13A,BIIB,Reuters,Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug.,https://finnhub.io/api/news?id=ddeef69ff92e123914deb6f09ec7a72547ab591b788c800534f5bff94c170cff
company,2023-01-26 19:22:58,UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen,118379808,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug.  The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo.  Eisai has also filed for approval of the drug in Japan.",https://finnhub.io/api/news?id=c4f65372f20cac2a0c1019ab7155cee0068d8014d5ec5be679254df0ba3d66a6
company,2023-02-03 11:40:00,Biogen Inc. stock underperforms Friday when compared to competitors,118503245,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.35% to $283.63 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=b81479f54a204884245e00f06f555ebb3abd963044e733b79d687ed61f3fb40f
company,2023-02-02 11:40:00,Biogen Inc. stock underperforms Thursday when compared to competitors,118503246,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.40% to $287.52 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=7610bb31ee5fadbab337d28b4fae7e7684c5b6d9779cd94c8b7d2e74f2fd76fa
company,2023-02-01 16:10:43,The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023,118472452,https://media.zenfs.com/en/investorplace_417/49d59d6b2c0a054aae935125e02570ff,BIIB,Yahoo,"Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange’s bias toward technology players (including biotech), wagering in this space carries the advantage of relevance. Even if circumstances look shoddy right now, at some point, these enterprises have a shot at upside eventually. Now, a word of caution is in order following the utterances of the last few words above. With the most underv",https://finnhub.io/api/news?id=586f08732fbf253cf48fd50d3a77da22784887d51a254e52c37162eef04c2408
company,2023-02-01 11:40:00,"Biogen Inc. stock rises Wednesday, still underperforms market",118503247,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.24% higher to $291.60 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=7712682bf16b9f39d86df4b58f6c5043a668636679685adee312771f79608a9d
company,2023-02-01 09:53:00,Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock,118488575,https://s.yimg.com/ny/api/res/1.2/yvovtVRWhf_Hdgo8lEGLug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/fec88414badfaf1d911defe7f17571c6,BIIB,Yahoo,"When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off.  In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it.  Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.",https://finnhub.io/api/news?id=11a1a126087cf83c3ee5cd5f7513f79360a96503d9c3ac88b939bcf1ee268e95
company,2023-02-07 11:40:00,"Biogen Inc. stock rises Tuesday, still underperforms market",118503238,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.09% to $291.43 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=62d280c1d5650e96fb84cd302ff238693b5b1421c331f8f33c486042847bea1a
company,2023-02-07 10:17:03,Sage and Biogen's NDA for Depression Drug Gets Priority Review,118491828,https://media.zenfs.com/en/zacks.com/7d0a870e8718511cdf6e5d72d84220a5,BIIB,Yahoo,"Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.",https://finnhub.io/api/news?id=c0a98e1d67fc8e555f43c1d3081135cfa6b9ad6732a62682e375cb89a395590a
company,2023-02-07 09:00:13,Is Biogen Inc. (NASDAQ:BIIB) Trading At A 24% Discount?,118491829,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"How far off is Biogen Inc. ( NASDAQ:BIIB ) from its intrinsic value? Using the most recent financial data, we'll take a...",https://finnhub.io/api/news?id=747013607644147366cb1e38a6c1708a2209e1862198fa36c6f4501422fe3523
company,2023-02-06 18:00:11,Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know,118488562,https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.",https://finnhub.io/api/news?id=90089b6d443e0d5bf46fcca6aa271c08cd1f9d5d5160eed072c32ab5e2fbaf54
company,2023-02-06 12:14:46,"Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'",118488565,https://media.zenfs.com/en/Benzinga/876c3e5d09ef6ad18c78e95147799d54,BIIB,Yahoo,"The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) zuranolone for major depressive disorder (MDD) and postpartum depression (PPD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023. William Blair views the acceptance as an important milestone for the company. The analyst believes the granting of priority review, though not surprising, is an incremental positive",https://finnhub.io/api/news?id=7787ff631d38e9ff2a2219aca5279a8d971119726f15716531de216b7cbd7dbe
company,2023-02-06 11:40:00,Biogen Inc. stock outperforms market on strong trading day,118503240,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.64% to $288.28 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=02d97aeff18c00ff4b6d589d655f042515f9dd66d98eb4a70ab34826d0f580ee
company,2023-02-06 06:30:00,Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression,118488571,https://media.zenfs.com/en/business-wire.com/b7516a4fb73d494a5ef4fdec89befc0e,BIIB,Yahoo,"CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie",https://finnhub.io/api/news?id=fda306ab540f69d73352426a25d843a9a91b5618a24aa08841a6005e940480c2
company,2023-02-06 06:30:00,Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression,118488567,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatme",https://finnhub.io/api/news?id=db9b0e9d9c7c4084f7d3d9ea5568d9a7bd60a12fa2e58da83805862d4d82f532
company,2023-02-06 03:19:00,FDA grants Priority Review to depression drug; Sage’s stock rallies,118503242,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Shares of Sage Therapeutics Inc. gained about 5% in premarket trading on Monday after the company said the experimental treatment for major depressive...,https://finnhub.io/api/news?id=842d79ad65347b45905e2e7d17ac577580c23dd98706fb4e3f2982945b0e657d
company,2023-02-06 01:49:00,"Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE",118503243,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Colin Kellaher Biogen Inc. and Sage Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted priority review to the application...,https://finnhub.io/api/news?id=48bfddc7e43114b3fcaaee95d18a8756f4f532a8d293440a8562157a059ee84a
company,2023-02-05 21:12:57,Biogen: What To Do Ahead Of Q4 2022 Financial Report,118477036,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359536024/image_1359536024.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. Find out why BIIB stock is a Hold.,https://finnhub.io/api/news?id=4c9fc64e0da9112835f6f69e68a2defa0ac278fc414314cc290d4f8be19c47f8
company,2023-02-11 07:00:21,"With 88% institutional ownership, Biogen Inc. (NASDAQ:BIIB) is a favorite amongst the big guns",118552960,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Every investor in Biogen Inc. ( NASDAQ:BIIB ) should be aware of the most powerful shareholder groups. We can see that...,https://finnhub.io/api/news?id=7022f4a0e52133ef3be57c11ffc9c3ad515aa0177090c43d126fdf3b95b86277
company,2023-02-10 22:45:26,IWS: Little Added Value In This Value Index,118545442,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220678853/image_1220678853.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,The iShares Russell Mid-Cap Value ETF tracks the Russell Midcap Value Index. Click here to read why I see little added value in IWS.,https://finnhub.io/api/news?id=1743b4364e886189884422be1147ee10e21032a4c8d46e32548eee973f3085a9
company,2023-02-10 13:40:27,25 Biggest Massachusetts Companies and Stocks,118526608,https://media.zenfs.com/en/insidermonkey.com/27724ca1374c6463a25b7def50922d8d,BIIB,Yahoo,"In this article, we will be taking a look at the 25 biggest Massachusetts companies and stocks. To skip our detailed analysis, you can go directly to see the 5 biggest Massachusetts companies and stocks. If all U.S. states were countries, Massachusetts would be 32nd largest economy in the world based on a 2021 GDP […]",https://finnhub.io/api/news?id=b6d2f2ce15cf0a2a741ef043a5830e55f97b0e73f00f7b91a9e0a968e62ec085
company,2023-02-08 14:00:00,2 Top Biotech Stocks Defying the Bear Market,118514262,https://s.yimg.com/ny/api/res/1.2/Dt4CQGySmgQWR3NkYVc_Hg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/426954c5a574369d49c30438c902effe,BIIB,Yahoo,"The bear market crushed many top healthcare stocks -- from young high-growth players to long-established companies generating billions of dollars in earnings.  Vertex is the worldwide leader in the cystic fibrosis (CF) treatment market.  In fact, last year product revenue climbed 18% to more than $8.9 billion.",https://finnhub.io/api/news?id=cfb9c5d1bcd76a1a54b3957c114131f0e733ddbbad57c21606c73c9125a0362b
company,2023-02-08 10:00:03,Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth,118514263,https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a,BIIB,Yahoo,Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=a1a0b664c35614c9dca046b64d83f2127e60ec5561d44840646d75eb6af7da2f
company,2023-02-08 09:47:02,Will Biogen (BIIB) Beat Estimates This Earnings Season?,118514265,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.,https://finnhub.io/api/news?id=51e8a1443845adfad43f0b15d8a43dbabfff8e35770ec9b9c9aec7bf31e107fa
company,2023-02-15 16:03:28,Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount,118625963,https://media.zenfs.com/en/ibd.com/62ea04b193c69f632062452b474d8cea,BIIB,Yahoo,Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales.,https://finnhub.io/api/news?id=f0793dcceb692ec071301598f2beb7da5dacf2b2f2315b9fd10e10a52cd1d712
company,2023-02-15 14:30:34,Biogen (BIIB) Q4 2022 Earnings Call Transcript,118625964,https://media.zenfs.com/en/motleyfool.com/ce68ea0b0cd2631701fe87e542e7a165,BIIB,Yahoo,"At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2022 earnings call and business update.  On today's call, I am joined by our president and chief executive officer, Christopher Viehbacher; Dr. Priya Singhal, head of development; and our CFO, Mike McDonnell.",https://finnhub.io/api/news?id=03b0b5c6470c65b74ef8ad18c0892f0287e3a7d0f453b571e150ac9e7cf01c73
company,2023-02-15 13:16:00,Biogen Boss Turns Corner on Alzheimer’s Miscues,118591790,https://s.yimg.com/ny/api/res/1.2/1WPRN9.rgmsQ_e3765a9fw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/191094d815a1ba36b3d748668d477fb6,BIIB,Yahoo,The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm.,https://finnhub.io/api/news?id=bcf642535f9b9c349e441b87cab7877fc4e81bff588b3cd9917d35c2bab32bab
company,2023-02-15 12:26:05,"Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics",118625966,https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b,BIIB,Yahoo,"Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",https://finnhub.io/api/news?id=b7561c01ade9a4bd3b172832e8891680c2868e80fe091def229b9fb4e1b64ef3
company,2023-02-15 11:58:00,Health Care Down as Biogen Weighs -- Health Care Roundup,118668744,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"Health-care companies fell after a selloff in one big biotech. Biogen shares slid after the biotech giant posted a sharp drop in 2022 revenue, and warned of...",https://finnhub.io/api/news?id=66a14ccdfed409fd50acde6fe67f07caad6964e50edac69e8317d3925c0b7f51
company,2023-02-15 11:43:06,"Leqembi: Medicare coverage needs ‘a convincing set of evidence’ for FDA approval, analyst says",118625967,https://s.yimg.com/ny/api/res/1.2/fgh1jfkxOtBj89almLjqDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-02/cd640820-ad4f-11ed-bfe5-307008d9ea35,BIIB,Yahoo,"William Blair Biotech Equity Research Analyst Myles Minter joins Yahoo Finance Live to discuss his Outperform rating on Biogen stock, Biogen’s Alzheimer and depression treatment drugs, full-year guidance, profit growth, cost-cutting efforts, and the outlook for the company.",https://finnhub.io/api/news?id=12bbda50498d1516ae2b1fe3df8366fdfb34e699f419900b8676f6ced285623e
company,2023-02-15 11:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",118668745,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 3.49% to $278.98 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=36adc619444b5d77bde32cf586e90afe918adcd2339c24cc25b844c084d0948b
company,2023-02-15 11:36:00,NEW YORK MARKET CLOSE: Stocks stage late rally to end higher,118655302,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1582f69887b6dcff14b5e01a37ac83cc17780c97353a1646ba6273f52c251df2
company,2023-02-15 10:57:03,"Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up",118609784,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.,https://finnhub.io/api/news?id=c08fac46d541989a0fdddf32c15996a6d4ece9feb831df53386ca5ded00c415b
company,2023-02-15 10:53:19,Biogen hints at more cost-cutting under new CEO as revenue falls,118625969,https://s.yimg.com/ny/api/res/1.2/0ZrROIzuSD7Kfe8lQdeSwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xODAw/https://media.zenfs.com/en/bizjournals.com/145530a39258f1a20d3f0eb121f50f00,BIIB,Yahoo,"Biogen Inc. may see new drug approvals this year — but first, new CEO Christopher Viehbacher is looking at ways to cut costs as the company continues to struggle with falling revenue.",https://finnhub.io/api/news?id=32a022a95bee9129790ef720dd5a0b85127c18ded1ae73c4a40492c200a34e25
company,2023-02-15 10:12:01,"Biogen CEO bets on Alzheimer's drug, pipeline to return to growth",118587750,https://static.reuters.com/resources/r/?m=02&d=20230215&t=2&i=1623739891&r=LYNXMPEJ1E0HU,BIIB,Reuters,"Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer's disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.",https://finnhub.io/api/news?id=834a5aa28b1be31ffdfe0e0675622866da0864fa38a17070b59f4e425885a9dd
company,2023-02-15 09:47:59,Why Biogen Stock Is Falling Today,118625970,https://media.zenfs.com/en/Benzinga/503aef32e2d918ad7c8c6c3569ecf6b4,BIIB,Yahoo,"Biogen Inc (NASDAQ: BIIB) posted Q4 sales of $2.54 billion, beating the consensus of $2.44 billion, down 7% Y/Y and 4% at constant currency (CC). Multiple sclerosis revenue of $1.27 billion decreased by 17% (down 14% CC). Multiple sclerosis drug Tysabri sales are down to $488.4 million from $512.7. Spinraza's revenue of $458.8 million increased by 4% at actual currency (increased by 10% at CC). Aduhelm generated sales of $0.3 million in Q4, compared to $1.0 million a year ago. Biosimilars' reven",https://finnhub.io/api/news?id=42d6a7fa9fd1ee74f5e60be0bc6bf8c2dcf874d71673c04a4cf815638a640401
company,2023-02-15 09:13:00,Drugmaker Biogen tops 4Q forecasts despite sales slip,118625971,https://s.yimg.com/ny/api/res/1.2/B.a9Z8_Q1CtlL_KYFBSWsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/ap_finance_articles_694/86564a21e38c58d95b79b9306dd6f0cb,BIIB,Yahoo,"Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for some key treatments.  The drugmaker said Wednesday that total cost and expenses fell 17% in the quarter, and Biogen’s bottom line grew nearly 50% to $550.4 million.  Adjusted earnings totaled $4.05 per share.",https://finnhub.io/api/news?id=783c246a5b6b34ae1f19806c81ed1149fd361863a473235aefe2c2f69cb899fb
company,2023-02-15 08:54:28,"Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales",118583923,https://media.zenfs.com/en/ibd.com/62ea04b193c69f632062452b474d8cea,BIIB,Yahoo,"Biogen stock inched higher Wednesday after the company beat quarterly expectations, but offered disappointing 2023 guidance.",https://finnhub.io/api/news?id=2a392ae7a6b9cdf77a0396de9e9fb707ca3a646c18e7c497d69c8457a55b7051
company,2023-02-15 08:25:01,Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates,118583924,https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9,BIIB,Yahoo,"Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=3b1e8ca8d6c4543e42b5b65814827c13b12dad77ecd7402636115b3bc3b7b2ba
company,2023-02-15 07:53:18,"UPDATE 2-Biogen CEO bets on Alzheimer's drug, pipeline to return to growth",118583925,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer's disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.  Industry veteran Viehbacher joined the U.S. biotech in November, at a time when sales have been hit by competition for top-selling drugs such as Tecfidera for multiple sclerosis and Spinraza for spinal muscular atrophy.  A controversial approval and problematic launch of previous Alzheimer's disease drug Aduhelm, which like Leqembi was developed with Eisai Co Ltd, have further dented investor sentiment.",https://finnhub.io/api/news?id=09916f8e6f65266d1edaeb4b2a055b73a942522c5265aead83f1a0e70abe27ea
company,2023-02-15 07:24:00,Biogen’s stock gains after company beats Q4 revenue and earnings expectations,118583927,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BIIB,Yahoo,"Shares of Biogen Inc.  (BIIB)  gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings expectations in the fourth quarter.  Biogen had earnings of $550.4 million, or $3.79 per share, in the fourth quarter, up from $368.2 million, or $2.50 per share, in the same three months of 2021.  Adjusted earnings per share were $4.05, against a FactSet consensus of $3.49.",https://finnhub.io/api/news?id=a3f2132c5d4c901883bc23215447f14dc534eeb5ce00f3f7f8f42ca1ece10bf3
company,2023-02-15 07:24:00,Biogen Tops Profit Expectations as Alzheimer’s and Depression Drugs Remain in Focus,118583926,https://s.yimg.com/ny/api/res/1.2/025Egcw8.o76BFlZaoLGAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a49e1a70f10df30d7028afed2d7072be,BIIB,Yahoo,The expected rollouts of both drugs this year are vital to the company's future because its remaining offerings face intense competitive pressure.,https://finnhub.io/api/news?id=decc5c99529ea54e7dba0a3ac142ceeb11aa3c52820be88ca36ee950fb80f752
company,2023-02-15 07:17:00,Medicare mulls limiting per month costs for generic drugs at $2,118610732,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a6b8cf78b81c3f51b5cac2b71fed1624ea3f23eefc552053e92dbe9a40e5d870
company,2023-02-15 07:04:06,Biogen sees modest 2023 revenue from Alzheimer's disease drug,118583928,https://media.zenfs.com/en/reuters-finance.com/f87fc45e05b475d952aca022a40c1e28,BIIB,Yahoo,"(Reuters) -Biogen Inc said on Wednesday that Alzheimer's disease drug Leqembi would bring in modest revenue for the year although it might not be enough to offset costs tied to its launch.  The company is banking on Leqembi, which was granted accelerated U.S. approval in January, to drive its sales at a time when many of Biogen's top drugs face increasing competition.  Biogen has a 50% share of U.S. profits on Leqembi, which it developed with lead partner Eisai Co Ltd.",https://finnhub.io/api/news?id=6af177aaf84b49a1c1af56374db2336a85d9ed62a358caca439eeadbbf2ac914
company,2023-02-15 07:01:07,Biogen earnings beat estimates on boost from muscle disorder drug,118587752,,BIIB,Reuters,"Biogen Inc beat Wall Street expectations for quarterly profit and sales on Wednesday, riding on strong demand for its spinal muscular atrophy drug, Spinraza, and forecast modest revenue from its Alzheimer's disease drug this year.",https://finnhub.io/api/news?id=634277e17fc08f39fc3d71136add03e1719ab09d76d91e55f3ade9963b3692f4
company,2023-02-15 07:01:04,Investors in Biogen (NASDAQ:BIIB) have made a respectable return of 35% over the past year,118583929,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...",https://finnhub.io/api/news?id=a501d3b4c1d04d015c99826161e1ff89d5b2f9e948e8c72e1eefc78cd7b8fe61
company,2023-02-15 07:00:07,Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript,118585987,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q4 2022 Results Conference Call February 15, 2023 8:00 AM ETCompany ParticipantsMike Hencke - Head, Investor RelationsChristopher Viehbacher - CEOMichael...",https://finnhub.io/api/news?id=fc878f8e1ac3c5990f6d3e3256617b003fc87dcc1dc0d24f68d9ca460f56e5b5
company,2023-02-15 06:00:00,What You Missed On Wall Street This Morning,118591452,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=17d167f952068f4a46ff6ff317a3629dc699cc3c0152114281d7b3ad2617b758
company,2023-02-15 05:22:00,Biogen expects new Alzheimer`s drug to weigh on 2023 outlook,118640420,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2024dc828de0079c36d8830f87c9ae66d14cb15fe4dd26c0fcaac8340e02eb83
company,2023-02-15 04:50:00,"Biogen Beats Q4 Earnings & Sales Estimates, Stock Up",118661128,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4ecdf771cf69eb9723a7a5ea17f3f892b2b6582faa47e3db758c10b817a9989f
company,2023-02-15 03:32:00,"Biogen net income up across 2022, fourth quarter; revenue down",118743960,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=90c1d2e61a8edade3e1a7296d51f206615e7bb597cc3d721b3649a29c29aa981
company,2023-02-15 03:15:41,"Stocks making the biggest moves premarket: Kraft Heinz, Paramount, Airbnb, Tripadvisor and more",118588456,https://image.cnbcfm.com/api/v1/image/106898212-1623865063010-gettyimages-1233327895-PGONCHAR_W6591.jpeg?v=1676466941&w=1920&h=1080,BIIB,CNBC,Here are the companies making headlines before the bell on Monday.,https://finnhub.io/api/news?id=a7bbb43c9d0491bc0fa6a095a46901744b73ef6c01048fb29d29fcc98b2cbada
company,2023-02-15 03:15:00,Biogen`s stock gains after company beats Q4 revenue and earnings expectations,118743962,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f4d725ae2695ce8b773877acd6831795c6147e3a4f11d6bdb3e0c151d0f5df6d
company,2023-02-15 03:00:20,"Airbnb, TripAdvisor, Tesla rise premarket; Barclays, Devon Energy fall",118583930,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Peter Nurse,https://finnhub.io/api/news?id=a5f3d98e2844984aea3137da5bd3464b39cb80850d6d7d3dc2fe2251188c182a
company,2023-02-15 02:56:00,Fly Intel: Pre-market Movers,118608770,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0a704b10c15b3283493ad70d4be2463cb4c1719b9000cfb1b7e7566c9262355f
company,2023-02-15 02:49:00,"7 stocks to watch on Wednesday: Telsa, Airbnb, Krispy Kreme and more",118616870,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=69bf10d2356d0a45d47d06d423b29c036e07c090acf953047b48417f45481713
company,2023-02-15 02:30:00,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and ChitogenX (OtherCHNXF),118656305,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6a96aa5e1a2a66caa58a7644ad406b3758fb112c288d330b2ddbff93a4f059dc
company,2023-02-15 02:20:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Applied DNA Sciences (APDN) and Provention Bio (PRVB)",118683403,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8b4a692bb37761027fedf7c7bb7b3c8aaf11c0b08f0be181722d9d8e1b4e2fc8
company,2023-02-15 01:18:00,Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook,118743972,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=93a1e2f2b379efcdc53d42c664e9ec64dfeb37be32f969bf4cb4cf2ca1b5adf3
company,2023-02-15 01:15:00,"Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72",118743974,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=227db0185ea732886e42e4191935b15ebfff6ed50f4a5c8f60171b413cb5ce75
company,2023-02-15 01:13:00,"Biogen reports Q4 EPS $4.05, consensus $3.48",118743976,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8e0066041b5822347ee4de37fc6fe300927b2e418e6df2ebd240fc7596978cbd
company,2023-02-14 22:32:00,What You Missed On Wall Street On Wednesday,118593882,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e9358b40eb4c56035f903e291f61065d6a65d155b2a6366ffa4d093eef7afaff
company,2023-02-14 19:41:00,GLOBAL BRIEFING: Stocks called lower ahead of UK inflation figures,118607948,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e43585f80ac9a2eb9a148675e37eda170bed648effd779ff6d80ccea59810054
company,2023-02-14 11:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,118668748,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.48% to $289.08 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=9a84926a0bcfff0410547c2233658b4e68737edff5b759039029ff2560bd3da4
company,2023-02-14 06:56:00,Notable companies reporting before tomorrow`s open,118608785,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=86af580e4950627055855f2ee5462f1d763c73d644e29f631fae39759374db54
company,2023-02-14 05:54:00,Biogen`s Alzheimer`s therapy Aduhelm gets updated warning on brain hemorrhage risk,118743987,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=395d137060404e347ae206882b9d1437f889e3faeb9c3777ce9caab62134fdc3
company,2023-02-14 05:43:00,All eyes on Biogen Q4 results with focus on future of Alzheimer`s drug Leqembi,118743988,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ec0ee7755fe426bb067a2d0592ee3ab3ac2ab8258b307f1f8fc8b2ef7d8670f9
company,2023-02-14 04:40:00,"Hyperfine could have `interesting` opportunity in Alzheimer`s, says Evercore ISI",118707107,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=80de1c1e6ca598caf660e79083f1a41c6f0b21092e231c4285c388fc255b8ae1
company,2023-02-14 03:01:00,"Tamarack Advisers, LP Buys 1, Sells 4 in 4th Quarter",118675908,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8da9692e8a834e626e44b995059e588432c77545087640784b435f9f5738a155
company,2023-02-14 01:01:00,Top 5 4th Quarter Trades of SEEYOND,118643547,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a2cbf9b69a4b392a568a2131fc93f10d4c5f9903782c7548ce578abb1282746d
company,2023-02-13 11:40:00,Biogen Inc. stock outperforms market on strong trading day,118668749,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 1.45% to $290.46 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=36e59f4f6a0241a24b5b784e83924903e6f0e6c88c458cc337a040eaf3f06067
company,2023-02-13 00:45:00,Investors Are Awaiting The Name Of The New BoJ Governor,118733219,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=80ce5f1555ac3a62d81fb42ca4cfeccefdfc45402b8c1bc6c164544a49a2be3d
company,2023-02-12 21:58:00,Earnings Growth Improves As Investors Ready Themselves For Retailers,118585444,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=184bc0ede841f6c31221fb51d9d72d9757f2cb9e98929f476faebd76654c2196
company,2023-02-19 06:00:15,Biogen Inc.'s (NASDAQ:BIIB) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?,118669929,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 7.7...",https://finnhub.io/api/news?id=b3bb54af733a079f997b62194a97a504e7934c06894d7b05fe1ac3edc0df91ff
company,2023-02-17 21:19:27,"Steven Cohen’s Point72 Hedge Fund Backs Salesforce, Broadcom And Meta While Cutting Palo Alto And Workday Stakes",118627532,,BIIB,Fintel,,https://finnhub.io/api/news?id=ec9a519c4b12ab6370c147f2cb4a0d0353bb66d23e44fd431e932b3f799dc23b
company,2023-02-17 11:40:00,Biogen Inc. stock outperforms competitors on strong trading day,118668742,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 2.52% to $278.38 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=d24f2254632d7ba183814ea8c044cc6a6ffc98da3be5ccecf85ec61e0fb43ff5
company,2023-02-17 07:53:13,"Stocks making the biggest moves midday: Deere, Airbnb, AutoNation, Moderna and more",118631166,https://image.cnbcfm.com/api/v1/image/107125022-1664286574327-deereai.jpg?v=1676656393&w=1920&h=1080,BIIB,CNBC,Deere shares popped on strong earnings. ,https://finnhub.io/api/news?id=f764e30b1125c133281a23583f574acef06e34250b805000376a731cf1a0d685
company,2023-02-17 07:01:00,"Jeff Auxier Buys 2, Sells 3 in 4th Quarter",118637349,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a3f2bc2e056cd4b5f5361fb4d2841f6d8e586c5e19b7891be940833b8455f17f
company,2023-02-17 06:57:00,Senators urge swift action to expand Medicare coverage for Alzheimer`s therapies,118661122,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cc9cb6488b49c022fd73996f2e01747af67196b07318a662b0171ab4ff703d10
company,2023-02-17 05:56:16,Senators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure grows,118643679,https://image.cnbcfm.com/api/v1/image/107196126-1676589635250-gettyimages-1421992136-_m020194_f4ed6512-2fb9-40b2-b86c-ab8790234367.jpeg?v=1676649376&w=1920&h=1080,BIIB,CNBC,"Eighteen Republicans and two Democrats, led by Sens. Susan Collins and Shelley Moore Capito, pushed Medicare to expand coverage for Alzheimer's treatments.",https://finnhub.io/api/news?id=2e6cb581b713c1737165f936bd35d3749fd5333aa3df61d031aaf40a00296f1b
company,2023-02-17 04:06:00,Biogen (BIIB) Gets a Buy from SVB Securities,118743903,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dec6f841397dbfb85e3478d686a6bd5988f71856e000a85ca03e5eee34c34bd5
company,2023-02-17 03:28:42,"Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage",118643680,https://image.cnbcfm.com/api/v1/image/107195820-1676565349306-gettyimages-1339206982-f0338857.jpeg?v=1676640522&w=1920&h=1080,BIIB,CNBC,"Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout will take years. ",https://finnhub.io/api/news?id=c17ecef229fa86f7a3bfb03359cd852fc85a8b45e21411c5d2929bb038fce8af
company,2023-02-17 02:26:00,Barclays Remains a Hold on Biogen (BIIB),118743904,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7533acd0f7a101aba184ec6e1e19c9d9041c3cfdd98e5c8c4f93b2fb8a0e95a6
company,2023-02-17 01:59:00,GLOBAL BROKER RATINGS: Citigroup likes Coca-Cola; DZ cuts Kraft Heinz,118636624,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=00117824a455def0f2931a0d0f033acf92106c0c42968b3ae2a751f97c7145c3
company,2023-02-17 01:01:00,"RA CAPITAL MANAGEMENT, L.P. Buys 2, Sells 3 in 4th Quarter",118694833,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f48d18f70465fae1765368ae0c35718bc1e34f388d43b28f3bcb458a88bffb6d
company,2023-02-16 18:49:50,Biogen Inc. (NASDAQ:BIIB) Q4 2022 Earnings Call Transcript,118625960,https://media.zenfs.com/en/insidermonkey.com/c4bdfea029c03bcc27a7e7282b69e190,BIIB,Yahoo,"Biogen Inc. (NASDAQ:BIIB) Q4 2022 Earnings Call Transcript February 15, 2023 Operator: Good morning. My name is Bettina , and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Full Year 2022 Earnings Call and Business Update. All lines have been placed […]",https://finnhub.io/api/news?id=d0aaa16c0e266069cea2d2532f8d67f27c8ce7aa7488b1690021618d5889d3ea
company,2023-02-16 13:41:58,"Biogen has nearly made good on reported plan to cut 1,000 jobs in 2022",118625961,https://s.yimg.com/ny/api/res/1.2/T2zcvuIfKZuWMxpvJ0aMpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/a145bac4656f48a6bf2a6c8424389b65,BIIB,Yahoo,"In late 2021, the Cambridge drugmaker reportedly began drafting plans to get rid of more than 1,000 positions. Now, it appears to have nearly accomplished that goal.",https://finnhub.io/api/news?id=646a67a2d9d868eeff69dfdcb60753fe38f56a1a4691d3101b3911727ac228a1
company,2023-02-16 11:48:04,"Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates",118624808,https://media.zenfs.com/en/zacks.com/c0c563b233f28a1874a33c46aadaa70e,BIIB,Yahoo,Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=6ce116d55e0c29117e6dcc58fa17c36030084d66744fbf844ac92ec7f440baca
company,2023-02-16 11:40:00,Biogen Inc. stock underperforms Thursday when compared to competitors,118668743,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 2.67% to $271.53 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=1e439ff8445c94609b73115e78a171e2e24918b41554d63880b6d59396ad8657
company,2023-02-16 05:50:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI)",118640415,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e0bb297351c5927d036092c7ac9769b7e28c1961198f03195669fa6b0954ed01
company,2023-02-16 05:40:00,"Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Biogen (BIIB) and Waters (WAT)",118707248,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e1e2e3aa419b1f16216c8a4f07ed905c7c7b10e11ba6fb74a72e37c454fcbc66
company,2023-02-16 03:08:00,Biogen price target lowered to $333 from $359 at RBC Capital,118743915,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94c9e2e9b4fa4721e50c65174e7d5eb5a0d1580295e5a6b619670ff797cbf365
company,2023-02-16 02:40:00,"Analysts` Top Healthcare Picks: Alkermes (ALKS), Biogen (BIIB)",118653140,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0167c16d71947c72743cfbc1d3fb93146cc01c71e64414c1397c0dacd1ac6f3c
company,2023-02-16 01:53:00,GLOBAL BROKER RATINGS: LBBW cuts LVMH; DZ Bank cuts Kering,118618819,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a530fcf682f50fd32cae492f5890d99f733888d67f590326063ae9c33c560cfa
company,2023-02-16 01:37:00,Biogen price target raised to $315 from $300 at Cowen,118743921,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dbe018a3a2d95df793e97b6e7a41845486d279adc4b6a6203e86f976bb0aa430
company,2023-02-16 01:26:00,BMO Capital Gives a Buy Rating to Biogen (BIIB),118743926,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=75d892d3044e90dac0c6b8f3edbc1ff310208d23a322329ef08b9cf602638654
company,2023-02-16 01:26:00,H.C. Wainwright Reaffirms Their Buy Rating on Biogen (BIIB),118743924,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=147b080d984d87aee6387b3610b2c419b25ba824d2ffd5f909f4a9315c8f7965
company,2023-02-16 00:43:00,Biogen price target raised to $351 from $345 at Morgan Stanley,118743929,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b4e0ba4e50ea00e36e297a62a14141180e26c42111fc45c8f2834a799ae44aaa
company,2023-02-16 00:34:00,Biogen price target lowered to $310 from $320 at Oppenheimer,118743931,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0bdc45215cea7bfe5f7874fbaff265b704e65eae8a4cdb981979a11ebf3846e9
company,2023-02-15 23:45:00,Bank of America Securities Sticks to Their Hold Rating for Biogen (BIIB),118743934,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c03fa8b7a629dd78d2c41d6fc242f76f749c7d937f11f61345b8ddb8c7ecc428
company,2023-02-15 22:55:00,Biogen (BIIB) Gets a Buy from Morgan Stanley,118743935,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d6f5fcd50b38650ba7e882f6e7871e165d0b685ea02cab444d20586d956af4b
company,2023-02-23 11:40:00,Biogen Inc. stock underperforms Thursday when compared to competitors,118878905,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.22% to $271.95 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=1169e698d7b74f406759623f2746c941ac10857a286251035d179283768f4e94
company,2023-02-23 06:00:13,We Think Biogen (NASDAQ:BIIB) Can Stay On Top Of Its Debt,118865073,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...",https://finnhub.io/api/news?id=adc82eb2cf381647a44c9b35a64338738a8ce6ecdfa74f831b5ff366040bc318
company,2023-02-23 05:47:23,Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi,118867491,https://image.cnbcfm.com/api/v1/image/107198777-16771566112023-01-20t224759z_376389922_rc2a2w9juz4s_rtrmadp_0_eisai-biogen-alzheimers-fda.jpeg?v=1677167243&w=1920&h=1080,BIIB,CNBC,"The Alzheimer's Association, in a statement Wednesday, said it was ""appalled"" by CMS' decision.",https://finnhub.io/api/news?id=84a720429fb47717d95656a0c6c4bdc29d1500d8753b935fcdd354675728842b
company,2023-02-23 05:03:22,TG Therapeutics' Briumvi: A Tough Sell For Multiple Sclerosis Treatment Market,118860481,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1353518675/image_1353518675.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,TG Therapeutic's Briumvi for MS is unlikely to make the company profitable before its patent expires. Click here to read why TGTX stock is a Strong Sell.,https://finnhub.io/api/news?id=9430b6f5045b6b53cd503401cee9e210a6acfab77c5b4106a89a560605da84d5
company,2023-02-23 04:09:00,TG Therapeutics` Briumvi: A Tough Sell For Multiple Sclerosis Treatment Market,118861506,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cd7643d6e0ee306232c56ee8f16d034f884b469a7fb1157952279f805357f353
company,2023-02-23 02:51:00,"Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Medtronic (MDT) and Biogen (BIIB)",118899895,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=652730addde1b62c8203b808209d5138369d15834d1a5959995cd65a7b861b4a
company,2023-02-23 00:58:00,Medicare says coverage limits on Alzheimer`s drugs is not under review,118861508,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=70f2adfd97e2931301ab721f480c612b5aa66243dece77de7a377054c12eb131
company,2023-02-22 21:07:31,UPDATE 1-U.S. Medicare says no change to Alzheimer's drug restrictions,118847659,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The U.S. government health plan for people over the age of 65  on Wednesday said it would not reconsider strict coverage limits put in place last year for new Alzheimer's treatments, rejecting a request from the Alzheimer's Association.  The Centers for Medicare and Medicaid Services (CMS) reaffirmed its policy allowing coverage for drugs designed to clear amyloid plaques from the brains of Alzheimer's patients only if a medication is approved under the Food and Drug Administration's standard review process, not under its accelerated review program.  The Alzheimer's Association said in a statement it ""is appalled that the Biden Administration is extending its unjust decision to deny access to FDA-approved treatments for people living with Alzheimer's - a fatal disease.""",https://finnhub.io/api/news?id=9c08e7d24cba704cd202b031e5f4eebe862f7e51ee387745176a8bc40de773f9
company,2023-02-22 11:40:00,"Biogen Inc. stock rises Wednesday, outperforms market",118837359,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.23% higher to $272.55 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=5ebf216485d0349023df1e2e519f7ff3033b0c276c4f222f2f0ee2ab16421fa6
company,2023-02-22 05:29:00,May 19th Options Now Available For Biogen (BIIB),118855896,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3eb5a6ea8c939d1a363d35dce545fc95d20f42d5cc5b48c03a516c8d96f8505c
company,2023-02-22 00:16:00,"Stanley Druckenmiller Buys the Dip on Nvidia, Exits Amazon",118843057,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=42c4f280e9898b961901d785b77f427d324013ab7d0d2bbeb71c5a905a984bce
company,2023-02-21 22:34:00,Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick,118855899,,BIIB,The Online Investor,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=af6be9ceda786b0c09e0ffb281b3c2606c004c1ae5e627a84a1e91da7e3a003d
company,2023-02-21 11:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,118837360,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 2.32% to $271.93 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=da13a9e3f2ffb5be7ebc88865ad2e6aaab0ac6990729e2652198bc041c0e212e
company,2023-02-21 03:01:00,"Jeff Auxier Downloads Adobe, Boosts British American Tobacco",118774375,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9d2305b1ce8f64293da4bc3c5e8ddebfa539a5a98900c8fb76af1bae3e085896
company,2023-02-21 03:01:00,"HealthCor Management, L.P. Buys 2, Sells 3 in 4th Quarter",118775274,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c0468110dba509abbeab8f2f96c8964cb0eb390bd44293149f3cce65bc3e70b2
company,2023-02-21 01:23:10,Sage Therapeutics Looking To FDA Approval Of Zuranolone,118762509,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358026033/image_1358026033.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Sage Therapeutics specializes in psychiatric drug therapies, and the stock price has fluctuated greatly over the years. Click here to read why SAGE is a Buy.",https://finnhub.io/api/news?id=5d07f1d94b4e457bb5625e6c9061486ba27cc09794bbd0b1329a6f21e2c23580
company,2023-02-27 18:30:00,Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration,118961177,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"TOKYO and CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril antibody, has been designated for Priority Review by the National Medical Products Ad",https://finnhub.io/api/news?id=fb911ef930d42c65b8d22e03d9098744920ca3fb88ff08855afcc50b8614fa48
company,2023-02-27 14:18:47,Lightning Round: This is Boeing's time if they don't screw it up,118959723,https://image.cnbcfm.com/api/v1/image/107200599-1677543005MM-Block-E-022723.jpg?v=1677543527&w=1920&h=1080,BIIB,CNBC,"Mad Money host Jim Cramer weighs in on all manner of stocks, including Accenture, Boeing, Biogen, Union Pacific, Meta, Nokia and Enphase Energy.",https://finnhub.io/api/news?id=93e29c3b65119c21119885898e3b432df23ee792c2d4f5a83963b426ef9900e7
company,2023-02-27 11:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,119013837,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slumped 0.30% to $269.20 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=20ee4e0821a91b3afe730f918c642ea95870c98fee325458dbf209c5e100287d
company,2023-02-27 08:00:00,Amyloid Gains Converts in Debate Over Alzheimer’s Treatments,118946986,https://s.yimg.com/ny/api/res/1.2/YOoSWnfH9m7OHmGmQQALCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/ff43142891219b8c69e701dc79ed6615,BIIB,Yahoo,"The drug’s success has helped quell a dispute over a theory of what causes the disease and how to treat it. However, critics say scientists still aren’t sure how amyloid removal slows down Alzheimer’s.",https://finnhub.io/api/news?id=5a369229a41d334fc0797d88b061c9b5f36536bfb3a8ffb77d82d96ee29fc5a8
company,2023-02-27 07:09:00,Reata in selloff ahead of FDA decision on lead asset as top agency official departs,118953152,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9acb6e155ce47b93381729600d4fb01367a949ce84e86c0700efb1fd748230e3
company,2023-02-27 00:32:00,Biogen license application for lecanemab designated for priority review in China,118968951,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c0788934df3616ad4ac2ea035e8312b4105d6cee8f75e6d2f859c576a137edbc
company,2023-02-26 20:14:00,Reata in selloff ahead of FDA decision on lead asset as top agency official departs (Update),118953163,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c35940f09d40b2ae4af4c80874b0af68ea36ea9fee9ab6450b7cf8f68cc04997
company,2023-02-26 18:05:00,Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca,118943755,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1362476720/image_1362476720.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca. Read more here...,https://finnhub.io/api/news?id=2b99becb257f14f8778be88abe6e36cede27534e74ef087689b050ced806d255
company,2023-02-25 15:44:12,3 Biotech Stocks To Watch Ahead Of March 2023,118932676,https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/02/biotech-stocks.jpg,BIIB,StockMarket,Do you have these three biotech stocks on your watchlist right now?,https://finnhub.io/api/news?id=66b474a450a940bd3d95f969c07aa8abb7a53faa8c86f1131d3d9b3692932e6a
company,2023-02-24 11:40:00,"Biogen Inc. stock falls Friday, still outperforms market",118937484,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.71% to $270.02 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=676df51012de0d7b2837b04097d96c50b50cae056f5fd4631dcdd84264f86b60
company,2023-03-03 11:40:00,"Biogen Inc. stock rises Friday, still underperforms market",119046713,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.57% higher to $270.27 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=6b30d381edba20dec1ac4c46d4ee40c7f8e63c22ec88a3822817d1971ccd20f2
company,2023-03-03 07:11:00,Biotech Stocks Fell on Fear of Less Flexible FDA. This Analyst Isn’t Worried.,119043808,https://images.barrons.com/im-735655/social,BIIB,MarketWatch,Investors panicked on Monday in response to the retirement of an official seen as a standard bearer for flexibility on approvals of certain neurological drugs.,https://finnhub.io/api/news?id=e2d2e75d6560178e8ce21c20700bb5738b873a8057cc87d9c249b22ddaca69cb
company,2023-03-03 00:08:00,"Medicare just crushed the hopes of 750,000 Alzheimer`s patients a year",119036301,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4f446c1a683da781b40d643f2c8cb3045ab708b22ddc91413a5d447c115e3c3a
company,2023-03-02 11:40:00,"Biogen Inc. stock falls Thursday, underperforms market",119029346,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.27% to $268.75 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=ea1dc6230f3f1e3989aa6721faa08f58b6478f1ef72e34c3ea8ef3c27e4933e4
company,2023-03-01 14:43:49,UPDATE 1-Genentech sues Biogen for royalties on blockbuster MS drug,119008093,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Roche's Genentech Inc sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri.  Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later.",https://finnhub.io/api/news?id=4a8249a34e4bad3729cfae129846fa09f7886b09d6cdd140d5bea138079ad8f8
company,2023-03-01 12:04:02,Genentech sues Biogen for royalties on blockbuster MS drug,118995329,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Roche's Genentech Inc sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri.  Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later.",https://finnhub.io/api/news?id=a4f60401b5022df819bddb9e14db2936f1c9360c632b068029a149a467eb7fb1
company,2023-03-01 11:40:00,Biogen Inc. stock outperforms market on strong trading day,119013835,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.87% higher to $272.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=943c2acef19cd48a73f68e3b31b77732cfd31db34349084098d3f1cf0c107225
company,2023-03-01 06:58:00,Roche`s Genentech sues Biogen over additional patent royalties from Tysabri sales,119036305,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2232661c7d14cf3f17068ec74ce65551285dab2d2e111b02e1f6f4661e1c7fa5
company,2023-03-01 02:50:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Outset Medical (OM) and Prometheus Biosciences (RXDX)",119006514,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dd22e2313a918bd5aef974ae7141f3104a0a5c4e7fc1c5b2700709c04a717be2
company,2023-02-28 20:14:00,Reata’s stock soars 150% after FDA approves rare-disease drug amid uncertainty about approach to neuroscience treatments,118987187,https://s.yimg.com/ny/api/res/1.2/jJ9EGe0fWT345kERR.OFrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/marketwatch.com/70abe0732446d7d8c8a27e6469743de9,BIIB,Yahoo,"The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.’s treatment for Friedreich’s ataxia, a rare inherited disease that causes damage to the nervous system.  Reata’s  (RETA)  stock jumped more than 150% in after-hours trading, after being halted in advance of the FDA’s decision.  The drug, omaveloxolone, is now called Skyclarys and has been approved to treat adults 16 and older with the degenerative disease, which often appears when a patient is a teenager.",https://finnhub.io/api/news?id=c7ad6cf4a0abd7ae660065b9558bc18185dc9635b6f81ea756821f986638130a
company,2023-02-28 13:41:45,"FDA neurosciences chief Billy Dunn to leave immediately, analysts raise concern",118973134,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The U.S. Food and Drug Administration neurosciences head Billy Dunn will retire from his role effective immediately, the health regulator told Reuters on Tuesday.  Wall Street analysts said Dunn's departure could impact the regulator's stance on neurological drug decisions in the near term, sending down shares of Reata Pharmaceuticals Inc 30% on Monday when media reports on the exit surfaced.  Texas-based Reata is expecting FDA's decision by Tuesday on its drug to treat a rare neuromuscular disorder called Friedreich's ataxia.",https://finnhub.io/api/news?id=a84598c51ed4229e1a840bed7b2c62d8467b8bb4c41d98bd477d7953099c0905
company,2023-02-28 11:40:00,"Biogen Inc. stock rises Tuesday, outperforms market",119013836,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.25% higher to $269.86 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=5d27835b90cf39f4defa9dc2efe86e74078f91b8c7ceff6f8d08432215a05464
company,2023-02-27 22:37:00,"Biogen, Eisai`s Alzheimer`s therapy lecanemab gets priority review in Chinna",118968947,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=833a1eba571afec326631c702ecd88823ecdd92f6fcade090daaf3ce6171d072
company,2023-02-27 19:16:28,"Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China",118959967,https://static.reuters.com/resources/r/?m=02&d=20230228&t=2&i=1624976266&r=LYNXMPEJ1R00G,BIIB,Reuters,"Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said on Tuesday that Chinese authorities have given priority review status to Lecanemab, their jointly-developed Alzheimer's disease treatment drug.",https://finnhub.io/api/news?id=2f1b9ed203a23c9a82f32c0d505504fe228b4ba4954e3ec6c901b2c6953c5369
company,2023-03-07 11:40:00,"Biogen Inc. stock falls Tuesday, underperforms market",119123690,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.99% to $264.88 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=ab11a76e9b3593954379f498a1b2e10102796cc417b794f01f8fe4eb527fffd4
company,2023-03-07 06:50:00,The Data Will Speak Louder Than Powell. Fed Rate Is Veering Toward 6%.,119098740,https://s.yimg.com/ny/api/res/1.2/K5yshcLVNVblrfgWOH2cUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/55569d33ffe9fd8ec697da35c5d24635,BIIB,Yahoo,"China ramps up U.S. tensions, JetBlue merger faces legal action, the return of luxury consumers, and other news to start your day.",https://finnhub.io/api/news?id=8cfb95fa6dbd96ba1f2de0d601c17e9e6a2b090c9282cc42b8b0615d7e212632
company,2023-03-07 01:37:00,Biden to announce plan to keep Medicare solvent beyond 2050,119099835,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f2cde5b9d169fc7f9afbda045573f4bfbae3b62fa9fa0877e9d5ebf3b9936fe8
company,2023-03-06 21:47:50,Biogen Should Resume Strong Growth With Zuranolone Approval,119095708,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368004903/image_1368004903.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Biogen's revenue will continue to decline if the FDA (or payers) declines to approve both zuranolone and Leqembi. Find out why BIIB stock is a Buy.,https://finnhub.io/api/news?id=dca1253b14379c8fbe8f2dc138c831dd87c46dde5c7d2a993fa13751460ccce8
company,2023-03-06 16:38:15,FDA to decide on full approval of Alzheimer's treatment Leqembi in early July,119092028,https://s.yimg.com/ny/api/res/1.2/lw.Mm5UUkqMdGE3eTk_FAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NjA-/https://media.zenfs.com/en/fox_business_text_367/e6eb8b416b03f83031444d07ee7c45b6,BIIB,Yahoo,"The FDA will decide on July 6 whether to grant full approval to the new Alzheimer's treatment Leqembi, Japanese drugmaker Eisai and its U.S. partner Biogen said.",https://finnhub.io/api/news?id=7d5808f54ebf45af09918e799335883bd25fb4c44a2a6e5c801df9a9f75ab3b9
company,2023-03-06 12:46:54,Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment,119088331,https://media.zenfs.com/en/Benzinga/59f0406dc2fb528b6febd59441b5c62b,BIIB,Yahoo,"The FDA has accepted Eisai Co Ltd (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection, supporting the conversion of the accelerated approval of Leqembi to a traditional approval. The Leqembi application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA plans to hold an Advisory Committee to discuss this application but has not publicly ann",https://finnhub.io/api/news?id=2846aa26cd4a28236f01502f0392a7004d6cb951abc2cf9be14e32da73aa8a7a
company,2023-03-06 11:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,119091336,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.01% to $270.25 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=b18138ddd3520c58d26a440dadc09f43ed601dc4d806b083511c46d90ccaacdd
company,2023-03-06 11:38:00,FDA Will Weigh Full Approval for Alzheimer’s Drug. Why It Matters for Biogen Stock.,119086093,https://s.yimg.com/ny/api/res/1.2/OwKKKg4jaDf67OKj3KmCIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/7c4c9273ac5d459f4a7a3ebb3b7c5890,BIIB,Yahoo,The drug already has accelerated approval. Full approval would open the door for Medicare to pay for the treatment for more patients.,https://finnhub.io/api/news?id=5865c7f5e5734707db2e811e5bb51832394893306a4053c7856c3dd14283f115
company,2023-03-06 11:30:20,Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference (Transcript),119089410,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Call Start: 09:50 January 1, 0000 10:21 AM ETBiogen Inc.",https://finnhub.io/api/news?id=fb252629dd1195b210409ed76180ea30bba2865d3d95512c4fd10dca5b9f6ee4
company,2023-03-06 11:30:20,Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript),119089075,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Biogen Inc. (NASDAQ:NASDAQ:BIIB) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 9:50 AM ETCompany ParticipantsChristopher Viehbacher - Chief Executive OfficerConference Call...",https://finnhub.io/api/news?id=58f6e12239919057c25bc9d3d43ae59b27ea01cb53f17e7e8454bb6d33936d8b
company,2023-03-06 08:16:01,"Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi",119086095,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,"The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.",https://finnhub.io/api/news?id=1f8af757ef0788c07fbde806a424048d52f2b4d5704357e43435cdb5ed7868d5
company,2023-03-06 04:19:29,FDA will review Eisai and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July,119088784,https://image.cnbcfm.com/api/v1/image/107203529-1678108303695-gettyimages-1158800046-is09c0i49.jpeg?v=1678112369&w=1920&h=1080,BIIB,CNBC,Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.,https://finnhub.io/api/news?id=069b5041b456c85284a44670b33f6f4275f19e2ba289705d658fc18df7d91f02
company,2023-03-05 22:37:00,"Biogen, Eisai`s Alzheimer`s drug Leqembi gets FDA priority review for traditional approval",119091240,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ab2d13ac58080aee6920391901f7ccdf4d50520902b5e65c20b1026478805f26
company,2023-03-05 20:59:00,US FDA accepts application for traditional Leqembi approval - Biogen,119091242,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=92feba72d33ea2a6255a012306ad05bda260e701c519ed21de10ada9eae3dae8
company,2023-03-05 19:16:05,"Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab",119078835,https://static.reuters.com/resources/r/?m=02&d=20230306&t=2&i=1625665349&r=LYNXMPEJ25008,BIIB,Reuters,Japanese drugmaker Eisai Co Ltd and its U.S. partner Biogen Inc said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab.,https://finnhub.io/api/news?id=eeb20405c86fd1e9f472c195b011e2834773a8b897ccda51e58c7025680eee1d
company,2023-03-05 18:30:00,FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease,119080271,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023 TOKYO and CAMBRIDGE, Mass., March 05, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.",https://finnhub.io/api/news?id=4ffa8644bd0cc5e37677210b8d8894d8b2ac722f8b74428a278fa8974d1d085f
company,2023-03-05 13:30:00,FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease,119091244,,BIIB,PR Newswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ff94df6348715c54fdd77b29bab9f961e9d315e9e6b6038e67138dea4b325982
company,2023-03-05 00:41:00,"Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review",119091245,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cf86401283fa28046691ea4dc0698ee512631ddbb6a57dc3b2f0b114242d38ac
company,2023-03-10 11:40:00,Biogen Inc. stock underperforms Friday when compared to competitors,119179815,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.94% to $256.56 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=82c7aa21df4998695ab9220af2bdfa2c95417c5f30c2356a637c55adcd5915de
company,2023-03-09 11:40:00,Biogen Inc. stock outperforms market despite losses on the day,119179816,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.53% to $258.99 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=4afae09e5c25ea7d771ea3f1b079d79b876cc6ccb5555e1311df2170c9a512ce
company,2023-03-09 09:37:27,Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed,119135310,,BIIB,Yahoo,Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.,https://finnhub.io/api/news?id=98c6fd966a3efef00a64f6d13dab23a6d7d5106431da3fb3d182ca3f3aaa451d
company,2023-03-09 09:33:02,Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study,119136955,https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707,BIIB,Yahoo,Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.,https://finnhub.io/api/news?id=b02f945074c6dc1c2560cd0ce6cbc4f7a6ba1f39c10939bb9845c75ece09ea02
company,2023-03-09 07:03:00,Needham healthcare analyst to hold an analyst/industry conference call,119150812,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=be2142fd214927133ad142257460595d9ff4c496bd14c557636147385edda451
company,2023-03-09 03:36:00,Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock,119135610,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=81e59ec4cbe77221f3215db219d4ec3769a05add63d926f1be55152870dae57f
company,2023-03-09 00:49:00,"No ad com suggests positive potential outcome for Sage`s zura, says BofA",119135613,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=862431c298ea33959242287aa6d6eaf94d0222588e5c2ca5764d2af52833cb31
company,2023-03-08 18:00:11,Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know,119127895,https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session.",https://finnhub.io/api/news?id=a624eed47ff04a04049d4c5d13ce63416960265bbcba7b3f246c2b02b658177c
company,2023-03-08 11:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",119123686,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.70% to $263.02 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=0cc7d9ef88da9b1415faa04a49b7f094db6d366555ead95188dc6b619ec8f695
company,2023-03-08 07:30:00,Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors,119127896,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 14, 2023. Ms. Dorsa will succeed Stelios Papadopoulos, Ph.D., who announced he would not stand for reelection to the Board at the Annual Meeting. Dr. Papadopoulos said: “The e",https://finnhub.io/api/news?id=aae3a3980541435a36fa62fa490df9ce07b9ff1d4e4bb8cff9caa7399485214e
company,2023-03-08 04:41:00,"Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8",119111522,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=26056a1b80e8fcea288a94ad965872e2d9b7b7983d53ed4806e2722cfd9e9a48
company,2023-03-08 03:00:00,Biogen Names Dorsa to Succeed Papadopoulos as Chairman >BIIB,119123688,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Colin Kellaher Biogen Inc. on Wednesday said it has designated long-time board member Caroline Dorsa to succeed Stelios Papadopoulos as chairman of the...,https://finnhub.io/api/news?id=8ddfd53ae8cbdad47e079916730ceef037e87f1d8f9020cc1429597b690d48de
company,2023-03-08 01:57:00,Biogen elects new board chairperson,119111524,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=aaa1cbc9ec01e170634887df3806abadf6ce849825dc6f1d1c6e9c6eb7bf7abe
company,2023-03-08 01:35:00,Biogen elects Dorsa as Chair of the Board of Directors,119111525,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a6b4a450edc7ac67f3c41ea15bea296f6291f65dab2322dfd7082e5a519e9f4a
company,2023-03-08 01:30:00,Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone,119109458,,BIIB,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=87066fdaa561b348bd01066c446ce99e9f92f7b5bcccafe1d2a17e9f117e76d9
company,2023-03-08 01:00:00,"FDA to not hold panel meeting for Biogen, Sage`s depression therapy zuranolone",119111527,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=be99ea4e00169a462b055ac9cc3b2aed3f1a7483af1d21021f11c09ac614a62f
company,2023-03-08 00:32:00,"Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone",119109459,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=98bb4a750eb29ad2d89df9ee86725a870a714d10c84b3c4ec88eb09d37761c90
company,2023-03-07 22:09:55,U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map,119105828,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,We are only interested in those targets that are attractively valued in historical comparison. Click here for our 3-step process that focuses on wide-moat stocks.,https://finnhub.io/api/news?id=7022d378ea8cb95f1300fc45c61a80c9738b88402ddac47b5ff9f699e6e5d1f3
company,2023-03-15 18:00:10,Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know,119262968,https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session.",https://finnhub.io/api/news?id=2380606026aac5b2c3a081fb3e03819b855503ff60c540cf129198ded08dc875
company,2023-03-15 12:40:00,Biogen Inc. stock outperforms market on strong trading day,119267810,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.01% higher to $262.37 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=422c2bdba6d0395fe18dac2d4e1fc9dee01b8f65c7323f47b8d32e74cf658ff5
company,2023-03-15 06:55:00,Needham healthcare analyst to hold an analyst/industry conference call,119257999,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=453cb2b304cc6e12f4d980edb51737de42c0b612ef44f672e28ca722bfd49a78
company,2023-03-14 18:15:10,Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know,119242500,https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,BIIB,Yahoo,"In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day.",https://finnhub.io/api/news?id=33d5d48155b724699f97328a0da72828c7839c145895d5c4d5060631d4ad3231
company,2023-03-14 12:40:00,"Biogen Inc. stock rises Tuesday, still underperforms market",119267811,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 1.47% to $262.35 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=06ef0f4b17b2bfce572d89f5e7b7ed038d0525af88a150075db616355a46eb3a
company,2023-03-14 10:52:00,The VA Will Pay for Leqembi. It’s a Step in Right Direction for Biogen.,119242501,https://s.yimg.com/ny/api/res/1.2/S6hgSaXSn5oFeQV4xr3iXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/16d22d12db3e7debab4f94af513b3a4d,BIIB,Yahoo,The biotech and its partner Eisai are seeking to get Medicare to pay for the new Alzheimer's disease therapy.,https://finnhub.io/api/news?id=2dc7d9f1b7aa409079e1d469cbd29f100dfd7ea328100071e68f0b48597944fb
company,2023-03-14 10:23:00,"1 Reason to Buy Biogen Stock, and 1 Reason to Sell",119242502,https://s.yimg.com/ny/api/res/1.2/lPXn1XYWv2PNdC2x7.cBSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/22c681b9d227305a26550adc0ea9eedf,BIIB,Yahoo,"Biogen (NASDAQ: BIIB) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons.  U.S. approval of Biogen's Aduhelm for treating Alzheimer's disease (AD) turned out to be a bit of a flop as the medicine isn't generating anywhere near the kinds of sales the drugmaker hoped to see.  Let's consider one reason the answer might be yes, and one reason to be wary of Biogen's future.",https://finnhub.io/api/news?id=0eaed98a4a81ff10f34dc9033cf469d802918ec54ac250088b8ba95154a6844c
company,2023-03-14 08:57:00,"Veterans Health to cover Eisai, Biogen’s new Alzheimer’s drug",119242503,https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BIIB,Yahoo,"Eisai Co. Ltd.  (JP:4523)  said Tuesday that the Veterans Health Administration will cover Leqembi, the Alzheimer’s disease treatment it developed with Biogen Inc.  (BIIB)  that received an accelerated approval in January.  The drug is not broadly covered at this time by the Centers for Medicare and Medicaid Services given its accelerated approval status.  “We see the VHA decision as the beginning of a potential series of wins on the reimbursement front for Leqembi, with the larger catalyst being the CMS potentially revisiting the currently restrictive [national coverage determination] after full approval,” William Blair analysts told investors on Monday.",https://finnhub.io/api/news?id=91c9361bb320c4df6b2132db9f90260a469b7c2ae5052e7c73fd9f9290351388
company,2023-03-14 07:30:00,Biogen Appoints Chuck Triano as Head of Investor Relations,119242504,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer. “Chuck will bring invaluable industry insights and a strong network of relationships to Biogen, and I’m pleased to welcome him to our leadership team,” said Michael McDonnell, Executive Vice Pres",https://finnhub.io/api/news?id=00d5a9c5ba37326b830cba1c0cc910ff1c0157f5367b5277d80c844ef9274ddb
company,2023-03-14 03:59:00,"Veterans Health to cover Eisai, Biogen`s new Alzheimer`s drug",119228223,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3c85ce1de325b14727fb5675fe4e8b639851719b4a9337500e59518c98a4262e
company,2023-03-14 02:35:00,Biogen appoints Triano as Head of Investor Relations,119228228,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0538f0b367509ec8396c02a3dd9a452a2c969357179f6c873c194aabf1bf1504
company,2023-03-14 01:11:00,"Analysts` Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)",119228230,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0e0b66a50fb74974fb1262d6d0a29a2922458d0626ea6dbd297e3c7e19e84e63
company,2023-03-13 15:27:00,Veterans Affairs to Be First Major Insurer to Cover Alzheimer’s Drug Leqembi,119204291,https://s.yimg.com/ny/api/res/1.2/FhDKoYmyZHh_oBzrrz3ayA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/97c56a5521e7e50d37e0ffd9ecde6f59,BIIB,Yahoo,"Eisai  ’s new Alzheimer’s disease drug Leqembi will be covered by the U.S. Department of Veterans Affairs, the first major insurer to agree to pay for the drug since its approval by U.S. regulators earlier this year.  Eisai said Monday veterans with the early stages of Alzheimer’s would get the drug covered under criteria set by the VA.  An estimated 167,954 veterans receiving care through the VA have Alzheimer’s dementia, according to government estimates.",https://finnhub.io/api/news?id=969cebb23c38917e46ae432b6a914ffcaf9d1a7dd0db1ade1c7a3fd945daaaa8
company,2023-03-13 17:02:02,"US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi",119211793,https://static.reuters.com/resources/r/?m=02&d=20230313&t=2&i=1626580322&r=LYNXMPEJ2C0SX,BIIB,Reuters,Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease.,https://finnhub.io/api/news?id=bd1af0ed1c17caefea9110b1663e29caf70608c37bf6bfd0b912aa19397d9ce6
company,2023-03-13 17:01:58,"UPDATE 1-US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi",119206032,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease.  The VA did not immediately respond to a request for comment, but a document on its website shows that the agency added Leqembi to its list nonformulary drugs, making it available provided patients request it, receive prior approval, and meet strict inclusion criteria for the drug's use.",https://finnhub.io/api/news?id=d71af111604f69cddb132e62f2a5d205d70b5fd70e9e1413fa9347fa5de4595c
company,2023-03-13 12:48:37,"Veterans Health Administration will cover Alzheimer's treatment Leqembi, Eisai says",119212435,https://image.cnbcfm.com/api/v1/image/107198790-16771574832023-02-23t020744z_307853963_rc2f2w9v65fn_rtrmadp_0_health-alzheimers-medicare.jpeg?v=1678740517&w=1920&h=1080,BIIB,CNBC,"Veterans with early Alzheimer's who meet certain VHA criteria can get the treatment covered, according to drugmaker Eisai. ",https://finnhub.io/api/news?id=0a1227172b0c90e1b0bc7acad31f89c803b05169c85f8ea098fccf093aabe3ad
company,2023-03-13 12:40:00,Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains,119219873,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.78% higher to $258.55 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=23e4f824b1068b4b2d304c57cc70c7244d11d3cf55bfc07205c334ea364cc0e9
company,2023-03-13 05:59:00,Sage upgraded to outperform at RBC on greater confidence in zuranolone approval,119200321,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d65657b95d22c9719ccbb215d07688e6dfe5796ab36d5b49414467f7dfe77a4
company,2023-03-13 02:10:00,Biogen price target raised to $350 from $335 at RBC Capital,119200322,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9588d9c0864595d73d9d45c76e73aed2c7ed43e4287d9fa267298fcf8d4621ed
company,2023-03-12 23:37:00,Biogen Takes Over #202 Spot From Bank of New York Mellon,119228233,,BIIB,The Online Investor,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=97d604aeddc01710687656fd42a8f3434b7e54b6663c9cf135ee7bb2b82c04ad
company,2023-03-12 22:50:00,Biogen `welcomes` VHA recent decision to provide coverage to Leqembi,119228235,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=70e825f648c4aa1250acf80f6e29bd1de4b6221c09294320a7868c35bc0be5c2
company,2023-03-12 22:13:00,"VA to widely cover new Alzheimer`s treatment from Eisai and Biogen, STAT says",119228236,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dbec90aa00918534dd1888c49db5b95cdae497a9745d08f2d80acdaaf2963f43
company,2023-03-12 21:31:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Crinetics Pharmaceuticals (CRNX) and 89bio (ETNB)",119205547,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0f8f8c8162f67ad0c88d3b8167e292f50171cb731ad521db8feb3096349a8dca
company,2023-03-12 05:01:00,Biosimilars expected to save $180B over next five years as more gain approval,119200323,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=00f298f3dd6590ee3446503afae7760dc6683d0c426d09af0dcb3fec412d468a
company,2023-03-19 05:30:00,Should You Buy Biogen Before a Big July Decision?,119308090,https://s.yimg.com/ny/api/res/1.2/zAIwE1brutFrrptPasYclw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/5a9ad7886207521986ab5297d8e4a53c,BIIB,Yahoo,"Over time, Biogen (NASDAQ: BIIB) created a true success story.  Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market.  Now, though, Biogen may have found that new growth source.",https://finnhub.io/api/news?id=0cd48a6b9267aa612d7a4e1ee804d4fcb9b141c4874b54e1334c44d28a2d798a
company,2023-03-17 15:44:00,"Stocks to Watch: Credit Suisse, First Republic Bank, Sangamo",119327741,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"By Sabela Ojea Credit Suisse Group AG is in discussions for all or parts of the bank to be taken over by UBS Group AG, the Financial Times reported on...",https://finnhub.io/api/news?id=930608b27320640e2d4f44d6b780bbcd6e212808f88efb8ba09fa4ab76df8a42
company,2023-03-17 14:45:00,"Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations",119327742,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Josh Beckerman Sangamo Therapeutics Inc. shares were down 8% to $1.84 after hours as the company said Novartis AG and Biogen Inc. terminated collaboration...,https://finnhub.io/api/news?id=6126d9aee62f0589a281c9cfea3bc935b7cf2202ff1a5de2f6da58e37cd9c748
company,2023-03-17 12:40:00,"Biogen Inc. stock falls Friday, still outperforms market",119349869,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.79% to $263.16 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=276304c02a5e3a06f7cc59742e18dcf0e9b9326323df76051b253d07c9f9bbc7
company,2023-03-17 11:30:03,Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?,119296256,https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9,BIIB,Yahoo,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=ec336c5948f4adffce34c611df8f1e43ce98f120bc89f43e1880a865abc0cb71
company,2023-03-17 08:00:19,Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 27% Undervaluation?,119289816,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Key Insights The projected fair value for Biogen is US$362 based on 2 Stage Free Cash Flow to Equity Biogen's US$265...,https://finnhub.io/api/news?id=776b4f83ffe6b2655fee7e0bda34a27650efda3049290ce302fecd4195a326c4
company,2023-03-17 03:51:00,"Stifel trims Biogen target, but has more confidence lecanemab `best-in-class`",119303952,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ba142dbbb812e2311d814a65417d937c3230de3806d25913126dcb4ea798abac
company,2023-03-16 14:00:51,Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments,119285478,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"https://cdn.benzinga.com/files/images/story/2023/03/16/dementia-3051832_1920.jpg?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 The Alzheimer's Association has launched a grassroots lobbying campaign while deploying 1,000 people, either patients or caring for someone with the disease, to meet with all 535 members of Congress across the U.S. and urge them to press Medicare program for the drugs starting with Biogen Inc (NASDAQ: BIIB) Leqembi (lecanemab). According to interviews with four Associa",https://finnhub.io/api/news?id=a29e7d56e9071b5dae37120e4e50829dbffeeaf819d2ec46bf3ec253337d2202
company,2023-03-16 12:40:00,"Biogen Inc. stock rises Thursday, still underperforms market",119349870,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 1.10% to $265.25 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=73082b600a06c15a2186d93b6f9f17258f3c3f575af113c8254f3c8d10d299fa
company,2023-03-16 08:43:12,Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges,119274665,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,"Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.",https://finnhub.io/api/news?id=9bb9d00e9c9e951c4ef4d9da995a03d908cdd8310d5f61f5081f1d3901fe1790
company,2023-03-16 06:30:00,Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection,119274666,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision annulling the EMA’s refusal to evaluate a generic version of TECFIDERA® (dimethyl fumarate) because of TECFIDERA’s regulatory data and marketing protection. With this favorable decision, Biogen believes that TECFIDERA i",https://finnhub.io/api/news?id=f0d4c5c074edbb4f964fe18ef316a1500bd421fed764e8ab715ddb861a2ac9de
company,2023-03-16 04:45:38,Biogen And Eisai's Leqembi: A Dose Of Reality For Alzheimer's Disease,119270420,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/87467742/image_87467742.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Biogen and Eisai are confident that the FDA will grant full approval for Leqembi for Alzheimer's disease. Find out why BIIB and ESALY could experience a substantial boost.,https://finnhub.io/api/news?id=0e254194e958ac001a0b38ebfef310ff5684b23d81c7c6d685176dc80a7a1e29
company,2023-03-16 03:57:38,Wall Street Breakfast: Credit Suisse's $54B Lifeline,119269998,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311092401/image_1311092401.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.",https://finnhub.io/api/news?id=5a7618d34ce7824bc8e7019d0077ccad26f40c1c982e62deb2bb30588c627b28
company,2023-03-16 03:50:00,Biogen And Eisai`s Leqembi: A Dose Of Reality For Alzheimer`s Disease,119280393,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c27ad758b58c4106e15a47d829dec9b10f1ae5c6b63e712fb0eeb08b4e5cca87
company,2023-03-16 03:09:00,Wall Street Breakfast: Credit Suisse`s $54B Lifeline,119272358,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fd2a32e29b8e69679e765d414c565f2dbdcb7bb7a966fc570e5c7158e43f13a1
company,2023-03-16 02:31:14,PBE: Healthcare Dashboard For March,119269693,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1175270464/image_1175270464.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold.,https://finnhub.io/api/news?id=c7491c8078cc18110f8ca9e1d2dcf1d8feefea9645b61548bc31df0b181e1f03
company,2023-03-16 02:05:00,Biogen gets EU court ruling in favor of blocking Tecfidera generic entry,119280396,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=edb3ad01e1d025edb200c1e88f43e04c377458f823f6c070440dee723ed1e9bb
company,2023-03-16 01:32:00,Biogen receives favorable court ruling on TECFIDERA,119280398,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b7d32b022842020263cba04edaff1f657d9fc3ecb2ca1b072f18f207147f3f2a
company,2023-03-23 16:03:26,Biogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key Endorsement,119382452,https://media.zenfs.com/en/ibd.com/616695ca8d8e75585248b67d063c72a1,BIIB,Yahoo,Biogen stock jumped — as Ionis stock gave back early gains — after a FDA panel offered a mixed view of their ALS treatment.,https://finnhub.io/api/news?id=a4651a5e3beb53bf63beb8ae3f8844c27fa6eaa63c2381495f4e77eb4061875e
company,2023-03-23 13:56:39,7 Blue-Chip Stocks Sitting in the Sweet Spot,119422022,https://media.zenfs.com/en/investorplace_417/49ba12efc6cb6e5091872131a59d98b4,BIIB,Yahoo,"Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won’t do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they’re tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts. Further, adding to the sweet nature of these blue-chip stocks, they’re all undervalued based on earnings m",https://finnhub.io/api/news?id=a2fa4d0d2f2faa290aef4da9920c0f84e4aaf8e1d35136390f2e8609858c7319
company,2023-03-23 13:51:05,"Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval",119382453,https://media.zenfs.com/en/zacks.com/378e912f39550fd9d3e26da87fee4c8a,BIIB,Yahoo,Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.,https://finnhub.io/api/news?id=4f3a6df994f0e5aaee56937484fb6240ed063767275e3031e3d582a2462a87a8
company,2023-03-23 12:40:00,Biogen Inc. stock outperforms market on strong trading day,119451158,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.51% to $265.17 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=41c442301c8685e1c8b7a7026eb7ae692c6f7535d28f4f780273ba81a0dd943a
company,2023-03-23 10:53:02,Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA,119382454,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.,https://finnhub.io/api/news?id=a12ad7105092a1a6d3cda3a23a5905de09c26baf62a1d5acee32189647de84c2
company,2023-03-23 09:12:28,FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder,119382455,https://media.zenfs.com/en/Benzinga/81eeef6a8436e6cdc37b167a40db2651,BIIB,Yahoo,"The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 9 yes - 0 no, indicating sufficient evidence showing a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict the clinical benefit of tofersen for SOD1-ALS patients. Biogen Inc (NASDAQ: BIIB) licensed tofersen from Ionis Pharmaceuticals Inc (NASDAQ: IONS) under a collaborative development and license agreement. Neurofilament light chain (NfL) is a",https://finnhub.io/api/news?id=a518aaefd9153b18b72249ae63ddf0cff141525a749f48e8412c968d140a01e1
company,2023-03-23 06:51:00,May 5th Options Now Available For Biogen (BIIB),119380788,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2b912da0f1664fae67067b7bf0bfb4a00eb2c923e90bba8e4a9a142708fbc59
company,2023-03-23 06:42:31,US FDA panel backs accelerated approval for Biogen's ALS drug,119374236,https://static.reuters.com/resources/r/?m=02&d=20230322&t=2&i=1627680162&r=LYNXMPEJ2L0XA,BIIB,Reuters,"A panel of advisers to the U.S. drug regulator voted that data on Biogen Inc's experimental treatment for ALS, also known as Lou Gehrig's disease, shows that the drug could work, potentially paving the way for an accelerated approval.",https://finnhub.io/api/news?id=541a8e25c08a8166e78ac0e49b7deebec703a1a98644b00aae760125e453cb17
company,2023-03-23 06:09:38,The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership,119370196,https://s.yimg.com/ny/api/res/1.2/o9HN4iBu6Xxshjpwl5TYpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDI-/https://media.zenfs.com/en/bizjournals.com/01e667f4bbc7bbf59f5ba702818b6c69,BIIB,Yahoo,Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial.,https://finnhub.io/api/news?id=06462b400cb1530a5767ee0ac89eb6ec7c926dee758171385fa6f60c760d26fd
company,2023-03-23 04:03:00,"Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23",119380789,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=49984d2336aa96c8e31c03d3841138168a8550b346937c86a2e0f5eee2e5a058
company,2023-03-23 03:31:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)",119378286,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7f67381e1c19b0942a43582e982a58f182b934a52d263b3a8d447b351361828e
company,2023-03-23 01:40:00,"Analysts` Top Healthcare Picks: Biogen (BIIB), Applied DNA Sciences (APDN)",119374194,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b7e9abb70742eafce3be1f2fe419d90e7b5729d3103d05495f040de10bca8c76
company,2023-03-23 01:35:00,Biogen (BIIB) Receives a Hold from BTIG,119380793,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6303daf8d037ad520b51f2ca986d2b16b8922acbd451264a95ae947c2da990a4
company,2023-03-23 01:35:00,Raymond James Sticks to Its Hold Rating for Biogen (BIIB),119380792,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dbba34e1e0fd9a0c9173e345631c5692e05c632570e695a3a2067b577cdb6641
company,2023-03-22 20:31:00,Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS,119362691,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United StatesCAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidenc",https://finnhub.io/api/news?id=7ef9af130f929efd8f82dba4033800ee955057c3383aa957274723cf76f54772
company,2023-03-22 18:32:55,US FDA panel says current data not 'convincing' for Biogen's ALS drug,119360250,https://static.reuters.com/resources/r/?m=02&d=20230322&t=2&i=1627680162&r=LYNXMPEJ2L0XA,BIIB,Reuters,A panel of advisers to the U.S. health regulator said on Wednesday there was not enough convincing evidence to show the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS).,https://finnhub.io/api/news?id=8927697b3dd5e3be271f8428b4ac18da6c0c705bf1a65c400bc35b4d643a94eb
company,2023-03-22 17:29:19,UPDATE 2-US FDA panel says current data not 'convincing' for Biogen's ALS drug,119362692,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"A panel of advisers to the U.S. health regulator said on Wednesday there was not enough convincing evidence to show the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS).  The U.S. Food and Drug Administration (FDA) panel voted 5 to 3 that the late-stage data for the drug, tofersen, did not show it was an effective treatment for ALS patients with mutations in a specific gene that leads to accumulation of toxic levels of a protein known as superoxide dismutase 1 (SOD1).  One panelist abstained.",https://finnhub.io/api/news?id=7800dcd1145a91b91b52d305c8070137e4499c2593e2ccd9e191af95aabb88dd
company,2023-03-22 14:27:00,Biogen ALS drug considered not effective by FDA advisory panel,119371960,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Biogen Inc. received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker’s proposed amyotrophic...,https://finnhub.io/api/news?id=0f288eabe6b72faf755661149992bf15abc9affccf53008e27cb648159c20d77
company,2023-03-22 13:36:36,FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease ,119360920,https://image.cnbcfm.com/api/v1/image/106893719-1623152809766-gettyimages-1233323372-ALZHEIMERS_BIOGEN.jpeg?v=1679520996&w=1920&h=1080,BIIB,CNBC,"FDA advisors voted against the effectiveness of Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.",https://finnhub.io/api/news?id=74080b8778d8302f18f4b9175ee095b24fba10bae9734b7f948455686c151723
company,2023-03-22 12:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",119371963,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.85% to $261.22 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=7bc58ac1a817f453d0ba97425e6821353219b90aa0d6da36594b37f7e0f00ec6
company,2023-03-22 06:40:00,Why won`t Medicare cover the new Alzheimer`s drug?,119358492,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2a2db7b12204cee0dc53f85cd4ce63271760e9749b9c698d5a47392efeb53be8
company,2023-03-22 04:05:00,FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting,119358493,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07144357f14eb88f5b33544826d1735d7c45feaecac3fd70332e4edf3dc1f4f1
company,2023-03-22 03:57:00,Biogen provides update on AdCom meeting on Tofersen for SOD1-ALS,119380796,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f7b2a4bcf3fdd3cc68d62ce5c5c22884bd4486fa2d967bf0791311d6b66f0e36
company,2023-03-22 03:37:00,Inozyme appoints Matthew Winton as COO,119353187,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ef892b2c7844ed40394766e603be9baba427466857033aa18a998ae6ca001030
company,2023-03-22 02:16:00,Veterans Health Administration will cover new Alzheimer`s drug. Why won`t Medicare?,119358495,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8e04dc683341b72e07b7f3af1c2488927d08e4811867c42991aac63f3c5fede1
company,2023-03-22 01:08:00,Biogen ALS drug tofersen earns mixed voting by FDA advisory panel,119358497,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ece52982509ae13c020a25e10a5099de0569abcdfea1fe491511c0f2bf6a313d
company,2023-03-22 00:10:00,Biogen ALS drug tofersen wins unanimous FDA panel recommendation,119358499,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=592a610f87b380abe41adb78ecbd0bd348287a9de88e5280557723d441795b9f
company,2023-03-21 18:00:10,Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know,119341733,https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.",https://finnhub.io/api/news?id=123de7197436adf50f02c0d7e68cb21b963965a77abbaeee7d96cd867144624f
company,2023-03-21 16:13:55,7 Healthcare Stocks to Buy for Long-Term Growth and Stability,119385737,https://media.zenfs.com/en/investorplace_417/7a6d7cf8fd09137bc1a8f5746ab0adba,BIIB,Yahoo,"Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation. All while the global economic backdrop is marred by China and the Russia/Ukraine War. Therefore, investing in defensive investment options, such as the best healthcare stocks to buy, is perhaps a more prudent strategy now. Healthcare stocks typically exhibit resilience during economic downturns. All thanks to heightened government healthcare spending,",https://finnhub.io/api/news?id=701264c1a1c4cfb8a5fe5916271a7b11875a39d41a4953b5aa4d5f082930bf1d
company,2023-03-21 12:40:00,"Biogen Inc. stock falls Tuesday, underperforms market",119349863,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 0.66% to $266.15 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=0cc9851f12e75f7bbab8e087eb1c07681f485f608050ac6a920c6591b17d41f8
company,2023-03-21 08:59:25,"Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit",119341734,https://media.zenfs.com/en/Benzinga/3b41b43bccd901619bdddc28e859fbe2,BIIB,Yahoo,"FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc's (NASDAQ: BIIB) ALS drug tofersen. FDA staff, citing a briefing document, said Biogen's investigational ALS drug might have a ""clinical benefit"" on a rare and aggressive form of the disease, despite failing a broader late-stage clinical trial last year. ""Despite the notable limitations of a failed study and the many post hoc exploratory analyses conducted after",https://finnhub.io/api/news?id=218a24a419bd6d8660ff2740147944cdb05d0d2710c1ffcec9c250baba74385b
company,2023-03-21 07:44:00,Wall Street analysts predict approval for another ALS drug,119349225,https://images.mktw.net/im-515422/social,BIIB,MarketWatch,An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to treat a rare form of Lou Gehrig's disease.,https://finnhub.io/api/news?id=7c55781132168796fb5b7c63f2014fda8f84d5ea02ec6bca07ec690f0280c90e
company,2023-03-21 06:46:00,Wall Street predicts approval for another ALS drug,119337926,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cbe78c20200bd671983a8c0fdd4ea0490ef5802e2b801435ceecfb14efea9205
company,2023-03-21 03:51:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Danaher (DHR) and Blueprint Medicines (BPMC)",119339382,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b8324fd3cbc1d9e97a51593695ebc4f511c7f3af93e9d24ef2cc121162a2c8f
company,2023-03-21 02:57:00,"FDA briefing docs suggest FDA in favor of Biogen`s tofersen, says BofA",119339384,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=10a6167ae33d0e1718345412dc9d09d7a0a1887d176af170aff8901566da5011
company,2023-03-20 12:25:22,Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo,119306990,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"https://cdn.benzinga.com/files/images/story/2023/03/20/sgmo_logo_light__df15263084666d45f8f072d9581b42da.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to rese",https://finnhub.io/api/news?id=62b215ca444924c2a0a2ccb2f96bc3493959cb3dd2ed1361c6aac61036df1efc
company,2023-03-20 11:34:28,FDA staff says safety issues with Biogen's ALS drug to not prevent approval,119305071,https://static.reuters.com/resources/r/?m=02&d=20230320&t=2&i=1627378285&r=LYNXMPEJ2J0JS,BIIB,Reuters,"The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval.",https://finnhub.io/api/news?id=2b2b2f113e84358ca23ab94aa6bbfbdb5abcc6fd25eafc0743793b2c56174a73
company,2023-03-20 10:53:03,FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease,119321381,https://image.cnbcfm.com/api/v1/image/106936821-1630602069094-biogen.jpg?v=1679338383&w=1920&h=1080,BIIB,CNBC,"The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a ""clinical benefit"" on a rare and aggressive form of the disease.",https://finnhub.io/api/news?id=7334bc6105a3c1b192ab03c0195c4e8925e982dccf4b7cef20ac92b767995a84
company,2023-03-20 09:51:30,UPDATE 2-FDA staff says safety issues with Biogen's ALS drug to not prevent approval,119308089,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval.  A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday will closely scrutinize mixed efficacy data from the drug's late-stage trial and vote on the drug's effectiveness, and if reduction of a key protein related to the disease is enough to conclude that it may benefit ALS patients.",https://finnhub.io/api/news?id=5654f66fce1cfcff2bd56d17e96e7ee212c9c8039e1c47a180f15f43a36c6ed6
company,2023-03-20 06:25:00,"Biogen, Eisai Alzheimer`s drug Leqembi covered by VA",119313379,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9f72d50ec83b5d99b72d1940b09d2fd28643d3aee95b3522594fcbf4f6c9210a
company,2023-03-20 05:51:00,FDA scientists weigh potential effect of Biogen ALS drug ahead of advisory meeting,119313380,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ac2dd6f3dad36bc59b056cb58b85a2a08f6219805e2d67d5eda0bd2ac772ac41
company,2023-03-20 04:19:00,FDA posts briefing document for advisors` review of Biogen`s ALS drug,119313382,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=84b7f101208910ddffcb96a5eb6147b8dc0c5cc77e9454c02a060dfb2a83ce3e
company,2023-03-20 02:01:00,"Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Sarepta Therapeutics (SRPT) and G1 Therapeutics (GTHX)",119313384,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2d20fcfa1161d7ce9b2544f283e92f487d27340587600ec1f7691e41781daec1
company,2023-03-27 18:15:10,Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know,119466906,https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day.",https://finnhub.io/api/news?id=3ac606d28daf09ab96d5309d60da1b134fecb9887d2b0de339a69abc826b042a
company,2023-03-27 12:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,119451155,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.02% to $269.98 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=0adacecdb370d59956b8f78bd01fdc5b8252bb70f9de00c1a29e4e03362953b5
company,2023-03-27 11:42:03,Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study,119439215,https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0,BIIB,Yahoo,"Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).",https://finnhub.io/api/news?id=8a9eeba01350afd1a2ab9405c01589156914d448739f0609c453a53929cef88e
company,2023-03-26 09:00:31,Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%,119423634,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...",https://finnhub.io/api/news?id=c84dac6cc9c766b8bed5e2611eadcba3c5294b893131e54d680e704d9aec6513
company,2023-03-24 12:40:00,Biogen Inc. stock outperforms market on strong trading day,119451157,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.83% to $270.03 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=7de9ab6855e2a5b9dc512bcd17d262c6ba690891a8fcc77cada8ade20fa30881
company,2023-03-24 01:33:00,"5 Best Healthcare Stocks to Invest in Now, According to Analysts",119445620,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=70e9632c57b18e83a8e6025f58e2d21e1f751d3898a3236660ab5be120d9421e
company,2023-03-31 12:40:00,"Biogen Inc. stock rises Friday, still underperforms market",119558909,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.05% to $278.03 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=d3273b1835ec834e9e2df62e4c263880391fef37566240d8e356b9db57be0049
company,2023-03-31 09:57:51,Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug,119549911,https://media.zenfs.com/en/Benzinga/5ed508a36079fa30c488f0d84fd31863,BIIB,Yahoo,"Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced that three additional detailed analyses from the Phase IIb clinical study (Study 201) of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD were published in the peer-reviewed journals. In the core 201 study, lecanemab was shown to reduce brain Aβ accumulation measured by amyloid PET in a dose- and time-dependent manner after 12 and 18 months of treatment, and corresponding changes in plasma",https://finnhub.io/api/news?id=675c16a7f033800bf5288a5b832797a12c59799c290d60bd1257850d0b8ffbef
company,2023-03-30 19:31:00,ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS,119525441,https://media.zenfs.com/en/prnewswire.com/ece9cbfc4b1b07ae5075e2c44bc00b8e,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals.",https://finnhub.io/api/news?id=8069d71d96f6e0d110ad2ba0ded3368bb7af0150a4c2e9e3e03b603a47d73bdb
company,2023-03-30 19:30:00,Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting,119549913,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL), from the re",https://finnhub.io/api/news?id=7598443ebf7c572f5e76abfc9c15e14246706d4e6e75e2a4b76278c21217040c
company,2023-03-30 12:40:00,"Biogen Inc. stock rises Thursday, still underperforms market",119558911,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.41% higher to $275.13 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=6e089d3876ae0e5ecd9a11c6f83a2553dd5c0956d1850cc222437bcff822239d
company,2023-03-30 11:30:03,Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?,119531080,https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85,BIIB,Yahoo,Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=3d64232f98d7b10fdd031af3851638ccc316b73c6b7752610056631d63344266
company,2023-03-30 06:25:32,15 Cheap Beginner Stocks to Buy,119514746,https://media.zenfs.com/en/insidermonkey.com/e5c13a317466af96b449fa84e2b6c862,BIIB,Yahoo,"In this article, we will take a look at 15 cheap stocks to buy now for beginners. If you want to explore similar stocks, you can also take a look at 5 Cheap Beginner Stocks to Buy. Morgan Stanley’s Big Bear: “It’s Just A Much Less Predictable World” On March 27 Morgan Stanley’s chief U.S. […]",https://finnhub.io/api/news?id=77e2847254420f65ad6b54ee009075ea9444f5dae618b7ac436b024c726382fb
company,2023-03-30 02:36:00,Biogen announces detailed analyses from phase 2 study of Lecanemab,119524127,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3c1a6880eb5f2eddd4f45386bdfaceeadb1823875eacc1d7845fd7cd7fd86aa2
company,2023-03-29 18:00:10,Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know,119508040,https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209,BIIB,Yahoo,"Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day.",https://finnhub.io/api/news?id=522422fe542e459b71a289eba9a8e4956ff866e84b98905146b1cce3afffe6eb
company,2023-03-29 12:40:00,"Biogen Inc. stock rises Wednesday, still underperforms market",119510293,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.39% to $274.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=c3d400e7587cc08a648e387d3a912a5617d2e5d4914a0079ff2e7c486e18b862
company,2023-03-29 08:45:00,New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease,119508041,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein (CSF t-tau and p-tau181) in the cerebral spinal fluid (CSF) throughout the open-label long-term extension (LTE)Neurofibrillary tangles in the brain are composed of tau proteins and are a key pathology associated with Alzheimer’s disease1 CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Biog",https://finnhub.io/api/news?id=3552da747623d6c6282693154e4a2e7312d77ac15bbacd31c8f34290c44ffafd
company,2023-03-29 03:54:00,Biogen says BIIB080 `substantially reduced` tau protein level in early-stage AD,119491246,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=179c12695ba47c596c311f574b35df70dae42508609c91e7cca1c0fcc1523b74
company,2023-03-29 03:49:00,Ionis Pharmaceuticals` IONIS-MAPTRx shows tau reduction efficacy in Alzheimer`s,119491247,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a57dc8881d5b05ab35dadf56b2c6e474a5b94d8f94d89628ce67e26941728dc
company,2023-03-28 12:40:00,Biogen Inc. stock outperforms competitors on strong trading day,119510294,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.10% higher to $270.25 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=47e224cc633dff1663284d0380241957fd60a37b709337fdb66bf855c51b913f
company,2023-03-28 08:41:00,"VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Return?",119473903,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=32182e74fa2f7ed6c27faf74e0ba2386ae5b735e1d858ab0abdea7811be4aac0
company,2023-03-28 08:35:00,"VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Returns?",119473904,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fd799ad7fa0677fe329a03f5122e1a0b5c88b12b265afa8b169d16cff713be0d
company,2023-03-28 08:26:00,"VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver Best Returns?",119473905,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b706dc28706adfd1bbb3857d337a6b184048dadd7e66d2d71e192d2bfb90d5ff
company,2023-03-28 08:22:00,,119473906,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f6781fb33b061e3b6e35a6c90baf04d0ea2139cf4a29c4091273434f2242ba07
company,2023-04-04 18:15:10,Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know,119622792,https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9,BIIB,Yahoo,"In the latest trading session, Biogen Inc. (BIIB) closed at $275.25, marking a -0.75% move from the previous day.",https://finnhub.io/api/news?id=4a3eddef44bd8639d326a6783705ed330007d5365225a1506cc6642401a282f9
company,2023-04-04 12:40:00,"Biogen Inc. stock falls Tuesday, underperforms market",119645928,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.75% to $275.25 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=15d6ae36f1406eb1cd984ddc911e3eb329b89471497ca760030dc23823bef36d
company,2023-04-04 07:30:00,Biogen Appoints Adam Keeney as Head of Corporate Development,119618092,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen’s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. “We welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable expe",https://finnhub.io/api/news?id=8f3e5e60409a6d17a334596892e5a10188cf32daa86bbc0ff144248a42bf05c8
company,2023-04-04 07:27:00,Biogen names Adam Keeney to head corporate development,119608496,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=23173a52224fd390e7842c717e4d4fffff9c40632829ea87476334f57f9cc53c
company,2023-04-04 02:38:00,Biogen appoints Keeney as Head of Corporate Development,119607642,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9e3f50e009941e146dcfcd0c09558d5985de0e503743f26eeb261f7dd8aca6a7
company,2023-04-03 12:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,119645929,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.25% to $277.34 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=584ffa0bebaa2cb7eac1b9d9be158b031c78f54421c1c4f66582bba6e79a5112
company,2023-04-03 02:10:00,US to create Alzheimer`s research database in ~$300M project - report,119590788,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1d538ec890dc5ff9b04824a917ecf59dce2d23e075cb35beb3adb806f5ec8cb6
company,2023-04-01 08:00:14,Do Fundamentals Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?,119553900,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Biogen's (NASDAQ:BIIB) stock is up by 3.0% over the past week. As most would know, long-term fundamentals have a strong...",https://finnhub.io/api/news?id=45d610d131c3e4659799c1ebd7c5909524c653920f4913dd18f8fa3f960c2ac2
company,2023-04-07 07:34:00,Steven Cohen Loads Up on Esperion Therapeutics as Shares Slide,119671771,,BIIB,GuruFocus,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=08542f14a3464aea87698ebabef75a2f67965e92ed5522c9823a364c4c57d530
company,2023-04-07 04:46:00,RBC Capital Sticks to Their Buy Rating for Biogen (BIIB),119687858,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=60c388e4ef0d3300ab67fb192253a2c6d38c69cd01b84b80a9ac361d4c5bdf11
company,2023-04-06 23:30:00,The 3 Best Millionaire-Maker Stocks to Buy for April 2023,119677618,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d7a0dc15548572ee0742e3cd0391c8bbbc1c1b26ee71848ba42f4414b4cfaab2
company,2023-04-06 13:20:35,"Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says",119663842,https://image.cnbcfm.com/api/v1/image/107041628-1649100842640-Biogen_121219-2066.jpg?v=1680816035&w=1920&h=1080,BIIB,CNBC,"Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows. ",https://finnhub.io/api/news?id=bb4920854ea4de7591ac5e88e42c8c21fe82ff3c8177d6af891ec9b10e21f683
company,2023-04-06 12:40:00,Biogen Inc. stock outperforms market on strong trading day,119689516,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.99% higher to $286.80 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=aff75cc30e815594906559880b34cc82aeaff18e4b9d7db3ccda9ed4e73dd6f1
company,2023-04-06 10:00:19,The 35% return delivered to Biogen's (NASDAQ:BIIB) shareholders actually lagged YoY earnings growth,119663560,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...",https://finnhub.io/api/news?id=bfbc6f47bdcfb85052157937b5cd747315e0dc0e5fdd53fe9fdef138a9b3760e
company,2023-04-06 07:51:32,Ionis And Biogen: Tofersen PDUFA Looms - Positive Outcome May Kick Off Bull Run For Both Stocks,119651205,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141315747/image_1141315747.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Ionis and Biogen have been partnering on antisense drug development for a decade. Read why significant growth could be ahead for this alliance.,https://finnhub.io/api/news?id=b67ce9ccca96f0a0af483b47f5c6f9ef16025f09fa993f1f39867ae37f03fb82
company,2023-04-06 07:38:00,FDA forces pre-term birth drug off the market after 12 years,119652508,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=36b4531d32d650b41ea739b23b3a10be33d6d7d3825b7ab427eacf3df35d3aeb
company,2023-04-06 02:28:02,"Biogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of Revisions",119649449,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1399362719/image_1399362719.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Biogen, Eisai, Cassava Sciences, and Anavex have all provided data for their Alzheimerâs drugs that hide a deeper reality. See why AVXL stock is a Buy.",https://finnhub.io/api/news?id=a0089c88947257e0c9e529ab08580b9754e049c4e67ff4de28ce87afacd050b9
company,2023-04-05 12:40:00,Biogen Inc. stock underperforms Wednesday when compared to competitors despite daily gains,119645927,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 3.18% to $283.99 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=a8a47a2e05c4a2c9bb228b7b18f26fc76bc035f0ecb2c6d77191597e7df5e7c2
company,2023-04-05 09:10:09,Top Insider Picks For March 2023,119633713,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1441687505/image_1441687505.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. Read more here.",https://finnhub.io/api/news?id=0104954ea4a39503e4cdf4d3eb101a023095e745da5fde2d0fc2f416313b71cb
company,2023-04-05 06:21:31,Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study,119637697,https://image.cnbcfm.com/api/v1/image/107220862-1680697969216-gettyimages-1244662753-porzycki-pharmace221110_npMth.jpeg?v=1680704491&w=1920&h=1080,BIIB,CNBC,Eli Lilly said a higher dose of the up-and-coming Alzheimer's treatment remternetug had a larger effect on clearing amyloid plaque. ,https://finnhub.io/api/news?id=efcd4a5e041acf2b0ce291ce0036b73730118d7608ad223e48067269c22eb683
company,2023-04-05 02:08:00,"JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data",119635270,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=572f6437f522d72ea8fb6133bf63f293d50323f5cd772054c435ab6b7d983d59
company,2023-04-04 23:09:19,U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map,119625466,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,We believe that the most widely used valuation multiples are terribly flawed. Click here for a complete analysis.,https://finnhub.io/api/news?id=ee4a063d864b68349f62d6e6a2993e7d9717d761f34297b653f46dc56aac3632
company,2023-04-12 17:11:25,Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation,119732684,,BIIB,Fintel,,https://finnhub.io/api/news?id=dde641b67642ba50440f21ae6ca8b933a248aefb77bbf7d531ab78269a926c26
company,2023-04-12 12:43:00,Biogen exercises option to license Denali treatment,119734112,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5f8d07fc9f834ccc21f3866e8a83425047f4c5876118b08c71ea742535796352
company,2023-04-12 12:40:00,Biogen Inc. stock outperforms market on strong trading day,119754852,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.74% higher to $285.79 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=d0409cc6a168c9441da936ef5374651acaf2a4a37bbdbd273bc7ed0a2ed6188e
company,2023-04-12 08:00:00,Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta,119749971,https://s.yimg.com/ny/api/res/1.2/l7uLiMxvb9OqaSx5ShRNWg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zMDg-/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b,BIIB,Yahoo,"Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in the brain is a defining feature of",https://finnhub.io/api/news?id=9076eeeabaf9d9d6281f57b24b29b3b3af2a8425f2679438e0c2ceaf2ebf419f
company,2023-04-12 04:25:00,Truist biotechnology analyst to hold an analyst/industry conference call,119734113,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7e5b37377cde4cd354bb5a57f45443902c8b536e87ca0fcca51339e195e1bd7d
company,2023-04-12 03:38:00,Biogen licenses amyloid beta-related program from Denali,119734115,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94da406d39853c52ead52462079481456be66c3910bb68b25663d81c69fb9da8
company,2023-04-12 03:07:00,Biogen exercises option with Denali to develop its ATV:ABeta program,119734116,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3c7808c7bc4f292e1b1f85f793a0fb371ffa104e6f2bec544ff16dc09ab16c11
company,2023-04-12 02:43:00,Biogen price target lowered to $349 from $351 at Morgan Stanley,119734117,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1dc1b07661eaa88685798a1a573c92e4a245f1e0a9ffca50dffe3706db9e1ea5
company,2023-04-12 01:28:00,Biogen price target lowered to $307 from $310 at Barclays,119734118,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7c0a9d90a358c7012f89afa61e72cc6084005457bf65039cdd325bc1296d72aa
company,2023-04-11 22:26:28,Why Healthcare Stocks Are A Prescription For Investors In Q2 2023,119725087,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413600685/image_1413600685.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.,https://finnhub.io/api/news?id=69173de72e70bacb9558918aee06ad651655d4ae31b435a26de7f0e4e7d3ba03
company,2023-04-11 17:52:20,Needham Reiterates Biogen (BIIB) Buy Recommendation,119723616,,BIIB,Fintel,,https://finnhub.io/api/news?id=44e3f0a234f10158f55b89064d349871fdf98ffd53ebafddee8b2e4cb4850e6f
company,2023-04-11 12:40:00,"Biogen Inc. stock rises Tuesday, outperforms market",119754854,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.29% higher to $283.69 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=2b859818c4e44b98c100146fa67b27d5e9124348d8a783b57799b05def7df39b
company,2023-04-11 10:00:13,Is Biogen (NASDAQ:BIIB) Using Too Much Debt?,119786850,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...",https://finnhub.io/api/news?id=9fb312b2a185b1cb06f09c8c26a5500c057b7a28f67095ff3c817cca69a96179
company,2023-04-11 07:40:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC), Ionis Pharmaceuticals (IONS) and Biogen (BIIB)",119721110,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0e35f95d3ca440a7952c59232abd5cffbbd169b3d3bbf9b5e638c5799f8c82fd
company,2023-04-11 04:51:00,3 Biotech Stocks to Watch for Potential Breakthroughs,119718495,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=57fd7a11d3c83c286e7b065f7d256cde3b37c73904e099b63150eae7fe7ae647
company,2023-04-11 04:03:00,US DOJ asks appeals court to block Texas judge abortion pill ruling,119717615,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b66c9602f2bd27fab81589057dbb2b1f2705c4f3e52d2e0ca687463ee4d1056a
company,2023-04-11 00:50:00,"Drugmakers call for abortion pill ruling reversal, Reuters reports",119718709,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ed6d7d0c7e4ceb0d5be41ce3a522fc8576cf22f50cce3a48eab566c35ae8f80e
company,2023-04-10 12:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,119708468,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.37% to $282.86 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=6310c3afad533700693b154dc8ec48f9dd64d7511ee773d1d7990ff494a12c36
company,2023-04-10 10:01:21,US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug,119704827,https://static.reuters.com/resources/r/?m=02&d=20230410&t=2&i=1629655812&r=LYNXMPEJ390D8,BIIB,Reuters,"The U.S. Food and Drug Administration (FDA) plans to hold a meeting of its outside experts in June to discuss full approval of the Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc, according to a federal filing on Monday.",https://finnhub.io/api/news?id=33e0a6a4b1f79fc936d290b0f96f784dcb6f16a8df73c16d9a7b220697a2b601
company,2023-04-10 08:56:00,"Biogen, Eisai to face FDA AdCom in June for full approval of Alzheimer`s drug",119705514,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4107ce3a58873bc10e45d24ed24f20f6aaeca6bcffec38436bd9f892e45ddf00
company,2023-04-10 07:34:02,Pfizer CEO signs open letter calling for reversal of Texas abortion pill ruling,119708056,https://image.cnbcfm.com/api/v1/image/107222561-1681140107886-gettyimages-1240924830-SWITZERLAND-DAVOS-WORLD_ECONOMIC_FORUM.jpeg?v=1681140842&w=1920&h=1080,BIIB,CNBC,Pfizer's CEO was among the more than 200 pharmaceutical company executives who signed the letter after a federal judge's controversial ruling on mifepristone.,https://finnhub.io/api/news?id=6f83b5552fc1bca6d91dfcc9d90aaef4fe58984d80241c7f5ec5488ccf33936a
company,2023-04-09 22:57:00,FDA AdCom to convene on June 9th to discuss Biogen/Eisai`s LEQEMBI in AD,119734129,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6802fc33d71a06980a397ea1ab3d94e0912fc34e9af1ac18d1b49066832ab71a
company,2023-04-16 12:08:24,3 Stocks to Buy That Could Be the Next Biotech Breakthrough,119836328,https://media.zenfs.com/en/investorplace_417/5b26667b636374ba0d30b9d1cff29b1c,BIIB,Yahoo,"In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky. If they fail, their stocks can languish at very low prices… or worse. But if they succeed, shareholders can see outstanding returns. It’s not quite a zero-sum game, but it’s close. That said, there are ways to limit risk when buying biotech stocks. Specifically, I look for undervalued companies that have already produced positive clinical trial data.",https://finnhub.io/api/news?id=52de63be60c28e95f6c02633418898c3499900a7c5682e4b1a3f85996feba9da
company,2023-04-16 09:00:28,Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 32% Above Its Share Price,119791359,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Key Insights Biogen's estimated fair value is US$379 based on 2 Stage Free Cash Flow to Equity Biogen's US$288 share...,https://finnhub.io/api/news?id=1404da247677339a64fd8d7214d70fc3cff3c14ba66bbaf4c58a1ab80504e42f
company,2023-04-16 01:38:00,7 Sorry Pharma Stocks to Sell in April Before It`s Too Late,119788263,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=914c69909e5c2ea74ca001e624ce224f11db5a020fe9a0ebdfad5aa6bb084686
company,2023-04-14 12:40:00,"Biogen Inc. stock falls Friday, underperforms market",119872569,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.54% to $288.13 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=a796269b10a7fc065a6fecbfe89f79d1b81d3a5891a1641a0ffa7d82891e3638
company,2023-04-14 08:32:00,"Catalyst Watch: Earnings season picks up steam, housing data due",119760890,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=11dc85a64d402870a3dcc93ec55f1d53d8671b0d47784f552cad3389bc50241c
company,2023-04-14 04:40:00,Biogen Moves Deeper In Alzheimer`s With Denali,119779766,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94c1bd6a852c6cf652423c555b5013973305a2d5c0e2a623ca248ccb3e1e4c2e
company,2023-04-14 00:37:00,Ghana 1st in world to approve new malaria vaccine by Oxford,119759936,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0098cc36acdfb00757eadf4f6bae45f003b53a7e1489c49f79df4e2cd87e2bf8
company,2023-04-13 21:37:00,"Earnings Week Ahead: Tesla, AT&T, Charles Schwab, Netflix, and more",119761751,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b2dddcecf14fedd933d055538dbe8b09ba745aecb30d7bfd8edf12ba38423734
company,2023-04-13 12:40:00,Biogen Inc. stock outperforms market on strong trading day,119754851,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 1.37% to $289.70 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=169140dde44772f3106c6cbbfb7a6254b03b0219f73846478ea120f4a9f782f3
company,2023-04-13 07:52:00,June 2nd Options Now Available For Biogen,119746907,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=87e7ea74298d87523dad585dc8b8fecf8b824f3cb177889f88124a597b603730
company,2023-04-13 00:09:00,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",119742868,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7cc43eb3c5b2a04048cf8fa5364f23b8b431c83958039937e57fa9185c5ad1ce
company,2023-04-20 14:00:00,Better Big Biotech Buy: Biogen vs. Vertex,119879804,https://s.yimg.com/ny/api/res/1.2/J9s2aWYYinZgKiv0E7ISMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/e4533a263a83ae392229a8d67f53b401,BIIB,Yahoo,"Two great examples are Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX).  Biogen is known for its blockbuster multiple sclerosis drugs, including top seller Tecfidera.  Biogen's immunology drug, Rituxan, has also seen sales slip due to biosimilars in the market.",https://finnhub.io/api/news?id=2f947f75705c2b6b1b7e985d1a5256c69d2c3e2b08a78f87911122ab3ead4a67
company,2023-04-20 12:40:00,Biogen Inc. stock underperforms Thursday when compared to competitors,119872560,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.68% to $290.27 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=a1a8922fca22805ac4bc7cba81ddc203d6a90a80783b01297665e8d113cfd07f
company,2023-04-20 10:03:02,Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?,119853598,https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a,BIIB,Yahoo,Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=94a615d67d8d32e69c4dc4bf2f4bad57e90beac2051668a51b33d06a3602b479
company,2023-04-19 15:32:00,Supreme Court Extends Decision on Abortion Pills to Friday,119836324,https://s.yimg.com/ny/api/res/1.2/RRpBpUwCI3d.OswGxy.M.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/97636d8c617e0d06836570a86122ea9e,BIIB,Yahoo,"The court’s decision has broad implications for reproductive rights, for the power of the judicial system, and for the pharmaceutical industry.",https://finnhub.io/api/news?id=7c65b3abf9a8973f5c9d99d7d67250c8c1d998a9fb8d637b57b0c66351216b11
company,2023-04-19 12:40:00,Biogen Inc. stock underperforms Wednesday when compared to competitors,119872562,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.53% to $292.27 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=ce942043180a8f0e3697ad62b1747a9682b032960f64a113a5fd82abfe481231
company,2023-04-19 10:29:02,Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect,119836325,,BIIB,Yahoo,"Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.",https://finnhub.io/api/news?id=09888ef9a3e2dadb939b43d9ea1806e856b70f3fc8d1fe10e424c4eb881b0388
company,2023-04-19 05:37:00,Four Biotech Stocks for Parkinson's Disease Awareness Month,119823431,https://www.nasdaq.com/sites/acquia.prod/files/2019-07/biotech1.jpg?1901666594,BIIB,Nasdaq,"Anyone whose life has been touched by Parkinson's disease knows the importance of awareness and the development of more effective treatments. Every six minutes, someone in the U.S. is diagnosed with Parkinson's.",https://finnhub.io/api/news?id=02bbbf5a92389140368e4cadefbd17713af7e685d8d22ac573959bafca8e1a91
company,2023-04-19 02:08:00,Agios Pharmaceuticals appoints Capello to board of directors,119834098,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d3e9308564294094382ad0043dedd2657cb92db4aef820033ad594de6105eda
company,2023-04-18 12:40:00,Biogen Inc. stock outperforms market on strong trading day,119872566,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.56% higher to $293.83 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=77bff207b3fce471b7e13c1b38a83cf8cf3c68efbc664f8abd96ebd4eedaafe5
company,2023-04-18 10:01:02,Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline,119836326,https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2,BIIB,Yahoo,Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=676179b0895772c8099d087859c136202e07be0296552b0ad06b80a6d870a551
company,2023-04-18 09:53:00,Is Biogen Stock a Buy Now?,119836327,,BIIB,Yahoo,"Biotech giant Biogen (NASDAQ: BIIB) has been trying to develop a successful therapy for Alzheimer's disease (AD) for a long time, and its efforts seem to be about to pay off.  Earlier this year, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Leqembi, a treatment for AD that Biogen co-markets with Japan-based drug company Esai.  Accelerated approval currently comes with severe restrictions in the U.S., but Leqembi is under consideration for full approval by the FDA.",https://finnhub.io/api/news?id=1e7edca9aba90b803863a7dbaa0b6772aa174d0eef89c96e2f3877cc848d42da
company,2023-04-17 22:28:00,"Notable Tuesday Option Activity: BIIB, NKE, SBUX",119834101,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dd5ce550a3b7b72f1665951210f3d3673f2e3adeef513ddb58d9a516e1a4c5b8
company,2023-04-17 22:19:30,Argus Research Maintains Biogen (BIIB) Buy Recommendation,119810069,,BIIB,Fintel,,https://finnhub.io/api/news?id=9f44d0dd079347e67a3f68c8e962bb6a69ae5d5a5bc1a40c5cabd708501c032a
company,2023-04-17 19:57:04,Piper Sandler Upgrades Biogen (BIIB),119809020,,BIIB,Fintel,,https://finnhub.io/api/news?id=a00803fa9f1d96350daad62965f89275894acb53e152538f031c5454a43cb249
company,2023-04-17 19:56:54,Wedbush Maintains Biogen (BIIB) Neutral Recommendation,119809021,,BIIB,Fintel,,https://finnhub.io/api/news?id=09e527b226b6646633c4be18bff6a3f67f769c36f8c59bc8675f3c3c279e0240
company,2023-04-17 07:27:00,Wedbush Sticks to Their Hold Rating for Biogen (BIIB),119806522,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b5bdc6342006c61340d3ff146efb0ded5e69155b9b0b7bee789c535315879aa
company,2023-04-17 07:07:00,What You Missed On Wall Street This Morning,119800729,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5bd366b9d4a3c63641a2c983fb9ce47c5681cbd8904b5215f8b8d2c18d806688
company,2023-04-17 05:07:00,"Biogen`s Leqembi has questionable efficacy, cost effectiveness, ICER says",119806526,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4fbefa2f283ae53569d0bd6b4ec6ba082b40651fbde269acacc7d2d743fb51c0
company,2023-04-17 04:59:00,"Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations",119801280,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=abbd65761c83041b9aa6d80cfb0d71957ed32ba6ae725874bc1aba1fc96b6b5d
company,2023-04-17 04:26:00,Biogen price target raised to $320 from $315 at Argus,119806529,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ec89a497b4ee51834ef89777a20d940f3dc6bcb25456940a0e038730a69e1299
company,2023-04-17 00:03:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Prometheus Biosciences (RXDX), Staar Surgical (STAA) and Biogen (BIIB)",119803148,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=556b8d5554a4de629b734621942e3bde9f5288234328ba62c3b0c643ae445d35
company,2023-04-17 00:03:00,Biogen upgraded to Overweight from Neutral at Piper Sandler,119806531,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b28abe3faec5cd6f584f4384b90fd6b1653973dcbe67d79a0246ed56375881b
company,2023-04-16 23:38:00,Biogen upgraded to overweight at Piper Sandler on bullish Leqembi outlook,119806048,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=173850a1bd08f345e697f6567c2e7c6376cc104d29bab72a4eda5e9952b300e8
company,2023-04-16 23:36:00,What You Missed On Wall Street On Monday,119804394,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1f6bafcd27c9f8ff1be09bcb2ce5eb66dff72a2c023cee2f6e3cd3f999f2d98e
company,2023-04-24 18:02:00,Biogen Reports Earnings Tuesday. Watch for Alzheimer’s Drug Updates,119907045,https://s.yimg.com/ny/api/res/1.2/2C3w7Y3bj69iN66su9b9dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/d98b23d360dbba3e91de9c40913f12c5,BIIB,Yahoo,"Investors already know that the biotech company's base business is shrinking, so few are looking there for growth.",https://finnhub.io/api/news?id=74fc9474cfeabc7f346e2e234dc6f7bb1dbaf29c61b4a31b668d0187125ef427
company,2023-04-24 12:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,119925165,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.33% to $293.03 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=16214fa8790de7fe686506a0771a33350f312e4a7b9991113e4a979764303c4b
company,2023-04-24 12:21:00,Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer’s Drug.,119925162,https://images.barrons.com/im-768796/social,BIIB,MarketWatch,"The biotch said it was dropping a number of drug-development initiatives, but is open to M&A. The CFO said the company could spend up to $10 billion.",https://finnhub.io/api/news?id=0cb264e9215aa697d1245080f494e5b5da3fc69340e47796ad267ff5a3dd4bd2
company,2023-04-24 06:54:00,"Biogen Q1 results in focus amid Leqembi conundrum, ALS drug future",119932423,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=45ab31d3e9f7edd057c2f522c509bc4a89e5daaf62242dcb2dd89da2d2f60b60
company,2023-04-24 05:26:00,Notable earnings before Tuesday`s open,119917782,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3169a99e2c55714b9a772c0e7d2281d5e7bdc55cd7a67765d94bdfdcce9a534f
company,2023-04-24 02:09:27,"Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap",119901545,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,By Vlad Schepkov,https://finnhub.io/api/news?id=f4aba8edea8a0c244c210b4fbc0e011553d5bee27e0bc302d476f1739821c3aa
company,2023-04-23 23:39:00,"FDA PDUFA Date for Ionis Pharmaceuticals & Biogen Tofersen is April 25, 2023",119928704,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5c5e83711c62909abe41ec39029d82725613936b2dfbc10d591e0cc2223b156a
company,2023-04-23 07:01:00,What is behind biotech M&A resurgence?,119893842,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d97dd35f9d656ac490e32852aa9c9ffaf85ffe6401aa6d80c1debd3d59b7a31
company,2023-04-21 14:03:15,Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!,119890836,https://media.zenfs.com/en/Benzinga/25c189386c7f6eea06382190fd20af7b,BIIB,Yahoo,"Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid brain plaques can help patients. Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June. More study data on Leqembi from Eisai Co Ltd (OTC: ESALY)/Biogen Inc (NASDAQ: BIIB) is also expected in the coming months. FDA granted accelerated",https://finnhub.io/api/news?id=756d80467d8b1b27937abe0e361190167c9db395e29340c7383e48adb6675d4b
company,2023-04-21 12:40:00,"Biogen Inc. stock rises Friday, outperforms market",119872555,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.28% to $293.99 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=70095ee62b880d27625afb1abbb09b18adb4c26026324637948d3cb0267e3c86
company,2023-04-21 11:42:36,B of A Securities Maintains Biogen (BIIB) Neutral Recommendation,119866842,,BIIB,Fintel,,https://finnhub.io/api/news?id=41ec41537c1db5f89bbe74c45f95896ee2c8ed0a3cae1d85501f9f347d036979
company,2023-04-21 08:32:00,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",119868296,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b5d1a1eba315838a32653301dce0a7b204eb1db04060a6a6033253c51d13efa
company,2023-04-21 07:33:00,Biogen To Report Q1 Earnings: Here`s What To Expect,119866929,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a472700c858ec6047d40ce5de8fdf47a938aa37e37c7a5fdced855900a4e960c
company,2023-04-21 04:04:00,Biogen price target raised to $300 from $295 at BofA,119876596,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=154f0a73168cd896f5c062b72ffcd7e490bac56869decda452c5f8fdf648b251
company,2023-04-21 03:11:00,"Analysts Offer Insights on Healthcare Companies: AmerisourceBergen (ABC), Biogen (BIIB) and Elevance Health (ELV)",119868208,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=633ef3791881f81af95a3e5251876d190c92de3356134db458a64d918605b5c4
company,2023-04-21 03:01:00,"Analysts Are Bullish on These Healthcare Stocks: AmerisourceBergen (ABC), Biogen (BIIB)",119870561,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7a099a703bb28017a5544b51ceaaee2b83319fdd4459eec4274adff90c92e96d
company,2023-04-20 22:02:00,"Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut",119869910,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d9a894de6c43e7fd2ad466d973d8e3523f73542f5797fc221884c019d61a59e6
company,2023-04-20 22:00:00,Biopharma Deals Are Hot. There’s More to Come—and These Stocks Can Benefit.,119866183,https://images.barrons.com/im-767256/social,BIIB,MarketWatch,"In the first quarter of this year, total healthcare and life sciences M&A in the U.S. was about $71 billion, according to KPMG.",https://finnhub.io/api/news?id=999923a93187b1f83cc124e8f37b4d26ba98d6588f60135660df5d8604842133
company,2023-04-28 12:40:00,Biogen Inc. stock outperforms market on strong trading day,120112901,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 3.58% to $304.23 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=490109a2d0bf73fbdd0c596bb9750b02ec12492ea1a4619db672bd2964c65092
company,2023-04-28 10:01:06,Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 87% of the company,120013669,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...,https://finnhub.io/api/news?id=15dafe68becbb66906e8838989e4142932243c98a6af9aa651ec9852db9d9914
company,2023-04-28 06:54:53,Biogen Inc. 2023 Q1 - Results - Earnings Call Presentation,120009693,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,The following slide deck was published by Biogen Inc.,https://finnhub.io/api/news?id=3596f8c158cb22207381d7d126d8b49dc5a807e3a9dde03c405d744c67df122e
company,2023-04-28 06:26:31,The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy,120099249,https://media.zenfs.com/en/investorplace_417/155568656c3c7c82033d9d467e5e2a90,BIIB,Yahoo,"The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022. The gains in biotech were in stark contrast to the broader market. All the major exchanges were down last year with growth investors finding few places to hide. But growth-oriented investors don’t have to look back too far to see how quickly things can change. In 2021, biotech stocks were down 25% and even the most innovative biotech stocks found it hard to get a bid. There are many reason",https://finnhub.io/api/news?id=61c304ead984753593f8c308a02de87f0b1b42b8577985a73791f5cd8e0c269d
company,2023-04-28 05:00:26,Buy Biogen For Runups To Imminent Regulatory Decisions,120007150,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442724/image_1284442724.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Advisory Committee meeting for Biogen's LEQEMBI is set for June 9 and the Prescription Drug User Fee Act action date is on July 6. Read why BIIB stock is a buy.,https://finnhub.io/api/news?id=e5a7be5a1965f31807739ac1abb43410818347765294a10021523207fc4387b0
company,2023-04-28 04:05:00,Buy Biogen For Runups To��Imminent Regulatory Decisions,120016057,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=92391aad1b89d52516afdcc6a8a6ac98c0b184113fcd71780eb201e76eb2a10e
company,2023-04-28 01:29:00,The 3��Most Promising Biotech Innovations in 2023 and the Stocks to Buy,120014618,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d0b792400447366d1ebdac56a4b5fb4e1ea7e58d4a9be938456477d9ed53f3db
company,2023-04-27 22:00:00,"PureTech Announces Annual Results for Year Ended December 31, 2022",119997541,,BIIB,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0278fe3f95d3565a376286c2c8583d4a565ad65e81ee7a55d86f9bb66495b856
company,2023-04-27 10:00:58,Drugmakers brace for serious headwinds ahead,119956633,https://s.yimg.com/ny/api/res/1.2/a_7XlhpGyZFWlIFIpNj8PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2023-04/eddfc080-e503-11ed-bf7b-d13bba659f1b,BIIB,Yahoo,"Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.",https://finnhub.io/api/news?id=a9a012c95633eadd0fa0b6cc2e7f06155b152a6644bb5cee1336f8fa03373942
company,2023-04-27 06:20:00,"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Lineage Therap (LCTX)",119962473,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1cb471a904b995fabe62769579a5c9593d086ea031e780732b09236554a481b3
company,2023-04-27 06:11:00,Biotech Alert: Searches spiking for these stocks today,119965335,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3278b6305cfa7f6d69c3d12b6c38aea9d66f613532d3d9b99b16d9079e25ba92
company,2023-04-27 06:10:10,"The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio",119954647,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,"Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.",https://finnhub.io/api/news?id=f7caf04818854bb2fc5dfda07a3fb47e845863b3f0cda1d7b9cc25c17ff829df
company,2023-04-27 03:37:27,Wall Street Breakfast Podcast: Meta Platforms Soars,119953020,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1349804313/image_1349804313.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Meta earnings call: Never mind the ad beat, here's the AI future (and present). Disney sues Florida Gov. DeSantis after district clampdown. Biogen gains as Medicare to cover Alzheimer's drug",https://finnhub.io/api/news?id=aa913a134ca48f6ab7642fca6cd5c152b161047cfcff2ddb79ace3ee94905b2b
company,2023-04-26 21:54:53,HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation,119946411,,BIIB,Fintel,,https://finnhub.io/api/news?id=ad641861cae898e926fb29a45bf39d564163ced96771d0296db822682403cafb
company,2023-04-26 21:54:51,Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation,119946412,,BIIB,Fintel,,https://finnhub.io/api/news?id=36be80fe5a59404e976262e370f8a26fe77078b9c5a330415cb2f428e2920050
company,2023-04-26 21:54:49,Wedbush Reiterates Biogen (BIIB) Neutral Recommendation,119946413,,BIIB,Fintel,,https://finnhub.io/api/news?id=cc2fc6a8042219fb85e5801a89032f773ea4d178f92e25c988f413ae1b8bebd8
company,2023-04-26 21:54:47,Canaccord Genuity Maintains Biogen (BIIB) Buy Recommendation,119946415,,BIIB,Fintel,,https://finnhub.io/api/news?id=f347d8115ead42a6ffb765b663504655ffe2a5ffeb69887a5b2514e8654c79c3
company,2023-04-26 21:54:47,RBC Capital Maintains Biogen (BIIB) Outperform Recommendation,119946414,,BIIB,Fintel,,https://finnhub.io/api/news?id=8f564fb4b410b1f41c6a603650c7951e5e50e04862c35944e6ca5e8cff37510e
company,2023-04-26 13:53:20,Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA,119944513,https://media.zenfs.com/en/Benzinga/b3109cc547169cade57daf0350f60205,BIIB,Yahoo,"The FDA approved Biogen Inc's (NASDAQ: BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on a reduction in plasma neurofilament light chain (NfL) observed in patients treated with Qalsody. Neurofilaments are proteins released from neurons when damaged, making them a marker of neurodegeneration. Continued approval for this indication may be contingen",https://finnhub.io/api/news?id=e37c57b8af4854fd0f9b31ae61734e321d71d4f50d2e9b68bd7c41e7b36e1142
company,2023-04-26 12:40:00,"Biogen Inc. stock rises Wednesday, outperforms market",120112905,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 1.99% to $288.04 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=5efc90a191f81188eecf1c0ea2f4ca7bc377c7f0143a3d832ccebbf201677c7f
company,2023-04-26 12:30:00,"Eli Lilly Earnings Are Soon. All Eyes Are on Its Diabetes Drug, Mounjaro.",119943403,https://images.barrons.com/im-770608/social,BIIB,MarketWatch,"Expectations for first-quarter sales of its diabetes treatment, Mounjaro, are $433 million.",https://finnhub.io/api/news?id=553cf7092ac6d693685861f299bcb690958b57f4aa2d77885ec325324011d853
company,2023-04-26 09:44:14,"Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says",119944665,https://image.cnbcfm.com/api/v1/image/107231474-1682524280131-gettyimages-1232324799-SENATE_FINANCE_009_04152021JPG.jpeg?v=1682531054&w=1920&h=1080,BIIB,CNBC,"Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.",https://finnhub.io/api/news?id=fd1b49ae1e7863cfc847f91971d9bd85fc58b49c200a7918225c111742b00aff
company,2023-04-26 07:06:11,"Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates",119944514,https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41,BIIB,Yahoo,Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.,https://finnhub.io/api/news?id=155d3dfd54790fed209126541b9e5f560013b5b61e957a321367efea0e186f2d
company,2023-04-26 06:37:00,Lilly to report Q1 2023 results with pipeline updates in spotlight,119960839,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5e2d30cb2eb26b233c7983d0f9fc37a2bcb23d3e2e5101a9180f5281a8db59de
company,2023-04-26 06:24:24,Needham Maintains Biogen (BIIB) Buy Recommendation,119937639,,BIIB,Fintel,,https://finnhub.io/api/news?id=2f851641898cc12a4aab7bd791c79ff5c8f09aa6f8d4814fc89dd33b0236428e
company,2023-04-26 06:24:22,Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation,119937640,,BIIB,Fintel,,https://finnhub.io/api/news?id=c0ab02fd2fa55281c6e9fff4a84124475aace27e5227045dbb7a84b3e6012c89
company,2023-04-26 06:24:20,Atlantic Equities Maintains Biogen (BIIB) Neutral Recommendation,119937641,,BIIB,Fintel,,https://finnhub.io/api/news?id=9d1873cc0250106b0b76efab305cfb82db994d66bc4b4b5f382dcb896511dd49
company,2023-04-26 06:24:18,Barclays Maintains Biogen (BIIB) Equal-Weight Recommendation,119937642,,BIIB,Fintel,,https://finnhub.io/api/news?id=9a6f84a11f093881a113cb1346936a85d1dda669f9293c0a5ff52c33881bccb8
company,2023-04-26 04:32:00,EU publishes proposed reforms for pharma industry,119957848,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c795f4e4b500619999f1bd65cb14ef1432b14bd429939cbe862a4d74e21a77f3
company,2023-04-26 04:19:00,Biogen price target lowered to $340 from $344 at RBC Capital,119994148,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=544f0c74016400101cb0d128291bb70f1f90e0dde1f8ff9e2a8dee8ae53ef411
company,2023-04-26 03:40:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Boston Scientific (BSX) and Danaher (DHR)",119964393,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e4c60d96d63118be37d61b80d3c0d0dfd873cac9be4c79f793a14f033d0f4495
company,2023-04-26 03:36:00,Jefferies Remains a Buy on Biogen (BIIB),119994150,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3f734b084a72931ee84584a6c526684a215adb4c1f1720bc739a21de2bfa0a41
company,2023-04-26 03:31:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Harvard Bioscience (HBIO) and Disc Medicine (IRON)",119972038,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cd232616b54e9b929d6dc1306d5461fa56fcca2ce155eabd76bc2112db41cfb8
company,2023-04-26 02:47:00,Biogen price target raised to $330 from $325 at Canaccord,119994154,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6ded90783873550dec3d1f5e743ec4afac3a86beda37b0752d841ce251ef4189
company,2023-04-26 02:43:00,Biogen price target lowered to $321 from $325 at Needham,119994156,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a7b60a16236ec52a9932329eb95352d15a844a6386d76109462c7acfcb06b97b
company,2023-04-26 02:32:00,Biogen price target lowered to $346 from $347 at UBS,119994157,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4f48032bf093870f51171db6779a8f0117290cfc5002bb2be2c04bb3e92a7282
company,2023-04-26 02:11:00,"Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Amylyx Pharmaceuticals Inc (AMLX)",119961940,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e1aa89908b6cacb339c8bc375b0a0ef4dfcd82979f801875256d661e8cd70746
company,2023-04-26 01:25:00,Biogen wins accelerated FDA approval for treatment for rare form of ALS,119984692,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0955ebc06dedf8b567fa9b0850533fe09d358e1fdbc29510a2e8817cadf39045
company,2023-04-26 01:21:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Lineage Therap (LCTX) and Laboratory (LH)",119964135,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e151a8a5fb680d04ded9f88e7fbbaa2c74da94ce418df83c2d5d08bc92c11709
company,2023-04-26 01:20:00,Biogen price target raised to $325 from $310 at Oppenheimer,119994162,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=56059b2776c0b5215d6554967683bb248859c58f51f2198dc8e239c687ab1839
company,2023-04-26 00:18:00,Biogen price target lowered to $302 from $307 at Barclays,119994163,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1dfed7e353ea3998e7026a159d33ea4c5aa84fb666f2d85da6023f6308cac433
company,2023-04-26 00:11:00,"Analysts` Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Centene (CNC) and Danaher (DHR)",119964407,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ae8d02bd670655910ee38c55b675fcaaf88263396ae5eb2f220728a92eb27a6b
company,2023-04-25 23:37:57,Q1 2023 Biogen Inc Earnings Call,119944515,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,Q1 2023 Biogen Inc Earnings Call,https://finnhub.io/api/news?id=c9555071864c13dfca40734dbfb4b78c396077e438564ac23d82c76c218c3769
company,2023-04-25 23:08:00,Biogen gains as Medicare to cover new Alzheimer`s drug with full FDA approval,119960845,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bea93ce4abe3588c44e7cf9a59ae139a12e96aef2c14d8c6e449f138cf228be6
company,2023-04-25 22:05:00,RBC says CMS clarity on Leqembi reimbursement should reduce Biogen overhang,119960846,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2ecf8b4987a3d05e448e163e47f476d24eb61688217558a9df781b441e77463d
company,2023-04-25 16:03:57,"Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat",119929512,https://media.zenfs.com/en/ibd.com/62ea04b193c69f632062452b474d8cea,BIIB,Yahoo,"The FDA approved Biogen's new ALS drug on Tuesday, but Biogen stock remained hamstrung on a ""low-quality earnings beat.""",https://finnhub.io/api/news?id=d3837de0c71da1d6c36be78ea931af1a86e92e28570a63cc8e6dc1ac37aa0f1c
company,2023-04-25 16:02:38,US FDA approves Biogen's ALS drug,119928998,https://static.reuters.com/resources/r/?m=02&d=20230425&t=2&i=1631313478&r=LYNXMPEJ3O0RI,BIIB,Reuters,"The U.S. Food and Drug Administration said on Tuesday it had approved Biogen Inc's drug for treating a form of amyotrophic lateral sclerosis (ALS), making it the first available treatment targeting a genetic cause of the disease.",https://finnhub.io/api/news?id=0bd313e5bf7d51613131c2ec535a5c388b3ebd1605ba3c58e9b9746a9dc74b9b
company,2023-04-25 15:04:00,"FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS",119929513,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly fatal,2 and ultra-rare genetic form of ALS3-4 with approximately 330 people in the U.S. living with the disease5 CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 10",https://finnhub.io/api/news?id=0c0537e9cdb561d7cc355410ee79c3353efc8ce2b197a4719a65ed58c2e9a89b
company,2023-04-25 14:39:39,Biogen shifts gene therapy focus as it builds $200M facility in RTP,119929514,https://s.yimg.com/ny/api/res/1.2/YCf1X8OIF.Ujr0Lk7XVBww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/727d62b2d003499cf78edfee359afe54,BIIB,Yahoo,Biogen is shifting its focus away from certain gene therapy programs as it builds out a nearly $200 million gene therapy manufacturing facility in Research Triangle Park.,https://finnhub.io/api/news?id=46f910ae92c3f58849bb7b2849da6edda62b514e01db3ba0bad359934a092e0d
company,2023-04-25 13:54:06,Biogen's ALS drug granted accelerated approval by the FDA,119929515,https://s.yimg.com/ny/api/res/1.2/WWauLSUu3C_fIBmXAJiXNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xODAw/https://media.zenfs.com/en/bizjournals.com/df7858dc483f8e2b72a47e7f79a48f00,BIIB,Yahoo,"On Tuesday, Biogen said the FDA had approved the drug — which will be marketed under the name Qalsody — to treat ALS patients with a mutation in SOD1 gene.",https://finnhub.io/api/news?id=819994222efc95430640a4ac7fb93d67f357de1077aea9e381ba8243015c8881
company,2023-04-25 13:38:28,Drug for rare form of Lou Gehrig’s disease OK'd by FDA,119929516,https://s.yimg.com/ny/api/res/1.2/JDed0hHwJiy_FjmJ84ql4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/ap_finance_articles_694/0ba1dcb4285d125a8e5ec6f2d984701f,BIIB,Yahoo,"Food and Drug Administration regulators on Tuesday approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease, though they are requiring further research to confirm it truly helps patients.  The FDA approved Biogen's injectable drug for patients with a rare genetic mutation that's estimated to affect less than 500 people in the U.S. It's the first drug for an inherited form of ALS, or amyotrophic lateral sclerosis, a deadly disease that destroys nerve cells needed for basic functions like walking, talking and swallowing.  Approval came via FDA’s accelerated pathway, which allows drugs to launch based on promising early results, before they’re confirmed to benefit patients.",https://finnhub.io/api/news?id=168200542498a63cc2f79155bc794bf89bab8ebfb2813521bebabbe6a8b3e708
company,2023-04-25 13:33:49,UPDATE 2-US FDA approves Biogen's ALS drug,119929517,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The U.S. Food and Drug Administration said on Tuesday it had approved Biogen Inc's drug for treating a form of amyotrophic lateral sclerosis (ALS), making it the first available treatment targeting a genetic cause of the disease.  Biogen will be required to provide more data on the drug's effectiveness for it to remain on the market and for the FDA to grant traditional approval.  Qalsody's approval is based on data that showed it reduced levels of neurofilament protein, an indicator of nerve cell degeneration believed to be tied with progression of the symptoms of the disease.",https://finnhub.io/api/news?id=45fe4273a4a1b507a6c1d3005c0c7078d30c108f2a75cca768e28818e7dc9740
company,2023-04-25 12:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,119925159,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 3.62% to $282.41 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=79004b6c15ce98dedb88d3a2051c3801d9395eb02846b4ceaf07f20b3e865ae7
company,2023-04-25 12:02:07,"Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs",119929518,https://media.zenfs.com/en/Benzinga/d8d375e01bcb523e4abc1b0bf33a3f0d,BIIB,Yahoo,"Biogen Inc (NASDAQ: BIIB) posted Q1 FY23 sales of $2.46 billion, beating the consensus of $2.34 billion, down 3% Y/Y and flat% at constant currency (CC). Multiple sclerosis revenue of $1.125 billion decreased by 19% (down 17% CC). Multiple sclerosis drug Tysabri sales are down to $472.8 million from $520.8 million. Spinraza's revenue of $443.3 million decreased by 6.2% in actual currency (decreased by 2.5% at CC). Biosimilars' revenue of $192.4 million decreased by 1%. Adjusted EPS of $3.40 decr",https://finnhub.io/api/news?id=9c1ced86789eb1adec20f77847c42f92779dc1217562092c1ed2b001df9caf6f
company,2023-04-25 11:36:03,"Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs",119929519,https://media.zenfs.com/en/zacks.com/88c5b382e5e9e4ea852e01bfc1435a7b,BIIB,Yahoo,Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.,https://finnhub.io/api/news?id=e85b2f5af2945232b0a8945d10c64254215b5a04aa161d1c40fd26869282ffff
company,2023-04-25 11:02:47,"Biogen trims pipeline programs to cut costs, focus on Alzheimer's drug launch",119916767,https://static.reuters.com/resources/r/?m=02&d=20230425&t=2&i=1631277127&r=LYNXMPEJ3O0ED,BIIB,Reuters,"Biogen Inc said on Tuesday it will pause or discontinue at least four studies of experimental drugs to focus on more potentially lucrative options including its second Alzheimer's treatment, Leqembi, in the latest attempt by the new CEO to trim costs.",https://finnhub.io/api/news?id=bd391fa42862b6d7e76d37b930906c7b99c5814e07aaf5d1c53df8b4140afd3a
company,2023-04-25 09:57:42,Biogen tops 1Q forecast despite sales slip for key products,119929521,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen beat Wall Street’s first-quarter expectations even as revenue from the drugmaker’s biggest product group tumbled.  Sales of Biogen's multiple sclerosis treatments, which include Tecfidera and Tysabri, fell 19% to $1.12 billion compared to last year’s quarter, the company said Tuesday.  Sales of the drugmaker’s spinal muscular atrophy treatment Spinraza also dropped 6% to $443 million in the quarter.",https://finnhub.io/api/news?id=8d829f01346b7fed5fd5061975332c0c4f2b8170f2ff29e8cbf49f487a636f21
company,2023-04-25 09:52:00,FDA grants accelerated approval to Biogen’s treatment for rare form of ALS,119918568,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,DowJones,"The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.’s torferson, a treatment for a rare form of amyotrophic...",https://finnhub.io/api/news?id=051b103537526bc0729e2463b934defc78937e2dc11e23a730860a43c84f6bb8
company,2023-04-25 09:40:18,"Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says",119919632,https://image.cnbcfm.com/api/v1/image/106893501-1623103150542-gettyimages-1233323396-ALZHEIMERS_BIOGEN.jpeg?v=1682444418&w=1920&h=1080,BIIB,CNBC,Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab. ,https://finnhub.io/api/news?id=c013659b5e29b6ad0ef9329ab985944300afb8afacfecac2fa7418132ec770ff
company,2023-04-25 09:30:01,Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say,119929523,https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9,BIIB,Yahoo,"The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",https://finnhub.io/api/news?id=ea661175c547e70dc098ab6bec8a6cc38b0a744334149714f6dbe52407466547
company,2023-04-25 09:20:41,FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease,119921907,https://image.cnbcfm.com/api/v1/image/106893719-1623152809766-gettyimages-1233323372-ALZHEIMERS_BIOGEN.jpeg?v=1682443241&w=1920&h=1080,BIIB,CNBC,The FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits. ,https://finnhub.io/api/news?id=29948e395b893120c7a6475520e292622bccbd1b88ca72f383fb8676cd09ece1
company,2023-04-25 08:53:00,FDA grants accelerated approval to Biogen`s treatment for rare form of ALS,119932397,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ada4f1ec73cd4750b545c7c51dee84ecd2b091e7970ac955ac792d15aca449e2
company,2023-04-25 08:49:00,"Biogen, Ionis win FDA nod for ALS therapy Qalsody",119928693,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c7bcdde5e7cc78421cb9f564847cb05070bd39bee3c3cf2db3a5a851f3f1401c
company,2023-04-25 08:37:13,Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript,119915969,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q1 2023 Earnings Conference Call April 25, 2023 8:00 AM ETCompany ParticipantsChuck Triano - Head of Investor RelationsChristopher Viehbacher - President...",https://finnhub.io/api/news?id=a22fdfdda16e5eeda0bf7415309483404df4029e4e397f87d4919ebe5601f887
company,2023-04-25 08:27:00,Biogen touts development pipeline despite quarterly revenue decline,119932399,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=02d501ffb0cae2aa0dffc0e96bef79bdee8249d2f525d9657b4c753017548869
company,2023-04-25 08:25:12,Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates,119929525,https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9,BIIB,Yahoo,"Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=8dfad4d5424c9c078e1b90a771c4c8187ae5b64c99307174513c04aba2160077
company,2023-04-25 08:25:00,BTIG Reaffirms Their Hold Rating on Biogen (BIIB),119932400,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6fef5f167bc2561609296885ad5587fc7547a2688e30f0bd7d209e1ea00e09af
company,2023-04-25 08:13:00,FDA approves Biogen`s Qalsody for ALS patients with SOD1 gene mutation,119932401,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b9ed9257768c24505e276c69149dfb4245f9c33b6ea69478acde81ba23fb9481
company,2023-04-25 07:32:00,Biogen On The Hunt,119932403,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5104d85b6193f485aea735b8f912916f9e14a05de676890512abc2178771c386
company,2023-04-25 07:31:12,UPDATE 1-Biogen beats profit estimates on strong Spinraza sales,119913199,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen Inc on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.  Biogen will also put on hold a mid-stage study of an ischemic stroke drug candidate and scrap its early-stage trial of an experimental treatment for a rare neurodegenerative disease.  The company's new CEO, Christopher Viehbacher, has been looking for ways to keep costs low as Biogen prepares for high-profile launches of its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone.",https://finnhub.io/api/news?id=ab03b1c1a020edc2590695a31da2012729933fc05a622aa20716d6d8045e964d
company,2023-04-25 07:21:00,Cantor thinks M&A premium `baked into` TG Therapeutics shares will increase,119926622,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=12444f618aaf75407776d88966949dc5320ff84892c83cb6b1658893cedcd848
company,2023-04-25 07:02:43,Biogen beats profit estimates on strong Spinraza sales,119913200,https://media.zenfs.com/en/reuters-finance.com/b7459ae52c706d075ae67655d5f2e91a,BIIB,Yahoo,"The drugmaker said it would terminate the late and mid-stage studies for an experimental neurological drug due to operational challenges that would help reduce full-year research expenses modestly.  Biogen will also put on hold a mid-stage study of an ischemic stroke drug candidate and scrap its early-stage trial of an experimental treatment for a rare neurodegenerative disease.  The company's new CEO, Christopher Viehbacher, has been looking for ways to keep costs low as Biogen prepares for high-profile launches of its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone.",https://finnhub.io/api/news?id=2499116cb28d4977df3b1991e5c5fe1bf0a39b8996e3b374006c95b5ecc4103d
company,2023-04-25 05:40:00,Biogen Inc. Beats Q1 Earnings And Revenue Estimates,119932406,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dfa77413165dfb809b4302ab8ca87d11a79aa88f6133f1ef3982a149ef08f618
company,2023-04-25 04:09:47,"PepsiCo, McDonald's and Spotify rise premarket; First Republic slumps",119929526,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Investing.com -- Stocks in focus in premarket trade on Tuesday, April 25th. Please refresh for updates.",https://finnhub.io/api/news?id=2705f091fe31e48c9c190c9c794c80a25aa0493b1a475acf1b1c92cf30f95cf4
company,2023-04-25 03:25:00,Biogen tops estimates as revenue slides 3% from a year ago,119925164,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,"Biogen Inc. said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the...",https://finnhub.io/api/news?id=16b67c84f78ff2a0e8c080a56951d3b512baed348b3c99591fb1f682689cc86b
company,2023-04-25 03:05:00,"Biogen trims down R&D programs, Q1 revenue dips but reaffirms FY23 outlook",119932408,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0765a109b0611640e44eeaa15be415ec90ca01a8da18a30422631c65d89e22d6
company,2023-04-25 03:05:00,Biogen (BIIB) Gets a Buy from Mizuho Securities,119932407,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8de54cb17037376dee0f7c6d7c04e3d3a2318d6c7036ed9770d296a22c5a7aac
company,2023-04-25 02:13:00,FDA approves Ionis Pharma/Biogen`s QALSODY as first treatment in ALS,119928696,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e3d09b27f78dba60072733b9fdc42a082939825449b928287d8c77b2c0fc2e6f
company,2023-04-25 02:09:00,"Biogen Non-GAAP EPS of $3.40 beats by $0.12, revenue of $2.46B beats by $120M",119932411,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1dd3b0295643d0a188ca3e7015f0fa156ddbd55bb2b3a0095c7def8b78827576
company,2023-04-25 02:06:00,"Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48",119932412,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=af13dd494ab9103a24526658ddb7f641b5a6768c0e23cb2c835ac9149dccf82f
company,2023-04-25 02:05:00,"Biogen reports Q1 EPS $3.40, consensus $3.28",119932413,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d69ed4261e5e9698b703b3caa3989322cbf7f2ab56b8e11e8e5be896b5939756
company,2023-04-25 01:06:00,Biogen (BIIB) Gets a Buy from Morgan Stanley,119932414,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=31e09faca9e9761601cfaa673408cf0b6b089da9a6b4b00399ba48d605d60600
company,2023-04-25 00:59:00,Biogen price target raised to $371 from $349 at Morgan Stanley,119932415,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3b07ef29e620e66a10da01ca4b66b520a9df7978f34d7207c460e93e4f8d4058
company,2023-04-24 23:31:00,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Cognetivity Neurosciences (OtherCGNSF),119932417,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=631d9a2b5986c1b695cabc6f864c80f4a520bf64bbfe8b00d7a57077f35e29a7
company,2023-04-24 22:08:00,Biogen confirms FDA grants accelerated approval for Qalsody,119928698,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=05cf48b8190adad9e5c14350d3f9007a6e1cf381f091348c6876cd184c47f180
company,2023-04-24 21:48:00,FDA grants accelerated approval to Biogen treatment for rare form of ALS,119928699,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c052ea84e0425df2d57026e82bc2a05294fa09362fb0b20da1d1f8d43418f577
company,2023-05-02 12:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,120112897,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 0.59% to $309.28 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=113674d8aabb34a8e926534a39060a17591a10db388e90bea4d732116e30a7b9
company,2023-05-02 08:14:00,"Biogen prices new ALS treatment at $14,230 per vial",120112898,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,"Biogen Inc. has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also...",https://finnhub.io/api/news?id=065152fb1633f29253dece3134ca2694922dc9133423424b062debf8b535872f
company,2023-05-02 06:42:00,Biogen prices ALS therapy Qalsody at $14K a dose - report,120108323,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=635a1f35ed0aad92e5a478893001a96e3ee4568e4a387c174fff37b3da9ecad3
company,2023-05-02 00:54:11,Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Call Transcript,120095752,https://media.zenfs.com/en/insidermonkey.com/1b68bb36c75ef75472617b8c48f21d38,BIIB,Yahoo,"Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Call Transcript April 25, 2023 Biogen Inc. beats earnings expectations. Reported EPS is $3.4, expectations were $3.28. Operator: Good morning. My name is Bettina and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2023 Earnings Call […]",https://finnhub.io/api/news?id=ed6f37e9c14f475f4dffb04d1e9fd3d89ebaafcc1408f9d364fcd88528d37700
company,2023-05-01 12:40:00,Biogen Inc. stock outperforms market on strong trading day,120112899,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 2.26% to $311.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=d4243e7fb026d41ef91ff32cd4ace32db23c922d8383b8553f14e74cdd90a675
company,2023-05-01 09:04:54,Guggenheim Upgrades Biogen (BIIB),120078275,,BIIB,Fintel,,https://finnhub.io/api/news?id=8049b82c82358db7826b3891758b55e595f27992c99cd22898549e6687a78c3f
company,2023-05-01 08:27:00,"Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations",120082027,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6dafede2787c785fbd055b441c95d4b3b17e6879d7f84745c90e0380738ca3b0
company,2023-05-01 05:00:01,Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments ,120089309,https://image.cnbcfm.com/api/v1/image/107198777-16771566112023-01-20t224759z_376389922_rc2a2w9juz4s_rtrmadp_0_eisai-biogen-alzheimers-fda.jpeg?v=1682948287&w=1920&h=1080,BIIB,CNBC,"Attorneys general from 23 states, the District of Columbia, and two U.S. territories called on Medicare to cover Alzheimer's treatments without restrictions. ",https://finnhub.io/api/news?id=4ad46befe730e01c2e620c9bdbf98f1ccc47948f4dd5e1f16365caf5fa666f59
company,2023-05-01 04:21:00,Biogen upgraded to Buy at Guggenheim on potential for growth,120084395,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8c492837314b6377ab6402f4251e2447092122a2326a297cea93c04d7d8af206
company,2023-05-01 03:53:00,Biogen up as Guggenheim upgrades citing full approval for Leqembi,120084068,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2080c86f071e08214369f565a0f593c9608c89b2858ec97074e7c8444c744e2e
company,2023-05-01 03:35:00,Morgan Stanley`s Wilson screens for stocks as earnings stabilize but data disappoints,120080427,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bed54da60243683e031c6daee5cbb522130237551bbc8fd47d352c328ef62d46
company,2023-05-01 01:19:00,Biogen upgraded to Buy from Neutral at Guggenheim,120084399,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a066c010ead0e7cfd810e0d10cd22d4dd10a94bd33096e6e12d57e3b5a18feee
company,2023-04-29 21:53:06,27 Largest Biotech Companies in the US,120066562,https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43,BIIB,Yahoo,"In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in […]",https://finnhub.io/api/news?id=1c88312f585716d7e65015addc46c9783ad8f961f7a60a18a6b2d39dd896ff7a
company,2023-05-06 03:15:00,Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB),120211398,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4aeb771a00e95713d5f9456de54cfec3c4489a4b2d1ca81cdc70a76ac093ee75
company,2023-05-05 21:02:00,Eli Lilly`s Donanemab: The Anti-Amyloid Saga Continues,120207020,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fccfdc82f515cc7eed3989019b2bbff90ed7d2044fd90be07c9c26a461ef7772
company,2023-05-05 12:40:00,"Biogen Inc. stock rises Friday, still underperforms market",120280411,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.43% to $318.06 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=b1d1150750190fd035430a15fafb4ca1ff5fc1e203b28f2a811c88380af3431f
company,2023-05-04 23:12:00,New Alzheimer`s drug trial seen as ���potentially very important`,120207022,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=827f664be73e393ac9a1db892e49f36709dec196bc646b8ef347cc978ad63747
company,2023-05-04 22:49:00,Buy/Sell: Wall Street`s top 10 stock calls this week,120184569,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=516d494455efa6964e9489585685c3181d399f3c47679055e6e3e8b0f63689ea
company,2023-05-04 12:40:00,Biogen Inc. stock outperforms competitors on strong trading day,120280412,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.83% higher to $313.57 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=2c898257b0d661bae3c8a8af715d3535956deb66c57c4302564778f8060dd139
company,2023-05-04 12:11:35,B of A Securities Maintains Biogen (BIIB) Neutral Recommendation,120148839,,BIIB,Fintel,,https://finnhub.io/api/news?id=0b16bfe182a021cd9a81e479061788abedbadac582b5fbe10de432485b3374ba
company,2023-05-04 08:58:12,"Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match",120147345,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.,https://finnhub.io/api/news?id=c276a5ab3f0da22dc52833d6d33fc8532f9f223af20ce4336d996880d3d71181
company,2023-05-04 08:00:19,Is Biogen Inc.'s (NASDAQ:BIIB) Recent Stock Performance Influenced By Its Fundamentals In Any Way?,120147346,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what...",https://finnhub.io/api/news?id=36cedb52a2134b091b2c3767e7ed4c4d2e20b1840685f8fb48264dee2b006d3f
company,2023-05-04 05:54:00,Ionis Pharma upgraded at Citi after quarterly update,120149009,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2e2df1033c8bf83572e6ccf4dcaa0b9864ebf8f211c6c1adf834af638f865c48
company,2023-05-04 05:30:00,Good results from Alzheimer`s drug trial seen as ���potentially very important`,120150923,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=44aee19714d7d83cea7c2d29476df380fb0d40dd97cd51b9da1ca11be627466e
company,2023-05-04 04:52:00,Eli Lilly price target raised to $505 from $430 at BMO Capital,120150924,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5d479be2a674c3b488c5e845fafff35c60b96408914492a851d5e36e809b7d09
company,2023-05-04 04:27:00,Biogen price target raised to $320 from $300 at BofA,120150926,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b7329fb06efbc3e5527f49df96f60256130110af343203e5df0cd21edb95193c
company,2023-05-04 04:10:04,Q1 2023 Ionis Pharmaceuticals Inc Earnings Call,120145005,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,Q1 2023 Ionis Pharmaceuticals Inc Earnings Call,https://finnhub.io/api/news?id=7b59c35b589d983a0e43ddc6425bdc6a5ba2a989ef99784e10e8636e1296dc6e
company,2023-05-04 02:10:00,Eli Lilly price target raised to $475 from $430 at JPMorgan,120150932,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6055ca1965a722d913caabcd9a4108a087aa69aa29e5e931f38ac3982154f733
company,2023-05-04 02:02:00,Eli Lilly price target raised to $490 from $420 at Credit Suisse,120150934,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c28a1dfd24d109bb3ba24b515562c8359865276d0b30e6e1e1e53a2f3d6c67fa
company,2023-05-04 00:00:05,AstraZeneca chair says it is paying CEO enough to ward off US rivals,120147348,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The new chair of AstraZeneca believes the drugmaker has extinguished the threat of chief executive Pascal Soriot quitting for lucrative roles in the US, saying that the benefit of increasing his pay in recent years outweighed the criticism from some shareholders.  Under Soriot, who has led AstraZeneca for more than a decade, the group has become the most valuable company on the London market, with a market capitalisation of £185bn.  Sales of its innovative cancer drugs has helped propel the group to three times the size of UK rival GSK.",https://finnhub.io/api/news?id=86862e22747520d8501a82866eb6dbf2b6989f6d8d52cc3d8201ae39e6c5ec04
company,2023-05-03 18:35:00,Lilly's New Donanemab Data For Alzheimer's,120139250,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Eli Lilly made headlines on May 3, 2023 with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial.",https://finnhub.io/api/news?id=d76d8ad6a494876ec6b7bbdd5e1cc896c58356fe80f6ad1f1bb621f05f7db757
company,2023-05-03 16:58:23,Eli Lilly: Positive results on its new Alzheimer's drug,120135517,https://s.yimg.com/ny/api/res/1.2/i3sPOibRB36HMYaOnXiN.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2023-05/f64353e0-e9ea-11ed-b41b-c3412d04c17b,BIIB,Yahoo,Eli Lilly stock is up on news that its new Alzheimer's drug showed reduction in cognitive decline.,https://finnhub.io/api/news?id=6c7837c337c4c0c5b4c7fd4b091c1f449ffa880fc7104ba0758cce3e2b73539f
company,2023-05-03 14:55:16,"Obesity drug could be a 'big upside' for Eli Lilly, says Wells Fargo's Mohit Bansal",120138169,https://image.cnbcfm.com/api/v1/image/107235266-1683154507191-1683153695-29293711261-hd.jpg?v=1683154516&w=1920&h=1080,BIIB,CNBC,"Mohit Bansal, Wells Fargo managing director, joins 'Fast Money' to talk Eli Lilly drug trials, it's competition with Biogen for an alzheimer's drug, and more.",https://finnhub.io/api/news?id=a1aedebfcb9c6a0d612f0d6a870f1cecc8d8b196271bea52fa7f2d99300168b7
company,2023-05-03 13:22:56,Eli Lilly Hits A Record-Smashing $400 Billion Market Cap Following Its Alzheimer's Win,120126169,https://media.zenfs.com/en/ibd.com/3b32d81431b6faad0a29129cfcabd1d9,BIIB,Yahoo,Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline.,https://finnhub.io/api/news?id=fec2d95934971834835bb1b33c2569e69e6766471588e9f4cc2fc6bf3a556915
company,2023-05-03 12:40:00,"Biogen Inc. stock rises Wednesday, outperforms market",120280413,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.56% higher to $311.00 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=e40040decfc424d85582b3362998f670b463b4c14e2619d5a2015e46068f1b4d
company,2023-05-03 10:16:00,Eli Lilly Results Signal Arrival of Blockbuster New Drug Class,120126170,https://s.yimg.com/ny/api/res/1.2/vq7TFtu.merCCsl_UA94nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/44fe0d79e5321003ec786004a5685ae3,BIIB,Yahoo,"Its Alzheimer’s treatment results might look better than Biogen’s, but both companies will likely benefit.",https://finnhub.io/api/news?id=5d502de7543972b56282b4ee1f8a4a256c4b726284d57dc1012dff5c863dedfc
company,2023-05-03 08:23:00,Biogen says EC extends Tecfidera regulatory market protection to February 2025,120136500,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e71785dac3b96d20e713824804952b6bf11fed19c29dad2303e60008d144ae17
company,2023-05-03 07:01:00,Eli Lilly stock jumps 5% after Alzheimer`s treatment slows disease progression in major trial,120136502,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fc701223690f5f6c67ac3a910fe75251b10f0579f94972562a164680f1f42a55
company,2023-05-03 06:21:00,Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial,120126171,https://s.yimg.com/ny/api/res/1.2/MO3cbOSi7Bxo8p5KqArOZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/a8d6253b4a15fc7f3dbc4d33d5e0730e,BIIB,Yahoo,"""This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline,"" Eli Lilly said.",https://finnhub.io/api/news?id=ae85e35b94536a845e3e5344052c677d6fa0343bb4ee585d5ae74ed30ee4c204
company,2023-05-03 05:39:00,Lilly`s New Donanemab Data For Alzheimer`s,120150937,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dca350bdbb13f894f2b3e724f24d8023a40ae72b4c6cef2cfc43682cc7b6696b
company,2023-05-03 05:09:00,Biogen wins EU exclusivity for Tecfidera until 2025,120136504,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=be861afc38224a83cccf27bf140e42d42edc851b916bfc8b91233f7980aef806
company,2023-05-03 04:50:00,Another Sucess In Alzheimer`s Disease,120134078,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e71cfe21ec6f3e058e981f10a883529d65ed21acb9fadd14d55cfb7b07ef6bb2
company,2023-05-03 04:13:34,"Stocks making the biggest moves premarket: Starbucks, AMD, Pearson, PacWest & more",120120204,https://image.cnbcfm.com/api/v1/image/107121732-1663722305110-gettyimages-1424338049-bbs_0224_4c47757b-db87-47a1-9717-1c941890598b.jpeg?v=1683116014&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in premarket trading. ,https://finnhub.io/api/news?id=2d451a995f38c4982c3dc192d9a5c222b17c72e0357a8dbd5258189808d9627d
company,2023-05-03 03:11:00,Biogen slips after competitor Eli Lilly`s Alzheimer`s trial hits target,120136508,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=35bcdc886524ed5db96e893f085aab46b31c069b1e057d7c55a85709162e1a4e
company,2023-05-03 02:57:00,Lilly`s Gain Is Biogen`s Pain After Promising Alzheimer`s Data,120136510,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6b6c21571e657c316e95918971b8dbdf7d0ff8dd5a4ea73d2bc720a0ccf5820f
company,2023-05-03 02:34:00,Eli Lilly Drug Aids Alzheimer’s Patients but Safety Is an Issue,120170525,https://images.barrons.com/im-311916/social,BIIB,MarketWatch,The company says a Phase 3 study shows that donanemab 'significantly slowed cognitive and functional decline' in people with early symptomatic Alzheimer’s.,https://finnhub.io/api/news?id=10d8b783504bd597ad43d4f7017fec370856531ad8e09434950516e07986d6e8
company,2023-05-03 02:18:00,Eli Lilly stock jumps 8% after Alzheimer`s treatment slows disease progression in major trial,120136512,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=326dbf374fcad225c80ffce3db36cccb8f1d30e3d597fc9ea61599001bc7318c
company,2023-05-03 02:14:00,Eli Lilly stock jumps 5% after Alzheimer's treatment slows disease progression in major trial,120170524,https://images.mktw.net/im-250699/social,BIIB,MarketWatch,"After one year, nearly half of the trial's participants showed no disease progression, Lilly said.",https://finnhub.io/api/news?id=4e06795b1625a4434ef600933ebacd35faea5e84bb9ef90c94b88cdfc27ea695
company,2023-05-03 02:01:00,Biogen price target raised to $340 from $315 at Mizuho,120136515,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=447eca685c7ac63afb99ff55732953a0001296dd515d742b987feed9555e02fc
company,2023-05-02 22:40:00,Lilly sends Alzheimer`s drug developers higher after trial data,120134080,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2e66e655e8b7a091e2e2e9d68322bf8828b316424e2f41c06f437b3c47dd3ee5
company,2023-05-02 22:26:00,"Notable Wednesday Option Activity: BIIB, GPRE, CHK",120136522,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1d6c4c8101984312f0d417b685ccda78970e0e6781bc4607b329cd221eba6514
company,2023-05-02 22:02:00,Eli Lilly`s positive results from a Alzheimer`s trial seen as ���potentially very important`,120136523,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=11fdc073983eb30104be212b3e00925aa7bc5c67380a926b39062c2c6903ef05
company,2023-05-10 12:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",120280402,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. sank 0.24% to $313.26 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=8e0d69d141e278a8859dabffe6f41cadd32327910510eb605b9dba760bd86025
company,2023-05-10 03:05:51,PTC Therapeutics: A Gem In The Rare Diseases Treatment Market,120266071,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366949758/image_1366949758.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,PTC Therapeutics specializes in developing and subsequently commercializing next-generation drugs to treat orphan diseases. Find out why PTCT stock is a Buy.,https://finnhub.io/api/news?id=1ed9e3f8bdeed3250b7f8091417811215af4c6fdf027855901d96e54f0e84e1c
company,2023-05-09 22:10:00,Meta Platforms Takes Center Stage Among Moat Stocks,120263535,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1356591356/image_1356591356.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,A punishing 2022 for Meta Platforms created a valuation opportunity - one that has paid off as it becomes the top contributor year-to-date for the Morningstar Wide Moat Focus Index.,https://finnhub.io/api/news?id=1b5e5c1119ea28d5188b957f46ef3986ca6d11aad1a8e4d2ddaf42754cb6394e
company,2023-05-09 16:09:59,15 Biggest Immunotherapy Companies in the World,120248234,https://media.zenfs.com/en/insidermonkey.com/152faade4bb55ed2f80bad06096a951e,BIIB,Yahoo,"In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]",https://finnhub.io/api/news?id=8f2ad8892373ea11de72ee1fef425193dffda9002847b675f7de14867872dc5b
company,2023-05-09 13:24:05,"Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus",120247113,https://media.zenfs.com/en/zacks.com/fcfa260efd46be54e9e6a92bfcc16781,BIIB,Yahoo,Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.,https://finnhub.io/api/news?id=473b48bcd7583537b526271bef6cc8633de387f908c41d79b286f4bebb9fbddf
company,2023-05-09 12:40:00,Biogen Inc. stock outperforms competitors despite losses on the day,120280404,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slumped 0.12% to $314.00 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=f54753f33f80f943a872b44b01bc75412b662d4d6eac139555c4354ad6b4760c
company,2023-05-09 08:50:00,See How Biogen Ranks Among Analysts` Top Picks With Strong Buyback Activity,120246074,,BIIB,The Online Investor,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e03f9c5c7fdff9ade9669cad44a1d5780706ad5218b75bce70cbeb932410f57b
company,2023-05-09 02:51:00,Vigil Neuroscience appoints Haeberlein to board of directors,120246075,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=452e0952c44f702cfab557dbb8fa3024a7955b0306e186628249bf9fdc898c04
company,2023-05-08 22:05:00,Cassava Sciences adds 14% most since September,120252984,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8eb10ccc90df00d6ab3b0e480072eb98f42162909ad6ada5e473044cdeeedbe4
company,2023-05-08 12:40:00,Biogen Inc. stock underperforms Monday when compared to competitors,120280407,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.16% to $314.37 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=cd12a306fbc8ca3855ca33b37386c05c03737c269b6fbed4c34bb456d47408b7
company,2023-05-08 10:29:00,Lilly and Biogen Want Medicare to Cover New Alzheimer’s Drugs. It’s Not Happening.,120225669,,BIIB,Yahoo,"Even after the latest Lilly data showing that its drug slowed the disease, the agency that runs the program isn't budging.",https://finnhub.io/api/news?id=db91de6068a0a91cd2b979138a10b055cc3d069c1e76c4773892d1da5d7d8e21
company,2023-05-08 04:00:00,Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune Diseases,120218779,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1356994681/image_1356994681.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Coyaâs pipeline candidates have undergone initial human trials depicting efficacy and safety of its Treg-modulating therapies. Read why COYA stock is a buy.,https://finnhub.io/api/news?id=69655de9a4890d037e6cb4501a48410207ef0778eb34a39aa37c52a8536e7171
company,2023-05-08 02:45:00,"Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8",120225510,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=98484635f14dcc02b780d0d0f3ac1619bffd0813006450f4c245067df9ca94cd
company,2023-05-08 00:00:27,Two Alzheimer’s drugs offer hope to patients after decades of waiting,120219283,,BIIB,Yahoo,"In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide",https://finnhub.io/api/news?id=1327f9dd2f9f702936cefaa765aa210b229b0fe01671828b579d0bfdd74a48df
company,2023-05-07 22:27:00,"Fly Insider: Zions Bancorp, Albertsons among week`s notable insider trades",120225511,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=72c09fe70fb8b04ba539770a361908b94acc4fb5713d6c59545ae8e27f4fb0be
company,2023-05-14 08:15:00,These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win,120348190,https://s.yimg.com/ny/api/res/1.2/nSUU5oFSOEtNHqSapArQrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/motleyfool.com/cc3f7a884a3bc1a65136a111219c8660,BIIB,Yahoo,"Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies.  Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat.  Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.",https://finnhub.io/api/news?id=5576e67accd2a07da40548e6e93a9a56fb5b1700760a5fe0c659f62882f620fc
company,2023-05-14 07:05:00,Biogen`s new Alzheimer`s drug to raise annual Medicare costs by up to $5B ��� study,120345667,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0345362a88d08bc93898ee2a9cb2e8a5b6395c2cea268221fee7ce6aa2a8c4e4
company,2023-05-12 12:40:00,"Biogen Inc. stock falls Friday, underperforms market",120402292,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.31% to $309.60 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=d5709391e3eb38cf903f82f550351e77fc6083909a6f64baed53beb3798480e5
company,2023-05-12 10:53:57,"Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates",120323158,https://image.cnbcfm.com/api/v1/image/107240452-16839077782023-01-20t224759z_1083470858_rc2f2w9147j4_rtrmadp_0_eisai-biogen-alzheimers-fda.jpeg?v=1683919553&w=1920&h=1080,BIIB,CNBC,The authors said the estimated costs of Leqembi to Medicare are conservative and spending on the Alzheimer's treatment may increase more than anticipated. ,https://finnhub.io/api/news?id=38bdb4b5bac83ba042ace0c80ca7b504f08fe39b4eac56c3ca4a3d336150292c
company,2023-05-12 10:15:00,3 Reasons to Buy Biogen Stock (and 1 to Sell),120326180,https://s.yimg.com/ny/api/res/1.2/HYbKaQohKUxoiHfEy0tLAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/57ad03171a9399f41b3424152f0ad2bf,BIIB,Yahoo,"The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.",https://finnhub.io/api/news?id=bef9069d579ec2df6535a9012596278c5ac2b0f87b48f8fe81a473d6f7bc6228
company,2023-05-12 03:25:00,"BiomX appoints Jason Marks, Michael Dambach to board of directors",120324395,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=11ccd87f49a08732152cc7629d723aab5943dfbade4fe306c416f6c043eeb834
company,2023-05-11 17:15:38,"Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 billion a year, study finds",120307339,https://static.reuters.com/resources/r/?m=02&d=20230511&t=2&i=1632533703&r=LYNXMPEJ4A0WU,BIIB,Reuters,"Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).",https://finnhub.io/api/news?id=34c21e699bb7d8de2ee7cf53886fdd1cbdc119fd5d5ebc90504e088754e52821
company,2023-05-11 15:35:00,"Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds",120314707,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).  Leqembi, sold by partners Eisai Co Ltd and Biogen Inc at an annual list price of $26,500, was approved this year under the U.S. Food and Drug Administration's accelerated pathway.  The Centers for Medicare and Medicaid Services (CMS), the agency that runs the health plan for people age 65 and older, currently covers the medication only for patients enrolled in clinical trials.",https://finnhub.io/api/news?id=9e7f213c753be04cb3e8ee64011857d654d07ecca21ccde52d919eb6e9e0732f
company,2023-05-11 12:40:00,"Biogen Inc. stock falls Thursday, underperforms market",120402293,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.86% to $310.56 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=2102e8b445ef559540d00d980f33d6a24232d7f779f9061f6733e2b5094c0afc
company,2023-05-11 10:12:33,Argus Research Maintains Biogen (BIIB) Buy Recommendation,120296288,,BIIB,Fintel,,https://finnhub.io/api/news?id=a3a8810addf385d4436b3075b43734edcef9ecb689b8ac82261ca9cfbe688349
company,2023-05-11 10:07:00,Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal,120312748,,BIIB,Yahoo,"Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.",https://finnhub.io/api/news?id=3210418899de6c0e62bd2692a186b70851c49b89c050bb0e9f5af33916f74ef0
company,2023-05-11 08:00:27,Biogen's (NASDAQ:BIIB) investors will be pleased with their favorable 64% return over the last year,120314709,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...,https://finnhub.io/api/news?id=d000a8102f621cc76d010a7adda072971cf382406ea96c38168277079b0b99f4
company,2023-05-11 03:48:00,Biogen price target raised to $350 from $320 at Argus,120296732,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=48e2b32a096a3b054150ee99ba46aaab189b86f173960995f7511d9141dca7eb
company,2023-05-11 00:59:00,"Lundbeck, Otsuka`s Rexulti wins FDA approval for agitation linked with Alzheimer`s",120296733,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4334c2d25095d1e96a6104fd84185c6acefaa33cd4602ad0b8006aee88a4fb45
company,2023-05-18 12:40:00,Biogen Inc. stock outperforms competitors despite losses on the day,120508624,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.26% to $305.45 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=9508887b23c4e94244f3669ffcfe13ca369356fd9267a86bc2c7bcdb06dd4775
company,2023-05-18 08:00:33,Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 29% Above Its Share Price,120418003,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Key Insights Biogen's estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Biogen's US$306 share...,https://finnhub.io/api/news?id=c16cb7b5282b187d2696a40af9e39ef5437e524deaa1d274d7a170edae3f4f0c
company,2023-05-18 06:34:00,Cognition Therapeutics stock rises after CT1812 shows promise in Alzheimer`s study,120418512,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0dc44cbc43bdf942df7ff2610613281e7d559821d14187c7c3e9c923bd9a19e1
company,2023-05-18 06:22:00,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,120418514,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=acb5f80ee815fbbac80585b098b9a9db54ae8da277a2b87428212291f6122de6
company,2023-05-18 06:16:00,Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron,120418515,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a4e5dc10449f7f5220cf0b00e7e09cf1d343ee747af6028511d73381d847fe2b
company,2023-05-17 22:35:00,"Sen. Wyden presses HHS, CMS on access to new Alzheimer`s therapies",120426224,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b67874b7d59431d1ca521995045742e07b56934fdd32f1847955a271e0023784
company,2023-05-17 12:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",120402289,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.44% to $306.25 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=192cae39bfac5e929d9f7afcfb95ccc2dc9c410feb59961b4d30633e39f27e00
company,2023-05-17 07:17:00,Prothena adds former FDA neuro chief Billy Dunn to director board,120398523,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a4600395b65249a7f86e81a0e964587f362fc43d74f3c013ca96990d21c90c70
company,2023-05-16 12:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,120402290,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.37% to $307.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=f5465e5cbc574869daec03d1fc4f8d788cc82d347be3064f7141a001b834cae6
company,2023-05-16 09:56:01,Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far,120380529,https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093,BIIB,Yahoo,"Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.",https://finnhub.io/api/news?id=9f24d5aee66cde06af7385d213892beaae7073773884d7dfde91c2411eb7ee7c
company,2023-05-16 00:16:00,Health Canada accepts Biogen's submission for Alzheimer's drug Leqembi,120371425,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=499fd0800ef0b09e0542178ff1ad05f91ef0438b1a9ede27111ce9c7a9f24557
company,2023-05-15 19:30:00,Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease,120388626,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of early Alzheimer’s disease (mild cogniti",https://finnhub.io/api/news?id=0f89b20c45102879d21314c1d2f4bb1c1cdb3e9dd843f7b73f0c7d344bb8442b
company,2023-05-15 16:05:59,"Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.",120387887,https://media.zenfs.com/en/ibd.com/1d988fec8a7a7d0d55f7efa41a259447,BIIB,Yahoo,"Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.",https://finnhub.io/api/news?id=792756a16ce4e4481426c1f18e807bbbeabf420e42532f5a8e0e849e3e976184
company,2023-05-15 15:27:00,Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on,120360363,https://image.cnbcfm.com/api/v1/image/107109969-NUP_198430_00200r.jpg?v=1684193220&w=1920&h=1080,BIIB,CNBC,CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty. ,https://finnhub.io/api/news?id=389e30786ae10205b1a58a6d424cfe30aa6374b05dc55a0e4e4afa4a07522ea3
company,2023-05-15 15:10:59,Jim Cramer compares market conditions to 2011 as debt ceiling showdown continues,120360364,https://image.cnbcfm.com/api/v1/image/107241441-MM-Block-A-051523_mezz.jpg?v=1684192259&w=1920&h=1080,BIIB,CNBC,'Mad Money' host Jim Cramer talks market performance after the Dow breaks its losing streak and compares market conditions to 2011.,https://finnhub.io/api/news?id=71c316d8d653ced072bc6713890eada4a4473455f3bf53104dec98ca9a6ebf00
company,2023-05-15 12:40:00,"Biogen Inc. stock rises Monday, outperforms market",120402291,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.73% higher to $311.87 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=76eadad5cbc45d70c7ed8d06e046db441ad09cc55593db28687c205e1f56b34d
company,2023-05-15 03:44:00,Eli Lilly price target raised to $507 from $478 at Morgan Stanley,120354470,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e02df01acabba2d58c99a5b20f615bf1fbb41b64a89ae0469731dca602219570
company,2023-05-15 03:00:00,Recurrent Energy Signs Aggregation Deal for 100 MW of Solar Energy in Texas with Industry Consortium,120355158,,BIIB,PR Newswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9cc7b0f182f650e8c556dfb5f7ad2175b1e254d45472281ef0fdd2a61f049026
company,2023-05-15 02:15:00,Biogen (BIIB) Receives a Hold from Bank of America Securities,120355159,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=08852f35a145f520c6ff578e3b0efc2229431826cf2fb0ea7cf71899ace3bcf6
company,2023-05-15 02:11:00,Canadian Solar subsidiary signs aggregation deal for 100MW in Texas,120355017,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=34b29700ab90638beb6a87386b0124332755cfbeab42ce8539a5028e76a86425
company,2023-05-22 12:40:00,Biogen Inc. stock outperforms competitors despite losses on the day,120508620,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.52% to $306.87 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=a5ea77506b5ac7249ea56c7048b39304ce07cf5ee60c80b8435efeefb65ca684
company,2023-05-22 08:00:32,Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?,120482024,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",https://finnhub.io/api/news?id=81582c7283210dd4948eec79a9f9620e609f453754a99ab7a98d900b0d6fb329
company,2023-05-22 02:29:00,Biogen reports Eisai submitted MAA for lecanemab for early Alzheimer's to MHRA,120488269,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=12b2e8e307f3b9ad049549efdf536d7c1f5ed8d58b833e0b2e81578e6683d0bb
company,2023-05-21 22:29:00,Biogen collaborator Eisai submits marketing application for Lecanemab,120488271,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=950039ff41e540301f933206f6a54fa03aa7deb169e4133628f4e5dc88fc015b
company,2023-05-21 07:01:00,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,120472958,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a50e5b8a8c0517c654a3de5252893321a2f0444c3f5d49324a52104d8618c929
company,2023-05-19 12:40:00,Biogen Inc. stock outperforms market on strong trading day,120508621,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.99% higher to $308.48 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=5b3a6fe072f47af3430ad8d392b8faa51703b561e6fad286b5fc2eb69479aaeb
company,2023-05-19 10:00:52,3 Biotech Stocks That Are Revolutionizing Healthcare in 2023,120502225,https://media.zenfs.com/en/investorplace_417/7a6d7cf8fd09137bc1a8f5746ab0adba,BIIB,Yahoo,"The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our society and healthcare system. But finding the best biotech stocks to buy is not always simple. Many biotech companies work on drugs for years. And these biotech stocks will swing wildly on the news. Positive results from a clinical trial can send stocks soaring. Conversely, disappointing results c",https://finnhub.io/api/news?id=c79c83c9c91260ccfd5e7e8509e0f273cea270b16d5d59fc9b404bbbd619b0aa
company,2023-05-19 08:15:00,1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market,120445082,,BIIB,Yahoo,"Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.",https://finnhub.io/api/news?id=23a7ec38208087cf90c415b0e60447a0482a0362b7692c77a37231d548d5bf2d
company,2023-05-26 12:40:00,"Biogen Inc. stock rises Friday, still underperforms market",120575226,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.51% higher to $298.66 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=cdb1939975670bcc510141d9b9373d30bc961a8f58faf7f521d072f51888a20b
company,2023-05-26 11:31:41,Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?,120568647,https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781,BIIB,Yahoo,Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=325db7c79f0a31f8aa6eabd87c6d3f1c2ef2619fd9a50655c5314d497a0252ef
company,2023-05-26 07:08:00,Biogen Unusual Options Activity For May 26,120573770,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ddf8394c6d72b1bfc91aedba02d0799787859c73b96a5a1a35656f5a5286fac0
company,2023-05-26 01:42:00,Elon Musk's Neuralink gets FDA nod to start human trial of brain implant,120568276,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=74a4d809f90a3dc6b24e024b5857bcffdfca430ef065274dfd760fed1bf4fd07
company,2023-05-25 15:36:30,"Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender",120555372,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1492311172/image_1492311172.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Biggest sales growth driver for Roche Holding AG is Vabysmo, approved for wet age-related macular degeneration and other uses. Click here for our RHHBF stock review.",https://finnhub.io/api/news?id=1e3b0ee958ea96d5e189d6c9098848cd215ee2f34c51e83fd55b3547ec511d1e
company,2023-05-25 12:40:00,"Biogen Inc. stock falls Thursday, underperforms market",120575228,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.47% to $297.13 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=29c36a1395ca64291a376c26fabc1587fe09a4718728fdc3d740e23f868e6b45
company,2023-05-25 11:31:00,Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?,120549380,https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f,BIIB,Yahoo,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=18f131a350f3de26c74261d7cd196fa85e268c26f386c707995feb01380f3fe9
company,2023-05-25 06:52:00,"New Alzheimer’s drug could bring hope to patients, but could be out of reach for people on Medicare",120545078,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=58aaa05aeee369baeb13c6cb4dc2b5516d0077aebb25880c043a013aafe702c9
company,2023-05-25 04:03:52,14 Best Biotech Stocks To Buy According To Hedge Funds,120540154,https://s.yimg.com/ny/api/res/1.2/RCKFyA_Orx5i7EcMSHyUbA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/bbad2545b3b325a6c633bba783765287,BIIB,Yahoo,"In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]",https://finnhub.io/api/news?id=ff97a82c779b607e8ec2abb9b141fe2da3a4c3bcde3559a105108d76f5c06c56
company,2023-05-24 13:46:33,10 Dementia Medications that are Approved or in Clinical Trials,120535217,https://media.zenfs.com/en/insidermonkey.com/453da4043fa460042e81678684af95dc,BIIB,Yahoo,"In this article, we will be taking a look at the 10 dementia medications that are approved or in clinical trials. To skip our detailed analysis, you can go directly to see the 5 dementia medications that are approved or in clinical trials. Advancements in medicine have absolutely changed the way we live right now, […]",https://finnhub.io/api/news?id=25ee711a9e144e90497a416df0d3d605ee6f4edd4168e2f2640f2bb20286f037
company,2023-05-24 12:40:00,Biogen Inc. stock outperforms market despite losses on the day,120575230,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. sank 0.52% to $301.56 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=49b16d05230ff2ef1d41f2d482a6448a42e0df83934af4b47d9cb01b5c21ed9e
company,2023-05-24 04:20:00,"Wednesday’s Top Analyst Upgrades and Downgrades: Chevron, Microsoft, Nucor, Salesforce, Wheaton Precious Metals and More",120523432,,BIIB,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fbd12387df5ed1b560b9b63bc0ab42492284113ba0ece201903aafabe7627e80
company,2023-05-23 12:40:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,120508618,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.21% to $303.15 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=1084d1586376b7152c965d13a56310947912c993e939da6b1b2d4a0378783ce6
company,2023-05-23 11:26:47,Wedbush Reiterates Biogen (BIIB) Neutral Recommendation,120498365,,BIIB,Fintel,,https://finnhub.io/api/news?id=80693ebc7f78ab25b9eda5551b1382dbe65e112b14a8478b4f11eaa15921d530
company,2023-05-23 03:41:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Blueprint Medicines (BPMC) and Cerevel Therapeutics Holdings (CERE)",120499158,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=01521d8bc2dc54157c0ad99c29fe2a0a8e5a06c5b3775a72796e07e2d6558367
company,2023-05-23 03:31:00,"Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Biogen (BIIB) and Blueprint Medicines (BPMC)",120499159,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fad6b1df6c13976317aa6f940213af1ca76ec9c4b6405a9703c194a68f38f571
company,2023-05-30 12:40:00,"Biogen Inc. stock rises Tuesday, outperforms market",120720846,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.01% higher to $298.69 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=54e66318518d5cb2df2e50b6b9ebab42d80832fdaea537c6b9520385dac9f189
company,2023-05-30 08:16:00,Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?,120614231,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3e75ef0550987f884e0f6f5d687c95b3991771311b2b53ea97e9bb60439a357b
company,2023-05-29 10:00:16,Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company,120601258,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...",https://finnhub.io/api/news?id=b3f867b4e0fd971206f410ce028865df8983ccd7962c04f9f37abd987e1caa43
company,2023-06-02 17:01:28,RBC Capital Reiterates Biogen (BIIB) Outperform Recommendation,120678828,,BIIB,Fintel,,https://finnhub.io/api/news?id=3082b2feb7ff756236884830991f613d8af2b8958fcb43283730733823ca7cc5
company,2023-06-02 12:51:00,"Biogen Inc. stock falls Friday, underperforms market",120720842,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slumped 0.73% to $300.20 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=76b65992a9c7566bc083e88cc2394793923d52c120f3b5413cbdcdae13e7bcb3
company,2023-06-02 12:35:00,Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study,120674344,https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5,BIIB,Yahoo,Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.,https://finnhub.io/api/news?id=5a58f6c79f7751b4b104525cc0a0797f7d3570d504079b70b2431d82fb4bd19f
company,2023-06-02 07:31:00,"Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Acadia Healthcare (ACHC)",120675693,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b185f0231fb22cfd18be50f491185cfbf1d28cb929c3b66908ba96f9d8447f74
company,2023-06-02 01:18:00,"Medicare will cover Biogen, Eisai's Alzheimer's drug, WSJ reports",120675694,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bc5cbe0f75d0110d7a1b8d7d85b5a4821ae154f73daa3b86995498dab70b0dcc
company,2023-06-01 14:29:00,Medicare Plans to Cover Alzheimer’s Drugs,120650806,,BIIB,Yahoo,Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer.  The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai’s treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works.  Most Alzheimer’s patients in the U.S. are Medicare enrollees.,https://finnhub.io/api/news?id=4d6ae98e80f5d87da95db10c9643c7e13021804d3d3053e5f191c724a1d491ea
company,2023-06-01 12:40:00,Biogen Inc. stock outperforms competitors on strong trading day,120720843,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 2.02% to $302.41 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=a57749430eff25ad0567bb054a07cbfc1669cfe48005a7c58d1c22e661ba7dfd
company,2023-06-01 12:17:10,"Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump",120650807,https://media.zenfs.com/en/ibd.com/62ea04b193c69f632062452b474d8cea,BIIB,Yahoo,Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.,https://finnhub.io/api/news?id=a08d77a7be60ede1c2a56c7fb03abb0fb8de01a5156c08882a1121fac3613368
company,2023-06-01 12:09:00,"Medicare Will Pay for Biogen’s Alzheimer’s Drug, With a Caveat",120650808,https://s.yimg.com/ny/api/res/1.2/wEonFv3UGMIia8k45nfADA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/5ff43d6c23e7bc585b84403b822027d0,BIIB,Yahoo,The agency that oversees the medical program for seniors will pick up the bill only if doctors submit treatment data to a nationwide registry.,https://finnhub.io/api/news?id=b4f1beb634b87596710504db71d7cf59998d4c05ac3c90986bd58776f0e435fc
company,2023-06-01 10:39:32,Piper Sandler Maintains Biogen (BIIB) Overweight Recommendation,120643139,,BIIB,Fintel,,https://finnhub.io/api/news?id=b66728d39dd96d276a3470e88e9093fe51302eb60f7a41c46b7f337d376eaf38
company,2023-06-01 10:04:07,15 Best Healthcare Stocks To Buy Now,120643076,https://media.zenfs.com/en/insidermonkey.com/d7b54ab6c172424f8eb29273c1277201,BIIB,Yahoo,"In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […]",https://finnhub.io/api/news?id=ebea16d843bf7aab37bb8209b8787431f61c079024b1439aa6de40c2b8485f1a
company,2023-06-01 09:07:04,Medicare to cover new Alzheimer's drug after full approval ,120647328,,BIIB,Reuters,The Centers for Medicare & Medicaid Services said on Thursday that the U.S. Medicare health plan would cover new Alzheimer's drugs such as Eisai Co Ltd and Biogen Inc's Leqembi if they gain full U.S. approval.,https://finnhub.io/api/news?id=9fb906ac030e22f9ca4385d7eef475e3441fb1512a3661b8131d643bd1728f79
company,2023-06-01 07:56:00,Goldman Sachs Remains a Buy on Biogen (BIIB),120655409,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c39906f41c6d452e8b78dbc75280ac1658ff12cd0da85a6669f61907fabcebdf
company,2023-06-01 07:06:00,Biogen (BIIB) Receives a Buy from Mizuho Securities,120655411,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=374c6d3f766cb3f5b277e20ca5ff1c70ee256fb4b5f1c4c17bac42abf756f361
company,2023-06-01 05:39:00,Medicare to cover Alzheimer's drugs granted full FDA approval,120654081,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8d56d4058ee6630de23a13bd14687d75fa494bfc62347799ef62c10144701ccf
company,2023-06-01 03:33:00,Biogen price target raised to $360 from $346 at Piper Sandler,120655414,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f7c2716d1207fa18ddd9294edb56af3b44c223366f6937107f47774d96d1f2ec
company,2023-05-31 21:35:00,Medicare unveils plan for coverage of new Alzheimer’s drugs,120654085,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2df4d340c2d920a2b0a205e2a7168781f587a2602ec08cf9454a957c393f583e
company,2023-05-31 12:40:00,"Biogen Inc. stock falls Wednesday, underperforms market",120720845,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.76% to $296.41 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=bb1054f59f23343afec514745c22c4f14d67628a27a5a80ebdf0c3c3a1f069a0
company,2023-06-07 19:08:34,Baird Reiterates Biogen (BIIB) Prior Recommendation,120764232,,BIIB,Fintel,,https://finnhub.io/api/news?id=4c042d77a9b97ff7f97433d30be2798eed3d30eb35b8bc591d96551702526ca9
company,2023-06-07 18:14:00,Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market),120767014,https://media.zenfs.com/en/zacks.com/007330111d2c5e922a50fd9d84783af9,BIIB,Yahoo,A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups.,https://finnhub.io/api/news?id=01f181d02f4a08c5e5e539c49d23a743c27b20a2da382d456c19c877339bafc1
company,2023-06-07 13:49:37,Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio,120754059,https://media.zenfs.com/en/Benzinga/9b2ada109cf33cc72e206c339fedd771,BIIB,Yahoo,"When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several questions must be answered: Are the tenants long-term and stable? Are they strong enough to survive recessions and market downturns? Is the portfolio diversified by location, type and annualized base rent (ABR)? Take a look at one of the largest office REITs today to see whether it answers the above",https://finnhub.io/api/news?id=971c967ef9432dce878f026a1866a0890fac94537bab9190c2635e20fc012d2a
company,2023-06-07 13:37:13,Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near,120756218,,BIIB,Yahoo,Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.,https://finnhub.io/api/news?id=d92041bd05d444ad409dff9b9ec1947f3886bf03e1e8131661dab5be5d0fd42f
company,2023-06-07 12:51:00,"Biogen Inc. stock rises Wednesday, outperforms market",120802600,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 1.70% to $304.90 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=e7fb6d691ed0697913c2597957d6568a95eca2331f1274ccab3f2f2feed153a6
company,2023-06-07 12:28:10,"Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says",120753665,https://static.reuters.com/resources/r/?m=02&d=20230607&t=2&i=1635142861&r=LYNXMPEJ560NR,BIIB,Reuters,Staff reviewers of the U.S. drug regulator said trial data on Eisai and Biogen's Leqembi confirmed benefits of the early Alzheimer's drug and the prospects of a full approval were unaffected by higher risks of brain hemorrhage.,https://finnhub.io/api/news?id=2ba5893f7c47ee829db81c7e58d785f1434180594d3bc93a6fb9a076e6f6201f
company,2023-06-07 11:06:35,FDA staff say Eisai's Alzheimer's drug may get full approval despite concerns,120756220,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Staff reviewers of the U.S. Food and Drug Administration (FDA) said on Wednesday that Eisai and Biogen's Alzheimer's drug, Leqembi, may still be eligible for a full approval despite concerns of brain hemorrhage from using blood thinners along with the drug.  The FDA staff's comments about the drug were made in documents released ahead of a meeting of the panel of external advisers on Friday to discuss the Japanese company's application for a traditional approval.",https://finnhub.io/api/news?id=953f349367aaf23b860d635870f2cfc21865a6b2e4582392a2f7351bef706ea5
company,2023-06-07 10:30:23,"Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action ",120766816,https://image.cnbcfm.com/api/v1/image/107250207-1685724860593-gettyimages-1495245678-_m021263_a3lsffup.jpeg?v=1686162623&w=1920&h=1080,BIIB,CNBC,"Sen. Bernie Sanders said the $26,500 annual price for Alzheimer's treatment Leqembi would financially burden on Medicare and increase premiums for seniors.",https://finnhub.io/api/news?id=f792da025bef152570d40c518037cbd8c9027b593c53ebbcea69ef13c0216274
company,2023-06-07 10:00:17,Do Its Financials Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?,120756221,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Biogen's (NASDAQ:BIIB) stock is up by a considerable 14% over the past three months. We wonder if and what role the...,https://finnhub.io/api/news?id=ce862562511938613da846135a64e70fbf0063d3d739f74d47aaf9788ad6834b
company,2023-06-07 08:10:00,Biogen gains on “super clean” FDA docs on Alzheimer’s drug ahead of AdCom vote,120756828,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fb49f293d65b6ffaf0c31a65c0ccce856e49a5b7f0df06977cde4e6c44af7230
company,2023-06-07 07:58:00,"Biogen's Lequembi likely to be granted full approval by FDA, says Baird",120756830,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d810396ecb4561734bdfed805f45645878271fd0ff17bcfa1c082d812d97c9ce
company,2023-06-07 07:42:00,"FDA briefing docs 'appear largely supportive' of Biogen's Leqembi, says Wedbush",120756831,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b67f204cc4346e54e558ca5a3f6223ec60de1e012b7ecd4770c2ed27365fc204
company,2023-06-07 07:32:00,Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day,120748582,https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364,BIIB,Yahoo,Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.,https://finnhub.io/api/news?id=2acfde8051ab27f767a5f175450216dc81b4019428e87986eb1de4db6919b3bc
company,2023-06-07 07:14:00,"Biogen briefing docs 'super clean' with no surprises, says Mizuho",120756832,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=081d1e854178970c5939125d127154e51120ff48c862c504bdc810815ca9ac14
company,2023-06-07 06:46:00,Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB),120756834,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1be22873dcb8cdf63742946c4cb2562e5ca384b350e08a22b800e9a6173c05d3
company,2023-06-07 06:12:00,FDA posts briefing document ahead of review of Biogen and Eisai's Leqembi,120756835,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7fd4856aed62b2b7be94d83cf835bc9b3233d03cae7f4231d9004700b0162ae0
company,2023-06-06 21:16:00,Biogen (BIIB) Receives a Buy from Goldman Sachs,120756836,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=54c069521c565228eb7ba4c0c6fd61b6086b5dc2b6c139db0e222182ec370785
company,2023-06-06 12:51:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,120758002,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.77% to $299.79 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=ecf42b4cc32ec8ff52fc147a2621a3111ed15e1434d2b42c686496087fd01408
company,2023-06-06 10:58:00,Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122,120729741,,BIIB,Yahoo,"Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's",https://finnhub.io/api/news?id=c832b0b77290ea04ed0504adc42e6a379822641f08656d6c2cbc797a67a71cb3
company,2023-06-05 23:34:00,"Notable Tuesday Option Activity: BIIB, OZK, TRUP",120756838,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0f60f1ab29113a2bd013913687197dfe5a120e0f20894c9ca90458afa610ebb2
company,2023-06-05 23:10:00,Biogen withdraws from Jefferies Healthcare Conference,120756839,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5190f82282a68361bb9177f6559af7197eefea1e13531b73c889d5b50ec0a17d
company,2023-06-05 18:15:15,Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure,120721173,https://media.zenfs.com/en/Benzinga/5167ed5a465897e24d894606b58173c8,BIIB,Yahoo,"In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson’s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ: DNLI). Before the planned revisions, the BIIB122 development program encompassed the following: The Phase 2b LUMA study in participants with early-stage Parkinson’s disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson’s d",https://finnhub.io/api/news?id=18f55f762701777a61bec06bba28366faed5cff1244f0ae660e92a960a71f9e4
company,2023-06-05 12:52:00,Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains,120720840,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.64% higher to $302.13 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=23b3a62d448832b83394c69c1b0c7ac77cd04a177a0e6aeb3ab4c1657f9a25c1
company,2023-06-05 08:21:00,IN BRIEF: Biogen revises development program of BIIB122 in Parkinson's,120712431,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=67eb1d552242a6d79bdf83d49d42c8935e46123c39861d6033935b9f8980963a
company,2023-06-05 04:10:00,"Denali's LRRK2 program changes 'unsurprising but negative,' says Stifel",120712436,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=39d9777fe0ad53ad955c4847e44d114a4b53b5e8bdfc0091d89c9c5ac0da381e
company,2023-06-05 03:57:00,"Biogen, Denali shift focus of Parkinson's Disease clinical development program",120712438,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=32d480883f0e3417a39cc551d48b70f84591c01114a7a89f350813afed798fbe
company,2023-06-04 22:25:00,Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.,120716191,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=07781a4488da2a2f2b16143ab9086452b067198e0b71b6f3453946b1aa0779a5
company,2023-06-04 21:02:00,$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today,120716692,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ef2c7fdc8674b48591303b38cb8750d60a637eb3af6eb938eec060502f2b8f40
company,2023-06-11 07:01:00,Alzheimer’s disease market expected to reach $14B globally in 2030,120818710,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=775763fd85bcad5f50c338d9f961a362e69dd8ff8641375392b2fe47129af22e
company,2023-06-11 01:43:00,FDA AdComm votes to confirm clinical benefit of LEQEMBI in Alzheimer's disease,120819242,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1838f5b5da682f992384dc7c029a417aba4b12ee5b486f71f658a49e5a22b2b3
company,2023-06-09 18:45:00,FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease,120808077,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer’s disease on January 6, 2023 TOKYO and CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -",https://finnhub.io/api/news?id=7d400bac5a1376306b8ecc4cc5fed5213a4ec2fb7faa04df2369094f1c9c1a1c
company,2023-06-09 18:20:55,US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi,120807924,https://static.reuters.com/resources/r/?m=02&d=20230609&t=2&i=1635409958&r=LYNXMPEJ580BN,BIIB,Reuters,"A panel of expert advisers on Friday unanimously agreed that a late-stage trial of Eisai and Biogen's Alzheimer's drug Leqembi verified the benefit of the treatment for those at an early stage of the disease, clearing the way for traditional U.S. approval.",https://finnhub.io/api/news?id=5b10f32d29ec25ab1e2d1cbb26442d6465f63422d13b595f85b0d60d50bb9026
company,2023-06-09 17:18:00,"FDA Advisory Committee Votes in Favor of Biogen Alzheimer’s Drug, Clears Path to Full Approval",120808078,https://s.yimg.com/ny/api/res/1.2/RKnHIKzwTXR9NCH.fJN38g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/ff7e18a2270e791de2e1a445e84bed54,BIIB,Yahoo,"The vote came two and a half years after the same panel dealt a decisive blow to Aduhelm, another drug from Biogen and Eisai.",https://finnhub.io/api/news?id=b9afda48715817cdced401b894068720466be10d24696015592ddae03349e08c
company,2023-06-09 16:15:46,Biogen Remains Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug,120819904,,BIIB,Yahoo,Biogen stock remained halted Friday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.,https://finnhub.io/api/news?id=f84ca19951c0d3ab7e91941df89e69200d47cb05a47dea87817ed1d23a3152e4
company,2023-06-09 16:15:46,Biogen Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug,120808079,https://media.zenfs.com/en/ibd.com/78d3bc5a06ce66f50e3b72166bcc394c,BIIB,Yahoo,Biogen stock remained halted Friday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.,https://finnhub.io/api/news?id=36ec24f3faabddab9fce43de8c88d6c3c01d6f99498f8bf9a9dc038ad27c709b
company,2023-06-09 15:54:21,US FDA panel back traditional approval for Eisai-Biogen's Alzheimer's drug Leqembi,120807925,,BIIB,Reuters,"A panel of expert advisers on Friday unanimously agreed that a late-stage clinical trial of Eisai and Biogen's Leqembi verified the benefit of the treatment for Alzheimer's disease, clearing the way for traditional U.S. regulatory approval.",https://finnhub.io/api/news?id=e111dfafc816566535ffa1659c71af62227c5649cb3e964e807498106137c95b
company,2023-06-09 15:27:00,Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval,120877951,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Biogen Inc. shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and...,https://finnhub.io/api/news?id=118e27c2ecc8d6a37db780bd57f9c5c0726d94caed6aba257b7cad881e37c631
company,2023-06-09 14:45:00,FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease,120810913,,BIIB,PR Newswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0734b3cc0bd5362d00a901456f1921795587bf6f3e0442d06f11386097ce0238
company,2023-06-09 13:11:37,Here's what the FDA's endorsement of the Alzheimer's drug Leqembi means for Biogen,120811760,https://image.cnbcfm.com/api/v1/image/107254544-16863444051686344402-29817761019-1080pnbcnews.jpg?v=1686345097&w=1920&h=1080,BIIB,CNBC,"Matt Herper, Stat News senior writer, joins 'Closing Bell: Overtime' to discuss the FDA advisers' unanimous vote to recommend Biogen Alzheimer's drug.",https://finnhub.io/api/news?id=57db5c6288b1825321f49ae239de356e5a28a3fca924ef590fe369d57cd5f105
company,2023-06-09 12:22:00,NEW YORK MARKET CLOSE: Stocks rise on growing optimism of rate pause,120802620,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9ae408ea21c1d8a9f7d90176f7ea3d2636c6df65d3efda1f63078bd23f383468
company,2023-06-09 12:08:46,Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment,120794780,,BIIB,Yahoo,"Biogen stock was halted Friday as a panel of experts to the FDA debated the merits of its Alzheimer's treatment, Leqembi.",https://finnhub.io/api/news?id=9e77e6e42d219a7586520e70ce24c340462805928cd9c5893a468643eefd9a3f
company,2023-06-09 12:02:00,Eisai shares jump on FDA advisers vote on Alzheimer’s treatment,120802597,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Eisai Co. Ltd. shares were up 9.4% Friday after advisers to the U.S. Food and Drug Administration voted unanimously in favor of the Eisai and Biogen...,https://finnhub.io/api/news?id=23e96086fa6a5287b58a196611e520fd55f4e916728d40ddedd495691f043b99
company,2023-06-09 11:26:45,Biogen Stock Halted as FDA Committee Considers Alzheimer’s Drug,120794781,,BIIB,Yahoo,Trading in shares of Biogen remains halted Friday morning as a Food and Drug Administration advisory committee meets to discuss whether the Alzheimer's drug Leqembi from the company and partner Eisai merits full approval.,https://finnhub.io/api/news?id=7bcf6c6e133cb265abfd21c528286e69a7f0b96815934160cbe30742d29321da
company,2023-06-09 10:50:38,UPDATE 1-FDA panel weighs US approval for Alzheimer's drug from Eisai and Biogen,120794782,,BIIB,Yahoo,"A panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.  Leqembi won accelerated approval by the Food and Drug Administration in January based on its ability to remove toxic amyloid plaques from the brain.",https://finnhub.io/api/news?id=fec743a6fc5f7184d6f45f268d86c8f70301c5dc575454e9072bb3d160bcac27
company,2023-06-09 07:00:00,FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen ,120796530,,BIIB,Reuters,"A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.",https://finnhub.io/api/news?id=3acff72e73c0a26f5110ea949688071882e3aa6540a254116effdef3a51eefc5
company,2023-06-09 07:00:00,FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen,120794783,,BIIB,Yahoo,"A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.  Leqembi won accelerated approval by the Food and Drug Administration in January based on its ability to remove toxic amyloid plaques from the brain.",https://finnhub.io/api/news?id=2a37be231906fac1ff1c293385ce8a9c216b81f4bcb6ea5dcf3a0c6d14276676
company,2023-06-09 06:07:03,FDA advisors weigh whether Alzheimer's drug Leqembi should receive full approval,120794028,https://image.cnbcfm.com/api/v1/image/107198790-16771574832023-02-23t020744z_307853963_rc2f2w9v65fn_rtrmadp_0_health-alzheimers-medicare.jpeg?v=1686319623&w=1920&h=1080,BIIB,CNBC,"Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.",https://finnhub.io/api/news?id=891522db4ed4cc46a013132248ea25b4dd83b239dd3aa529490ca9577c13ab1e
company,2023-06-09 06:04:42,Biogen shares halted as FDA advisory panel meets to discuss Alzheimer's drug,120794784,,BIIB,Yahoo,Investing.com -- Biogen Inc. (NASDAQ:BIIB) announced that the Nasdaq (NASDAQ:NDAQ) exchange had halted trading of its stock on Friday.,https://finnhub.io/api/news?id=56f7af9ae0d599fbed624303598a04569cdcdc39f42d54bcf94d7b1a2aebee68
company,2023-06-09 04:51:00,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Zimmer Biomet Holdings (ZBH) and Innate Pharma SA (OtherIPHYF)",120810865,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b7b02de134ec99329d887e56559025d677e09ba7a9abd176300f7a16d1dd39f5
company,2023-06-09 04:47:00,SVB Securities Sticks to Its Buy Rating for Biogen (BIIB),120805200,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d0d5cff2b8d259806300e2d38b0b566b333f595d12893413e29ea8c5b85a8247
company,2023-06-09 04:09:00,Biogen Stock in Focus on Key Vote on Lequembi,120805201,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=df2b70b0e1742f5f755af1977152cd48328176a17a5860310b8df5c0302a3baf
company,2023-06-09 03:53:00,Biogen trading on Nasdaq halted as US FDA probes Alzheimer's drug,120805203,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=688bc9dbb2cd65d2a0255057c7f4b8028ef907c00b02161c23cff0cb810c6fd6
company,2023-06-09 02:42:00,Biogen on hold for trading ahead of FDA AdCom vote on Alzheimer’s drug,120805205,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1d5f89b316e7614d518808292a6f9845630f4bf88c15fed0163444212ed92601
company,2023-06-09 02:00:00,Biogen Takes Alzheimer’s Drug to FDA Advisers. The Last Time Was a Disaster.,120788776,,BIIB,Yahoo,The agency's Peripheral and Central Nervous System Drugs Advisory Committee will consider whether a Phase 3 study confirms the drug's clinical benefit.,https://finnhub.io/api/news?id=67e74d209662083b525d5fb55f97875fd9f478c8cf18af46ff67c94862332a6a
company,2023-06-09 01:50:00,"Eisai, Biogen: FDA panel votes unanimously to confirm benefit of Leqembi",120810917,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2b98fe5690e678080793fd868a288bba10bf33b379d72687382f22037baf441b
company,2023-06-09 00:13:00,FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment,120805206,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=aea899e67313eb64b27b139f3e55246e5f1646ab42c7e582a976b95a7b74fa00
company,2023-06-08 23:24:00,"FDA panel recommends full approval for Biogen, Eisai Alzheimer's drug",120805208,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b4ddd2238e3efe8512b00c4428a9224bb6a7983b8f56bc047c718b4e1cf93254
company,2023-06-08 23:06:00,"FDA panel recommends full approval for Biogen, Esai Alzheimer's drug",120805210,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8019e40be9977d6c82dad9bf48c18bc03433a42f8abd880a1c7dec09f22cf661
company,2023-06-08 22:54:00,"FDA panel votes 6-0 to back Biogen, Eisai's Leqembi",120805213,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f5bf4884041951b23fdc1ac65dd671dcacac352063b413e5cdc8c35a13cbd262
company,2023-06-08 16:52:37,Barclays Maintains Biogen (BIIB) Overweight Recommendation,120783202,,BIIB,Fintel,,https://finnhub.io/api/news?id=3bfc085fb501dd837cb6574c14e509cd50113c1d6427eab68dd6066c9ad6ca28
company,2023-06-08 13:27:15,"Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'",120788777,https://media.zenfs.com/en/Benzinga/3742eeabffbcbe6842010515a888ec1b,BIIB,Yahoo,"Senator Bernie Sanders urged the U.S. Department of Health and Human Services (HHS) to immediately address the exorbitant cost of Eisai Co Ltd (OTC: ESALY)/Biogen Inc (NASDAQ: BIIB) Alzheimer's treatment Leqembi (lecanemab). Wednesday, the FDA released briefing documents ahead of the meeting that appears to support a full FDA approval for Leqembi. In a letter to HHS Secretary Xavier Becerra, Sanders, who chairs the Senate Health Committee, expressed his deep concern over the annual price for Leq",https://finnhub.io/api/news?id=c1b2a1cdcf3eef96488771611497c5835112c4af6e1a7416d7ebabf6f3529f34
company,2023-06-08 12:51:00,Biogen Inc. stock outperforms market on strong trading day,120802599,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. advanced 1.31% to $308.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=1eeb7c44f0c550a012266b46d7163a88e107d32cb1f0338a9b76317bf245d2fa
company,2023-06-08 12:41:00,"Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod",120779130,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,"Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.",https://finnhub.io/api/news?id=562bdaee370b05e8b6c430d81be6fe40ff579cabeee4fa90c4e601abaa0d158b
company,2023-06-08 12:38:00,"Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More",120779555,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.,https://finnhub.io/api/news?id=d13e9a027822b2dfaf25666495acbb7ae52864d082ab2dd9974ee13a8f5a2ea2
company,2023-06-08 10:34:50,FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval,120788780,https://media.zenfs.com/en/Benzinga/724803abdbee5d63ce67797451ecf4fc,BIIB,Yahoo,"FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of the disease. The Leqembi application has been granted Priority Review, with a Prescription Drug User Fee Act action date of July 6. Eisai is collaborating with Biogen Inc (NASDAQ: BIIB) for lecanemab. The A",https://finnhub.io/api/news?id=f458f530ab014891e102f555b76acca95a077c8f32528eac82c4091249200a6a
company,2023-06-08 10:02:41,Needham Reiterates Biogen (BIIB) Buy Recommendation,120773403,,BIIB,Fintel,,https://finnhub.io/api/news?id=db3a85223f73be117352381b799461a89f58ee393ae5d251abe62dc2754e5478
company,2023-06-08 08:19:00,Eisai submits marketing authorization application for lecanemab in South Korea,120779576,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d1eb6cea1d451220df83f60bb24c776514cf18d09ae5556a8855c48b43e72551
company,2023-06-08 06:37:00,Interesting BIIB Put And Call Options For July 28th,120779577,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b16768a8b4c6ad054f7e0d341a1b96121b0ae3fd5c4b2f538cba331fd1142958
company,2023-06-08 04:06:00,Expert Ratings for Biogen,120779579,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=57a5119e17b8eda5bb90ab1f88f61f4f07e3cee05cef71a0dce0d9c34e7c24af
company,2023-06-08 03:31:00,"Analysts’ Top Healthcare Picks: HashiCorp (HCP), Astria Therapeutics (ATXS)",120774789,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b5cdc67b9e82fa4fa478da73c1f9ee51a4224aa5070f86df0fc4b01df5e4b795
company,2023-06-08 02:31:00,"Analysts Offer Insights on Healthcare Companies: Paycor HCM (PYCR), Crispr Therapeutics AG (CRSP) and Biogen (BIIB)",120776863,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=27971ab535b1241536ac2b9cfcb6a38c40d6193e88bd5f7efa7389aa52a38915
company,2023-06-08 01:33:00,"Biogen briefing documents bode well for full approval, says Canaccord",120779583,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0c0fb3d3f38883b83d0173b73d89bb1117815624f0a28d06d73db3ad96242780
company,2023-06-08 00:31:00,"Biogen briefing documents 'appear benign,' says Barclays",120779585,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f9e9fbd6e0261f5ed84a684f29454934fc591307dd6c0ee9d21ea2a68286e008
company,2023-06-08 00:01:00,"Analysts Conflicted on These Healthcare Names: Avita Medical (RCEL), 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)",120776153,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b4d3bdb1fa1143fa197fbb8e45b4449a0c781234f9950a3bc55bd05adce9d775
company,2023-06-07 23:34:00,Biogen notes Eisai files marketing authorisation for Alzheimer's drug,120779589,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f1832220260b7b185ac7944271879a9a74c52fbb601f0347bdf2726d777aa182
company,2023-06-07 21:53:04,Eisai and Biogen’s Alzheimer’s Drug Moves Closer to Full US Approval,120768845,https://s.yimg.com/ny/api/res/1.2/heGYVdKyKNUTFqJtGL0YGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/96129e7b946f791333bc501bd9dff9f4,BIIB,Yahoo,"(Bloomberg) -- Eisai Co. and Biogen Inc. moved closer to full US approval for their Alzheimer’s drug Leqembi after the Food and Drug Administration posted documents indicating it sees no barriers to clearance, setting the product up for likely government health-plan coverage. Most Read from BloombergMystery Bet Before SEC Crypto Crackdown May Mint Trader MillionsThese Are the World’s 20 Most Expensive Cities for Expats in 2023Messi Spurns $400 Million Saudi Offer to Join Beckham’s MiamiFlights t",https://finnhub.io/api/news?id=b8fbadcd29858cd0ee1bad2bfc529d524ecc4f568e39cc228c53d45b9ab35290
company,2023-06-15 18:55:08,Clene's ALS drug shows reduction in disease indicator levels in trial,120903491,,BIIB,Reuters,Clene said on Thursday its experimental amyotrophic lateral sclerosis (ALS) drug showed reduction in levels of an indicator believed to be tied with the disease progression in a mid-stage trial.,https://finnhub.io/api/news?id=4ec8778d6882322754203d03830ec7864823ac4956381fc3ef6e475fa3f26088
company,2023-06-15 14:32:17,ISS backs election of Langer to replace former Biogen director Denner,120904663,https://media.zenfs.com/en/reuters-finance.com/18f88e705913d3ff71f662bc6f61f17c,BIIB,Yahoo,"Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen  shareholders elect Susan Langer to replace long-standing director Alex Denner, who abruptly left the board earlier this week.  Biogen said Langer, a former corporate strategy chief at the biotech company, would stand for election to replace Denner.  ISS issued its recommendation after the unexpected announcement on Monday that three directors -- Denner, William Jones and Richard Mulligan -- would not stand for reelection.",https://finnhub.io/api/news?id=d1f976581660424c792f7994960fae718b92e30ca89ef27227c2381f6d8fcad1
company,2023-06-15 14:29:23,UPDATE 1-ISS backs election of Langer to replace former Biogen director Denner,120904664,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen shareholders elect Susan Langer to replace long-standing director Alex Denner, who abruptly left the board earlier this week.  Biogen said Langer, a former corporate strategy chief at the biotech company, would stand for election to replace Denner.  ISS issued its recommendation after the unexpected announcement on Monday that three directors -- Denner, William Jones and Richard Mulligan -- would not stand for reelection.",https://finnhub.io/api/news?id=6af38645c6c1394fb3bb06b6f44fc03dfd2d3b23c833a1ce03b9c7e29da5e3d1
company,2023-06-15 12:52:00,"Biogen Inc. stock falls Thursday, underperforms market",120940070,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.72% to $297.83 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=b69ef73eb3e2ef33e5f1d5c170c4799245a1a4d02634837cf2ba3fc00e3a344b
company,2023-06-15 10:21:00,"Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More",120891649,https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96,BIIB,Yahoo,Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.,https://finnhub.io/api/news?id=597e0eeebce15fd12e72f7a6ff7bd66b7cc24aaf8e4050b3238ef02665bc48e6
company,2023-06-15 04:36:00,7 Undervalued S&P 500 Stocks to Buy in June,120912302,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=204cddf3fe41510e2e53887b5844006d40fc5635e63be2f047b722d4c8d4441a
company,2023-06-15 02:49:00,Sage Therapeutics price target raised to $66 from $61 at BofA,120888953,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7bc6c063888d8bdacbd4275b8c5764ff2425bbece67b63e099aa62f5b049abb8
company,2023-06-14 22:56:00,"Notable Thursday Option Activity: BIIB, UA, MET",120919290,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dd6f240b8846b2adb7c4a3970834cbc861c323ef0a9b3cd35bc19a87fc2ba151
company,2023-06-14 12:51:00,"Biogen Inc. stock falls Wednesday, underperforms market",120940071,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 1.51% to $299.99 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=48b267a5a7bea09ea191517cf5010e6b9bac4d2572902801e7eb4298166055dc
company,2023-06-14 08:55:00,Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed,120875714,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=920cfb268ab5c138cb6fe00afe699969f470a4ffa64b535c194f8e8977f26429
company,2023-06-13 20:29:00,GLOBAL BRIEFING: US judge temporarily blocks Microsoft-Activision deal,120867604,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8adb4cb9d41e425b008a398c4701598083619c6ef2c4086d7c04c9a6f9ad42fb
company,2023-06-13 19:14:02,UPDATE 1-Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes,120855477,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.  The hedge fund's founder, Alex Denner, 53, one of three Sarissa candidates running for seats on Alkermes' 11-member board, on Monday said he would give up his board seat at biotech company Biogen.",https://finnhub.io/api/news?id=fdd8bbfd13a7a49305e5c460dbe2d0e9a49a943bfc31be2c18a762a16edf34f2
company,2023-06-13 14:17:05,"Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz",120855552,https://image.cnbcfm.com/api/v1/image/107256148-16866940511686694047-29872944109-1080pnbcnews.jpg?v=1686694625&w=1920&h=1080,BIIB,CNBC,"Jared Holz, Mizuho Securities healthcare sector specialist, joins 'Fast Money' to talk controversy brewing at Biogen, Alzheimer's drug approval roadblocks in Europe, and more.",https://finnhub.io/api/news?id=4f88605a3a0e70a91555bc32043b6b88dc1de85fa73d159a3660bb85c5ae7b29
company,2023-06-13 13:54:00,"Biogen Inc. stock falls Tuesday, underperforms market",120940072,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 2.81% to $304.60 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=b329812ef691c4b8e433f310c61069ccd5af687a8f31031802b5df5ce5dfd90b
company,2023-06-13 13:52:33,Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes,120848751,https://media.zenfs.com/en/reuters-finance.com/71c9a04944dbdbffa35e4c2052c8169a,BIIB,Yahoo,"Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.  The hedge fund's founder, Alex Denner, one of three Sarissa candidates running for seats on Alkermes' 11-member board, said this week that he will give up his board seat at biotech Biogen.",https://finnhub.io/api/news?id=60aa22f7a3afe24825fe432c845af904abdc1379cdd8f9950573152b9b21b909
company,2023-06-13 12:20:56,Markets Rise Midday as Inflation News Raises Expectations of a Rate Hike Pause,120850001,https://s.yimg.com/ny/api/res/1.2/I1evCwsRGF8yZ.VE5GCtVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia.com/dc5147136b95ee885a839231e97e44a0,BIIB,Yahoo,"U.S. equities gained at midday on Tuesday, June 13, 2023 as lower inflation raised optimism the Fed could pause its rate hike cycle.",https://finnhub.io/api/news?id=835be472de3f66ac4cff8b78fac03153f920524d3382b69744324a2ceead927f
company,2023-06-13 10:30:17,Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources,120850002,https://media.zenfs.com/en/Benzinga/c024e3b7ef45d294435a3813960050c0,BIIB,Yahoo,Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow cognitive decline may not outweigh its health risks or justify the strain it would place on limited healthcare resources. The drug is currently undergoing regulatory review in Europe and is likely to receive traditional approval in the U.S. next month after the FDA adcomm unanimously voted to favor the dru,https://finnhub.io/api/news?id=e4e3ab409203275d827dfc4bb3db30db8c4e3da648a287104fe730acf3985886
company,2023-06-13 08:38:01,"Stocks making the biggest moves midday: JD.com, Biogen, Oracle and more",120849647,https://image.cnbcfm.com/api/v1/image/106993115-1640239227235-gettyimages-541117216-000096738405_Unapproved.jpeg?v=1686674703&w=1920&h=1080,BIIB,CNBC,These are some of the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=4b4d73ae1b302f2be42badf6f7fd0faab50cc7a0c01b97f6cba2ac877a68b98d
company,2023-06-13 07:56:00,SVB Securities Sticks to Its Buy Rating for Biogen (BIIB),120875720,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=adb3636d77a26f303d1e51278d8512dc5de15bf6321550584dcd53a2d34cbf02
company,2023-06-13 07:17:00,"Video: Nasdaq 100 Movers: BIIB, JD",120852273,,BIIB,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b75f6e5374d98a0f871f572fffd587bf97891bc3bebc55998f09ec0af96b0da3
company,2023-06-13 06:52:15,Top 20 Most Profitable Pharmaceutical Companies In The World,120841576,https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918,BIIB,Yahoo,"In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading […]",https://finnhub.io/api/news?id=f9453e0ad0f9118449511fe1790b1a08bef5c3c5e71d8572193ad52a813a0e87
company,2023-06-13 05:42:00,"Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday",120844189,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2c7a9c94acc9f4ac5352e4a9d0711548df8b0cbfe36ab66212625315b90ee535
company,2023-06-13 05:10:00,"FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories",120844236,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d329459056f837436b28cd2d6fd4e558ca7b66fbbf525b4dbd4ea5d5ad8ea46f
company,2023-06-13 05:04:00,"FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, European Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories",120844238,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ced2a09dfcbcc30012c1f9fea5574c2cec3027c0ede56ef112719bd723045620
company,2023-06-13 04:29:00,Biogen in pact with NeuroSense for ALS biomarker study,120847369,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bd5b24d59f091f979daa737fbcefbb5b7432c5e2da910da1d83966d07d9ac76a
company,2023-06-13 04:20:44,"European Alzheimer's experts unconvinced by new Eisai, Biogen drug",120841200,https://static.reuters.com/resources/r/?m=02&d=20230613&t=2&i=1635698218&r=LYNXMPEJ5C06K,BIIB,Reuters,"Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.",https://finnhub.io/api/news?id=21e21500d140775ed31fc617ac073996091c67c034dca44b165b300933e7cb1c
company,2023-06-13 03:00:00,"FOCUS-European Alzheimer's experts unconvinced by new Eisai, Biogen drug",120840921,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.  Lecanemab, branded Leqembi in the U.S., is under regulatory review in Europe and likely poised for traditional U.S. approval next month based on trial data showing it slowed cognitive decline by 27% in patients with early Alzheimer's.  In Europe, where cost-conscious countries rigorously weigh new drugs before adopting their use, nine neurologists and researchers across six countries told Reuters lecanemab is unlikely to be widely used if approved.",https://finnhub.io/api/news?id=f1de3fa748f7b42e5c7a9d75963d6e21c247e488ea6c34893516dfd90923000a
company,2023-06-13 02:07:00,Biogen's Leqembi may not be widely used for Alzheimer's in Europe - report,120852279,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=922a5c549ad57df9af61ef09b263e56ed20e044d3eb9c925cc96c2b9cd1c168b
company,2023-06-12 17:14:00,Biogen Announces Changes to Its Board of Directors,120836962,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate CAMBRIDGE, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced several changes to its Board of Directors today. The changes will refresh the composition of the Board and follow the Board’s continual interaction with company stockholders to solicit their perspective on a range of issues around the company’s performance",https://finnhub.io/api/news?id=6e236521a09aabeb60b4797b7fa692f0bb0190bd2e13d0a757b5283ca017789b
company,2023-06-12 13:31:00,Biogen Makes Board Changes Ahead of Shareholder Meeting,120940073,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,"By Denny Jacob Biogen on Monday made several changes to its board, part of its efforts to achieve sustainable growth. The biopharmaceutical company said...",https://finnhub.io/api/news?id=9ebc26cb06c45957acc55012bd9a9dae07aa432b22254186d9afcb87bad6a2bc
company,2023-06-12 13:17:14,Needham Reiterates Biogen (BIIB) Buy Recommendation,120829180,,BIIB,Fintel,,https://finnhub.io/api/news?id=352a055a4dcc63899760b2c9c9eacc97bc1ba6eb60fbc7ce1652b04342b2646b
company,2023-06-12 13:17:11,Canaccord Genuity Maintains Biogen (BIIB) Buy Recommendation,120829182,,BIIB,Fintel,,https://finnhub.io/api/news?id=f73807c476f9d5e708a7724489e2d9733ec8a8d407e8585360c39efb447965a9
company,2023-06-12 13:17:11,Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation,120829181,,BIIB,Fintel,,https://finnhub.io/api/news?id=b3a64668e33a133ffabd2592fea862675390ec9ea19500f16561e2566ad60fd7
company,2023-06-12 13:00:00,Biogen's Charts So Far Appear Free of Major Side Effects,120829233,,BIIB,Yahoo,"Biotechnology firm Biogen  has pushed up to a new 52-week high Monday on the heels of a Food and Drug Administration panel voting unanimously in favor of its newest Alzheimer's treatment.  The daily On-Balance-Volume (OBV) line shows a rise for the past twelve months.  The 40-week moving average line is rising, The weekly OBV line is bullish and so is the MACD oscillator.",https://finnhub.io/api/news?id=d39b7ba7c63ab2b2fba5b236a479d1a813465c5eaa6ecac77d8b65ec3f8d23ae
company,2023-06-12 12:50:00,Biogen Inc. stock outperforms competitors on strong trading day,120940074,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 1.47% to $313.41 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=8bad9b4094bf9c9215df49fbcc1c16e1bed63432c58f33fe9d51878f83e43088
company,2023-06-12 12:06:46,Biogen Rises After 'Drama-Free' Panel Votes Unanimously In Support Of Alzheimer's Drug,120829234,,BIIB,Yahoo,Biogen stock rose Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.,https://finnhub.io/api/news?id=699ed4d70f0ef3b7122789df829a51c09312487faa08b1798fb5485245fc3c3e
company,2023-06-12 11:07:15,"3-Stock Lunch: Oracle, Biogen and SentinelOne",120838366,https://image.cnbcfm.com/api/v1/image/107255226-16865960471686596044-29857511454-1080pnbcnews.jpg?v=1686596835&w=1920&h=1080,BIIB,CNBC,"Eva Ados, ERShares chief operations officer, joins ‘Power Lunch’ to discuss three stocks: Oracle, Biogen and SentinelOne.",https://finnhub.io/api/news?id=465cb3746f950d2d223052aa3bc2af21bf85b9fd2053f181db5cc17e892c1cdb
company,2023-06-12 10:48:40,"Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns",120829377,https://static.reuters.com/resources/r/?m=02&d=20230612&t=2&i=1635600985&r=LYNXMPEJ5B0BQ,BIIB,Reuters,Biogen's shares rose 2% on Monday as a unanimous backing of its Alzheimer's drug by the U.S. health regulator's advisers strengthened the case for a traditional approval with no major new safety warnings.,https://finnhub.io/api/news?id=b1d21404b29290ed6a7d8188a3a4e4cce353943b4fc7be818ec73267f48b05f5
company,2023-06-12 10:37:43,"These Stocks Are Moving the Most Today: Tesla, Carnival, Nasdaq, NIO, and More",120826828,https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e,BIIB,Yahoo,"Tesla is rising for a 12th consecutive day, Carnival trades higher after Wall Street upgrades the stock, and Nasdaq falls after agreeing to acquire software company Adenza for $10.5 billion in cash and shares.",https://finnhub.io/api/news?id=0d4298c6e5d8050fb03ec1e0a70119cb2d16c72ed2f5910977bfdc207a0f4047
company,2023-06-12 10:30:00,Trading the Alzheimer's Space: Here's My Plan as Companies Try to Slay the Beast,120826830,,BIIB,Yahoo,This will obviously be a huge market. It's time for me to diversify my exposure after positive news on Biogen and Eisai's Leqembi.,https://finnhub.io/api/news?id=1980d60a812c7fe29f7c29b0d6ddfee9afab1ff30c60567d4b5087e07d21d128
company,2023-06-12 10:16:57,"CORRECTED-Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns ",120829378,,BIIB,Reuters,Shares of Biogen Inc rose 4% in premarket trade on Monday as an unanimous backing of the company's Alzheimer's drug Leqembi by the U.S. regulator's advisers eased concerns that a traditional approval for the treatment will come with major new safety warnings.,https://finnhub.io/api/news?id=2ed78b38b225bbd87a8686e5475ffeafc68ce1cfb50a9465fa4d8a65d5689a85
company,2023-06-12 09:58:41,FDA recommends Biogen's Alzheimer's drug for approval,120826833,https://s.yimg.com/ny/api/res/1.2/G7Nxnqt.GgNRraBKH2mMBQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-06/00c71420-0929-11ee-8e3f-dd9779919c5b,BIIB,Yahoo,Shares of biotech company Biogen are rising this morning after an FDA panel recommended its Alzheimer's treatment drug for approval. Yahoo Finance Live takes a look at the stock action.,https://finnhub.io/api/news?id=392553be166cf60066aaf346534cf503acda03ca35455c6e4a473babf10d1ee6
company,2023-06-12 09:29:46,Biogen Jumps After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug,120826835,https://media.zenfs.com/en/ibd.com/78d3bc5a06ce66f50e3b72166bcc394c,BIIB,Yahoo,Biogen stock jumped Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.,https://finnhub.io/api/news?id=78a1e7df170a8b4e7a3135e96726f4a7312b8107db2aebb863d517a1f6872e53
company,2023-06-12 09:25:00,"Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement",120826837,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.,https://finnhub.io/api/news?id=a64b3af313cf4b2578506a1b2ca22d6b0765bc90b53bca02cf88aabafa5299d1
company,2023-06-12 08:13:52,"Stocks to Watch Monday: Biogen, Illumina, Oracle",120826840,,BIIB,Yahoo,**↗️** [**Biogen (BIIB)**](https://www.wsj.com/market-data/quotes/BIIB): The biotech company's shares rose 1.3% after an advisory committee [recommended the Food and Drug Administration approve Leqembi](https://investors.,https://finnhub.io/api/news?id=f0b23331cd580d2c754e0d0c92d52321f7e26b990cfb0cfda58f03516c70be68
company,2023-06-12 07:22:52,5 Things to Know Before Markets Open,120826841,https://s.yimg.com/ny/api/res/1.2/p7f6VsMB_1rWBTQhmgLCrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia.com/05788248553bc0b71d5d14593658e1d4,BIIB,Yahoo,UBS completes its takeover of Credit Suisse and Biogen wins key FDA support for its Alzheimer's disease treatment. Here’s what investors need to know today.,https://finnhub.io/api/news?id=55f7e25e8c9b9ab0f48908fea676b36ff2639caa66018500ea0e28eb19f71240
company,2023-06-12 07:05:48,HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation,120825307,,BIIB,Fintel,,https://finnhub.io/api/news?id=c5450308904b137ab6e49cc02992b706c3facec7610c96876fee15756309d295
company,2023-06-12 07:02:00,What You Missed On Wall Street This Morning,120827512,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9b937aee0ced7bb96ae16775077f0311413203232cae724bd134cce549ca6918
company,2023-06-12 06:50:00,Global company events calendar - next 7 days,120827602,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=84611524898fcc5009c98a3bbc6698e9ed6a267f368249b7b851536f13253f58
company,2023-06-12 06:14:00,"Why Are Cruise Stocks CCL, RCL, NCLH Up Today?",120831267,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c9aaea549cb796226b8cf35e06b1565023134b5d5ebfd01b09d17cfe9bfe4df5
company,2023-06-12 06:00:00,Biogen stock doesn't see big boost from FDA panel endorsement of Leqembi,120835193,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=79cfcab753de6162f6d836f0a344bc256dad1df6d53d474f5366af0c8cefa3f7
company,2023-06-12 05:48:00,BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing,120830212,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e5c68748da4b75e97c9cf9d0a47cb830787a785bfc3d71020289079f080ccadc
company,2023-06-12 05:37:00,"Stocks Higher, Fed Decision, Inflation In Focus, Biogen Surges, Oracle Earnings, Silvio Berlusconi Dies - 5 Things To Know",120825094,https://s.yimg.com/ny/api/res/1.2/sno6oc2yWNfho.RvhpGp3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/thestreet.com/e74b50ac16b5d9112f1a36e50165fa17,BIIB,Yahoo,"Stock futures higher ahead of key market tests; Week Ahead: Fed, inflation, retail sales in focus; Biogen surges as FDA panel gives final nod to Alzheimer's treatment; Oracle set for new record high ahead of Q4 earnings and Silvio Berlusconi, billionaire media mogul and former prime minister of Italy, dies at 86.",https://finnhub.io/api/news?id=a3024a3baf06a3d044ae34343da283d4fc823372805934466cfa5973b8220712
company,2023-06-12 03:55:00,Fly Intel: Pre-market Movers,120827520,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a376c023003f0f23ae8521c3b4794648ede68803da596438d0da13742b31d451
company,2023-06-12 03:51:00,"Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), Biogen (BIIB)",120827152,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=952500cbe8406925b8b7f6a335c3ccd0a729dcf22544370689c19a6bd730b66a
company,2023-06-12 03:32:00,"Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN), Humacyte (HUMA) and Biogen (BIIB)",120833123,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7e966c952a3bfa40a323bb92d023e48e4e3502977d15ff4ef5543f53fe22fb56
company,2023-06-12 03:30:00,"S&P 500 Futures Rise in Premarket Trading; Nasdaq, Globant Lag",120877834,https://s.wsj.net/public/resources/MWimages/MW-HA919_barron_NS_20181226134502.png,BIIB,MarketWatch,"With U.S. stock markets set to open in two hours, (CCL) was up 5.4% in pre-market trading, and (ZBH) was up 5.1%. (ORCL), (PLNT), and (BIIB) were all posting...",https://finnhub.io/api/news?id=ffbbe7d0dbf229304933f99bffe3deda3f4b756dc32029d91feb31f6cdbe7f10
company,2023-06-12 03:11:00,Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Biogen (BIIB),120828062,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e7cf8a339197b29d3203038afd895be1a2cdb590c2b9aeb5648122edd8a4e97b
company,2023-06-12 02:54:01,Biogen shares jump after FDA advisory panel backs Alzheimer's drug,120826854,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,Investing.com -- Shares in Biogen Inc (NASDAQ:BIIB) surged in premarket trading on Monday after an advisory panel to U.S. regulators gave their support to the early-stage usage of an Alzheimer's drug co-developed by the biotech group.,https://finnhub.io/api/news?id=0b80d6085db2c918ea698ee3f713914166cc6262cc185731cc826166df550d41
company,2023-06-12 02:37:00,Biogen price target raised to $350 from $330 at Canaccord,120835199,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d039151393fd08c0cb7e8f36256500855d7aba6fcb066181c4c8b24a7309e156
company,2023-06-12 02:08:00,"Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low",120829992,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fafed2b42385eda0a7ff45335409c3749df8d2b0ac135399bacdac126e038f7e
company,2023-06-12 02:00:00,Here’s Why Biogen Stock (NASDAQ:BIIB) is Trending Higher,120833440,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=38460dedd847ce64013b155e226a89514a9f9df379a290cb8e947e074b1e8c80
company,2023-06-12 01:38:00,"Biogen, Carnival and Oracle post solid gains, while Nasdaq and KeyCorp slump",120872337,https://images.mktw.net/im-705451/social,BIIB,MarketWatch,Here are some of the biggest movers on Monday.,https://finnhub.io/api/news?id=f323ae972d9c2bf0fa9f60f8f1438ea7c191c61a6daf3de346d4d44291316d00
company,2023-06-12 01:31:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,120828903,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=689cd808a4007edfa3ea0f28817431f9cc3820e2df5893a8fe648ba157b94952
company,2023-06-12 01:27:00,"Biogen announces board changes, new date for annual meeting",120852280,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=687fd3b592e0124f6acf8dcd1a1aef6f7779cbe9b2ff2bcd5167adfb0e8449f3
company,2023-06-12 01:08:00,Biogen price target raised to $360 from $350 at Oppenheimer,120835205,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=56a92b1c9744fabf823fc6486d94f52d5b3bf9e9c4cf99323189543d487462c0
company,2023-06-12 00:29:00,"These Stocks Are Moving the Most Today: Tesla, Carnival, Nasdaq, SoFi, and More",120872909,https://images.barrons.com/im-676095/social,BIIB,MarketWatch,"Tesla is rising for a 12th consecutive day, Carnival trades higher after Wall Street upgrades the stock, and Nasdaq falls after agreeing to acquire software...",https://finnhub.io/api/news?id=95874881e17768f52f633270f8aa7fdb5294343b8da8fd7f6a78304dca189c21
company,2023-06-11 23:21:00,What You Missed On Wall Street On Monday,120833428,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=57a4bd93439e3d0ff08624d2691ec90707e76332e8898c51e907d0a36c544627
company,2023-06-11 21:56:00,US FDA confirms clinical benefit of Biogen's leqembi for Alzheimer's,120835208,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cf630fb3b988e5259cf2599ab7c7b2d58ef6842c71f98f7b0ac3045206498a7c
company,2023-06-11 21:53:00,"Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground",120832256,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9072050a678518b62c772b6d5fe7ec65e0b03151527e93db45af9ded0c264b26
company,2023-06-11 21:30:00,Tech Sector Powers S&P 500 To 10-Month High While Oil Stocks Struggle: What's Driving Markets Today,120830622,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2ea37f0783476ef547d8cb43c2104e8616af53ef83d85fd18dd15201df9f1cd0
company,2023-06-11 21:24:00,"Tech Sector Powers S&P 500 To 10-Month High, While Oil Stocks Struggle: What's Driving Markets Today",120830624,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f06cd30430475e3c88de4926223d6b7f0e152708a68fca4b3ecc6d63c72ba9fc
company,2023-06-11 21:03:00,Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote,120835212,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=14cc680069824b66c6d26fa5d4dba507ee3a7112c13d644b0efa8d8ede6a511c
company,2023-06-11 20:22:40,"Eisai, Biogen Clinch FDA Advisers’ Support for Alzheimer’s Drug",120824268,https://s.yimg.com/ny/api/res/1.2/9cR3HIq.AQu6RN3k9t.V1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03OTc-/https://media.zenfs.com/en/bloomberg_markets_842/bd6b78e01a4c0eb3b79e0bcad0dff921,BIIB,Yahoo,"(Bloomberg) -- Eisai Co.’s Alzheimer’s disease drug developed with Biogen Inc. gained support from advisers to US regulators, paving the way for a likely full regulatory approval that could lead to broader insurance coverage. Most Read from BloombergOil Traders Are Daring to Defy Market Kingpin Saudi ArabiaAs Fed Signals Rate Pause, Powell Will Have to Placate HawksUBS Completes Credit Suisse Takeover to Create Bank TitanJeff Bezos Has Gained $10 on Mystery Purchase of One Amazon ShareUK Politic",https://finnhub.io/api/news?id=e1c0df66cec116b1240a99ea072736fffa2d8e83e320d1a674ef1f4583cae0bb
company,2023-06-19 07:00:00,"Alzheimer’s Blockbuster Is Coming, but Slowly",120944442,,BIIB,Yahoo,"As any patient or family member dealing with cognitive impairment knows, getting diagnosed with Alzheimer’s disease isn’t simple.  With  Eisai  and  Biogen  anti-amyloid treatment Leqembi likely to receive full Food and Drug Administration approval and subsequent Medicare coverage next month, the focus will shift to tackling the hurdles to patient access.  For Eisai and Biogen, the challenge isn’t just convincing patients and doctors that the drug provides real clinical benefits.",https://finnhub.io/api/news?id=0464c548974cef3c766e81617c81cd238940aac1c604195921e7f0abc1c2bec3
company,2023-06-19 05:30:00,Does This Signal Trouble for Biogen's New Alzheimer's Drug?,120944443,,BIIB,Yahoo,"Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug, Leqembi.  The FDA earlier granted Leqembi accelerated approval and now is considering it for traditional approval.",https://finnhub.io/api/news?id=c23b511e829dfe343d5078deae34e92f327c89e202a1a5b2cfa44b9f72d7c138
company,2023-06-19 01:16:46,PBE: Healthcare Dashboard For June,120943664,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/655188172/image_655188172.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.,https://finnhub.io/api/news?id=b567e115a5c67f869d3513574b36147a748861f565307e34181e9fd2427d266f
company,2023-06-18 16:56:10,How to Retire Rich: Biotech Stocks Edition,121032614,https://media.zenfs.com/en/investorplace_417/155568656c3c7c82033d9d467e5e2a90,BIIB,Yahoo,"Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",https://finnhub.io/api/news?id=30a100653ec7406368a3a5492184101887e35c42255ecfcadc8086b9b655a955
company,2023-06-17 10:07:00,2 Market-Beating Stocks With Major Catalysts on the Way,120928550,https://s.yimg.com/ny/api/res/1.2/Y4ReOklbfghVj9uOgyd4hQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/e812962fa399e82abe410b5540a29029,BIIB,Yahoo,"For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start.  Two drugmakers that have done particularly well for themselves are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB).  Vertex Pharmaceuticals has a rich portfolio of cystic fibrosis (CF) drugs that generates growing revenue.",https://finnhub.io/api/news?id=f3471d20701a45ff3b0c74fca80fa596be3a40edf9c6c2c6e6e4ab0226790404
company,2023-06-17 09:00:13,Biogen Inc. (NASDAQ:BIIB) Shares Could Be 24% Below Their Intrinsic Value Estimate,120926703,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Key Insights Biogen's estimated fair value is US$392 based on 2 Stage Free Cash Flow to Equity Current share price of...,https://finnhub.io/api/news?id=bbf12701b84a4626ae80ca3b342ed26e145d5d0c20abbd6527abc8e6e42cfbf2
company,2023-06-16 15:36:00,A Schwab Wealth Survey Reveals a Paradox,120938185,https://images.barrons.com/im-802157/social,BIIB,MarketWatch,"Nearly half of the respondents averaging $560,000 in net worth said they were wealthy, when including nonfinancial factors like health and family. But when...",https://finnhub.io/api/news?id=73b4c318e7d74ae594a97066d2fa648a0d91a7f4f4e0d98fbd5b01644c238d99
company,2023-06-16 12:52:00,Biogen Inc. stock outperforms market despite losses on the day,120940069,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 0.12% to $297.48 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=ecc6e12555f35e4155dc69c8e87797e9b17a3a7c57e48f70214c7cbb570c8b1b
company,2023-06-16 04:51:00,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Grifols SA (GRFS),120929583,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=96f60985295bcdc0ec6f9a16ec563714f9c593d7e1fbcb3c1ae14b78c520bab9
company,2023-06-15 21:35:50,7 Undervalued S&P 500 Stocks to Buy in June,120988915,,BIIB,Yahoo,"When attempting to build a portfolio of reliable entities, you probably can’t go wrong with undervalued S&P 500 stocks. Featuring the market performance of 500 of the largest companies listed on stock exchanges in the U.S., you’re dealing with proven winners. To be fair, you might not receive a blistering performance. At the same time, these ideas are less likely to leave you stranded on the road. In addition, ChatGPT points out that the best S&P 500 stocks to buy offer diversification. Specific",https://finnhub.io/api/news?id=0f39bd9f28dabd3866779418970f92329566f512d4b604fc8e081f59d011fa10
company,2023-06-23 12:52:00,Biogen Inc. stock underperforms Friday when compared to competitors,121078156,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 3.21% to $284.52 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=3868c3e3ff902f9959035a78fe0426e4a43775b5aa53873ab463fe7800cccb07
company,2023-06-23 07:30:00,Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?,121016872,,BIIB,Yahoo,"It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and Drug Administration (FDA).  Today, however, the company has given up on Aduhelm and is instead focusing on a potentially more promising Alzheimer's drug, Leqembi.  It has already obtained accelerated approval and next month it could hit a much more important milestone: full, traditional approval.",https://finnhub.io/api/news?id=67b2d47aab51b26df43aa59c472b5779fddf5e0b560600558c5262158058ad11
company,2023-06-23 02:26:00,Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB),121041520,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=753eceb25e2f26e8f36ea7d84638e1e150b8829205ab821eb22fe5edd2ffed3e
company,2023-06-23 02:01:00,"CMS update 'incremental positive' for Biogen, says William Blair",121041521,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1374b00cc14d90736113ba44bf2b84b8e3c6ee28ef88388ed2e826dac3abcbd7
company,2023-06-23 00:45:00,Mizuho Securities Remains a Buy on Biogen (BIIB),121041522,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f655b44b47dd1dde977366015328c8d700592c1d96ceb286d3a2b02cc136a327
company,2023-06-22 12:52:00,Biogen Inc. stock underperforms Thursday when compared to competitors,121010549,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. sank 0.14% to $293.95 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=a502ba6907474241bc0da5ddb2dfa70c2fe9e81e7819681dfece389ffd98ea4a
company,2023-06-21 12:52:00,Biogen Inc. stock outperforms competitors on strong trading day,120993521,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.19% higher to $294.36 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=a46a8d5fce19d5ce8078dd255364124615bf33b577b9c7fcf87b10230a025553
company,2023-06-21 06:08:00,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,120977868,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9ef1ade9dd466fe074090d354892e925425c3f963fb59f6bb6b14037d350c013
company,2023-06-21 04:07:00,"Wednesday’s Top Analyst Upgrades and Downgrades: ADM, Baidu, Melco Resorts, Palantir, Peabody Energy, Philip Morris, Shopify and More",120975975,,BIIB,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1e3a6e1500430f31b67ea26ca578f8a12ccbb3e38392bb30dcd9eb84b451c1f4
company,2023-06-20 21:32:00,$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today,120982243,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=44dd6beb6517f1ae41b7132ca9bfbe1c2c38ab1bfaea1de69c4d968c2b8c5a9a
company,2023-06-20 12:52:00,"Biogen Inc. stock falls Tuesday, underperforms market",120993522,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 1.24% to $293.79 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=0c96ba2fc25c91e20ff3ffa1d90c6edae93a6610493bce11a507f2108ce191ed
company,2023-06-20 09:24:38,ISS recommends one of Sarissa's three nominees for Alkermes board,120955059,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Proxy advisory firm Institutional Investor Services urged Alkermes shareholders to elect one of three director candidates proposed by activist hedge fund Sarissa Capital, arguing more outside pressure on management is needed right now.  ISS said Sarah Schlesinger, a physician with experience serving on public company boards, should be elected to Alkermes' 11-member board at next week's annual meeting.",https://finnhub.io/api/news?id=0866c18e610e392247798450c42fe17c7b72821b162e09e35184b38f403c507f
company,2023-06-20 02:58:24,Ionis: Potential Advancement Into HAE Space Makes This A Must Watch,120953921,https://media.gettyimages.com/id/1498156001/photo/colorful-test-tubes-in-a-chemical-laboratory.jpg?b=1&s=170667a&w=0&k=20&c=FvFrBq3b5yzV3vWkYbckJwXCuFer7JuM1KArsFE-LBI=,BIIB,SeekingAlpha,Ionis Pharmaceuticals should be watched closely because it is advancing a drug for the prevention of hereditary angioedema attacks. Find out why IONS stock is a Buy.,https://finnhub.io/api/news?id=ad2f0b570b684bdedea1da5f01685f6c755d8744243183806c8b7d1ec2ffccb4
company,2023-06-20 00:20:00,5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies,120965429,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a88b8d9d016dfc2080095894929c44b1527dcfe9b732b8fcb30d3eed33ceddcf
company,2023-06-27 12:52:00,"Biogen Inc. stock rises Tuesday, still underperforms market",121078152,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.49% higher to $282.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=ea4f66542b5446b61b6e7bbe13a58e12e99f641569f317934376150705abf613
company,2023-06-27 04:23:00,"Tuesday’s Top Analyst Upgrades and Downgrades: Advance Auto Parts, Alphabet, Micron Technology, Ross Stores, Tesla and More",121068034,,BIIB,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=54d271b306cb38beefc95f493ebddabf205c78eab8d579b7736547f1e74b1ded
company,2023-06-27 03:00:00,Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen),121068824,,BIIB,PR Newswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=450b73209fd7404c63765063b6577468f0493d940dc544e3302140f2fc82a47c
company,2023-06-27 02:05:00,Alcyone Therapeutics gets FDA IDE to initiate study of ThecaFlex DRx System,121075052,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d745114a843d63677c2cb4dcdd2aa8ad5041a949d0cab316348e200818f2342f
company,2023-06-27 01:21:00,Biogen: Mounting Expectations Ahead Of Leqembi Decision,121075053,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c9f75593977fc3c9e8a5eb5095e09a501ee9e2770f9efed045fc063c68105f7a
company,2023-06-27 01:14:31,"Biogen: Highs, Lows, And Mounting Expectations Ahead Of Leqembi Decision",121064999,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440458360/image_1440458360.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Biogen's problem has always been that its products target very difficult-to-treat diseases where signs of success are difficult to establish. Find out why BIIB stock is a Hold.,https://finnhub.io/api/news?id=4f8d71bb44e7fec40d3bfbc2974f6094e767d09060ef7b8f6fe4e8dd160fb5bd
company,2023-06-26 21:06:00,A Look Into Biogen Inc's Price Over Earnings,121075055,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d1763f37f08887b85f7c11f54ac06c505302b5d4b8c24c5b59b34c12edfd9cbe
company,2023-06-26 13:07:45,Biogen shareholders back Susan Langer as director,121052161,https://media.zenfs.com/en/reuters-finance.com/562197d000b2178eaac08be6cf36238f,BIIB,Yahoo,"Langer, 32, had served in various roles at the biotech company from 2013 to 2019.  Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee.",https://finnhub.io/api/news?id=1603839ee10385ddaff4f7cd39f33975d9f4dd7c35d732369955408b20429baa
company,2023-06-26 12:59:45,UPDATE 1-Biogen shareholders back Susan Langer as director,121052164,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him.  Langer, 32, had served in various roles at the biotech company from 2013 to 2019.  Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee.",https://finnhub.io/api/news?id=0e79601faa2d1b3934a44e07fb6bc155f37244d4162e57dc823b4ea1a3d279a4
company,2023-06-26 12:52:00,Biogen Inc. stock outperforms competitors despite losses on the day,121078154,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 1.03% to $281.58 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=7946b8ed213ece01ce3519a3685f05edf850d64dc425c6d1281b124ed7df8d69
company,2023-06-25 21:46:00,Biogen (BIIB) Receives a Buy from Robert W. Baird,121053412,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b3b5b326154fb3e2c39738648ce5d42b7d421cde3bc5041a7c5317efd61d72ef
company,2023-06-25 20:47:00,GLOBAL BRIEFING: Vladimir Putin weakened by attempted Wagner revolt,121050485,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ece2826e8b0d3684a30b01aa91d0937c14eab7598b10a2732b8f427d650a5aa2
company,2023-06-24 14:26:40,10 Personalized Medicine Stocks Billionaires Are Loading Up On,121032694,https://media.zenfs.com/en/insidermonkey.com/a3355b66f8b9be42d814254460df8013,BIIB,Yahoo,"In this article, we will take a look at the 10 personalized medicine stocks billionaires are purchasing. If you want to skip our detailed analysis of the industry and its growth prospects, go to the 5 Personalized Medicine Stocks Billionaires Are Loading Up On. According to Allied Market Research, the global personalized medicine industry is set […]",https://finnhub.io/api/news?id=7e30d700aa58b0903a204ea68e180d28bb1fc14d88efc479fa89d3078e7102f6
company,2023-06-30 23:03:00,"Lilly, Vertex top pharma performers in H1; Moderna, Pfizer the worst",121169588,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b133d23f232c21ebcf38d04ef1d77594bf89bfe9388aa230fd9e23b8b78803bf
company,2023-06-30 16:06:00,New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy,121156412,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community.",https://finnhub.io/api/news?id=713c3deb5b7fb597c05b582641e488f4a4240fc56e79a2039dab3dfe3b98f660
company,2023-06-30 12:53:00,"Biogen Inc. stock rises Friday, still underperforms market",121168114,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.96% higher to $284.85 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=a3293114d36ccd691e80cc0e13535905a87b6ead8477cbf55475bfb52c6e8b1e
company,2023-06-30 09:15:02,"Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain",121144177,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299611046/image_1299611046.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Sage Therapeutics should find out in August whether its drug, zuranolone, will be approved. Click here to see our take on SAGE stock.",https://finnhub.io/api/news?id=185469031f47adf1831492d61f9bb1450233720c359ee29b2b03a44883f570cf
company,2023-06-30 08:42:00,10 Health Care Stocks With Whale Alerts In Today's Session,121145492,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2eb0dd773f7fa5a55128e450f726689bb4392a998f40ed3a14e5730774e9958e
company,2023-06-30 07:45:00,Medicare revises guidance on drug price negotiations amid lawsuits,121143519,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9995d69366d1eb03a503aedbca7566d037f9ef099dec3aaed5ff87e49f1a862a
company,2023-06-30 00:03:00,Amgen Inc. Dividend Stock Analysis,121144152,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=db4cfe5426261e2de5cc92c868ea1f3362aa544720c00ac5e66b8332e7c50e7b
company,2023-06-29 23:13:00,Biogen announces new SPINRAZA data,121175076,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c8dbb3c9de47317ebb251d019ae76e1e3d3ca76d191d5ae3daf8c5000129751c
company,2023-06-29 22:05:00,"Catalyst Watch: BorgWarner, Biogen, iRobot and Coty are in the spotlight during holiday-shortened week",121147270,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1a1484b1e1be7bf426443bbedeaa6f7e32e19c9449ffc3d0d61afeb913e1ce5e
company,2023-06-29 12:53:00,Biogen Inc. stock underperforms Thursday when compared to competitors,121122268,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.67% to $282.13 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=7de9fa8d68acffbab34e3ce4f2997e2623be45fc953beb6b380858c2de3c7bec
company,2023-06-29 10:00:28,Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the favorable return generated for shareholders over the past year,121122708,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...",https://finnhub.io/api/news?id=4f3e8f5fc6120b3023c3682351dcd006d7f155cb5238710d3cd77ff4a8740d95
company,2023-06-29 05:05:00,How Is The Market Feeling About Biogen?,121128785,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3d2047b4e6b044bfea5970fb293617873b117a31832b5afe021331079b51cae6
company,2023-06-28 23:38:00,Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call,121125890,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=120a1d7ba2704edf34ef28dafa20e171ce8a393ca3007bea2d6fa20dc3c213c9
company,2023-06-28 23:30:00,"A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?",121122269,https://images.barrons.com/im-808967/social,BIIB,MarketWatch,What a shot that treats pet eczema reveals about how pharma companies actually price their drugs.,https://finnhub.io/api/news?id=d441fc0ed72f1643d3deaa09b9d4a74da987ee630d1c0889ae59c05498cc3f1b
company,2023-06-28 12:53:00,Biogen Inc. stock outperforms market on strong trading day,121122270,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.38% higher to $284.02 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=842e9ab016a97d07c0aaea0a571b86650150acdb33a35d881ef8fa972c07a388
company,2023-07-05 12:53:00,Biogen Inc. stock outperforms market on strong trading day,121275916,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.16% higher to $285.89 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=3732cea53db6df9940ebd7f675d35a9dcb38b087b8df9c21dfce793024bd2a02
company,2023-07-04 08:00:59,Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 88% of the company,121203115,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...",https://finnhub.io/api/news?id=5dc5d9057c66149b7d9d289d26755400db67a6f144c8d75620594d50ad0699e5
company,2023-07-03 21:00:00,FDA set to make decisions on several drug applications in July,121201283,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1925e8af5b0e388afa810d957d66661daad45f7da8507d45050e1f1aa780e025
company,2023-07-03 03:38:00,Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment,121184053,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b140ec74f9b394e868724a2a36680cf983c83b5fc7b10e5d338922b11b5d7bb7
company,2023-07-09 19:52:19,Biogen And Alzheimer's Disease: Too Early To Celebrate,121287631,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395741078/image_1395741078.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,The FDA granted full approval to Biogen and Eisaiâs anti-amyloid antibody drug Leqembi. Click here to read why BIIB stock is a Hold.,https://finnhub.io/api/news?id=338006d0c82a6ff415b176fdbedd8d196727865df9c9120318e5b20c5f6e8be4
company,2023-07-09 07:00:00,Goldman Sachs sees rays of hope in underperforming health sector,121283860,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=06213154d705d1d21de35238e56a94d433ff70c58826c039c5a22b1ac80ef9b3
company,2023-07-09 06:00:00,Eisai: Looking To Upside Targets Following Leqembi Full Approval,121283108,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1257405518/image_1257405518.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"FDA approved Eisai's Leqembi label last week, developed with Biogen, for treatment of adult patients with Alzheimer's Disease. Find out why ESALF stock is a Buy.",https://finnhub.io/api/news?id=464a18f17030596c5e4d6f28a3263a0c095c7c353746e035f6d6a4d20cdda6dc
company,2023-07-09 06:00:00,Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?,121283002,https://s.yimg.com/ny/api/res/1.2/d6TH0kUAlNWEUzSvW5YbtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/7b7f23bc74c4e5bc3b5473d41b096650,BIIB,Yahoo,"Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies.  Biogen turned its attention to Alzheimer's disease.  Along with partner Eisai, Biogen advanced Leqembi -- and the companies just reached a major milestone.",https://finnhub.io/api/news?id=47deaec2a40314739978a50976cd31d73c0d114171e926b825b3c4f4b0cd599e
company,2023-07-08 03:00:01,Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know,121272268,https://image.cnbcfm.com/api/v1/image/107198790-16771574832023-02-23t020744z_307853963_rc2f2w9v65fn_rtrmadp_0_health-alzheimers-medicare.jpeg?v=1688814001&w=1920&h=1080,BIIB,CNBC,"Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.",https://finnhub.io/api/news?id=2b6e50b2f11412cab38568d758e17ef61cfe42698a2d2a2cb420bfffdca6c8d6
company,2023-07-07 23:16:00,Needham Reaffirms Their Buy Rating on Biogen (BIIB),121275589,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cd45a25c9a11ba7a06abee5c43bb2fa15a6e29a3199f79982477c949319aa8a0
company,2023-07-07 21:01:00,Biogen/Eisai's Leqembi set to become Medicare's single highest drug spend,121275590,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e720dfee5fbcee3aa36d243c16bf7bca44c59b809f652fcd45d1c312f8a3146d
company,2023-07-07 16:22:14,"Biogen, Eisai stocks fall despite receiving FDA approval for Alzheimer's drug",121266441,https://s.yimg.com/ny/api/res/1.2/7A1S2DvIPGvYglBGt_FZVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-07/6411a750-1d03-11ee-9bd4-9f935ab2234f,BIIB,Yahoo,"Shares of pharmaceutical developers Biogen and Eisai are falling in the after-hours session. This comes following the companies received official FDA approval for their Alzheimer's treatment drug, Leqembi. Yahoo Finance Healthcare Reporter Anjalee Khemlani joins the Live show to detail the treatment plan.",https://finnhub.io/api/news?id=fe406db9ac0f159a3a60724ac4a8133b381c6d309d34fcd92e3449efda9132be
company,2023-07-07 16:21:00,"Rivian, Tesla, Alibaba, Levi Strauss, First Solar, and More Stock Market Movers",121265766,https://s.yimg.com/ny/api/res/1.2/0GSGUv276EZRtwfEgGMfFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a18653ce054d84e55fb14129ea1c917d,BIIB,Yahoo,"Analysts boosted their price targets on Rivian and Tesla, Alibaba stock rose after Chinese authorities fine Ant Group—a fintech company of which Alibaba owns a third—almost $1 billion, and Levi Strauss cut its fiscal-year outlook.",https://finnhub.io/api/news?id=80c1b5e0fc66a22031c706d33ce2c7bf016f3a7dafb3fc758153a8aa3dcd5b30
company,2023-07-07 16:02:57,Biogen Skids As Analysts Debate Uptake For Newly Approved Alzheimer's Drug,121266443,https://media.zenfs.com/en/ibd.com/c1625f1f8b75121675b6ada9243ba22d,BIIB,Yahoo,"Biogen stock skidded Friday after the Food and Drug Administration fully approved its Alzheimer's treatment, Leqembi.",https://finnhub.io/api/news?id=ccd703d254e953963c1fd9322286028c0bf06139f2a4fdc2f954074357443c76
company,2023-07-07 14:40:08,"New Alzheimer's drug from Biogen, Eisai gets government approval, but faces long road ahead",121261023,https://s.yimg.com/ny/api/res/1.2/sfARarzNQnWVLA.EireXuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03NDY-/https://s.yimg.com/os/creatr-uploaded-images/2023-07/4b5689d0-1cf2-11ee-ad9e-781ac1328be6,BIIB,Yahoo,Biogen and Eisai's second attempt at a new class of Alzheimer's treatments faces pressure despite regulatory and CMS greenlight.,https://finnhub.io/api/news?id=52529f6b459dbfe3c950edb6c7ff439745cd49fd5f6de076e4e08fbed3de7bd7
company,2023-07-07 13:17:00,Biogen’s Alzheimer’s Drug Rollout Could Be Slow,121266445,https://s.yimg.com/ny/api/res/1.2/2JWs50Y.4HK9rGbXK0_ZIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/975f0e857628cde6cb49a73437ae6246,BIIB,Yahoo,"Biogen has said it doesn't expect to clear a profit on Alzheimer's treatment Leqembi, which was approved by the FDA Thursday, until late 2024.",https://finnhub.io/api/news?id=17b6a44c2773022ca7a255489b6d98c9a844ac52d2655799638f866bdd6ea571
company,2023-07-07 13:14:11,"These Stocks Are Moving the Most Today: Rivian, Tesla, Alibaba, Levi Strauss, and More",121266446,https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e,BIIB,Yahoo,"Analysts boost their price targets on Rivian and Tesla, Alibaba stock rises after Chinese authorities fine Ant Group—a fintech company of which Alibaba owns a third—almost $1 billion, and Levi Strauss cuts its fiscal-year outlook.",https://finnhub.io/api/news?id=08c218f30205e10fd4c06d81cd0338532d6f24e2b36614367c476fdcf84ad6e3
company,2023-07-07 13:00:23,More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning,121266447,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"With U.S. approval of Eisai's and Biogen's Alzheimer's drug Leqembi secured, Wall Street analysts said they expect other region's health regulators to follow suit even if they share similar concerns about a potentially severe side effect.  Leqembi won standard approval from the U.S. Food and Drug Administration (FDA) on Thursday, but the FDA placed its strongest ""boxed"" safety warning on the drug's label, flagging the risk of potentially dangerous brain swelling in it and similar drugs.  Outside the United States, Eisai and Biogen are seeking approval for Leqembi, whose chemical name is lecanemab, in Japan, the European Union, China, Canada, Great Britain and South Korea.",https://finnhub.io/api/news?id=d06c5029cad744e9b74dd41ae375cbe28ac5aa40bea6766f2b374cd967920cba
company,2023-07-07 12:53:00,"Biogen Inc. stock falls Friday, underperforms market",121275908,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 3.48% to $275.07 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=f58afa78316089eb633e6048900ad48592f4ea8987a9ba56e89445ac3de6f9f1
company,2023-07-07 11:12:13,"Three-Stock Lunch: Meta, Biogen and Levi Strauss",121266011,https://image.cnbcfm.com/api/v1/image/107268445-16887566751688756670-30204298454-1080pnbcnews.jpg?v=1688757133&w=1920&h=1080,BIIB,CNBC,"Gina Sanchez, chief market strategist at Lido Advisors, joins ‘Power Lunch’ to discuss her thoughts on three stocks: Meta, Biogen and Levi Strauss.",https://finnhub.io/api/news?id=c02804008d8723cc30d0f235c2ade937f1b4da4ed1ef92170d17fe1635ab3f96
company,2023-07-07 09:59:37,Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024,121262568,https://image.cnbcfm.com/api/v1/image/107268376-1688751190899-gettyimages-1421992292-ALZHEIMERSDRUG.jpeg?v=1688752777&w=1920&h=1080,BIIB,CNBC,Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term. ,https://finnhub.io/api/news?id=13050360a8add27b815f984020706b771c302e413835f85454de6a7d12e84102
company,2023-07-07 09:57:51,Eisai-Biogen's Alzheimer's treatment drug receives FDA approval,121257452,https://s.yimg.com/ny/api/res/1.2/dslXLuUvoVg_YPeB7xWQ6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-07/3fbf81e0-1cce-11ee-bebf-7c0626c75fe2,BIIB,Yahoo,Shares of Biogen and Eisai are lower amid news of label updates to the FDA officially approved the Alzheimer's treatment drug Leqembi. Yahoo Finance Live breaks down the story.,https://finnhub.io/api/news?id=925b212730a4dd0510b55fbf2e42335ec3a34f358d60db80d249a3eb6cd3b47c
company,2023-07-07 09:51:00,"Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's",121255962,https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507,BIIB,Yahoo,"Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.",https://finnhub.io/api/news?id=1d6df911a5c96830a72ef2136ef3b1caa758f09030acc343d190edee89f08d77
company,2023-07-07 08:52:42,"Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more",121260388,https://image.cnbcfm.com/api/v1/image/107164505-1670837928683-gettyimages-1242039491-RIVIAN_AMAZON.jpeg?v=1688748762&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=3e263fb642bf0b84941e99980960a6958b7d1df3d7a1e4bbb374dbd626d4bbd5
company,2023-07-07 08:45:00,What You Missed On Wall Street This Morning,121258497,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4f7a4441dde4eabb528a39fcca874b453209980007ad2c06bb77f304dd3185b3
company,2023-07-07 08:27:00,"Stocks Rebound, Dollar Tumbles As June Jobs Data Eases Fed Hike Wagers: What's Driving Markets Friday?",121258418,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2ea9138fe609f5c42d76aa236d3f7b5f1c75260ddf85b29c55acae901673483
company,2023-07-07 08:27:00,Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts,121261196,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cd1111d27b643cde86fddea569fc183485d90905bfd5e681f2422b42e43c91ee
company,2023-07-07 08:13:08,Dow Jones Futures Fall With Jobs Report Due; Meta Leads 7 Resilient Stocks,121253506,https://media.zenfs.com/en/ibd.com/95f549dcc0e7b86294954e5cb8854f9c,BIIB,Yahoo,The jobs report looms with Treasury yields soaring. Meta is among stocks holding up as Threads had record first-day downloads.,https://finnhub.io/api/news?id=728f215dd376df204472c2fdf585e2979cbf986854d7784ef96fcd8c6944dc4a
company,2023-07-07 07:41:31,HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation,121252849,,BIIB,Fintel,,https://finnhub.io/api/news?id=a3f8882df770b25387afa5425293179297940ab95b57ddf4d2e5538145e04e13
company,2023-07-07 07:41:27,Needham Reiterates Biogen (BIIB) Buy Recommendation,121252850,,BIIB,Fintel,,https://finnhub.io/api/news?id=b000c3e681d33845cea8445211b46a958ee1003b03dbb1d824cf39a683863867
company,2023-07-07 07:40:00,"These Stocks Are Moving the Most Today: Rivian, Tesla, Levi Strauss, Paramount, and More",121252406,https://s.yimg.com/ny/api/res/1.2/0GSGUv276EZRtwfEgGMfFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a18653ce054d84e55fb14129ea1c917d,BIIB,Yahoo,"Analysts boost their price targets on Rivian and Tesla, Levi Strauss cuts its revenue outlook for the fiscal year, and Paramount shares are downgraded.",https://finnhub.io/api/news?id=ef3d381622f94980c91345cafc67fabbe10cc4e30ce0b135a2ffa1c4596a40e0
company,2023-07-07 07:24:23,"Why The Market Is Likely Wrong About Cassava Sciences, Again",121255385,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/660654876/image_660654876.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Cassava Sciences stock crashed in reaction to top-line data from a Phase 2 trial. Click here to find out why SAVA stock is rated a strong buy.,https://finnhub.io/api/news?id=20f8a590b347f81f5a6796db5c8720a3e7563c5ddf16f4a866234fbe3a4cfd2b
company,2023-07-07 06:49:00,Biogen’s big Alzheimer’s drug win fails to boost the stock as analysts see slow Leqembi rollout,121275910,https://images.mktw.net/im-448250/social,BIIB,MarketWatch,"Milestone Leqembi approval is “a mixed bag,” analysts say, given drug label's risk warnings and infusion-center bottlenecks.",https://finnhub.io/api/news?id=5e6dd235576402101d07254308160e171c6f9c065a5c7847dbdbce1bedaba9c1
company,2023-07-07 06:46:49,"Demand for Biogen's new Alzheimer's drug will surprise to the upside, says Piper Sandler analyst",121263420,https://image.cnbcfm.com/api/v1/image/107268215-16887398421688739839-30201545297-1080pnbcnews.jpg?v=1688741209&w=1920&h=1080,BIIB,CNBC,"Christopher Raymond, Piper Sandler, joins 'Squawk on the Street' to discuss the market's reaction to Biogen's FDA approval, what demand will look like for Biogen's new drug and the serious side effects of the Alzheimer's drug.",https://finnhub.io/api/news?id=2f135a664837c98b6029daac8dd6afb8108933cf4b7878ecbcbbf0931f2dd0e3
company,2023-07-07 06:20:40,Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?,121254634,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/97873871/image_97873871.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Read more here.",https://finnhub.io/api/news?id=f615f9ce52f12022474a6c406aad1473e726c74a3e0fdc9cbba2bc75ad775ed1
company,2023-07-07 06:07:00,FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today,121257086,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8fee38029aafed68fb45dc76b6e31693ad85c99c2b74d52a65bb6f0fba721094
company,2023-07-07 05:48:29,EISAI - FDA GRANTS TRADITIONAL APPROVAL FOR LEQEMBI FOR THE TREATMENT OF ALZHEIMER'S DISEASE,121254300,,BIIB,Finnhub,"TOKYO - Eisai Co., Ltd.  and Biogen Inc.  announced today that the U.S. Food and Drug Administration  has approved the supplemental Biologics License Application  supporting the traditional approval...",https://finnhub.io/api/news?id=61bcb31d45bdc8caea0aed69d5a2bd1ef4e839efdd7be8876f7ef3ef2285ee12
company,2023-07-07 05:30:00,Why Is Alibaba (BABA) Stock Up Today?,121257943,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3327d407f4bc8d31a3cd555889755facf90effd77ed49e0f99ff027c4b73d55d
company,2023-07-07 05:03:00,BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug,121257944,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9486d61712c1b147ee433f5c5a3284d19838295304e2a4541c26ae7e99900390
company,2023-07-07 04:22:33,"Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more",121254006,https://image.cnbcfm.com/api/v1/image/107221641-16807836042023-04-06t120233z_618975994_rc2hks9w7bbp_rtrmadp_0_levi-strauss-results.jpeg?v=1688732553&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in the premarket.,https://finnhub.io/api/news?id=b0173e200763761424c2d34dfd07f8f7e83506dce08c177ea9d5828cbe53ea9e
company,2023-07-07 04:02:00,What 29 Analyst Ratings Have To Say About Biogen,121261206,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=43ba116d793256dc1be2bdd371223941833c46592df503606fa7ccf6a9d73fb4
company,2023-07-07 03:29:00,Biogen’s stock slides premarket as analysts take mixed view of Alzheimer’s disease drug approval,121275913,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,"Biogen Inc.’s stock rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval...",https://finnhub.io/api/news?id=3c2f99dc39e57a289ff4c9494abba9fce233947433e85397117bb1f601b68456
company,2023-07-07 03:06:00,Jefferies Remains a Buy on Biogen (BIIB),121261207,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=61b928cca6e84cae023f04afd9bcccf2ac38832a61ff27e1eecb1c0deeef3ac3
company,2023-07-07 02:51:00,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Simulations Plus (SLP),121256757,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=afecb1180049e0f2b57a3f2d533148a00c467cdb16c6597bc1cea99d56f885d6
company,2023-07-07 02:22:00,Biogen shares little changed after resumption of trade,121261210,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=321224796ef06122e619d11d52060bfff61af7bcd20a12c064b8c1e2ffd35400
company,2023-07-07 02:08:00,"Label for Biogen's Leqembi not barrier to treatment, says William Blair",121261211,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=acb8b05e93f846376e4b8fca67e2878f211d76e121791ecc2982c2a4cf0d6535
company,2023-07-07 02:05:00,BMO Capital Sticks to Their Buy Rating for Biogen (BIIB),121261212,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ee748f4d9af7a16bba29a6f7627a3345779297d3741c7f2c1887be1eea0687df
company,2023-07-07 02:00:07,Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug,121252030,https://image.cnbcfm.com/api/v1/image/107268019-1688712816812-gettyimages-1246775562-JAPAN_EISAI.jpeg?v=1688724007&w=1920&h=1080,BIIB,CNBC,Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval.,https://finnhub.io/api/news?id=f93a6ff5580f9eb73493a65e2c6f017c44ce948ff3dc86443d4df98d532d08f3
company,2023-07-07 01:58:00,Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move,121256144,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e04a363b5085c6a101a6e9230800626bd9be0f8c9241e445c2011b7cc3ee6289
company,2023-07-07 01:46:00,"Label for Biogen's Leqembi generally as expected, says Mizuho",121261214,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=48f3b289af1b14f377707bda6028d0d7b2edb23725ea480d7ff5ba7f5127fe50
company,2023-07-07 01:43:00,"Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX)",121261215,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fdb463c0ae108ee947412cef95bfa983f75627aa9be9b6c0312b87c3489de7e5
company,2023-07-07 01:34:00,"Black box warning on Leqembi  'bit if a surprise,' says Piper Sandler",121261216,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f9f0efd9a34a6c09bd6589d11084d64b23d9a82059d90f3fdd57e91231faebc2
company,2023-07-07 01:26:00,H.C. Wainwright Remains a Buy on Biogen (BIIB),121261217,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=064948e3e960ca89e891e1da0b56e882b2cb86ea9aa910f7651958dbda6fbc1f
company,2023-07-07 01:15:00,"Biogen set up nicely to generate upside, says Canaccord",121261218,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3156317f6eebe283738c0aced1c90e543a34d5b36d0575993de4d9449681de17
company,2023-07-07 00:11:00,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), Biogen (BIIB) and Boston Scientific (BSX)",121259087,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ce5f1cc8288826df6332f907eaa8ca9944989ec39bf31d31db46c39d1e0d4d35
company,2023-07-06 23:55:00,Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call,121259891,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b3d2809787667624aa6831d411fa299cad5553093046e78f3a6f1f57b0c376d2
company,2023-07-06 23:11:00,What You Missed On Wall Street On Friday,121262628,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7b70a6887f8ce8684b5bdea60c5d0b994c9e56a10f2fb69fe3b8c5667459d52c
company,2023-07-06 22:54:00,"Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets",121262533,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fd023124bec89e0cfc50d8b6781dabdebe71cb045051bfaccf8d7f64f5475474
company,2023-07-06 22:27:00,"Biogen, Eisai’s Alzheimer’s Drug Scores Big With FDA’s Full Approval",121261221,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2fac00c6de95968c39d603cebd27ce392010303e406099cb1ff0e1067b661ef9
company,2023-07-06 22:24:00,"Noteworthy Friday Option Activity: BIIB, LLY, AVGO",121261222,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0e9013988cd6ab0580319d467cfff6d7b35119d382745a76f425e2aba4fd8463
company,2023-07-06 22:13:00,Notable Two Hundred Day Moving Average Cross - BIIB,121261223,,BIIB,Market News Video,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f457a3b8de9d44c9bd97b4aa0e8f6532835c82de0e34ca07d621ce32906d5409
company,2023-07-06 17:46:08,Dow Jones Futures: Jobs Report On Tap; Threads Off To Record Start As Elon Musk Rips 'Cheating',121244694,https://media.zenfs.com/en/ibd.com/95f549dcc0e7b86294954e5cb8854f9c,BIIB,Yahoo,"Stocks retreated as Treasury yields jumped on hot economic data ahead of Friday's jobs report. Meta's Threads had record first-day downloads as Elon Musk decried ""cheating.""",https://finnhub.io/api/news?id=3410ad040979d4a239fbb873cb06f4a32aca90e596468ae6b685f570bdeffe85
company,2023-07-06 21:02:00,"If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today",121261224,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=46e6c2567590d101164261cef8f096ee78af5d5e7f55ec0d4f40e1e728b4e961
company,2023-07-06 20:48:00,TOP NEWS: US FDA approves Biogen's Alzheimer's treatment Leqembi,121259295,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4c86bda7a6ba7448569df2c25013f4e508a29dd0535a866661b6178a53400ade
company,2023-07-06 20:25:05,"Trending : Eisai, Biogen's Alzheimer's Treatment Gets Full FDA Approval",121249105,,BIIB,Finnhub,"0408 GMT - Eisai is one of the most mentioned companies in the news over the past 12 hours, according to Factiva data, after its Alzheimer's drug Leqembi secured traditional approval from the U.S....",https://finnhub.io/api/news?id=c7b738a50e3f37ce068c4333ebfacfd40e7b2653a2fd8406c0508030c82d953f
company,2023-07-06 20:00:00,FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease,121248850,https://media.zenfs.com/en/prnewswire.com/d30e18f019eaafbb1208c128be7c03de,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and only approved treatment shown to reduce the r",https://finnhub.io/api/news?id=f8c3e603e3204f04b845ed499d8d851af688708c26d1d8944c1ae62e79954059
company,2023-07-06 18:57:00,"FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients",121247175,,BIIB,Yahoo,"A treatment for Alzheimer’s disease is on its way to many more patients across the U.S.  The Food and Drug Administration on Thursday granted full approval to Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry.  Most of the six million people in the U.S. with Alzheimer’s are eligible for Medicare.",https://finnhub.io/api/news?id=0fc16f8d36bb0a210d6af069b6d5867841aa3c0037253ec2787e2ab319570ee9
company,2023-07-06 18:10:00,FDA Gives Full Approval to Alzheimer’s Drug,121252409,https://s.yimg.com/ny/api/res/1.2/RajTmd_MIBwp6byza2RAIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/f021aeb3bd9a26e3cb375cb07b7ccbbc,BIIB,Yahoo,Federal approval for the treatment marks a major step forward in making the drug accessible. The Centers for Medicare and Medicaid Services said in January it would cover much of the cost.,https://finnhub.io/api/news?id=77d74ea176e96edcea0e141114e2c868a100b79a27d8743180181111505ef08a
company,2023-07-06 17:33:55,US regulators approve first drug to slow progression of Alzheimer’s,121248852,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The US Food and Drug Administration has approved the first Alzheimer’s drug to slow the progression of the neurodegenerative disease, paving the way for millions of American patients to access the treatment.  The regulator said on Thursday it would grant full approval to lecanemab, now known by the brand name Leqembi, which was developed by Japanese drugmaker Eisai and US biotech Biogen.  Teresa Buracchio, acting director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, said a confirmatory study had shown that Leqembi was a “safe and effective treatment” for patients with Alzheimer’s.",https://finnhub.io/api/news?id=adb5e80f4cbbe7eb969ec3bb88995a82fbdff7486a2a11a0ea2ad78da06be6eb
company,2023-07-06 17:13:10,"Levi Strauss & Co., Costco, Biogen: After-hours movers",121247184,https://s.yimg.com/ny/api/res/1.2/.r_pUN9rHKNAubSmLUgzmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2023-07/e5eb0220-1c41-11ee-bef7-96d45787b1a0,BIIB,Yahoo,Levi Strauss & Co. shares drop as the company slashes 2023 guidance. Costco reports a 0.4% increase in net sales for June. The FDA approves Eisai and Biogen's Alzheimer's drug Leqembi. Yahoo Finance Live's Seana Smith breaks down the after-hours movers.,https://finnhub.io/api/news?id=37992fc4f9da13bc42e4f973019d4a074ea33292be8e47a386f9acbe7f6c8c65
company,2023-07-06 17:03:57,Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted,121248854,https://media.zenfs.com/en/ibd.com/c1625f1f8b75121675b6ada9243ba22d,BIIB,Yahoo,"The FDA fully approved Biogen's Alzheimer's treatment, Leqembi, on Thursday. Biogen stock was halted in late trading.",https://finnhub.io/api/news?id=226b91e74ba6713214bc20c514245551aa616fb8a763e7abd5fcc2a64c2d64ea
company,2023-07-06 16:53:05,UPDATE 5-US FDA grants standard approval of Eisai/Biogen Alzheimer's drug,121248855,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Eisai and Biogen's Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer's treatment to achieve that goal, clearing the way for wider insurance coverage of the drug.  The FDA decision marks a new milestone for a fatal disease that has eluded drugmakers' efforts for decades.  Trial data showed that the treatment slows progression of the brain-wasting disease by 27% for patients in the earliest stages of Alzheimer's.",https://finnhub.io/api/news?id=11f74867508ecc8467fddebd00ce9687fb49a2e636fb2df6dc5eed75c201baaf
company,2023-07-06 16:46:01,Eisai-Biogen Alzheimer's drug gets standard approval in US,121248856,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen's Leqembi that has slowed cognitive decline in Alzheimer's patients at an early stage of the memory-robbing disease.  It is the first traditional approval for a drug shown to modify the course of Alzheimer's and is expected to increase use among U.S. patients who have had limited access to the treatment since it received accelerated FDA approval in January.,https://finnhub.io/api/news?id=0ca04ba99887607889397aeb3d8288a3fd62b783eeb29e8984f7497788b3cbaf
company,2023-07-06 16:00:00,FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease,121261226,,BIIB,GlobeNewswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ec52b77d1ec57456291d3dc784266efb78d469018a63bcf4df2eec208a216768
company,2023-07-06 14:42:16,"Many health systems are already ready for 'Leqembi' roll out, says Eisai CEO Ivan Cheung",121249817,https://image.cnbcfm.com/api/v1/image/107267870-16886815831688681580-30192422595-1080pnbcnews.jpg?v=1688683336&w=1920&h=1080,BIIB,CNBC,"Ivan Cheung, Eisai U.S. CEO, joins 'Fast Money' to discuss the FDA approving Biogen's 'Leqembi' Alzheimer's drug.",https://finnhub.io/api/news?id=2f7792ceb3422a25e5194cb9cbd2f50bd32093f6f7edb59cfda4b1d9e555020d
company,2023-07-06 13:20:42,Who is eligible for the new FDA-approved Alzheimer's drug?,121243891,,BIIB,Finnhub,"July 6 - The U.S. Food and Drug Administration on
Thursday granted standard approval to Eisai and
Biogen's Leqembi for patients with Alzheimer's disease.
             ...",https://finnhub.io/api/news?id=25f7c9934265c3333b655817c7fc1265422833b9a79e69dfc9582086075fe934
company,2023-07-06 13:06:37,"FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage",121252033,https://image.cnbcfm.com/api/v1/image/107267822-16886773471688677345-30191717771-1080pnbcnews.jpg?v=1688677597&w=1920&h=1080,BIIB,CNBC,'Closing Bell Overtime' breaks latest from the FDA concerning Biogen's Alzheimer's drug.,https://finnhub.io/api/news?id=8b6b4bfe116102df853a66ffac74df9422e47bfb4c9d4d280e223b35afedb57e
company,2023-07-06 12:55:00,FDA approves Biogen and Eisai Alzheimer’s treatment Leqembi,121243295,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,"The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen and Eisai Co. Ltd. Alzheimer’s treatment Leqembi, a step that secures...",https://finnhub.io/api/news?id=8043e2349392a94de535351d6ef6605cc40f1cf672ead16da08cd84c73db1077
company,2023-07-06 12:53:05,US FDA grants standard approval of Eisai/Biogen Alzheimer's drug,121242931,,BIIB,Finnhub,"The U.S. Food and Drug
Administration on Thursday granted standard approval to Eisai
and Biogen's Leqembi for patients with
Alzheimer's disease, clearing the way for wider insurance
coverage of the...",https://finnhub.io/api/news?id=ccc2df2b02d6050a661571e07edd019bde7e2aca0ef33c6df4d44e334adcfcb6
company,2023-07-06 12:53:00,Biogen Inc. stock outperforms market despite losses on the day,121275915,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. sank 0.31% to $284.99 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=a6eb8306a0ac19664168cb3198cf1a048932b1b829a87991fd40dedec0675e78
company,2023-07-06 12:44:19,"FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage",121249818,https://image.cnbcfm.com/api/v1/image/107198777-16771566112023-01-20t224759z_376389922_rc2a2w9juz4s_rtrmadp_0_eisai-biogen-alzheimers-fda.jpeg?v=1688676259&w=1920&h=1080,BIIB,CNBC,"Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.",https://finnhub.io/api/news?id=dd90117565fd003ebdd0efdb738a6a1e7d574dab027e30d13e72fff2243e2aef
company,2023-07-06 10:27:57,Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment,121235495,,BIIB,Yahoo,"The FDA could fully approve Biogen's Alzheimer's treatment, Leqembi, on Thursday. The decision could give a lift to Biogen stock.",https://finnhub.io/api/news?id=8ffc8415e59c6f4f8e4d6a208fe232be5f35122c01ce9b7741af78994edd6bba
company,2023-07-06 05:31:03,U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map,121230596,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know.,https://finnhub.io/api/news?id=d1c977c4217647aa1e4024d94a38bb2e25fd80e3d508cf8b838976a6fff7db6f
company,2023-07-06 03:34:00,"Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval",121261230,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=329ea20f83efa0041593567cde3f9ec7f5075a46d20e2f6f4de43b1d796b17b1
company,2023-07-06 03:06:00,Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB),121261231,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b6ceb0fbfe789ab8ca17d47a4378beb7858d04d5b64201e1c6fd96c6a7b5aeb5
company,2023-07-06 01:32:00,Quanterix launches LucentAD biomarker test for early Alzheimer's disease,121261232,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=928f8ac3fb106653045c9cb45a2fdb38c853fe29d1afe5a209a2a0fcbf7b7403
company,2023-07-06 00:54:00,"FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverage",121261234,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=499c57c9793c1b1f0f4d72ef973aaf94c6d41ab4e55476e6ab3bcc8893dc03e8
company,2023-07-06 00:16:00,"Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi",121261236,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=32375156ea7d605b0e1095b5006ea6f50b2594f792926c7b7c9e6cb9315bec7b
company,2023-07-05 23:45:00,FDA converts Biogen Alzheimer's treatment to full approval,121261240,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=70f3a564fbb6a7a019667c10ebf8661a151a1c4da8526a6deb36c2114e89f8da
company,2023-07-05 23:44:00,3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True,121261241,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b255918b1b7eaa8895bd377d512d2040b0a1cada62a670b4a9b651cc1a19c7bb
company,2023-07-05 23:23:00,"Biogen trading halted, news pending",121261242,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=51b61bbbc36ab11545fad6a68e22dd660506761501d49809663933435f69d417
company,2023-07-13 12:55:00,"Biogen Inc. stock rises Thursday, still underperforms market",121432096,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.13% higher to $277.97 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=d66c917d3b240ba628be74ba4d3ac537b51351ee34a51b18a6c3229ae7a1e76c
company,2023-07-13 09:22:00,"Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment",121361118,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,BIIB,Yahoo,Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.,https://finnhub.io/api/news?id=10c319e20ddba5889e70c0ea030594e892d40e8261b29f37872b11b08bd4e1fe
company,2023-07-13 08:30:00,7 Stocks That AI Says Will Make You a Millionaire by 2025,121365324,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6cf87dce3938e6993705c869d1d9d1298b4e191a35d2238fa2650df49254a2be
company,2023-07-13 08:15:00,Why Isn't Biogen Stock Soaring After This Major FDA Approval?,121367526,,BIIB,Yahoo,Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi.  Here's why investors might still be hesitant about buying the stock despite the approval.  The FDA previously approved Leqembi on an accelerated basis.,https://finnhub.io/api/news?id=f94b7939b61fddf5b3702579766571eba3b6224f3861aa84f48df8e6ca832f84
company,2023-07-13 04:41:00,"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Silence Therapeutics (SLN) and Biogen (BIIB)",121362170,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1c8c0192e3a236ff6fe08c697d4f8673afbc70622b9f94b47240a20d841442ea
company,2023-07-13 04:03:58,Acumen Pharmaceuticals: A Risky Bet Through Upcoming Data Readout,121359295,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/648706624/image_648706624.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Acumen will present Phase 1 topline data on its Alzheimerâs therapeutic candidate, ACU193, at the annual AAIC. Check out our recommendation on ABOS stock.",https://finnhub.io/api/news?id=d555dc30b9a68720b85210e33e5318b96913e9be7e317a6cec0687deff9d51f1
company,2023-07-12 17:50:18,Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know,121355715,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $277.41, moving -0.87% from the previous trading session.",https://finnhub.io/api/news?id=3bcce8ae394074ccbcab3d7188daa606e55345879be19ff1a562464c8f6c447d
company,2023-07-12 12:54:00,Biogen Inc. stock underperforms Wednesday when compared to competitors,121347434,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. sank 0.79% to $277.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=15f22061ee392ab9c472dc86f226a0c60205f8687a97a3e82ffbe6cf77004e1f
company,2023-07-12 12:10:12,Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again,121342790,https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462,BIIB,Yahoo,Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.,https://finnhub.io/api/news?id=83b2b2375bff0e7de7c1484e208d81f62a290ce552355039e8062615d6681242
company,2023-07-12 07:21:00,P/E Ratio Insights for Biogen,121338145,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=65ab64e3afadd589246ec2759a5e96fc74978f84fddbffcd617979e3202a2ca6
company,2023-07-12 07:00:37,Biogen Inc. (NASDAQ:BIIB) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?,121331026,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"With its stock down 11% over the past month, it is easy to disregard Biogen (NASDAQ:BIIB). But if you pay close...",https://finnhub.io/api/news?id=cd4e40ff8a18827986d493ddff04919a48c8da4a9c7fe52fb3d5af6af0a494e9
company,2023-07-11 13:23:24,"We've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen Richter",121322451,https://image.cnbcfm.com/api/v1/image/107269937-16891094661689109462-30260687636-1080pnbcnews.jpg?v=1689110604&w=1920&h=1080,BIIB,CNBC,"Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space.",https://finnhub.io/api/news?id=6187a319c9c49cdd3e6f3210049a94dadd212b6af2cdb07a01616feeb197b718
company,2023-07-11 12:53:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,121347435,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. dropped 0.62% to $279.84 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=af633a5644837035940036d7da6b42d09f6bf1575bf179a61a24842ec1341a2b
company,2023-07-11 11:21:22,RBC Capital Maintains Biogen (BIIB) Outperform Recommendation,121310337,,BIIB,Fintel,,https://finnhub.io/api/news?id=9d00e151864556177d54350732c264034852a1286d0f1b2eb71f71bac788a26a
company,2023-07-11 11:21:22,Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation,121310336,,BIIB,Fintel,,https://finnhub.io/api/news?id=bfd828e0e4a5e8fae9df83d846c919900d731c82dc5fcb7ce3be8cf6db76feba
company,2023-07-11 09:40:00,Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study,121310162,https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5,BIIB,Yahoo,"Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).",https://finnhub.io/api/news?id=96128d5a605f03256795873e7870d84452c28c274a07d89050d4186c7bc31988
company,2023-07-11 03:22:00,Biogen price target raised to $341 from $332 at RBC Capital,121336002,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a6db76fc6e9b3d440521e1196d8ab4323dc70ce1cb4ad3658c8d04002739adc3
company,2023-07-11 03:17:00,ADC Therapeutics falls after pausing mid-stage trial for lead asset,121313306,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a522effc86830061b766526acdf8fb991adbc07e9f041aed05912f4130150e2b
company,2023-07-10 15:52:00,Why Biotech Stocks Keep Falling on Good News,121298460,,BIIB,Yahoo,"It’s a sign that investors are increasingly wary of the biopharma sector.  It happened in late June, when  Sarepta Therapeutics  (ticker: SRPT) dropped 16% over the course of a few days after the FDA approved its new gene therapy for Duchenne muscular dystrophy.  On June 29, the FDA approved another gene therapy, this one a hemophilia A treatment from  BioMarin Pharmaceutical  (BMRN); BioMarin shares fell 3.6% that day and 2.5% the following day.",https://finnhub.io/api/news?id=7ec261ad506513b7884b3e8196760ed7b10c7c92f75eb85fc0369e39df98bc65
company,2023-07-10 12:54:00,Biogen Inc. stock outperforms market on strong trading day,121347436,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 2.37% to $281.58 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=9ca1568a41998095bc039a2595f6876f3fb0deac2bd0305c4501950593dfec47
company,2023-07-10 12:12:06,"BIOGEN : TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS JULY 25, 2023",121298463,,BIIB,Finnhub,"Cambridge, Mass.- Biogen Inc.  today announced it will report second quarter 2023 financial results Tuesday, July 25, 2023, before the financial markets open.
      
      
       ...",https://finnhub.io/api/news?id=7fba7b38a79854be1b849e6478eeb8c48e7e56ea68882d6ebca6823b9e5bd780
company,2023-07-10 11:22:00,Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug,121296652,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.,https://finnhub.io/api/news?id=10864b1eec7a620346828de8d13ec1ccae307b48d6289bd3c38a6977f90712c5
company,2023-07-10 04:58:00,"Biogen shares ‘an under-owned turnaround story,’ Jefferies analysts say",121347442,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,"Shares of Biogen Inc. which last week received a milestone U.S. Food and Drug Administration approval for Alzheimer’s treatment Leqembi, “remain an...",https://finnhub.io/api/news?id=ea3eb7e1c99950aa909b3a7076a3595397cd51d605e96011bbb90d3be65b03e4
company,2023-07-10 04:05:00,"Monday’s Top Analyst Upgrades and Downgrades: Biogen, Bloom Energy, ConocoPhillips, DraftKings, Humana, IBM, JP Morgan Chase, Newmont, Playtika, Williams-Sonoma and More",121292616,,BIIB,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d287cb38eee0a9af0d9580547ddc63c68c4f68f06ba93830de06eb9cdc6e72a2
company,2023-07-10 03:21:00,"Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Galapagos (GLPG) and Biogen (BIIB)",121298850,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6e998c46d654508d9e4f5d7c5564f925a3f424f9c0672837ab997c69ee21dd8e
company,2023-07-10 01:44:00,Icahn Enterprises shares jump on loan agreement and other stocks on the move,121345331,https://images.mktw.net/im-280130/social,BIIB,MarketWatch,"Icahn Enterprises, Alibaba and Northern Trust are stocks on the move.",https://finnhub.io/api/news?id=ff8bce0d090c771b576520c459fe4f5137a53d7804f87e55439bfcbedf640b6d
company,2023-07-09 22:11:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,121293805,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d62138fa31367578bc7903b4fef6f579ba9ee25c688e8994ec8f3c6f83d0c24d
company,2023-07-17 12:56:00,Biogen Inc. stock outperforms competitors despite losses on the day,121511057,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slumped 0.19% to $278.40 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=4a6dbb1675f3eb8c65a7788137a7013752fd5e9746a14138fc82facd4486b71f
company,2023-07-17 09:45:00,Should You Buy the Dip With Biogen Stock Right Now?,121427944,,BIIB,Yahoo,"With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling biotech stock?  On the positive side, the company's new Alzheimer's drug Leqembi secured full approval from the Food and Drug Administration (FDA) on July 6.  For people with early-stage Alzheimer's disease, Leqembi slows the rate of progression by around 27%, such that their cognitive capabilities remain relatively more intact for longer than they would otherwise.",https://finnhub.io/api/news?id=02b250531389c145d48d4d56a3a7df4c0d72f5c6a7c220a0679cabc2c820c0f3
company,2023-07-17 08:27:00,Eli Lilly full phase 3 data confirms benefit of Alzheimer's asset donanemab,121455317,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c07bcbee75733bfb8cdea2c4c647490cef7f32f406c38213372354437f767358
company,2023-07-17 06:15:03,Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year,121425649,https://image.cnbcfm.com/api/v1/image/107261723-1687535077484-gettyimages-1302141489-cailly03.jpeg?v=1689603303&w=1920&h=1080,BIIB,CNBC,"Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.",https://finnhub.io/api/news?id=e2a183704544e4c55df9f77dced0305a6e49a3564c01ebae9bd2fc8867b68cec
company,2023-07-17 05:02:00,Acumen stock rallies over 60% on Alzheimer's drug data,121436374,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fd2f37750eabc59bc055b4027b63b78f5125f260962c0898a81fa2246f598d80
company,2023-07-16 09:00:24,Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?,121414477,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",https://finnhub.io/api/news?id=7d2f0f61ad4f0efaa47781fd6e8e8914f05defe91ac8c267018f23f78a3cdc3b
company,2023-07-16 07:15:00,These 2 Numbers Should Scare Every Biogen Shareholder,121414478,,BIIB,Yahoo,"Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why.  As a pharma company, Biogen needs to consistently use its research and development (R&D) capabilities to discover, test, and commercialize new medicines over time.  For the business to grow, and for shareholders to earn a return, it needs to make more money from selling its medicines than it costs to develop them.",https://finnhub.io/api/news?id=640cb8d2982ca5a7265a8b11492718b013486cc2bbe30b32efd7b37361dc402e
company,2023-07-16 07:01:00,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",121414757,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c2c9a2ea7de3c0791fb606978f40b1cc363b868fac7a37d1f4210a3e4e826e6f
company,2023-07-14 12:54:00,Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains,121432095,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.35% higher to $278.93 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",https://finnhub.io/api/news?id=ac252939d359948515af59cb992172c8ddb0e2070a9c7d33207f91a7ce92aeab
company,2023-07-21 07:25:00,Biogen Unusual Options Activity,121551300,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1ef7a5bb03e7469b37e186c0d0aadef8ab47ce438f416dfdfec299f9312a2adb
company,2023-07-20 23:56:00,Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains,121551301,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=619ad24c9da978c3be36406bc82ea415396a1503a365ed333cab74e7d6041429
company,2023-07-20 23:30:00,"Earnings week ahead: Microsoft, Google, Meta, Boeing, Coca-Cola and more",121537391,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7e8fcb1fce5d0c30b373e9d0ca9b2eada7522ac2c7e32987e9e10b92f3fcd943
company,2023-07-20 22:59:00,"Eisai hopes to start new Alzheimer's drug trials in 2024, Nikkei Asia says",121551303,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f9a7e30b31fab5de17ebb56683116b3b1dfe686434ad2d2782dc24f3fed66c3c
company,2023-07-20 12:59:40,"Final Trades: Charles Schwab, Biogen & more",121511402,https://image.cnbcfm.com/api/v1/image/107274402-16898743085ED3-FMHR-FINAL-072023.jpg?v=1689886780&w=1920&h=1080,BIIB,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=2198b10afdf8cd10b55a1ed73f01e807cfbef9135d08288e076ed24351f3cf59
company,2023-07-20 12:55:00,"Biogen Inc. stock falls Thursday, underperforms market",121511041,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.79% to $274.70 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=0730a0d263a28ea81c40d60a2107a7cdeb352f9b51508c5a99f2e08cf9838e6e
company,2023-07-20 07:00:29,Are Investors Undervaluing Biogen Inc. (NASDAQ:BIIB) By 31%?,121499200,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Key Insights Using the 2 Stage Free Cash Flow to Equity, Biogen fair value estimate is US$402 Biogen is estimated to be...",https://finnhub.io/api/news?id=b971d46e830893161180819952c4e3a49f203239504ca9d7c41165aab2359aac
company,2023-07-20 06:56:00,Robert W. Baird Sticks to Their Buy Rating for Biogen (BIIB),121500793,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=815cf5dceb4b15adbb285294629dd5b580e580b4aab167061399de642ebf449b
company,2023-07-20 05:32:00,(BIIB) - Analyzing Biogen's Short Interest,121500795,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b13e67b9ef05c412d891908c73db3682ff8af2f4616884d6504946c3101f8c64
company,2023-07-20 03:39:32,EISAI PRESENTS LATEST ANALYSIS OF LECANEMAB'S EFFECT ON BIOMARKER CHANGES AND SUBCUTANEOUS DOSING AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2023,121493225,,BIIB,Finnhub,"TOKYO - Eisai Co., Ltd. and Biogen Inc.  announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb  treatment showed reductions in...",https://finnhub.io/api/news?id=238687443d07cc1d8d45cd0bf5e9bf5fd61bdcbeae69c16ee63f3c65810b851f
company,2023-07-19 19:30:00,Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023,121486556,https://media.zenfs.com/en/prnewswire.com/8fbe328e0f2d5337d2839c8345101b15,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI®) treatment showed reductions in amyloid-beta (Aβ) pathology and downstream biomarker changes. This analysis, and the latest findings on the lecanemab",https://finnhub.io/api/news?id=4da8c54d2325120625899bee009ccb9dc67b66421a4cfe9a112a0e08c14bcf03
company,2023-07-19 15:30:00,Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023,121500799,,BIIB,GlobeNewswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=20aa3989c37110dd34f3e3775b60a70b52c81a58d4bad60408fa8beb5facdb62
company,2023-07-19 12:54:00,Biogen Inc. stock outperforms competitors on strong trading day,121511043,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.26% higher to $276.89 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=e66bccae6d9a4625e67af1eb21b79527ae2864a327ac02cf39792a81c25f509c
company,2023-07-19 10:56:00,Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect,121477491,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,"Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.",https://finnhub.io/api/news?id=f314d35478353b95afc933c932c43ade8c8b1dbea78a320af2058b163c7ccd28
company,2023-07-19 10:01:46,GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release,121471915,https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1,BIIB,Yahoo,Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=3456fb1d719391b87e200eb162a128c814a6bc81d4747b6972d27080e897e618
company,2023-07-19 08:30:00,Is Biogen Stock a Buy Now?,121477495,,BIIB,Yahoo,"Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine.  On July 6, the company announced that along with its longtime partner, Japan-based Esai, it had earned traditional approval for Leqembi, a therapy that targets patients with early AD.  Leqembi had previously earned accelerated approval in January.",https://finnhub.io/api/news?id=85e521a699a3fc20aad42a85b979e758e283bd07932d3863691626db3cd545eb
company,2023-07-19 05:30:00,Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030,121470639,,BIIB,Yahoo,"When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps.",https://finnhub.io/api/news?id=ec495598a4aafba5a7e293ef1c34e16a7fba831996b13e3134ac354106e3db49
company,2023-07-19 03:15:00,"At-home Alzheimer’s testing is on the horizon, researchers say",121472727,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7166f90dbc61859d86de7afe16b23bf26e76f8d26077188e9ecfb822f0978937
company,2023-07-18 17:50:20,Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know,121462946,https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2,BIIB,Yahoo,"In the latest trading session, Biogen Inc. (BIIB) closed at $276.17, marking a -0.8% move from the previous day.",https://finnhub.io/api/news?id=734da73bc842a29cf329a2cea4d59f68c3beec8649debc466d7fd50618876cec
company,2023-07-18 17:36:00,"The Fight Against Alzheimer’s Goes Beyond Plaque. Tangles Are a Target, Too.",121467295,https://s.yimg.com/ny/api/res/1.2/YNaPhP9GtQaf35UByBQlOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/6ea3fcadd204a0c76975e6b00803fd87,BIIB,Yahoo,Several companies at an Amsterdam conference reported progress in going after tau protein tangles. Prothena probably has the most at stake.,https://finnhub.io/api/news?id=6c0c2f726aa8f4837aa21da83c00bbd570169811888dd7e3f021714ef0092d09
company,2023-07-18 17:36:00,The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too.,121462947,,BIIB,Yahoo,Several companies at an Amsterdam conference reported progress in going after tau protein tangles. Prothena probably has the most at stake.,https://finnhub.io/api/news?id=ffe3fd73fb2f60cb8df36caa0d3d048c5c9fb101d4c7de5ddcfd23e45a81e2b1
company,2023-07-18 13:11:20,IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout,121455391,,BIIB,Yahoo,"Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears ""very competitive"" with Biogen's.",https://finnhub.io/api/news?id=2cd56d23c230f9638674acca06ffe51d5fb441783107fb72057e904ec30d01ef
company,2023-07-18 14:13:00,Alzheimer’s Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off.,121455390,,BIIB,Yahoo,Two similar Alzheimer’s drugs are likely to be on the market and accessible for Medicare patients sometime in 2024.,https://finnhub.io/api/news?id=55e21fc0c76c7c51adaa652f93e16f92ac52bae1d4a5c7acc06ceae818ce6672
company,2023-07-18 12:55:00,"Biogen Inc. stock falls Tuesday, underperforms market",121511047,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.80% to $276.17 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=cf70f956acbdd9793e3e62defe6de5560c979969038247ea7ebf231c4bc1b2c6
company,2023-07-18 11:30:00,Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression,121455397,https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523,BIIB,Yahoo,Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.,https://finnhub.io/api/news?id=2bade1ac20dea371171937a86d59b0265dcf843d9a88bab1a71350e9becdc881
company,2023-07-18 10:22:18,New Alzheimer's drug success 'was built on failures': Eisai exec,121447501,https://s.yimg.com/ny/api/res/1.2/1RLmOzMBGmGNGZsmbf3ulA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NjA-/https://s.yimg.com/os/creatr-uploaded-images/2023-02/e604d6f0-ad4c-11ed-87fa-ddb0e7765c7a,BIIB,Yahoo,Eisai just reached the finish line with its long-fought battle to gain Medicare approval for Alzheimer's drug Leqembi. But the company says more work remains.,https://finnhub.io/api/news?id=7fc6f07b6131988859cd4bb47ca2919b0eec569bd18ce62c015e86e63f1dcbce
company,2023-07-18 10:01:22,Earnings Preview: Biogen Inc. (BIIB) Q2 Earnings Expected to Decline,121462951,https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9,BIIB,Yahoo,Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=1290e5e0f5d530219c8b6343a287b697ec29d36ab0474b9afdc175edba3c5942
company,2023-07-18 06:29:00,Sanofi expands collaboration with Scribe on CRISPR genome editing,121455307,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6f6a86c7d772373d0b52e2002aecfbb887f5a8b433c065f7d95dc1f7689d0acf
company,2023-07-18 04:39:00,"Biogen, Eli Lilly likely to split the Alzheimer’s drug market, analysts say",121511051,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Eli Lilly and Co. and Biogen Inc. are likely to reach an “equitable split” of the Alzheimer’s drug market after Lilly on Monday released more details on its...,https://finnhub.io/api/news?id=f78aa355cd06ed4e518d4ad861e6df472af75bb5a0a88107cbf40e3d8873e672
company,2023-07-18 04:34:40,"Acumen: A First In Targeting, May Lead To Improvement For Early AD Patients",121444712,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1543173516/image_1543173516.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Acumen reported positive topline results from its phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early Alzheimer's Disease. Read more here.",https://finnhub.io/api/news?id=ef1a9522a8bef4c6c6c4e854b1bc2146202837601293524d34ca062065d77c83
company,2023-07-18 03:17:06,5 things to know before the stock market opens Tuesday,121443593,https://image.cnbcfm.com/api/v1/image/107270407-16891749352023-07-12t151110z_248228036_rc2p12a3uibf_rtrmadp_0_usa-stocks.jpeg?v=1689679026&w=1920&h=1080,BIIB,CNBC,Here are the most important news items that investors need to start their trading day.,https://finnhub.io/api/news?id=383a16477151847839b255c735305de5627689c69e036bcf04c70eecdb26ef76
company,2023-07-18 02:28:00,"The Tech Stock Rally Has Reached a Critical Moment. Watch Tesla, Netflix Earnings.",121511054,https://images.barrons.com/im-818976/social,BIIB,MarketWatch,"AT&T hit by report about lead on cables, Eli Lilly’s Alzheimer’s drug shows promise in latest trial, and other news to start your day.",https://finnhub.io/api/news?id=b04f2eeb8e66010386f1bbb6cb3f2c288d81f58c2e5cc688179cb31a246f39b0
company,2023-07-18 02:01:00,Biogen price target lowered to $357 from $380 at BMO Capital,121457022,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d40b65a2d0820911733d16fd36617c8d1c6b88ca356c7ee7a71e815efeb75a86
company,2023-07-18 00:22:00,Eli Lilly’s (NYSE:LLY) Alzheimer’s Drug Inches Closer to FDA Approval,121455312,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1c90607c952d099cf446e0af6685b12b85053798237fad9173b006ee359ff289
company,2023-07-25 19:27:34,Stifel Maintains Biogen (BIIB) Buy Recommendation,121591782,,BIIB,Fintel,,https://finnhub.io/api/news?id=f8c506420783e970817766bfe6ea53e22d4c1c6ae570977065ecf352b369f047
company,2023-07-25 19:27:34,Needham Reiterates Biogen (BIIB) Buy Recommendation,121591781,,BIIB,Fintel,,https://finnhub.io/api/news?id=4de55042d3bcf266945661e4e87e6c93e81b1949349aaa03d10e51d224200b23
company,2023-07-25 18:09:46,Why Biogen Stock Got Sick Today,121591166,https://s.yimg.com/ny/api/res/1.2/90vM1EYA_M.JaorwgxMDGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDE-/https://media.zenfs.com/en/motleyfool.com/04b1c19622439a5fc56c62a4d98398ea,BIIB,Yahoo,"While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light.",https://finnhub.io/api/news?id=692381730a42af8d9e984c7c030a5c09eb9890a5baac3410dec0a171e3c12c27
company,2023-07-25 10:48:51,Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates,121587955,https://media.zenfs.com/en/ibd.com/e8881d1e842d2200879a5248d851c75b,BIIB,Yahoo,"Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.",https://finnhub.io/api/news?id=15a06f402196e5e780b57cb9af232edafc92b1755b84dc0d2c2bd7251cee222c
company,2023-07-25 15:30:45,Biogen (BIIB) Q2 2023 Earnings Call Transcript,121591171,https://media.zenfs.com/en/motleyfool.com/ce68ea0b0cd2631701fe87e542e7a165,BIIB,Yahoo,"BIIB earnings call for the period ending June 30, 2023.",https://finnhub.io/api/news?id=b09bc826879f190b48e4fc6f79c3052c0bcd3de49344e21f2e5307f84e57f91c
company,2023-07-25 13:20:00,Biogen to Lay Off Roughly 11% of Workforce to Focus on Big-Return Drugs,121591173,https://s.yimg.com/ny/api/res/1.2/_0kLGFMTth_hfEIWP8_gNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/37569f7d9309e2532da72f6c0e93d3c6,BIIB,Yahoo,The biotech company cited the launch of Alzheimer’s drug Leqembi as part of its new focus on big-return products.,https://finnhub.io/api/news?id=afaf3931bcb779a4e9a8e7f9226435070e541790d2f905a742fa2ee39e9cfb6b
company,2023-07-25 12:31:00,Biogen Stock Drops Despite News of Layoffs as Company Rolls Out Alzheimer’s Drug,121591174,https://s.yimg.com/ny/api/res/1.2/esxtbAnhATnBm1bnj7S89g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/6fd0f18acb169a40759285723d99c1c2,BIIB,Yahoo,"The company is reducing its staff by about 11%, in a cost-cutting effort it expects it will save $1 billion a year in gross operating expenses.",https://finnhub.io/api/news?id=39d790856f90ad461519bce03c8618f14743c385f7f5b497f4e84e92dc576a69
company,2023-07-25 11:56:39,"Biogen to cut 1,000 jobs as focus turns to Alzheimer's drug Leqembi launch",121591177,https://media.zenfs.com/en/fox_business_text_367/858b7de755d191a1c62d854937e472aa,BIIB,Yahoo,"Biogen said on Tuesday it expects to eliminate roughly 1,000 positions in the U.S. to save money ahead of launching a new drug to treat Alzheimer's disease.",https://finnhub.io/api/news?id=7d78416e901a9da7bd3b6d42a11815062be78ee4d52aa6b3d87ba466d98a88f7
company,2023-07-25 11:41:00,A Surprising Beneficiary of New Alzheimer’s Drugs: GE HealthCare,121587953,https://s.yimg.com/ny/api/res/1.2/xQg.HL1FJvHDEKsi29QgAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/94aec0d150f19e43eddb000ce76f0bcd,BIIB,Yahoo,"With a new drug for Alzheimer’s disease set to unleash a massive new market, attention is now shifting to the imaging needs likely to be created by this patient group.  For patients to be put on Eisai and  Biogen  Leqembi, they will likely need to undergo at least one PET scan to confirm they have the disease and then repeated MRI scans to assess them for safety.  While those requirements might create a bottleneck for the drugmakers given the limited number of PET machines in the country, they represent a growth opportunity for developers of imaging equipment such as  GE HealthCare Siemens Healthineers  and Philips.",https://finnhub.io/api/news?id=0868633fd144f3da87d681a064a5a6cba782ec88a7018dc4e34e8e2d75b1f0e7
company,2023-07-25 11:21:00,"Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts",121591183,https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093,BIIB,Yahoo,Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.,https://finnhub.io/api/news?id=09536e097f8a8f317d786ce26772f66af58edf17f7e5c32cd0ae8b1cb34b59ff
company,2023-07-25 10:01:41,"Biogen to cut another 1,000 jobs in 'complete redesign'",121591185,https://s.yimg.com/ny/api/res/1.2/0ZrROIzuSD7Kfe8lQdeSwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xODAw/https://media.zenfs.com/en/bizjournals.com/145530a39258f1a20d3f0eb121f50f00,BIIB,Yahoo,"Biogen Inc. is making sweeping cuts again as it works to offset declining revenue due to competition from generic drugs.  The Cambridge drugmaker (Nasdaq: BIIB) said in its second-quarter earnings report Tuesday morning that it would cut another 1,000 jobs, part of an overhaul that also includes the elimination of some early-stage R&D programs.  Biogen shares were down 2.4% at market close, giving the company a market capitalization of $39.1 billion.",https://finnhub.io/api/news?id=b33dcbb27d07eff68e70ebb31c4a197a0ab1684e92e154ccc85d596adc0bf305
company,2023-07-25 09:30:27,"Compared to Estimates, Biogen Inc. (BIIB) Q2 Earnings: A Look at Key Metrics",121591188,https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619,BIIB,Yahoo,"While the top- and bottom-line numbers for Biogen Inc. (BIIB) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",https://finnhub.io/api/news?id=53b3c9f61ad3fbfc4edc75a7338157a44d133e5493e352f95d4b8ef67eea79ea
company,2023-07-25 08:54:00,"US Stocks Climb Before Big Tech Earnings, Fed Meeting As China Stimulus Boosts Excitement: What's Driving Markets Tuesday?",121588485,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=70efe343800377d10b646b4c9d15fa6fcaf4f6ad8394689a2cebfe2bb4263074
company,2023-07-25 03:21:23,"GE, General Motors, Verizon rise premarket; Goldman Sachs, Dow fall",121584604,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Investing.com -- U.S. futures edged higher Tuesday, as investors digest a deluge of corporate earnings ahead of a key Federal Reserve meeting.",https://finnhub.io/api/news?id=a530468322ccbb2e936673bfc25aec5366ee9d338cfe2b714078c482d5f1ffc7
company,2023-07-25 08:43:10,Biogen Inc. (BIIB) Q2 2023 Earnings Call Transcript,121586669,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BIIB,SeekingAlpha,"Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q2 2023 Earnings Conference Call July 25, 2023 8:00 AM ETCompany ParticipantsChuck Triano - Head of Investor RelationsChristopher Viehbacher - President and...",https://finnhub.io/api/news?id=1a8503921b5d68e9fc73dfdd834f7a1f5e371a63cd7cf66d051f9288eb2b239b
company,2023-07-25 08:25:07,Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates,121591194,https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a,BIIB,Yahoo,"Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=c4d6e7084d9024dd9da5ed5d4693cd4ddaf8cfb998625dcf111793e32b55131a
company,2023-07-25 08:16:51,"Stocks making the biggest moves midday: Spotify, RTX, General Electric and more",121594766,https://image.cnbcfm.com/api/v1/image/107185770-1675083546074-gettyimages-1246649629-raa-spotifyi230129_npcVH.jpeg?v=1690301811&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=342520a002b1cdffe1bdd6afab875cb5836040f7c5bf6d807eb49e290c56738d
company,2023-07-25 07:21:00,Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Biogen (BIIB),121636052,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a7fd7c653a7fb05e8292cd4ba5c89b1ab3869ee4b1d0e5a4c76a664617de2dd3
company,2023-07-25 07:04:56,"Biogen announces job cuts, turns focus to Alzheimer's drug launch",121591195,https://media.zenfs.com/en/reuters-finance.com/089a53aa3d2fd0d81a513569270a17d9,BIIB,Yahoo,"(Reuters) -Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or 11% of its workforce, in a fresh round of cost-cutting as it looks to the launch of a new Alzheimer's drug to help it return to growth.  The company said its costs are elevated compared to rivals and that it would focus on higher-growth products such as the recently approved Alzheimer's drug Leqembi, which it sells with partner Eisai.  ""I don't think we as a company have really made the changes in our ... cost base to really reflect that transition,"" Viehbacher said after the job cuts were announced.",https://finnhub.io/api/news?id=c24cb42874f9ad292cee1eeed8aa0dfb92f9cad21d4b085890d3c5c402989239
company,2023-07-25 07:00:04,"Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace",121591198,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, to save costs as the company ramps up the launch of a new Alzheimer's disease drug in efforts to return to growth.  Investors have pinned their hopes on Leqembi, which Biogen sells with Eisai, to power growth as money spinner multiple sclerosis and spinal muscular atrophy (SMA) treatments face fierce competition from cheaper versions and rival drugs.  ""Biogen's business is in transition,"" CEO Christopher Viehbacher said in a statement.",https://finnhub.io/api/news?id=a4d051b0623b6052e9eea3d612502e1445e0af1cb1992f009ace942ee1658b0e
company,2023-07-25 06:34:00,Wolfe says Biogen 'struck a more cautious tone' on possible Tysabri biosimilar,121591092,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1cb24b281cb4ada1b61b26fd98278624fd1945298b4d4a07bfd351e77f714384
company,2023-07-25 06:22:46,"Biogen, Eisai, And Eli Lilly: Goldilocks-Like Treatments For Alzheimer's May Hurt",121584101,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368821405/image_1368821405.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Biogen, Eisai, and Eli Lilly's Alzheimer's drugs have shown little efficacy, particularly in non-APOE4 carriers. Read more here.",https://finnhub.io/api/news?id=f00aa6789d9801c28525802329afafd27b4b5123a8267b99b53fbf8146e0adfe
company,2023-07-25 05:51:00,Biogen price target lowered to $320 from $324 at Stifel,121591093,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1698db50c26eb3b4fa8585af09f39b95d85455aa56572ed5a2a77295efa19229
company,2023-07-25 05:45:00,"Biogen to slash 1,000 jobs as it looks to save $700 million",121591094,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f7e296b906c76d3ca96d5da95149c60e6f2e0b7bc4e73af701acba7b1225bb24
company,2023-07-25 05:33:00,"Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories",121585105,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f74d3515d2dda16a6ff89ec2768bc1f52a074d1d446847bff4024b99926f7650
company,2023-07-25 05:09:00,WMT Stock Alert: Is Walmart Really Worth $210?,121586526,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6fc1a5b645e851013f751e7322175368c8acd69a94f3d1c155d89ca4704e192f
company,2023-07-25 04:55:00,Biogen Inc. Tops Q2 Earnings And Revenue Estimates,121591098,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0970c602085c07e142d0423aba5d9fb4867addebaf725e28283079e7830e12d1
company,2023-07-25 04:53:00,MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage,121586527,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0483836f5dc2c543273a748785a977eef397d14f77b700265dc72cb4169f8e8e
company,2023-07-25 04:39:48,"Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch ",121610253,https://image.cnbcfm.com/api/v1/image/106936821-1630602069094-biogen.jpg?v=1690288788&w=1920&h=1080,BIIB,CNBC,"Biogen, in its second-quarter earnings report, said the plan will result in $700 million in net operating expense savings by 2025. ",https://finnhub.io/api/news?id=dc1649738a043d5e3c488415e6c2bfcb15f5882afc74ebe9ca9f02e20c6ebece
company,2023-07-25 04:37:00,Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts,121591100,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5d14dd534b91f6b7fe26df3d3d553ff849f505dae88e12f40416bee02ad8653c
company,2023-07-25 04:33:00,Biogen backs yearly guidance after second-quarter revenue fall,121591101,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e8fb6c39dfceeb0bb56f8841f44872c6b46dfc1651c0bb3337d2e73a19a3b788
company,2023-07-25 04:11:00,"Tuesday’s Top Analyst Upgrades and Downgrades: American Express, Apple, Conagra, Estee Lauder, Livent, Microsoft, Netflix, Nvidia, Shopify, Tesla and More",121586022,,BIIB,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fd00ce34a04c5b9f01dd50cc38c05661ccedfeb6d9e9823ade2658f15e38f496
company,2023-07-25 03:57:00,Fly Intel: Pre-market Movers,121585114,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ce94e5c21ec5b8997e6d27440ab1cb75f3a0094cf2f9e08919d5d85303aff849
company,2023-07-25 03:38:00,"Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff",121591104,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=adb6eeaad9f28f384ad5684efa16e04151c685c65b065ead9a1acde4be15b32c
company,2023-07-25 03:32:00,Biogen announces layoffs as focus turns to new products,121591105,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6558e9a34ae7ec3ff421b12ab7faf24c8caa6aeb9b91d0c5f03bc7da2dbce22d
company,2023-07-25 03:31:00,"Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Biogen (BIIB)",121591106,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cbc24a1387e7c8bcafe735ab6f18a688ee5aa30b2c91635c1618a99a7d41af91
company,2023-07-25 03:21:00,Biogen sees saving about $1B in gross operating expenses from 'Fit for Growth',121591107,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=33787939169d9fae3cdab546ef52b11959b9bf359fc0bff789951b1955cbe2c7
company,2023-07-25 03:07:03,Biogen : reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S - Form 8-K,121582529,,BIIB,Finnhub,"Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;
    
    
      LEQEMBI launched in the U.S.
    
    
      
    
    
      Second quarter revenue $2,456...",https://finnhub.io/api/news?id=d70489519b890dad223a5cfee3de33a7c07b2536a5ecc18a0ec74a8a7d297202
company,2023-07-25 03:07:03,Biogen : Reports Second Quarter 2023 Results,121582477,,BIIB,Finnhub,"Press Release
      
      
        Cambridge, Mass. - July 25, 2023
      
      
        Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;
      
    ...",https://finnhub.io/api/news?id=54e42ad6b4a10735826ce4833fe48601fbba252ea3f040c4f17c2493185a9eb7
company,2023-07-25 03:06:00,Biogen (NASDAQ:BIIB) Gains On Q2 Beat,121591108,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1bc21f9813ff2913b8a545fe33a6e8792303f89741ade78a692c83fd807ffdd
company,2023-07-25 03:02:03,Biogen : Q2 2023 Biogen Earnings Presentation,121582458,,BIIB,Finnhub,"Second Quarter 2023
        
        
          Financial Results and Business Update
        
      
      
        
          
            
              
               ...",https://finnhub.io/api/news?id=c3b902c0069e4ad98571a86bb15cadd9eacc01bc961e8f82fc668ff9d49ec871
company,2023-07-25 03:02:03,Biogen : Reports Q2 2023 Earnings,121582457,,BIIB,Finnhub,"Press Release
      
      
        Cambridge, Mass. - July 25, 2023
      
      
        Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;
      
    ...",https://finnhub.io/api/news?id=57d90b622693cd347635cf990ca03df90ee194ffc5441a297db8ac9ec238aa44
company,2023-07-25 02:45:00,"Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting'",121585126,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3c67f73ac9432e9828f8674912d915ad0f1e2aee9e17dcfd42103a22afb578d2
company,2023-07-25 02:37:00,Biogen tops earnings estimates and says it will shift resources to higher value areas,121591110,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a8308f30409399f086783951dc6aba14070fc52e430febf6792548b28b4047e6
company,2023-07-25 02:16:00,"Biogen Non-GAAP EPS of $4.02 beats by $0.26, revenue of $2.46B beats by $100M",121591111,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=41f364dd4a26b2819614a488dae108953cd145d431d68f00a7f90c02a7484fb6
company,2023-07-25 02:07:00,"Biogen backs FY23 EPS view of $15.00-$16.00, consensus $15.43",121591112,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d226a440684c28c6b283c22552ba9225a1dc049c84cfe244e17e936f70b7bf5b
company,2023-07-25 02:04:00,"Biogen reports Q2 EPS $4.02, consensus $3.77",121591113,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=02aa82f85a2edd69c50054f5cc13bc44a3fad5c713196000da81442994492630
company,2023-07-24 23:57:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,121591114,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dc6f429d26ecfff4e75a353b1fee361ee7d4c44c522be173235526dc657698d8
company,2023-07-24 20:34:00,GLOBAL BRIEFING: Beijing pledges support for faltering economy,121578551,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4a904b778520cdff7984df9ffecb54f2b08db7419c7077c6fcd55d2d46578913
company,2023-07-24 17:46:51,"All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings",121575325,,BIIB,Yahoo,"Biogen stock is trading flat in 2023 ahead of earnings as analysts await news from biotechnology firm about its Alzheimer's drug, Leqembi.",https://finnhub.io/api/news?id=ac62c17d5147024ea17f164d8094db9950ca85e1241278ca8539dbcb1c0b47b9
company,2023-07-24 11:08:24,Eli Lilly: Does 'Miracle' Weight Loss Franchise Justify Rising Price Tag?,121569469,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/933896402/image_933896402.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Eli Lilly's share price won't stop climbing on the promise of its miracle diabetes and weight loss drug, tirzepatide. Learn more about LLY stock here.",https://finnhub.io/api/news?id=0374b9a7e7f7937a3110281ab52d89105e459d8b7c072cd04f34e926d595d7c0
company,2023-07-24 10:09:27,Better Big Biotech Buy: Vertex vs. Biogen,121575326,,BIIB,Yahoo,"When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products.  Two top examples are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB).  Vertex brings in billions of dollars in earnings annually thanks to its cystic fibrosis (CF) portfolio.",https://finnhub.io/api/news?id=43778faec341af0b9535777ead94945bef614d057ff59091c5d2a9adb78e4e64
company,2023-07-24 07:19:00,Biogen Q2 2023 Earnings Preview,121569172,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=981e719f7a447e7da599c925c3cecc8c8c03a8fc6ef836339c0d9c5e18d49df7
company,2023-07-24 06:26:00,Notable earnings before Tuesday's open,121567843,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a51a02088f73c1b6021c9adc3eadbdd6757121a5145e569deb8e6773ca16d268
company,2023-07-24 03:25:00,Notable companies reporting before tomorrow's open,121575772,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1fe5fd20031e250e55d07abdabbc42105f36c10946532812ee79a8cac82fcb71
company,2023-07-24 02:05:00,Editas Medicine appoints Burkly as Chief Scientific Officer,121569174,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5dee7287978b5a11261e8eb4443dd1ac41bd907775c7e2397a5820c8c83c65df
company,2023-07-24 01:51:00,"Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Biogen (BIIB) and Johnson & Johnson (JNJ)",121576754,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=35558c6d86c8b8aa283a8f16669faa519971b239c4a1bc3162a028a586592354
company,2023-07-23 23:57:00,"Biogen Inc. stock rises Monday, still underperforms market",121591118,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=40c590e6206459b1b2eac64171a52ba3d0dabf830968f3e9560f2a51df5a7650
company,2023-07-23 22:15:00,Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick,121591119,,BIIB,The Online Investor,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7300497884a96adb7eec4e7d0d00dcf5ccbcca64dd4ad4206a1c354017d1cb6f
company,2023-07-23 03:54:18,4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys,121556188,https://media.gettyimages.com/id/1423260813/photo/back-to-school-lovable-adorable-puppy-and-vintage-books.jpg?b=1&s=170667a&w=0&k=20&c=e0cBemk4n3YwqhSm5Q93yv01rxL-jJs6q7ebn3fl4do=,BIIB,SeekingAlpha,"Barronâs Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies. Read more here.",https://finnhub.io/api/news?id=5ab330942fdbf4a3cbf52412ba5a106d0e56ab9c6512d6e98f43280252e771f1
company,2023-07-29 09:08:21,Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil,121818801,https://media.zenfs.com/en/investorplace_417/7a6d7cf8fd09137bc1a8f5746ab0adba,BIIB,Yahoo,"As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new executives, new boards and new strategies. The specifics of each case vary, but the biotech stocks in sharpest focus have been those whose earnings and revenue have disappointed investors. Of course, it’s no accident this happens. Investors want to protect their investments. And if the company isn’",https://finnhub.io/api/news?id=9dfef7abafbc77cc583f3a37066eefe55b0122459fc003541d2402e42bb924fb
company,2023-07-28 16:45:24,S&P 500 Gains and Losses Today: Stocks Jump as Inflation Cools,121682632,,BIIB,Yahoo,"U.S. equities rallied on Friday, July 28, 2023 after a report showing inflation cooled in June, and the S&P 500 rose 1%.",https://finnhub.io/api/news?id=38243b356816977f7a6340fe6d9f10f45214e22e577ff7400531df0b3da8101f
company,2023-07-28 16:24:01,"Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs",121678198,https://s.yimg.com/ny/api/res/1.2/C_mWqvZPWpBjCPlV_Ejbvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia.com/1edf52106833bd06e06865e2174b33c6,BIIB,Yahoo,"Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio.",https://finnhub.io/api/news?id=407895b7c400927ec15c5b6d77e9d5e545ba19b5bd329ccfa60e0cdf0080ff56
company,2023-07-28 16:07:47,Biogen to buy rare-disease drugmaker Reata in $7.3B deal,121678200,https://s.yimg.com/ny/api/res/1.2/49T6yem.W_qCijLJxQhMFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-07/64e769f0-2d82-11ee-9f2f-10e9fec4f951,BIIB,Yahoo,"Biogen will pay $7.3 billion to buy Reata Pharmaceuticals, company that makes a drug for a rare neurological condition. Analysts have been generally positive on the deal, with one calling it ""low-risk."" Yahoo Finance Health Care Reporter Anjalee Khemlani recaps some of the biggest stories from the health industry.",https://finnhub.io/api/news?id=9a6d586a1247ea913915d9417c84ad17b38ed499ff0c054a993ac4c6f80f4f2b
company,2023-07-28 14:21:27,Why Biogen Agreed to Acquire Reata for $7.3 Billion,121674704,https://s.yimg.com/ny/api/res/1.2/LfdmsVKlMJhIBVa5iPgU7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/bloomberg_markets_video_2/4faa9496b01e484f3d0fc4fe094deb06,BIIB,Yahoo,"Biogen agreed to acquire Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on ""Bloomberg Markets."" Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on... Twitter: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness/ Instagram: https://www.instagram.com/quicktake/?hl=en",https://finnhub.io/api/news?id=d2090e2a78da24c0773d4f61d87d9e1cce13f4d448f807dc89e9949950de1580
company,2023-07-28 13:20:10,Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors,121676896,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1153436387/image_1153436387.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Biogen Inc. now plans to acquire Reata Pharmaceuticals, Inc. for $7.3 billion, validating the potential of Skyclarys. Click for my updated take on RETA shares.",https://finnhub.io/api/news?id=b3ea612104149037edc6544c23b6f712865389de566d6b6303eb344c782b6ed6
company,2023-07-28 12:41:00,Biogen Buying Rare-Disease Drugmaker In $7.3 Billion Deal,121670479,https://s.yimg.com/ny/api/res/1.2/74y6KO178dHc9WO_Cx6kLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/539b88ca2fcf95f7b622981ca12e7de4,BIIB,Yahoo,The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases.,https://finnhub.io/api/news?id=68dfaf9a489d44417fbb3a08da52ac3bfb0073c10e95d9c39606d030c6a6bcce
company,2023-07-28 12:23:00,NEW YORK MARKET CLOSE: Tech stars as stocks end winning week on high,121676026,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a177ba3dcf59e2946eea6be54c76ce695ac94812f9e1b8b23d459af143655d90
company,2023-07-28 12:00:00,Eli Lilly: There Is No Logic To This Over Optimism,121675170,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185410983/image_185410983.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's stock thus far.",https://finnhub.io/api/news?id=4c58fd05f7f273b4d4161eac92ab70dcf2cd7a5c2458ccde3a303824a0f63dc8
company,2023-07-28 11:11:24,"Biogen's Alzheimer's drug is the biggest growth catalyst for the stock, says Jefferies' Yee",121675637,https://image.cnbcfm.com/api/v1/image/107278716-16905698521690569833-30513375206-1080pnbcnews.jpg?v=1690571484&w=1920&h=1080,BIIB,CNBC,"Michael Yee, Jefferies biotech analyst, joins 'Power Lunch' to discuss what Biogen's purchase of Reata means for the former, the biggest catalyst for Biogen stock, and more.",https://finnhub.io/api/news?id=8f5779588e0fc2a393ecb7ac13317ceb553592319cf4348c1a160d7f9f51235f
company,2023-07-28 10:53:19,"Enphase Energy outlook, Biogen-Reata deal, Boston Beer stock: Top stocks",121670271,https://s.yimg.com/ny/api/res/1.2/XSYKSfwtcZBzJKRjbVYEUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzQ-/https://s.yimg.com/os/creatr-uploaded-images/2023-07/0ebe8b70-2d56-11ee-afdf-1d478afa46cf,BIIB,Yahoo,"Enphase Energy shares slide on a cloudy outlook stemming from an elevated interest rate environment. Biogen is set to acquire Reata Pharmaceuticals in a $7.3 billion deal. Boston Beer Company stock soars on increased demand for its Twisted Tea. Yahoo Finance Live's Brad Smith, Julie Hyman, and Rachelle Akuffo take a look at several stocks trending in the morning session.",https://finnhub.io/api/news?id=138a5725cd551022503aba224ee35737cf5373f9ded8e1f146e0a4d478b5ee5a
company,2023-07-28 10:50:59,Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce,121670481,,BIIB,Yahoo,"Biogen announced Friday it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion, boosting biopharmaceutical company Biogen's drug offerings for serious neurological diseases.  Reata stock surged early as Biogen stock slid.  RETA stock skyrocketed 52.4% to 165.24 early Friday during market trade after Biogen reported it plans to pay $172.50 per share in cash for Reata.",https://finnhub.io/api/news?id=74e207f802078d49322c91e60ecd3cd9f8b608145303f20ccf651073b871785d
company,2023-07-28 10:39:00,Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash.,121670482,,BIIB,Yahoo,"Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.",https://finnhub.io/api/news?id=dd2798f6204506fb910a9792105705a503cb93a2178c43a2dda6d413878ecdfb
company,2023-07-28 10:35:47,Biogen to Buy Reata for $7.3 Billion in Rare-Disease Deal,121670483,https://s.yimg.com/ny/api/res/1.2/u7MKsquzeeBRYVIK3cKwww--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/f57aa2ccf29cf14c666f8f4be95acc81,BIIB,Yahoo,"(Bloomberg) -- Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion, including debt, to expand its rare disease treatments in one of its biggest-ever acquisitions. Most Read from BloombergLargest US Grid Declares Emergency Alert For July 27BOJ Sends Yields Soaring With Surprise Change to Rate LimitSubway Offers Free Sandwiches That Come With a Lifetime CommitmentChina’s Push to Expand BRICS Membership FaltersS&P 500 Up 1% as ‘Goldilocks’ Data Embolden Bulls: Markets WrapThe",https://finnhub.io/api/news?id=68fc35b205d5f677d7da060ed310828e4b866b715c21c59e28f16463a73adce0
company,2023-07-28 10:31:18,Biogen to buy a Texas-based rare disease firm for $7.2B,121721561,https://s.yimg.com/ny/api/res/1.2/T2zcvuIfKZuWMxpvJ0aMpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/a145bac4656f48a6bf2a6c8424389b65,BIIB,Yahoo,Biogen is paying $7.2 billion to buy a Texas-based biotech as new CEO makes good on his promise to expand into the rare disease space.,https://finnhub.io/api/news?id=0fc080aeb0992c2a1ed5d0a5935e9bd3f79bff3364489e3718ecb275c9f8822e
company,2023-07-28 08:43:21,Will Biogen's Deal Splash Give Biotech a Lift?,121666464,,BIIB,Yahoo,"It’s a merger Friday, and that means payday for shareholders of Reata Pharmaceuticals. Shares of Reata, which specializes in developing drugs to treat rare neurologic diseases, are up 51% in premarket trading.",https://finnhub.io/api/news?id=45bacdc49113a639d2a07e41cf6efaaa171964f1f2863f008cbdb6d12389d22d
company,2023-07-28 08:28:00,"Larimar, Design higher as they benefit from Biogen deal for Reata",121672515,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b98519bf00d3d3e98b0a7eaea936aeaada0c3468447e7f0dce6ccedc3c6282ea
company,2023-07-28 07:57:15,Biogen to bulk up rare disease treatments with $7 billion Reata acquisition,121670485,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.  The Alzheimer’s treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year.  Plano, Texas-based Reata focuses on developing treatments that regulate cellular metabolism and deal with inflammation in serious neurologic diseases.",https://finnhub.io/api/news?id=71adb0ba1bad3eeded3dbb2ff8ea596f17434abc4f2a42b345688cbcf5d881f8
company,2023-07-28 07:21:40,Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio,121670486,https://media.zenfs.com/en/reuters-finance.com/64279516233c3a4945b49b939dccb4b5,BIIB,Yahoo,"(Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the drugmaker to growth.  Viehbacher was hired in November to put Biogen back on a growth path after a series of missteps around the controversial Alzheimer's drug Aduhelm hurt the company, which was already grappling with intense competition to its top-selling drugs.  Through the deal, Biogen said it will gain Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system.",https://finnhub.io/api/news?id=165e4cad2031de9c0be715fb643761b6f86d19458a463f26efb5bd922fa869f5
company,2023-07-28 07:09:19,UPDATE 4-Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio,121670487,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Biogen agreed to buy biotech firm Reata Pharmaceuticals for nearly $6.5 billion to bolster its position in the rare disease drugs market while its older multiple sclerosis drugs face intense competition.  Through the deal, Biogen said it will gain Plano, Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system.  Biogen has said it has been hunting for deals, especially in areas such as rare diseases and immunology, to expand beyond its multiple sclerosis drugs portfolio that is under pressure from competition.",https://finnhub.io/api/news?id=aa79db581d8511bda665e392ab5adbfaf634a7b38eebb819bf87b0458ba16de2
company,2023-07-28 07:05:00,Biogen to Acquire Reata Pharmaceuticals,121662877,https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d,BIIB,Yahoo,"SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen’s Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE",https://finnhub.io/api/news?id=2328746db12ace57553ea217147f065a0c0e532e32b3ffb828617267435a3bf3
company,2023-07-28 07:01:00,What You Missed On Wall Street This Morning,121668613,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d0b6112b2dc2dd6b0c309d7f49d36f59f0bd46259c52233b07aa8f263ba686f4
company,2023-07-28 06:46:00,Reata Pharmaceuticals downgraded to Hold from Buy at Stifel,121676570,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e9e5d83a276f1bdddbf156a96bebe2d7cb139c5ce92670ae976aa9bc5a620d64
company,2023-07-28 06:41:00,Biogen bolsters rare disease treatments with USD7 billion Reata buy,121676571,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=69baf2bbf1edd990a991cbbdb5acd2e381b8f50edfa1ff2e604390747ddbf890
company,2023-07-28 06:11:00,Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals,121676572,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0edad1ad2da34d266302da7adf5b17ac5008b38d5ed5a4b7c8c1efaefe87e108
company,2023-07-28 05:52:00,Reata Pharmaceuticals Shares Soar on Takeover by Biogen >RETA,121698138,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Colin Kellaher Reata Pharmaceuticals shares surged to a multi-year high Friday after the biopharmaceutical company struck a $7.3 billion deal to be...,https://finnhub.io/api/news?id=cb03300650383ef50cb4aa28aa1a76fe85aed2ff374beabd03ebbf0cac94c045
company,2023-07-28 05:27:00,"Intel, Reata Pharma and Roku rally, and other movers",121673709,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1b065cd35099970097fbcb5a312126780f5b2b89500baf388f05030c4b0b864f
company,2023-07-28 05:24:00,Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?,121676574,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7ce9fff40aa167773f2f60141fff7d10a9eed914888e76aba287482383e145b9
company,2023-07-28 04:48:00,Biogen Snaps Up Reata Pharma In $7.3B Deal,121676575,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=83143d6d13a47ba453c407cb5110308acd2513b9cb4f58a8763ef9af2af415d5
company,2023-07-28 04:07:00,"Friday’s Top Analyst Upgrades and Downgrades: Apple, Boeing, Carvana, Coty, Meta, RTX, Southwest Airlines, SunPower and More",121669746,,BIIB,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9f823be23714d991f2a83eac78ef1cbb46df3eeb29fe9003bc1e98176e39c605
company,2023-07-28 03:56:16,"Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more ",121665760,https://image.cnbcfm.com/api/v1/image/107186186-1675118079202-gettyimages-1246677801-INTEL_EARNS.jpeg?v=1690545376&w=1920&h=1080,BIIB,CNBC,These are the stocks posting the largest moves in premarket trading. ,https://finnhub.io/api/news?id=19e9d20b49201befab9d9359bdb2d34b826835743cd2afc06ddbece8b2860acd
company,2023-07-28 03:32:10,Biogen : Business Update,121663460,,BIIB,Finnhub,"Reata acquisition expected to meaningfully advance Biogen's
        
        
          return to growth objective
        
      
      
        
          
           ...",https://finnhub.io/api/news?id=60cae8e1dd216adde550227c36898cb24c0a7168a8a10d622a9d6ecec1548816
company,2023-07-28 03:16:00,Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering,121698135,https://images.mktw.net/im-705451/social,BIIB,MarketWatch,Biogen's all-cash deal is a rare-disease play.,https://finnhub.io/api/news?id=eb653185a0239d7d49dd38b84ba9affab4c5559a1a5f22db1a0ac18d00c3164e
company,2023-07-28 03:01:31,Biogen considering takeover of biotech Reata - Bloomberg Law,121662789,,BIIB,Finnhub,"Biogen is exploring an
acquisition of biotech firm Reata Pharmaceuticals,
Bloomberg Law reported on Friday, citing people familiar with
the matter.
              Shares of Reata surged about 13% in...",https://finnhub.io/api/news?id=dc69311f664f8b52ceb2a2ba4bc993826d616766e7d7919499adab15a8669d6a
company,2023-07-28 02:31:00,Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B,121676583,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ee502bb2b8f73f363dc4e1d0183f2d950a8cec4a33b9b739ebd5f3ffde6f7139
company,2023-07-28 02:24:00,Biogen agrees to buy Reata Pharmaceuticals for $172.50 a share in cash,121676585,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f5b397899f71a611e7f41d05f377dbf06b2694685cfb0b47edc6b4ccf677cb6e
company,2023-07-28 02:18:00,Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash,121676586,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b4f1e3289cafbeef51a1e87060597d57189831e4525cb851d772610824cd555a
company,2023-07-28 02:09:00,Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash,121676588,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=abf61bd2f66dff51ebc46c7f3fe0033a491f0e6c2b7c2e8b36e17ce019f50783
company,2023-07-28 01:07:00,Reata downgraded to Market Perform from Outperform at SVB Securities,121678170,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dc7a5e98ab6c2fa821ce1bfef8c72ac13611acd4fa10609d88aeaa904d0de351
company,2023-07-28 00:44:00,"Intel is chipper, Boston Beer fizzes, and other movers",121665885,https://images.mktw.net/im-771999/social,BIIB,MarketWatch,Roku shares rally after the streamer's results beat expectations,https://finnhub.io/api/news?id=f91277706ef39d4701f83138c79906cb1ddef3259c790282207440fa57d59546
company,2023-07-27 23:58:00,"Biogen Inc. stock rises Friday, still underperforms market",121676591,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bb0994d138e9cec8f47262896a08e12e3a1487fc4c76da4f75d668df53e6d7d4
company,2023-07-27 23:37:00,What You Missed On Wall Street On Friday,121675979,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a08eecb3eb8ca1b2a8039da1b7f73bec5bd611cb5fbaf18178c80a4b5d512519
company,2023-07-27 23:11:00,Reata Pharmaceuticals downgraded to Hold from Buy at Jefferies,121676593,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=42cde74a299f86a7d222391e8fa87d0a62c4830ed0cf3f86c408f7888f5bd70f
company,2023-07-27 21:31:00,Buy/Sell: Wall Street's top 10 stock calls this week,121676595,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=180dbdeeb48ada025ac24cc38c5a934f772a349a79760f462f8959f8af448636
company,2023-07-27 19:10:04,Scotiabank Initiates Coverage of Biogen (BIIB) with Sector Outperform Recommendation,121641509,,BIIB,Fintel,,https://finnhub.io/api/news?id=2c3770a0ccbd14fda8a630139a77024e013a4c1501b932254a3b0adf6a78fe22
company,2023-07-27 09:56:33,"Meta Platforms upgraded, Estee Lauder downgraded: Wall Street's top analyst call",121621778,https://media.zenfs.com/en/the_fly_169/135b0749a3ad5e86fe326a9da1d664b6,BIIB,Yahoo,"Meta Platforms upgraded, Estee Lauder downgraded: Wall Street's top analyst call",https://finnhub.io/api/news?id=729fa1a1119c5b418f406f3a27c85c2cdcde9029c055d0181eec9bd7f01d9e38
company,2023-07-27 06:00:00,I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO,121622741,,BIIB,Yahoo,"When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind.  As a result, revenue has been on the decline, and the share price has stagnated.  Biogen prepared for the loss of exclusivity by developing new products, most specifically one to treat Alzheimer's disease.",https://finnhub.io/api/news?id=1234b3c193e34c9bdab72df54bdf352217eb69f84ff88a747dcc803d00c396bc
company,2023-07-27 04:08:00,"Thursday’s Top Analyst Upgrades and Downgrades: Alphabet, Disney, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, RTX, Spotify and More",121622943,,BIIB,247WallSt,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c987dcdee1f82ce6d90a61a3a4c71dff845a6b543c9c4ecd947f5bdde8a87c3d
company,2023-07-27 03:25:00,Biogen initiated with an Outperform at Scotiabank,121636040,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=de9a2e1fef6359ad54085a414d9623efcd9b71331ca90e2c73b3477d28acf79a
company,2023-07-26 23:57:00,Biogen Inc. stock underperforms Thursday when compared to competitors,121636041,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6278816cd72ace351bc3faab920c5f8eb44b67dd728b402a86a554f7f7ffef90
company,2023-07-26 18:10:01,Needham Maintains Biogen (BIIB) Buy Recommendation,121606385,,BIIB,Fintel,,https://finnhub.io/api/news?id=c10e33110bb5b3af06c295d07ce214d06fb68f84a66c3f51bcc73824d05864b4
company,2023-07-26 18:09:53,HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation,121606386,,BIIB,Fintel,,https://finnhub.io/api/news?id=d22eba553defa2ed33e889759ec021003d9f7d4e8e0fb724639547251899f037
company,2023-07-26 18:09:49,BMO Capital Maintains Biogen (BIIB) Outperform Recommendation,121606387,,BIIB,Fintel,,https://finnhub.io/api/news?id=a784f0e9dd767c8c368453251a792946441a88e73a8551612063ff93f8bd842f
company,2023-07-26 18:09:16,Wedbush Maintains Biogen (BIIB) Neutral Recommendation,121606388,,BIIB,Fintel,,https://finnhub.io/api/news?id=f9abdd84b3095373e01c6fe33df77b44e94064035a125257c0f788c368df7fa1
company,2023-07-26 18:09:08,Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation,121606389,,BIIB,Fintel,,https://finnhub.io/api/news?id=7c4e8e37d629ed007a8d807be2f906159214d257d69e7db0c8aed3d51df8ca0a
company,2023-07-26 18:09:07,RBC Capital Maintains Biogen (BIIB) Outperform Recommendation,121606390,,BIIB,Fintel,,https://finnhub.io/api/news?id=d7a3646384a997ce4dd8e3723743197c9f75021268b3c4a7e608dd2d8798a798
company,2023-07-26 15:46:00,Why Sage Therapeutics Stock Is Tumbling Today,121613390,https://s.yimg.com/ny/api/res/1.2/tRSS75LKV40gz540DrSJSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/faa05df2d0e522d7d357b19975c809bd,BIIB,Yahoo,A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.,https://finnhub.io/api/news?id=3d2879263a864826f180d8b864adbc5c110f0a0e4743dde0ad6454fdb184e5d9
company,2023-07-26 14:08:57,12 Out of Favor Stocks That Hedge Funds Love,121607493,https://s.yimg.com/ny/api/res/1.2/HwWipV6TL22Wu4Vo6fW9mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/814fa34a7e846775ea56dd10487b2571,BIIB,Yahoo,"In this article, we will be taking a look at 12 out of favor stocks that hedge funds love. To skip our detailed analysis of investing moves today, you can go directly to see the 5 Out of Favor Stocks That Hedge Funds Love. Investing in stocks will always be a tricky exercise. The market […]",https://finnhub.io/api/news?id=aa09af6c149fe8672d147c2298dce90c567d9f586825884f875d705a748b3b7d
company,2023-07-26 11:01:00,Biogen’s CEO Didn’t Mention an Impending FDA Decision. Investors Got Spooked.,121613391,https://s.yimg.com/ny/api/res/1.2/86ZnlwRTvBtwmPpXZ_E7qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/188a1da1050a501e9abb1dcf1268490a,BIIB,Yahoo,"Despite generally positive earnings and a cost-savings plan that will reduce the company’s head count by 1,000, shares of Biogen have traded down sharply since Tuesday's earnings call.",https://finnhub.io/api/news?id=b104ae33a8b5d4939f9e9f90971017aec33ba53431250d353a3d11a1c4420b56
company,2023-07-26 10:08:00,"Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More",121613544,https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e,BIIB,Yahoo,Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.,https://finnhub.io/api/news?id=d12c8b823a13a6e8effa8579b85f15ba37315e3afb8d87ceafbe00a62f47dfde
company,2023-07-26 08:42:00,Sage hits eight-month low as FDA decision on depression therapy nears,121636042,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1189645650948a64fbfb496bc3f6fcd87b9ebe0802439c723d6c56bdce3fe91
company,2023-07-26 05:26:00,Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB),121636043,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=af77fc3cb3095aadbad656071c6954b2fe17868f7a4c0ba873a663c58895b0b8
company,2023-07-26 04:22:00,Biogen price target raised to $379 from $341 at RBC Capital,121636044,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6c1aa18ea5d1d6e4d0ce8dd655fb6bb97849f8fc2d3cf039b93f95517f9e6e02
company,2023-07-26 03:26:00,GLOBAL BROKER RATINGS: HSBC cuts Glencore; LBBW likes Adidas,121623674,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9c5df4d82b15f8860d385db0f4dacf91d319272078c96d7ff643ed255ebe4d4a
company,2023-07-26 02:34:00,Biogen price target raised to $323 from $320 at Needham,121636046,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=74f88908b5456d2e91c14e0f3e2e3543156f56810d8a423d3c81806f60b98ce6
company,2023-07-26 02:11:00,"Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Terns Pharmaceuticals (TERN)",121636047,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2405b8dfd118edcef53e83c8dbe02a36f6c02711c869f573990098269d8e1c67
company,2023-07-26 01:55:00,Biogen price target lowered to $310 from $320 at BofA,121636048,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7365504573c3c6dad21791eceac6e97c703ec29dfb10ed8b5ba8db3c2f0dc2cd
company,2023-07-26 01:21:00,"Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Abbott Labs (ABT)",121630591,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4faf1087fa9b31a0b68f234f56740994264f7ab065053382bb8413f65aedd187
company,2023-07-26 00:21:11,Q2 2023 Biogen Inc Earnings Call,121599584,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,Q2 2023 Biogen Inc Earnings Call,https://finnhub.io/api/news?id=bbd2051fdb8fb18e47a8b49f0f8db85a43e7e21183ce5caeabf770f8d900c7ba
company,2023-07-25 23:57:00,"Biogen Inc. stock falls Wednesday, underperforms market",121636050,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=383ce607c211ccea85d92301e7918c30f6f9dfff4a9ee79d7f813362072ce627
company,2023-07-25 22:51:00,Analysts’ Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (IMGN) and Biogen (BIIB),121630623,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7866b6e09a47015ca83ae189c6277503372242236ba814fd06bdbca79b25856a
company,2023-08-02 15:17:56,3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now,121902388,https://media.zenfs.com/en/investorplace_417/7bb0fe2e42d5e10717d42c6cfa18869c,BIIB,Yahoo,"Medical stocks, in general, aren’t enjoying the market-wide reversal we’re seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical device and healthcare facility companies, has returned less than 1% since January. Compare that performance to the S&P 500’s rapid mid-March reversal and 20% jump since then, and healthcare stockholders’ woes are understandable. Despite strained supply chains and an industry-wide inability to readapt to",https://finnhub.io/api/news?id=576d5a8a7d25eae8e15b4de71a8ff84dd9c7140a3191ee2affc93b821911b149
company,2023-08-02 04:23:00,Earnings Insight: Analysts Raising Full-Year 2023 Estimates For U.S. And European Equities,121764159,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397011551/image_1397011551.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Weâve seen a shift in analyst sentiment over the last two weeks when looking at data in This Week in Earnings and STOXX 600 Earnings Outlook report.,https://finnhub.io/api/news?id=8bcf64eb9ffc8060a5b807e6343e7b1f178804678ba12fd8b729c7c071435fff
company,2023-08-02 02:02:15,Larimar: Friedreich's Ataxia Drug With Significant Potential,121762597,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1571254123/image_1571254123.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,Larimar therapeutics has been making significant progress in advancing its drug known as CTI-1601. Read more about LRMR here.,https://finnhub.io/api/news?id=899c4f37c5948ebeabf0f6da565feccefd8d6f3ba876a4ab9689abf97e8e212d
company,2023-08-01 23:58:00,Biogen Inc. stock outperforms competitors on strong trading day,121782106,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=eef03e6d9492e193942e9a4b84fa6a27cd846ea91e8de16d91df6dd2a2a8f488
company,2023-08-01 22:37:00,Biogen Unusual Options Activity For August 02,121782107,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=968db04dab4c4768832fb0c6ad8981078e0fdbe658e94a53b0efb568a80261ac
company,2023-08-01 14:59:01,Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points,121878063,https://media.zenfs.com/en/investorplace_417/b65ecbd3cc97c34115d1ca93c78611f0,BIIB,Yahoo,"The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo",https://finnhub.io/api/news?id=c105937fcc560d724aa85e8cd4194f96e95e1d05251f6a5ec0535fe595fbb268
company,2023-08-01 09:46:00,"For Dementia Patients and Their Caregivers, Help Could Be Coming Next Year",122225638,https://images.barrons.com/im-827365/social,BIIB,MarketWatch,A voluntary nationwide program starting next year aims to improve care for the more than 6.7 million Americans living with dementia and their unpaid caregivers.,https://finnhub.io/api/news?id=09ed2c2fea2b82dbf0ee4221f6ee911ced9becb77d62adb87609aa6049a05b51
company,2023-08-01 05:45:00,Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know.,121737261,,BIIB,Yahoo,"Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth.  The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in declining sales.  All this has weighed on share performance too, as investors wonder about what the company and its earnings will look like in the future.",https://finnhub.io/api/news?id=59bdfed9e8150a9eb187be7926ca05df72dd24b14fb6f4e2f28492f17787f2fb
company,2023-07-31 23:57:00,Biogen Inc. stock underperforms Tuesday when compared to competitors,121782109,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=452953659ea35f2614f3def22c985bfc28d53db137cf2961d8771d35ceed18b7
company,2023-07-31 23:55:11,RBC Capital Maintains Biogen (BIIB) Outperform Recommendation,121727261,,BIIB,Fintel,,https://finnhub.io/api/news?id=f009108509e9d918566a5fc5223e5bffd7910e61f98e26c39bffe183f8ed8b13
company,2023-07-31 23:55:11,Needham Reiterates Biogen (BIIB) Buy Recommendation,121727260,,BIIB,Fintel,,https://finnhub.io/api/news?id=72b1c4040bde1bc0f5cea06dc4d9a9b5a9662f33315b8246dc25cf1626263d05
company,2023-07-31 13:11:08,10 Most Oversold S&P 500 Stocks Right Now,121719335,https://media.zenfs.com/en/insidermonkey.com/afeaf58f871cbecccd3b2fb6895eeb81,BIIB,Yahoo,"In this article, we will take a look at 10 most oversold S&P 500 stocks right now. To skip our analysis of the recent market activity, you can go directly to see the 5 Most Oversold S&P 500 Stocks Right Now. The stock markets have been through the wringer in the recent past especially since […]",https://finnhub.io/api/news?id=f98435e89b793ec7b050472986e8e4b7f9a59bf3cfbc8c899d500e788380b684
company,2023-07-31 07:45:00,Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen,121721354,https://s.yimg.com/ny/api/res/1.2/fkGPkYLAiLJbXRhjfRwJNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/32c2b835b4477cd985a2c112b39817d2,BIIB,Yahoo,"Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease.  Both drug developers see the market for such medicines as being a major one in the coming years, and their candidates are set up to duel for the first leg of growth.  Let's dive in and evaluate the case for each on the basis of how their medicines seem to perform so far.",https://finnhub.io/api/news?id=20a407e4047cddc4d349871597d43786c0a3467cbd0c374747e71e255d711cb3
company,2023-07-31 07:00:00,"Biogen’s New Boss Is Delivering, but Stock Isn’t Pricing It in Yet",121721559,https://s.yimg.com/ny/api/res/1.2/zmoti5Pq.ckp9timoPMbTA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/a1811680d740d4b05d50c7a1253ce629,BIIB,Yahoo,"The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street’s skepticism presents an opportunity.",https://finnhub.io/api/news?id=2f694599796948d8b7d6442ee125b26d2858f24f1ccc33337d7e2f850ca54772
company,2023-07-31 06:24:00,"Rising Stars, Falling Trends: July's Industry ETF Winners And Losers",121714630,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a2513ac2c4e93ac45d5789202c68488577f66e023b45bf60ebb00af1e564493d
company,2023-07-31 06:11:00,Biotech Alert: Searches spiking for these stocks today,121715569,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=dc9693d817f16edfd49b5f8c418b4013ad57d34a1b5c993b3612991b86d6b48d
company,2023-07-31 05:15:41,US announces trial payment program for care providers of dementia patients,121711752,,BIIB,Finnhub,"The U.S. government said on Monday
it would trial a new payment program for people who provide
dementia care coordination services for patients covered by the
Medicare health plan.
              The...",https://finnhub.io/api/news?id=4da1edcb67a13da23b64ac3955b10134a34c98f15051a4d10bb039995eb60447
company,2023-07-31 03:23:00,Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer’s disease,121710873,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,DowJones,Quest Diagnostics Inc. said Monday it has brought the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease to market and...,https://finnhub.io/api/news?id=352b0f24acf11cacda3ced5bcdf956c22ec1e88f0d5926dd24930c66552984f4
company,2023-07-31 02:18:00,Reata Pharmaceuticals price target raised to $173 from $85 at Baird,121715570,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e2cd0df0b78caef3dfebd04dee8546d7a4c06d0d816d86469fb349f66481958e
company,2023-07-31 01:44:00,Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg,121715571,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b7a868bc6bd0a61963944ad979c657f749f93b4587a1480f46c83bfc464bfac8
company,2023-07-31 01:00:00,Promising new Alzheimer's drugs may benefit whites more than Blacks,121709644,,BIIB,Finnhub,"Groundbreaking treatments
for Alzheimer's disease that work by removing a toxic protein
called beta amyloid from the brain may benefit whites more than
Black Americans, whose disease may be driven by...",https://finnhub.io/api/news?id=084b8b789d90f8c2a5542a086c4e3de6622945e4c25f5cf95bf44b29dc47b221
company,2023-07-30 23:33:00,TOP NEWS: Biogen to acquire Reata Pharmaceuticals in USD7 billion deal,121715572,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8a9e00a5663f23d7490c5d17328b94a8e04e855a0e62368edc8c4da4ff8f4f91
company,2023-07-30 07:01:01,Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the return generated for shareholders over the past year,121701937,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"It hasn't been the best quarter for Biogen Inc. ( NASDAQ:BIIB ) shareholders, since the share price has fallen 15% in...",https://finnhub.io/api/news?id=42231d13ba9a79d6d6268fdb96e59e307ebd80602aa776aea434072cb69f39fb
company,2023-07-29 22:05:00,3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes,121705817,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5d986ce65866cd711c230112fcb28412eff61f2404fb0260a18b85dc253adf7e
company,2023-08-06 08:07:00,"CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed",121860559,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4f13fb40aeaf460588c749c784b329636ac84a406af35901458f1e49aceb5cee
company,2023-08-06 05:17:00,"Biogens, Sage Therapeutics postpartum depression treatment approved",121860560,,BIIB,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9a1e225c84861d4aa64d9efe73192c7df898d60dbc2052b176e00064347825ba
company,2023-08-06 00:08:12,DiaMedica Therapeutics: Risk-Reward Favors Following Insider Optimism,121857423,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1426271120/image_1426271120.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on recombinant proteins to treat life-threatening diseases. Read more here.,https://finnhub.io/api/news?id=0aea35c6204d05b6ef0be6a13248b624effc8ebdf10c2090a6040ccab2a5d186
company,2023-08-05 22:41:00,2023 shaping up to be biggest year for biopharma M&A since pandemic,121863052,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ff39439a9159e57cbad13212f0d70bf892448c751f4cd2f2c1d308b07a2f32c6
company,2023-08-04 22:42:00,"FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder",121842228,https://media.zenfs.com/en/business-wire.com/fff52e749044d96f4e33b51fa4576d6d,BIIB,Yahoo,"CAMBRIDGE, Mass., August 05, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAETM (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. ZURZUVAE is expected to launch and be commercially available in the fourth quarter of 2023 shortly following sch",https://finnhub.io/api/news?id=1fbfc61052f9474c2114d503fa73f9c27478df7a6ae3f8af6ed339088fe5b774
company,2023-08-04 20:44:33,"Postpartum depression drug developed by Sage, Biogen approved by FDA",121842229,https://media.zenfs.com/en/bizjournals.com/986e4829c4ce71dd157ea22c50057e64,BIIB,Yahoo,"A new depression drug has received the green light from the U.S. Food and Drug Administration after years of development by two Cambridge drugmakers. Zuranolone, a new drug co-developed by Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics Inc. (Nasdaq: SAGE), scored an FDA approval late Friday — but the approval was only for postpartum depression, not major depressive disorder. The companies had applied to market the drug as a treatment for both.",https://finnhub.io/api/news?id=3bacf3480b7bd4f4f7d926000ef6fc7c1b02e1baada22166453ba1fad04988f2
company,2023-08-04 20:13:04,UPDATE 1-US FDA approves Biogen-Sage Therapeutics pill for postpartum depression,121842230,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill to treat postpartum depression (PPD) in adults.  The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder), or clinical depression, as well as postpartum depression (PPD), which affect millions of people.  Analysts were anticipating the stocks of both companies to fall if the drug was approved only for postpartum depression due to the smaller patient population.",https://finnhub.io/api/news?id=6ab967f7e05a935d9060841a77c91e046fb0b5526f2738ece1432c249957d5a7
company,2023-08-04 19:24:00,First Pill for Postpartum Depression Is Approved by FDA,121842231,https://s.yimg.com/ny/api/res/1.2/z6f_tB4.Oa.wpsCnVrUJFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/846b30bf699d9f90c653727ab53d4bc2,BIIB,Yahoo,"The pill, to be taken daily for at least two weeks, significantly reduced postpartum depression among new mothers in a recent trial.",https://finnhub.io/api/news?id=269e6f8b5b29580b1bfd59a264bfb5b93b4fc3ad65543d8b8952c0f35a824e47
company,2023-08-04 19:11:09,US FDA approves Biogen-Sage Therapeutics pill for postpartum depression,121849299,https://media.zenfs.com/en/reuters-finance.com/968785c065b7fa17081c270c215792b5,BIIB,Yahoo,"The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical depression, as well as postpartum depression, which affect millions of people.  PPD severely affects a woman's ability to return to normal functioning, while also potentially affecting the mother's relationship with her child.",https://finnhub.io/api/news?id=180634e12523904518dbad0dd767350b9e5b08d6724e7f22cadf0cfa1a463124
company,2023-08-04 18:42:14,"FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder",121841331,,BIIB,Finnhub,Postpartum depression  approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with...,https://finnhub.io/api/news?id=5872b281d09d19ca4f89427b20b9c30e6b23ed5e7d22730e5e2df553fc0d36d1
company,2023-08-04 16:33:00,"The Biotech Game Is Changing. Watch for Disruptions, Says RBC.",121835721,https://s.yimg.com/ny/api/res/1.2/OqSSbTDlbHYP2f.3c4q5ew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/d1b5dedcaf855b32d997f67e0d05033d,BIIB,Yahoo,"SECTORFOCUS BLOG  The rules of the biotech game could change dramatically if several trends play out in science and regulation. Investors should be on alert, say analysts from RBC Capital Markets. Government programs could command deep discounts.",https://finnhub.io/api/news?id=dd90c4bd8518b87a696c3ac14c17672269bcdad731f4b00f330de6542c0f8bbe
company,2023-08-04 15:40:00,FDA approves first-ever pill for postpartum depression in new mothers,122225630,https://images.mktw.net/im-830415/social,BIIB,MarketWatch,Biogen and Sage Therapeutics are behind the first FDA-approved pill for treating postpartum depression.,https://finnhub.io/api/news?id=f6b5d8a99cd0d9d14017997efbfce10cd0938adddcd7928628380cf2e81d894f
company,2023-08-04 08:09:00,"5 Healthcare Stocks to Buy Now, According to Analysts – August 2023",121828758,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8daef503e1e7128fa57d06f5e6fbfb34b4be3a1e19322c5a327537027c2b7279
company,2023-08-04 06:40:00,Eli Lilly Stock Is on a Tear. Expect More Gains After Earnings.,121971569,https://images.barrons.com/im-829881/social,BIIB,MarketWatch,"Despite its strong start to the year, the drugmaker’s report on Tuesday should lift shares even further.",https://finnhub.io/api/news?id=38f582af2321ceaf04720b1961efa848288bb5388f46b6e7ec10937ed383de65
company,2023-08-04 02:55:00,"Sage, Biogen postpartum depression pill zuranolone wins FDA approval",121838576,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2409dbd0bc73977c8d4e0d45140e2b516cb3fad3703cc60cf882271c72181cfb
company,2023-08-04 01:58:00,FDA approves Zurzuvae for postpartum depression,121838580,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=702172fb8d3e4a791a8706a773eea44fd525fc824664571d2bdc627280b0137b
company,2023-08-04 01:38:00,"Biogen trading halted, news pending",121838583,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=cbb6e74a371a34af651372239429745aa26fc193e819528c03094e74ec133267
company,2023-08-03 23:57:00,Biogen Inc. stock outperforms competitors on strong trading day,121838584,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fbbdd53c20d694ae939af628ba06bdeac8ee87db222ae7dc3b5eb6043c10a3a4
company,2023-08-03 08:01:24,Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%,121806333,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...,https://finnhub.io/api/news?id=d37397b4c3652ad11218dfeb7730cd68b52c63a95578eb114f301728b28e5461
company,2023-08-03 02:42:00,"Goldman in, Microsoft out of BofA Alpha Surprise Portfolio",121792941,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=62c872d0c1781bb19cde8f53aa3bc597324eeff1460c9526ac7c7483097a6247
company,2023-08-02 23:57:00,Biogen Inc. stock underperforms Thursday when compared to competitors,121801490,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ad51f3d5e2edbc95b7491694b337e610e6e1ddcbf959f9907f6ce34a1e9e8d2f
company,2023-08-10 12:02:00,Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues,121961794,https://media.zenfs.com/en/zacks.com/c027d373b37df8dc327c7d25da56f8f0,BIIB,Yahoo,Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.,https://finnhub.io/api/news?id=886e8998d0783c741ef8f3fbc475f1ca42fa137647587ec1d8013be3e59b0ee4
company,2023-08-10 11:31:00,"Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates",121956079,,BIIB,Yahoo,Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.,https://finnhub.io/api/news?id=dac1226718404ceefd2efdea8e59b794895e38a0cbc0d25183504e71560ec444
company,2023-08-10 09:00:00,Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?,121956080,,BIIB,Yahoo,"Biogen (NASDAQ: BIIB) is an intriguing stock right now.  For starters, the company's Alzheimer's treatment, Leqembi, obtained approval from the Food and Drug Administration (FDA) earlier this year.  Plus, it announced a significant $6.5 billion acquisition last month that could bolster its portfolio of drugs.",https://finnhub.io/api/news?id=454ca0c0f362880afa89ee7230a54bcc6e28fde84ffd287254e7dc2d34735097
company,2023-08-10 07:06:15,Wall Street Analysts Trim Price Targets for These 10 Stocks,121949768,https://s.yimg.com/ny/api/res/1.2/IkagRrpf6IyIILaejIB2hg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/insidermonkey.com/3396bb4f3022d56ffc3c8e8fadaaf1c7,BIIB,Yahoo,"In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Trim Price Targets for These 5 Stocks. A series of daily 1% changes in the S&P 500, whether it goes up […]",https://finnhub.io/api/news?id=1fbda05e5b3fd7292b4b293ee8ba809c1a2d0789e75c5742f822a165bab6fc86
company,2023-08-09 23:57:00,Biogen Inc. stock underperforms Thursday when compared to competitors,121983990,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=04c2683a6618e01cf6d727ddb9cbdedd7fecfa70ca98f3fd2afe2feb87f55366
company,2023-08-09 13:58:16,U.S. Wide-Moat Stocks On Sale - The August 2023 Heat Map,121936438,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Discover our 3-step process for identifying undervalued wide-moat stocks, including a heat map of top investable candidates. Click here to read our picks.",https://finnhub.io/api/news?id=68c46811154f6adbf26935b5b28e1742a72b043138abf648690f4393dd19ba5f
company,2023-08-09 09:53:00,More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection,121927245,,BIIB,Yahoo,"Alzheimer's patients could soon have more treatment options available.  Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli Lilly, donanemab, may not be far behind.  The one drawback, however, is that those drugs treat Alzheimer's when the disease is in its early stages, and thus, many people won't be able to benefit from them.",https://finnhub.io/api/news?id=145fc5df4be187f5edfbec472abbabfffe5459834006f85635a13a0c6c3d6f8b
company,2023-08-09 08:30:00,"With an Acquisition on the Way, Is Biogen Stock a Buy?",121919762,https://s.yimg.com/ny/api/res/1.2/6k76QW5At90vJF6Da6UTmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/a43cbd882c4d17f00de56205d7c9e553,BIIB,Yahoo,"Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news.  After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it would acquire Reata Pharmaceuticals, a company that focuses on developing treatments for serious and life-threatening diseases.  Biogen has been a relatively volatile stock to own over the past few years, but could this new acquisition move help the company turn things around?",https://finnhub.io/api/news?id=7d36a5761a865f118564c72ad7b045506bc75ec0f567aacd1ea9d6ba298170c2
company,2023-08-09 08:00:42,Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?,121919763,https://media.zenfs.com/en/ibd.com/3b32d81431b6faad0a29129cfcabd1d9,BIIB,Yahoo,Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer’s drugs. But is LLY stock a buy now? Here's what you should know.,https://finnhub.io/api/news?id=af59c7e2ae45fac9396b84ce27d54e65398e5fac3078da91cc0f8b9d98f96a27
company,2023-08-09 07:21:00,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Caliber Imaging & Diagnostic (OtherLCDX),121924169,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=372bcf6744f06ee34554673aa6eecf7d14a1d00dfb6eb2511a3d5da012cd6978
company,2023-08-09 06:15:00,Biotech Alert: Searches spiking for these stocks today,121923083,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=be56a3ac335df1cb18daabfc3c3f8c31f329551c43b6e9ba7fde41162f342689
company,2023-08-09 05:43:04,Barclays Maintains Biogen (BIIB) Equal-Weight Recommendation,121918153,,BIIB,Fintel,,https://finnhub.io/api/news?id=4c41cdf317383f62ad9b20928bfc0843d6033e2b04b688fcd6a317c1561cfae5
company,2023-08-09 05:43:03,Atlantic Equities Maintains Biogen (BIIB) Neutral Recommendation,121918154,,BIIB,Fintel,,https://finnhub.io/api/news?id=abd0b083f034c9efbf0c5b43f4d143529da86a32485325f934d059cb622e6135
company,2023-08-09 05:43:00,Needham Maintains Biogen (BIIB) Buy Recommendation,121918156,,BIIB,Fintel,,https://finnhub.io/api/news?id=9436247a0bb2aad843c0773aba90a81c7fdc8d7add9704d917b5a632477f0838
company,2023-08-09 05:43:00,Truist Securities Maintains Biogen (BIIB) Buy Recommendation,121918155,,BIIB,Fintel,,https://finnhub.io/api/news?id=9d095dc342da0a79bc85a165623fd1c0f5f9db5107ac35b7f03f5e180d07382c
company,2023-08-09 02:59:00,Denali Therapeutics price target lowered to $31 from $37 at Wedbush,121923165,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0ee95715c2768d73d76f5646f3e4618082e2092e4a7a19d4f0a11922ed75bd87
company,2023-08-08 23:57:00,"Biogen Inc. stock falls Wednesday, underperforms market",121961440,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=219e2bd0da9afb39a9e2cc6a33bd25271cb2ac016bc58ae1476cb5da56ca2253
company,2023-08-08 22:50:00,Regional Bank U.S. Bancorp Tops Moat Stocks In July,121916031,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283813790/image_1283813790.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"While U.S. equities extended their rally, Morningstarâs Moat Index extended its year-to-date lead over the S&P 500 to nearly 800 basis points. U.S. Bancorp stood out as the top contributor.",https://finnhub.io/api/news?id=7895d1e31c2dd75f107b4a8eadc7cb8143446d4e51376c929e7bc09daee90a12
company,2023-08-08 12:36:12,Is Biogen Inc (BIIB) Modestly Overvalued? A Comprehensive Valuation Analysis,121899385,https://media.zenfs.com/en/us.finance.gurufocus/ae71feffcc1f8e4fb97a9a6cda32208b,BIIB,Yahoo,Exploring the intrinsic value and financial health of Biogen Inc (BIIB),https://finnhub.io/api/news?id=d37bac1f116aa8e3a157ca562150c11bc8ba90f7a1d23bfb2444d37f97acac0b
company,2023-08-08 10:26:00,Eli Lilly Stock Is Flying After Strong Results. Obesity Drugs Delivered the Goods.,121898305,https://s.yimg.com/ny/api/res/1.2/dWwy_ASqMmaO2yjWifFhpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/caa6be5cee80ea04cd0a498ae1bf718f,BIIB,Yahoo,Things couldn't be going much better for the drugmaker. The stock is up about 50% over the past 12 months and nearly 25% so far this year.,https://finnhub.io/api/news?id=a3dfa770489ce4ec2c4e7f0792af24fdbe26201ca9c89b663ba81cc8d924a851
company,2023-08-08 09:00:00,Is Sage Therapeutics a Contrarian Buy?,121899387,,BIIB,Yahoo,"Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders.  The stock plummeted by more than 53% after the company revealed that its blockbuster drug candidate, zuranolone, failed to win approval from the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD).  Zuranolone, which Sage Therapeutics developed in collaboration with Biogen (NASDAQ: BIIB), is a novel antidepressant designed to offer fast and durable relief from depressive symptoms, with a short course of treatment and minimal side effects.",https://finnhub.io/api/news?id=b99d6ddf943227781842d6f6379afc462659f1bbb203432c8dbdab1a80749bf2
company,2023-08-08 05:29:00,"Lilly reaches all-time high on Q2 results, 2023 guidance boost",121904209,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b72fc587433974b0786750ecc550029c4e3cb123581578e5ab31cfdf6fe4d83e
company,2023-08-08 04:45:22,Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation,121887235,,BIIB,Fintel,,https://finnhub.io/api/news?id=7a15349200b8d1f7b9857daa1f5e6f09980d5c004af3250674b7b541d603f8be
company,2023-08-08 04:45:02,RBC Capital Maintains Biogen (BIIB) Outperform Recommendation,121887237,,BIIB,Fintel,,https://finnhub.io/api/news?id=ea27c1d577bd3a81d1b1896b42f7422a8241c4555cc041b7eb86e1a4061a5d10
company,2023-08-08 04:45:02,Wells Fargo Maintains Biogen (BIIB) Overweight Recommendation,121887236,,BIIB,Fintel,,https://finnhub.io/api/news?id=c7b90c614fff5edb4dd397bf4418c1b48e9c4265495120946d14753fcab0c6d4
company,2023-08-08 04:35:00,Biogen price target lowered to $340 from $3500 at Truist,121904293,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e0e8a480148d0b3e47fe920fbe67b7205dd29ffcd94f10dfe305282bbc379439
company,2023-08-08 04:05:00,Needham cuts Sage Therapeutics to Hold on reduced zuranalone opportunity,121897536,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6fdcd9a296ac3f0d11494a002198b6194101f160d579d7f762c08c79b35e3329
company,2023-08-08 04:04:00,Looking Into Biogen's Recent Short Interest,121904296,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7cadc282f7de9ca8ea8de50db6ae2bffe09138470062ee31a02394e2171867fb
company,2023-08-08 03:22:00,Biogen price target lowered to $336 from $347 at BMO Capital,121904297,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=59ab61ce2d7099ddca77451e09c6c51625394bd049cefd21bbe9599f07cd9fb1
company,2023-08-08 02:48:00,DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday,121894840,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8208aba281dbf9664d6bf029d0f22dcad63aead5d84cf36f74afb6c9cda477df
company,2023-08-08 01:14:00,"BofA upgrades Axome to neutral, cites improved outlook for MDD drug",121923085,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=954604c2c4b6b16aea867b664ce947be29a650a85e94f26c5af3d703e9650f80
company,2023-08-07 23:57:00,Biogen Inc. stock outperforms competitors on strong trading day,121924178,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fb3112ff44a6c892a1790a4c01f05d6489772cf3ede1db1f9360496d33f1ecc7
company,2023-08-07 17:22:00,Eli Lilly to Report Earnings as Hope Soars for Weight-Loss Drug Mounjaro,121884775,https://s.yimg.com/ny/api/res/1.2/dWwy_ASqMmaO2yjWifFhpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/caa6be5cee80ea04cd0a498ae1bf718f,BIIB,Yahoo,Things couldn't be going much better for the drugmaker. The stock is up about 50% over the past 12 months and nearly 25% so far this year.,https://finnhub.io/api/news?id=c5dc41e80f3c3dc98f2b792c7a88caadd453a84f224d6a687a93f876289d6a3c
company,2023-08-07 15:50:29,Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug,121879568,https://s.yimg.com/ny/api/res/1.2/5dhr9u6wGXBiRms7qUXiNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia.com/e2a6dd4a25d114ae3eca7007c6ed05dc,BIIB,Yahoo,Sage Therapeutic shares fell to an all-time low after the FDA rejected use of its treatment for major depressive disorder.,https://finnhub.io/api/news?id=251fb492116de92ca1cc75121ef7da5bd5f6db41cd4c589841a19a244937839b
company,2023-08-07 13:44:22,Future Prospects For Johnson & Johnson Following Strong Q2 Performance,121880242,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1042651550/image_1042651550.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. Read why JNJ stock is a hold.",https://finnhub.io/api/news?id=ea74e3a360ba579aa30b3787eeef5a35f93c31e286f47c542cbf4986da153865
company,2023-08-07 11:44:32,Why Sage Therapeutics Stock Is Crashing Today,121879570,https://s.yimg.com/ny/api/res/1.2/BlmnaFbBYtqaAh.jpHJvOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD03MTM-/https://media.zenfs.com/en/motleyfool.com/1e196b38cd901d666ee24e33408f817f,BIIB,Yahoo,"The huge sell-off came after the company and its partner, Biogen, announced following the market close on Friday that the U.S. Food and Drug Administration (FDA) didn't approve Zurzuvae (zuranolone) for major depressive disorder (MDD).  The FDA did approve Zurzuvae for treating postpartum depression (PPD).  The big problem for Sage -- and the main reason the biotech stock is plunging -- is that Zurzuvae will have a much smaller market size to target now.",https://finnhub.io/api/news?id=ff7ec68ec735ca90880c5c91fae7a3306b067e24359b7afd8dd6498883b2162c
company,2023-08-07 10:32:46,Sage shares cut in half after postpartum drug approval. Here's what happened.,121879571,https://s.yimg.com/ny/api/res/1.2/8j2dhF6vjOrAHACPV.on_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bizjournals.com/0707a589dff218228cbe598309f61f7e,BIIB,Yahoo,"The Cambridge drugmaker saw its market value drop by about $1 billion in the first minutes of trading Monday, following a partial approval of a new depression drug late Friday. Cambridge-based Sage had applied to market the depression drug, zuranolone, as a treatment for both major depressive disorder (MDD) and postpartum depression (PPD). The U.S. Food and Drug Administration approved zuranolone, now marketed under the name Zurzuvae, for PPD but rejected it as a treatment for MDD, citing a lack",https://finnhub.io/api/news?id=c0c76a7dc1ba06728dbdca666c73796938b8d4874116dc7b432826882d2c6d2b
company,2023-08-07 10:14:11,"FDA approves first postpartum depression pill from Biogen, Sage",121879572,https://s.yimg.com/ny/api/res/1.2/eqazDYHkz9HQ3eQwS9a67Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2023-08/9f26b010-352c-11ee-aefe-bd05130351d3,BIIB,Yahoo,"The U.S. Food and Drug Administration has approved the first pill to help treat postpartum depression. The pill was co-developed by Biogen (BIIB) and Sage Therapeutics (SAGE). The approval was a mixed bag for the companies. It was not approved to treat for major depressive disorder, which would have been made the pill marketable to more patients. Also, there was a surprise warning from the FDA about not driving for 12 hours after taking the pill. The drugmakers say the pill should be ready for launch in the fourth quarter of 2023. Yahoo Finance Health Care Reporter Anjalee Khemlani explains the pill's approval.",https://finnhub.io/api/news?id=b40824a94c50f9c7b73d987aaad6dda71c5b3877bdffeb234c193d89738a2875
company,2023-08-07 10:04:00,"Split FDA Call on Depression Drug Upsets Strategies for Biogen, Sage",121879573,https://s.yimg.com/ny/api/res/1.2/Cwr7FBiHxaBWHrYi3Q0_pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/7063b00596e087cbc1b5609c900f3ad4,BIIB,Yahoo,"Sage Therapeutics says it is 'evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.'",https://finnhub.io/api/news?id=26ea2deea3fa087dffa056db7b1f3c4fe77d1de63ac7c02e1dc7788409bf4924
company,2023-08-07 08:50:00,What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead,121881186,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6b48b52b9631cf7948a9c350b66d50a09f16c671b40f82d7cb38faade7d88df2
company,2023-08-07 08:44:17,Sage tumbles to record low on clinical depression pill setback,121873108,,BIIB,Finnhub,"Shares of Sage Therapeutics slumped to a record low on Monday after the U.S. health regulator approved the company and partner Biogen's pill for postpartum depression, but rejected it as a...",https://finnhub.io/api/news?id=19328575554b417864c944039807f2fc9fe1c32d41350adddec9b958662a2ab4
company,2023-08-07 08:09:00,Sage Stock Tumbles After FDA Decision on Depression Drug,121868860,,BIIB,Yahoo,"Sage Therapeutics says it's 'evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.'",https://finnhub.io/api/news?id=448cc04cdd4921b0a3f72adc3cbe03ff9a956101f5d40b25667d8ca480b6bd62
company,2023-08-07 08:06:09,Sage Tumbles as Depression Pill Approval Omits Major Disorder,121879577,https://s.yimg.com/ny/api/res/1.2/b71.RwVvlU1BbPcU3dFagQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NTc-/https://media.zenfs.com/en/bloomberg_markets_842/e61ee570a6e6d8d11aca86e6a5a859b8,BIIB,Yahoo,"(Bloomberg) -- Sage Therapeutics Inc. slumped in early trading after regulators granted approval to its fast-acting pill only for postpartum depression, denying the drug clearance for major depressive disorder.Most Read from BloombergMusk Says He May Need Surgery, Will Get MRI on Back and NeckTexas Power Prices to Surge 800% on Sunday Amid Searing HeatPayPal Launches a Stablecoin in Latest Crypto Payments PushUkraine Black Sea Drone Attacks Signal Rapidly Expanding WarHSBC Executive Slams ‘Weak’",https://finnhub.io/api/news?id=03674ccc5e0023cc8509a24f3bf2b08184a3ae26874576cc293e22dd3e80035b
company,2023-08-07 07:18:00,Sage Therapeutics downgraded to Neutral at BofA after MDD CRL,121881192,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3c62678c20f0a92fe0b2be6e430c1048f2fc6aaebba28f85dfd627938a889bb3
company,2023-08-07 07:15:00,Dow Rises Over 300 Points To Start The Week,121873832,,BIIB,TalkMarkets,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=69c4c248667233325a0360cb11ef831592b4603cd3d642d2d5b16ebb444fa852
company,2023-08-07 07:13:00,"FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says",121878804,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=71007806fd4b7ec71fd6026aebc3844b2a22bf6105c3f273b792bf4d365da1d8
company,2023-08-07 06:52:26,Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug,121876395,https://image.cnbcfm.com/api/v1/image/107282724-1691416994265-gettyimages-1232777091-PGONCHAR_W8860.jpeg?v=1691419946&w=1920&h=1080,BIIB,CNBC,"The FDA approved the pill zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder. ",https://finnhub.io/api/news?id=fa115a0e931bcb5375de2216ff7a710dfc1f63a22db8f964578bfdfd7d62e13d
company,2023-08-07 06:04:18,Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market,121870562,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1136755765/image_1136755765.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Sage Therapeutics faces challenges with declining cash, rising expenses, and limited market potential despite FDA approval for Zurzuvae in PPD treatment.",https://finnhub.io/api/news?id=733dbc26427814de014f5bc72ba29572a43f4fb6f179609231d84f912d5b0d2f
company,2023-08-07 06:00:00,Major US health systems expect to offer Alzheimer's drug Leqembi in a few months,121867844,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Five major U.S. health systems said they would offer Eisai and Biogen's promising new Alzheimer's drug Leqembi after working out payment and administrative policies, and how to assess and monitor patients, most likely in the next month or two.  Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's.  The disease affects an estimated 6.5 million people, most of whom are part of the U.S. government’s Medicare plan for people 65 and older.",https://finnhub.io/api/news?id=7b2c71f59275aeffeebdfeddcc33f1a8b930b609488d60a07147704d16da156b
company,2023-08-07 06:00:00,Retirees' Biggest Social Security News of the Year Is Less Than 10 Weeks Away,121867843,https://s.yimg.com/ny/api/res/1.2/67Kv7HPgvN4_7hNhUiNi9w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04OTc-/https://media.zenfs.com/en/motleyfool.com/019e20d8e680ccd0a136a6536f02ae51,BIIB,Yahoo,"Retirees don't only have cooler temperatures to look forward to.  The Social Security Administration (SSA) hasn't officially announced when it will reveal the cost-of-living adjustment (COLA) for 2024.  SSA provided its update for the 2022 COLA on Oct. 13, 2021.",https://finnhub.io/api/news?id=34a43e74f399522bbaf5d0e52041059a593951b91a2e3eeda53e9e173a30c6b2
company,2023-08-07 05:56:20,"Biogen, Sage face challenges as FDA rejects pill for clinical depression",121870453,,BIIB,Finnhub,"The approval of Biogen and
Sage Therapeutics' depression pill for a
smaller-than-expected patient cohort has fueled concerns over
its growth prospects, analysts said on Monday.
              The U.S....",https://finnhub.io/api/news?id=bfdd3ce4858559a4b51c1a95e08101694eacd18b6b43ea498aee7f8b1d1a26a6
company,2023-08-07 05:50:00,Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Pharvaris (PHVS),121872053,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5be9daf8effae666a2113fa4565f91eacaae0d1446c9643240ba79f7f1acfaba
company,2023-08-07 05:38:00,"PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories",121872054,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6e68b96f24991da9c252c17e25bccea806216a8e58816a49efcf5584bc7723c5
company,2023-08-07 04:34:00,Biogen price target lowered to $354 from $374 at RBC Capital,121872057,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ff1fa26f76cbf965c7097e5321e86f76d8f24a354859bfb45494117558d8ddbd
company,2023-08-07 04:05:00,Biogen price target lowered to $294 from $311 at Barclays,121897548,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3094ac38b5717596ef122963e1addd30c437235a2499aa3bce82563b53bd1fac
company,2023-08-07 04:03:00,Fly Intel: Pre-market Movers,121871923,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e1d7b1fd9359681b25c71e2f36847a0b86fab95ae065ee3f1cd7ee778591b780
company,2023-08-07 04:02:00,Biogen price target lowered to $343 from $350 at Wells Fargo,121872059,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=83d621026481dc21660230e795d231c785adb833c1de72a3001e2817a2f2f762
company,2023-08-07 03:48:00,Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback >SAGE,122225628,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BIIB,MarketWatch,By Colin Kellaher Shares of Sage Therapeutics tumbled more than 45% in premarket trading Monday after the U.S. Food and Drug Administration rejected a key...,https://finnhub.io/api/news?id=fdf1ae188b353bbda30caac2396781ce3d7463fd8901ef4f313d2e57790ac0ec
company,2023-08-07 03:29:00,"Biogen, Sage face uphill battle with postpartum depression pill",121868197,,BIIB,Finnhub,"The U.S. drug regulator's approval of
Biogen and Sage Therapeutics'
first-of-its-kind postpartum depression  pill is unlikely
to allay the drugmakers' growth concerns, analysts said on
Monday.
       ...",https://finnhub.io/api/news?id=e558af84c72c5efb2f7081333759a54a81b9fd4cc9fc2ef1bd5a4bfde09ddcc2
company,2023-08-07 03:11:00,Analysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB),121872060,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d59793f06f7085072859deadad647a6a23d6d09a38026cd5519a8887e367042f
company,2023-08-07 03:09:00,Biogen price target lowered to $350 from $380 at Piper Sandler,121872061,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2f1ab17fffc09bba79c7c65d71785d34fb18745c505e5ecfe0b10d0406f7129a
company,2023-08-07 03:04:00,Biogen price target lowered to $290 from $360 at Oppenheimer,121872062,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a1057d3ab0c38e0569bc83492af31053459cbd5f2eb9aac3b05eab6b2b014436
company,2023-08-07 03:02:00,"Sage Therapeutics’ stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder",121872063,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=40c5cc080af676ee60512866bf4a7cf510b8971701aa5fd736aa82de51f45cc3
company,2023-08-07 02:56:00,Biogen price target lowered to $290 from $310 at BofA,121872064,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2fbe116aac2185d25fb12ebba9f5cf81ca024e583942e7f01d3e40bc524a590e
company,2023-08-07 02:54:00,Biogen price target lowered to $269 from $276 at Wedbush,121872065,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=47f1b22c96bd25d6a8f86f7bdfc17827d8373064a7bf792fa25d72dbe600b5b3
company,2023-08-07 02:52:00,"Wedbush downgrades Sage Therapeutics to Neutral, lowers price target to $22",121872066,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=44f002fa8a72e7608eca52d08ccab9eda69ab90b2dc4c4214c96184fff0a852e
company,2023-08-07 02:45:00,Sage plummets 46% after FDA declines zuranolone in major depression,121872067,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=94318ea0b89fa9090743c8ca727ad146f3ff183e3d80ce2ae4712972bc9f59ca
company,2023-08-07 02:44:00,Biogen price target lowered to $333 from $340 at Baird,121872068,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c92933054f765ab9c14dac63002620eacd748a19d46125038572f80a62d9d86f
company,2023-08-07 01:35:00,Sage sees cash and equivalentes enough to support operations into 2025,121872069,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9bc4314b597ba0c505cced29fcd16c8c076eb9c1a4700c677718082de831a00c
company,2023-08-07 01:21:00,"RBC Capital cuts Sage to sector perform, calls FDA decision ""major setback""",121881230,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=50bf8033a78e97aeaa19d85f5de6484349e58c820fc2ce37a667f3bf51d4964a
company,2023-08-07 01:21:00,"Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX), Aurinia Pharmaceuticals (AUPH) and Biogen (BIIB)",121872021,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5ef3d268f55aa8b928377e7e2f81d36e53b6c86dd465159e79441ae88944587b
company,2023-08-07 01:06:00,J.P. Morgan Sticks to Its Hold Rating for Biogen (BIIB),121872071,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c0ad1b3d7ececde0ba80e8d2526867adbd3c8122ab720f923db56ed9521bde89
company,2023-08-07 00:46:00,"Wedbush cuts Sage to neutral, questions Biogen's future funding of zuranolone",121881231,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=92421c903bd9418149319ed3ddacd749b6e3e9a7ea9e32b351f9c636d8490ef2
company,2023-08-07 00:21:00,"Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)",121872072,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f1879cdbc9243efc1f3a6adae3bc83272bb366f5a6a6885025b8855961db25c6
company,2023-08-07 00:17:00,Biogen (BIIB) Receives a Hold from Barclays,121872073,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b323e15ca1417fa58e318fd9621fe2f67e2adfceb5d3f480f2bfbf0acb12679d
company,2023-08-06 23:57:00,"Biogen Inc. stock rises Monday, still underperforms market",121904309,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fef80a18f62fab1665a3992c07606b3b1f0429b7492b01b7c16a125c97499eca
company,2023-08-06 23:52:00,"Sage, Biogen receive CRL for zuranolone in major depressive disorder",121872074,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2944b3f1801afb2b49b6a715d2df14c974cb81214cdd4127cf5116522399bf29
company,2023-08-14 12:38:10,Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity,122029825,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1420207647/image_1420207647.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Sage Therapeutics, Inc. is revolutionizing the treatment of postpartum depression, while also tackling CNS disorders. Click here to read more on SAGE stock.",https://finnhub.io/api/news?id=69c8594f22c6fe3cf94e62e808ae3d1f5f0e8053fa344d042111096ff05caae6
company,2023-08-14 10:17:29,Mizuho Maintains Biogen (BIIB) Buy Recommendation,122022532,,BIIB,Fintel,,https://finnhub.io/api/news?id=438f349b94ad6320a3a7666f511711f6dacf65c77e487d6f792e454b69d41436
company,2023-08-14 03:00:00,Second Half Outlook For Biotech Stocks,122020901,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1135352098/image_1135352098.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts.",https://finnhub.io/api/news?id=a07177ca11c3822b3066921c2b90b02d4d96fa59771bca0c5129d11cb3fcb5ea
company,2023-08-14 01:53:00,Biogen price target lowered to $335 from $340 at Mizuho,122031320,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d6a963f87192fc3da9d8bb0442f647fb20254aa6906d2681b28eba1b573134b0
company,2023-08-14 01:45:30,Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics,122020443,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1434534146/image_1434534146.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Coya Therapeutics aims to target inflammation-related diseases, like ALS, with Treg-enhancing therapeutics. Click here to read my analysis of COYA stock.",https://finnhub.io/api/news?id=b8efac08f8dee4ab8ee73c620504ff77ac2ec83ecc2ac08b48476f8b9f42b646
company,2023-08-13 23:57:00,Biogen Inc. stock underperforms Monday when compared to competitors,122031323,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e46da5aa172fed854a56f3abb310eb23397320874be785c7132eebf86e118846
company,2023-08-13 09:12:48,13 Best Wide Moat Stocks To Buy According To Hedge Funds,122012396,https://s.yimg.com/ny/api/res/1.2/Cn4Bl.9c6p2ILDyjTXZ2Sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://media.zenfs.com/en/insidermonkey.com/fb93572079378a3999d8bfe3ea4298a9,BIIB,Yahoo,"In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies […]",https://finnhub.io/api/news?id=e2b4f99bf62293fa7dc6dc9f143fcd827e5bda07ab3152ddf8f4cd45e8878c22
company,2023-08-12 05:00:00,INSIGHT-What happens when a $2 million gene therapy is not enough,122001366,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.  It leaves children too weak to walk, talk, swallow or even breathe.  So when in 2021 his parents heard about Zolgensma – a one-time therapy costing millions of dollars that promises to replace genes needed for the body to control muscles – they had high hopes.",https://finnhub.io/api/news?id=622f72fa1d8700ea95687e4849874390690c2e12d8e6012d557f8c7c0644cfc6
company,2023-08-11 12:05:14,15 Most Important Medical Discoveries in History,121984488,,BIIB,Yahoo,"In this article, we take a look at the 15 most important medical discoveries in history. You can skip our detailed analysis of the global medicine industry and go directly to the 5 Most Important Medical Discoveries in History. Medical discoveries have done wonders for civilizations and helped humans to thrive. Since the evolution of […]",https://finnhub.io/api/news?id=8d6ede2d8239b7151eb01575572d5a84a4f29e2fa5f3228a69ac5fd22aab12b2
company,2023-08-11 10:23:56,"Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects",121987196,https://media.gettyimages.com/id/1435012411/photo/senior-man-and-nurse-looking-at-photo-album-in-the-living-room-in-a-nursing-home.jpg?b=1&s=170667a&w=0&k=20&c=_9WvSHFmmBQx0GN6NcFMBhdOfFVWs3NlMyXQ9YvXUO0=,BIIB,SeekingAlpha,"Biogen focuses on neurological therapies, recently acquired Reata Pharmaceuticals, and shows mixed financial performance. Click here to read more.",https://finnhub.io/api/news?id=e8232304c10a2030609fe40ae5ee1ddf330202475a16b68909258ddbbba4c97b
company,2023-08-11 08:00:35,Should Weakness in Biogen Inc.'s (NASDAQ:BIIB) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?,121982406,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 13...",https://finnhub.io/api/news?id=0531eba897ba4f2d633c86d9904dcab7d46e9f0754a974435de202fbf026dc82
company,2023-08-11 07:32:00,Biogen/ Sage expected to hike price for new depression drug after narrow label,121996300,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d3bb80911387753d4de81ca56cfbc9352b7064f048a8b627083ea7a276bc71ff
company,2023-08-11 06:11:00,Insurers won't cover new Alzheimer's treatment for some customers,121983989,,BIIB,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a8354ef23f58987504e89a2398f39bf8fb90049fd26078005e26c16061a96c98
company,2023-08-10 23:57:00,"Biogen Inc. stock rises Friday, outperforms market",122004659,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b92fc2e1d25bc6463d7982fa7dd6afa7e044c21f1441bf4ca8b031170f04d3ef
company,2023-08-10 22:56:00,Biotech Duo Sage (NASDAQ:SAGE) and BioGen (NASDAQ:BIIB) Jump on Pricing Data,121996303,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=846fb23bed06dd8a20b7170909e9537e009de5c015ac7c7c9d5f6287b30dbf85
company,2023-08-18 12:56:00,"Biogen Inc. stock falls Friday, underperforms market",122225623,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slumped 0.13% to $261.15 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",https://finnhub.io/api/news?id=6e5e825bfb1ed72bcc0ae45e8085edd4ea968748e8676ddfbf05a12628bcbf72
company,2023-08-17 16:54:10,"Biogen's 1,000-person layoff begins in Cambridge",122105964,,BIIB,Yahoo,"Cambridge-based Biogen (Nasdaq: BIIB) employees began posting about the changes on LinkedIn on Thursday. Some offered help to departing colleagues, while others announced that they were open to work.",https://finnhub.io/api/news?id=ad9a6991e38593fde50e5bc533b290b1afaef2bb9f914b428222af8e506b4361
company,2023-08-16 23:57:00,"Biogen Inc. stock falls Thursday, underperforms market",122095929,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=78a343c1eded5673546fbb0cdff03c4bcc17f5ccf368622f4858d69beec37563
company,2023-08-16 11:08:28,CORRECTED-INSIGHT-What happens when a $2 million gene therapy is not enough,122070149,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.  It leaves children too weak to walk, talk, swallow or even breathe.  So when in 2021 his parents heard about Zolgensma – a one-time therapy costing millions of dollars that promises to replace genes needed for the body to control muscles – they had high hopes.",https://finnhub.io/api/news?id=a7c148857e6570c81b2990ff96be45d1e89c021625ccb92ef90fdcbac5770340
company,2023-08-16 07:03:00,"Wells Fargo starts GE HealthCare at overweight, sees increased imaging demand",122093533,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=1e46be073f53fa151fbe9b77a4d304459f3d8399fe66fa2b7550657e33e93b75
company,2023-08-15 23:57:00,"Biogen Inc. stock falls Wednesday, underperforms market",122095931,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=8b04ba23ce6833389ed4c822b3a6d98b00cd22a02f65f2b4f53b12dc757658e9
company,2023-08-15 21:14:00,"BofA upgrades Axsome to neutral, cites improved outlook for MDD drug",122095932,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5f0fcd389ffe4218b9d7aa693f249a7ce3ec2e0947b8c60769e30808111f891c
company,2023-08-15 10:00:39,Is Biogen (NASDAQ:BIIB) A Risky Investment?,122045046,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,"Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...",https://finnhub.io/api/news?id=7af755ec5d82c441e8313af7b3e0c9210a4189b1bbd2b581b1aed1cf53f04d70
company,2023-08-14 23:57:00,"Biogen Inc. stock falls Tuesday, still outperforms market",122054036,,BIIB,MarketWatch,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=38208fb22961612c277f7504a5a87a322616377db394f30d4e238de79ce8009b
company,2023-08-14 23:34:00,Sanofi was mystery suitor in Reata Pharma bidding war - report,122054037,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e415ab24119aea086e4558e6359424d5c674e047d805df612c7212bcf0e94fb2
company,2023-08-14 23:22:00,Sanofi was mystery bidder in Reata Pharma bidding war - report,122054038,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=58e3d574f753d548c59af7a6eec2308a8288c517854783dcb4b0617f384ecc80
company,2023-08-14 22:44:00,"Sanofi was second bidder for Reata, Bloomberg reports",122054039,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=3190bf351edb63dec05272d664101bb93f5d395bf6883124a6628d91f207c7b7
company,2023-08-14 22:38:00,"Sanofi was second bidder for Reata, Bloombreg reports",122054040,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=18e3ee0a234c82ec669df2374687e147df48209529cd070566f1f0c436279f6b
company,2023-08-22 12:56:00,Biogen Inc. stock outperforms competitors despite losses on the day,122225620,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slumped 0.79% to $262.98 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=6d7a807fd503160ef4584dd18eed35741e23042ac3804a3c0ca254a6bc840fad
company,2023-08-21 12:56:00,Biogen Inc. stock outperforms competitors on strong trading day,122225621,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rallied 1.50% to $265.07 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=0cb33fa2710ee26b84ce60c13bbd9a4c90654d3dca7551ab2b440de772efbff9
company,2023-08-19 08:00:26,Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 47% Undervaluation?,122133244,https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305,BIIB,Yahoo,Key Insights Biogen's estimated fair value is US$496 based on 2 Stage Free Cash Flow to Equity Current share price of...,https://finnhub.io/api/news?id=814cf4fe2c9443c6690952ea816c80806b1a3aa1fefc4a38d064884cb0279831
company,2023-08-25 21:04:00,Crohn's disease drugmakers set to benefit from expected rise in cases,122258977,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=102e61002195f60bfb7e2a88844a5fca3be10ce56e825fcc853d850580f670e0
company,2023-08-25 13:02:00,"Biogen Inc. stock rises Friday, outperforms market",122293521,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.76% higher to $264.43 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=98f282fdce3dce026ff591291745ab2aae4ed6c2743b8d4d3569344076b9c2df
company,2023-08-25 12:17:53,Novartis comes for a Biogen MS drug with new biosimilar,122250112,,BIIB,Yahoo,"On Thursday, the U.S. Food and Drug Administration approved a new biosimilar designed to mimic Tysabri, one of Biogen's (Nasdaq: BIIB) MS products. Biosimilars, like generics, are typically more affordable versions of brand-name drugs.",https://finnhub.io/api/news?id=c07c845ca3e5dacd49114523b5189c8ef80dc383f71642904b30c62568224ac9
company,2023-08-25 01:55:00,Novartis’ (NYSE:NVS) Sandoz Bags FDA Approval for Tyruko in Multiple Sclerosis,122237712,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=937c7b0e9fcd878d48be15b2e7317e0d71ba6e80d240ebe1cabfbe717e7d747a
company,2023-08-25 01:51:00,"Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Cooper Co (COO)",122237434,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6c07fc66aa7f226e07129695fc564e4c7fc83797a0231f5af88f875271276163
company,2023-08-24 14:07:00,Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment,122220845,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,MarketWatch,Biogen Inc. shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis AG spinoff approval for the...,https://finnhub.io/api/news?id=1be50496ab9a965b08baa96dfd05d8b84db4a0bfce9205d29cea5117b0a6fec1
company,2023-08-24 12:56:00,Biogen Inc. stock underperforms Thursday when compared to competitors,122225616,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slid 0.90% to $262.43 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...",https://finnhub.io/api/news?id=91ea80bed3fa0225ad11d498c3ddd8cc784eae00f33bbb5c240939ec96f401c7
company,2023-08-24 11:30:41,Biogen Inc. (BIIB) Down 0.2% Since Last Earnings Report: Can It Rebound?,122231088,,BIIB,Yahoo,Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.,https://finnhub.io/api/news?id=01a8515e3e39f8de3c2e20cab39aceaebd331c2f4e916293f1a5540afa7223bd
company,2023-08-24 07:04:00,October 6th Options Now Available For Biogen (BIIB),122243426,,BIIB,Stock Options Channel,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=03da244f1c6c93a1d1fc56d406510c3a096b652a6420920197b0b567107dc187
company,2023-08-24 04:46:00,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,122205516,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=323e62aa4a2526bd984da085607284014db2dbfc15837237f94a2ae0977a2d3c
company,2023-08-24 04:33:00,Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock,122207980,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2aeaa2103ec105acda8b3dc67816c7cf7c4c57206998338a00974ab069e62de0
company,2023-08-24 02:20:00,FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri,122237715,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=39ab960f4fd357050247dbc937ea68160a9f6f9bf6898aa7dc9dcd484dff427e
company,2023-08-23 22:20:26,Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition,122195778,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536,BIIB,SeekingAlpha,"Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.",https://finnhub.io/api/news?id=8aadcfcce666098da02f8040842f7d3e8f37654e9d67d2dbd3c0d80938b0f419
company,2023-08-23 12:56:00,"Biogen Inc. stock rises Wednesday, still underperforms market",122225618,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.69% higher to $264.80 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...",https://finnhub.io/api/news?id=2b1c5dda5eb2f368cd5472e250d89107091821673cfef2ee5cbb76cdd2398984
company,2023-08-22 21:12:00,Biogen's Leqembi set for strong uptake based on Baird physician survey,122243438,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a808f23ef034135db344d2ebde2195509814b90eb4f0e8e4c2d0bfeae8a9fd90
company,2023-08-30 17:50:19,Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know,122334950,https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $267.18, moving -0.31% from the previous trading session.",https://finnhub.io/api/news?id=ad4b77399ce7b1584f777aebef5b2fdff9b1203598b2ae71b3803e37ee56c8ac
company,2023-08-30 12:56:00,Biogen Inc. stock outperforms competitors despite losses on the day,122398597,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. shed 0.31% to $267.18 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=af12c7f6f145bf95eb4f13a47289841a41dac840d5e87a0f5b3854ff4736f9d3
company,2023-08-30 12:10:02,Biogen : to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference,122325337,,BIIB,Finnhub,"Cambridge, MA, - - Biogen Inc. announced today that Christopher Viehbacher, CEO, will participate in the Morgan Stanley 21st Annual Global Healthcare Conference. The webcast will be...",https://finnhub.io/api/news?id=f4c96ff93e4c0a1a16bba4d1777f227a8381b6e4f795932cee183115a81a9d54
company,2023-08-30 00:25:00,The 3 Most Promising Pharma Stocks to Own Now,122323269,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=f55cd8e369f3f0fdf5b80ebf84aff6a4cfea1c0760b553d8aae8968ed2a63586
company,2023-08-29 18:11:54,RBC Capital Maintains Biogen (BIIB) Outperform Recommendation,122311992,,BIIB,Fintel,,https://finnhub.io/api/news?id=85299d7d044e4ff2c0f9426ddc1761119b58ca55a0a82aee8e39e84b3a341594
company,2023-08-29 12:56:00,"Biogen Inc. stock rises Tuesday, still underperforms market",122398598,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. rose 1.11% to $268.00 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=0e5872876f5abf4659f2a3663a13650abc970bd2b41f6996a6fc68c05e72e895
company,2023-08-29 11:39:00,Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns,122304490,https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5,BIIB,Yahoo,"Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.",https://finnhub.io/api/news?id=b5e9f10d9c5ab72782bf8cb04a0e51680a5fd87e1ac86b73699b2c6f5c03cdeb
company,2023-08-29 10:07:00,Better Buy: Biogen vs. Eli Lilly,122304491,,BIIB,Yahoo,Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to dominate an area with a severe and growing need for new therapies: Alzheimer's disease (AD).,https://finnhub.io/api/news?id=b4fbba559ffcde63253e62d3f1da35d782d0059ea9c10bc058b05e6beb13ee23
company,2023-08-29 01:26:00,RBC Capital Remains a Buy on Biogen (BIIB),122302702,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9bcc8cfd90d2d5a198cddf08835c7ad62a079769f8259147b440c3d5c98e2956
company,2023-08-29 01:21:00,Biogen price target raised to $357 from $354 at RBC Capital,122302704,,BIIB,Thefly.com,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=85f89ac6fbb245c6c04d1386154530f7e5861aadaf3f7d88895cb58f316439d5
company,2023-08-28 23:28:00,Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet Partnership,122321901,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9f5519a743b80f4d1f52ad557c678004b3cf5fe2595626d10b7a72cbf27dc5eb
company,2023-08-28 22:59:00,Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet (NASDAQ:GOOG) Partnership,122321902,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=fc9eb3a9472304045d37509957a30109bcf7959864fa4a9eac566a38968a63c0
company,2023-08-28 22:58:00,Gingko Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet (NASDAQ:GOOG) Partnership,122321903,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=b57b804868a11a6a608c0c109296bf4ae0ad355ed5723e07e932806c7e90a8d9
company,2023-08-28 22:28:00,RBC Capital sees Biogen stock undervaluing Leqembi prospects,122330162,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5c54224ab002b17d57bd4408932c6cdb2c1a8f04df41a71c521289f59848a4a5
company,2023-08-28 12:56:00,"Biogen Inc. stock rises Monday, still underperforms market",122293520,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.23% higher to $265.05 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=19db20885882fe2328eed90948339a1578d4bc5e7866010242713deb890eaf49
company,2023-08-28 10:57:00,Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar,122279371,https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,BIIB,Yahoo,"Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.",https://finnhub.io/api/news?id=401e160785750370a8182aa9e9d901d9649f37875ba570c32998ea3f29f7b056
company,2023-08-28 09:39:25,12 Undervalued Wide Moat Stocks To Invest In,122275885,https://media.zenfs.com/en/insidermonkey.com/7fce214e14d6a0b0a624c5fe20813220,BIIB,Yahoo,"In this piece, we will take a look at 12 undervalued wide moat stocks to invest in. If you want to skip our primer on wide moat investing, then check out 5 Undervalued Wide Moat Stocks To Invest In. The strategy of wide moat investing has gained a lot of traction over the past few […]",https://finnhub.io/api/news?id=d541fcf43cce06e52f548e79f261e3a365647a3fa7e98e6cdc2f86daab4fe554
company,2023-08-28 04:31:00,Wall Street Analysts Are Bullish on Top Healthcare Picks,122281142,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=79b21e91e723ef0bcb74e780b1a9e12806fabbafd0e94027e27ea31e991886a8
company,2023-09-01 12:56:00,Biogen Inc. stock outperforms competitors despite losses on the day,122398594,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. slipped 0.07% to $267.17 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...",https://finnhub.io/api/news?id=0e96969a57d19fcc72e80ed7daa499cb2355af854b1eb5ed9bd1c32ea7aaaa1e
company,2023-09-01 04:20:00,(BIIB) - Analyzing Biogen's Short Interest,122377752,,BIIB,Benzinga,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4c4699fb756358a2132c3a916e1b9bf2e553ea294683044c876239a32704620f
company,2023-09-01 01:34:00,Biogen in $1.5B unsecured loan facility for Reata acquisition,122391200,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d678ab4e1cdfd621d4c5dcdbecb7a8440a24fd714ae8a8be978abb614a358405
company,2023-08-31 17:45:17,Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know,122353679,https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9,BIIB,Yahoo,"Biogen Inc. (BIIB) closed the most recent trading day at $267.36, moving +0.07% from the previous trading session.",https://finnhub.io/api/news?id=fd3971f3c82304cf7d95474f10c2f9fd7c4c86a48ca8a5f7fedc8c507fc07305
company,2023-08-31 16:07:34,FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected,122353423,https://media.zenfs.com/en/ibd.com/68f07dfc6c90f9ef93a88aa7dad8ecc4,BIIB,Yahoo,Sage said Thursday it will cut about 40% of its workforce following a setback for depression treatment Zurzuvae. Sage stock edged higher.,https://finnhub.io/api/news?id=6ffae54564e41e6dffe1ad86e5101e6f08e5fc3a35889069e65188339400d877
company,2023-08-31 12:56:00,"Biogen Inc. stock rises Thursday, outperforms market",122398595,https://images.mktw.net/im-220105/social,BIIB,MarketWatch,"Shares of Biogen Inc. inched 0.07% higher to $267.36 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=990af9fb64113816a1afddc03f0577ff8b30cac10edb94fbc046ea8b19726969
company,2023-08-31 10:10:59,Sage cuts nearly half its staff in wake of partial FDA rejection,122353424,https://media.zenfs.com/en/bizjournals.com/986e4829c4ce71dd157ea22c50057e64,BIIB,Yahoo,Sage Therapeutics is letting go of around 276 workers following some mixed news from the U.S. Food and Drug Administration.,https://finnhub.io/api/news?id=5ebab563909e7edfc52d2992c5d5dc825638ec3f6f4fd7a1f0091b7823015200
company,2023-08-31 07:00:11,UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback,122339931,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BIIB,Yahoo,"Sage Therapeutics said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.  The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen's pill for postpartum depression (PDD), but rejected it as a treatment for clinical depression, which is a much larger market.  Sage said the job cuts, which are part of a reorganization plan, will help it launch the drug for women with PDD and also position the company for long-term growth.",https://finnhub.io/api/news?id=9505d7539caf38ba817a4a70cadbe28c2b887224a199cae789f7cae3d9b81f97
company,2023-08-31 04:21:00,Sage Therapeutics (NASDAQ:SAGE) Slashes 40% of Positions with Zurzuvae Launch in Mind,122350322,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=5f7aaace9e6d7b57971efe5a998402cb9be38bb921c156bc2a4c171aec9d43f2
company,2023-08-31 04:00:00,Sage Therapeutics (NASDAQ:SAGE) Slashes 40% Positions with Zurzuvae Launch in Mind,122350323,,BIIB,TipRanks,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=93084076e102137cd22c99f5861e44f2f945db6d5e8ce0da99f9f5d59ac703a9
company,2023-08-31 03:59:00,Sage Therapeutics to lay off 40% of staff as it gears up for launch of postpartum-depression treatment,122340762,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BIIB,DowJones,Sage Therapeutics Inc. said Thursday it is reorganizing its business operations and workforce as it gears up for the launch of its postpartum-depression...,https://finnhub.io/api/news?id=904e7d2552958a6762fe34285b6bde391a1434819f13ac5a5d269bb454215cda
company,2023-08-31 03:31:00,The 7 Most Promising Momentum Stocks to Own Now,122343741,,BIIB,InvestorPlace,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=2e31735fdf340d4929a1d312e985743ca74aa949ca57435f348400d404d2d8d9
company,2023-08-31 02:27:00,Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch,122350327,,BIIB,Seeking Alpha,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a61a0aa1162297f0b1aa900e863f785a7b219da435f48e5cca5955158d4bda2d
